SEC Info℠  
    Home      Search      My Interests      Help      Sign In      Please Sign In

Biolase, Inc. – ‘10-Q’ for 3/31/21 – ‘JSON’

On:  Thursday, 5/13/21, at 5:23pm ET   ·   For:  3/31/21   ·   Accession #:  950170-21-226   ·   File #:  1-36385

Previous ‘10-Q’:  ‘10-Q’ on 11/13/20 for 9/30/20   ·   Next:  ‘10-Q’ on 8/13/21 for 6/30/21   ·   Latest:  ‘10-Q’ on 11/9/23 for 9/30/23   ·   23 References:   

Find Words in Filings emoji
 		  in    Show  and   ↓Hints

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 5/13/21  Biolase, Inc.                     10-Q        3/31/21   81:9.4M                                   Donnelley … Solutions/FA

Quarterly Report   —   Form 10-Q

Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 10-Q        Quarterly Report                                    HTML    900K 
 2: EX-31.1     Certification -- §302 - SOA'02                      HTML     27K 
 3: EX-32.1     Certification -- §906 - SOA'02                      HTML     24K 
10: R1          Document and Entity Information                     HTML     77K 
11: R2          Consolidated Balance Sheets (Unaudited)             HTML    115K 
12: R3          Consolidated Balance Sheets (Unaudited)             HTML     54K 
                (Parenthetical)                                                  
13: R4          Consolidated Statements Of Operations And           HTML    108K 
                Comprehensive Loss (Unaudited)                                   
14: R5          Consolidated Statements Of Redeemable Preferred     HTML     87K 
                Stock and Stockholders' Equity (Unaudited)                       
15: R6          Consolidated Statements Of Cash Flows (Unaudited)   HTML    108K 
16: R7          Description of Business and Basis of Presentation   HTML     35K 
17: R8          Summary of Significant Accounting Policies          HTML     37K 
18: R9          Revenue Recognition                                 HTML    105K 
19: R10         Redeemable Preferred Stock and Stockholders'        HTML    225K 
                Equity                                                           
20: R11         Inventory                                           HTML     41K 
21: R12         Property, Plant, and Equipment                      HTML     59K 
22: R13         Intangible Assets and Goodwill                      HTML     27K 
23: R14         Accrued Liabilities                                 HTML     81K 
24: R15         Debt                                                HTML    111K 
25: R16         Leases                                              HTML     85K 
26: R17         Commitments and Contingencies                       HTML     33K 
27: R18         Segment Information                                 HTML     59K 
28: R19         Concentrations                                      HTML     64K 
29: R20         Income Taxes                                        HTML     31K 
30: R21         Subsequent Events                                   HTML     25K 
31: R22         Summary of Significant Accounting Policies          HTML    127K 
                (Policies)                                                       
32: R23         Revenue Recognition (Tables)                        HTML     93K 
33: R24         Redeemable Preferred Stock and Stockholders'        HTML    213K 
                Equity (Tables)                                                  
34: R25         Inventory (Tables)                                  HTML     41K 
35: R26         Property, Plant, and Equipment (Tables)             HTML     57K 
36: R27         Accrued Liabilities (Tables)                        HTML     79K 
37: R28         Debt (Tables)                                       HTML     79K 
38: R29         Leases (Tables)                                     HTML     82K 
39: R30         Segment Information (Tables)                        HTML     55K 
40: R31         Concentrations (Tables)                             HTML     62K 
41: R32         Description of Business and Basis of Presentation   HTML     41K 
                - Additional Information (Detail)                                
42: R33         Revenue Recognition - Additional Information        HTML     33K 
                (Detail)                                                         
43: R34         Summary of Opening and Closing Balances of          HTML     33K 
                Contract Liabilities (Detail)                                    
44: R35         Summary of Disaggregation of Revenues Related to    HTML     32K 
                Geographic Areas (Detail)                                        
45: R36         Summary of Revenues Disaggregated by Timing of      HTML     32K 
                Goods and Services Transferred (Detail)                          
46: R37         Summary of Sales by End Market (Detail)             HTML     32K 
47: R38         Redeemable Preferred Stock and Stockholders'        HTML    162K 
                Equity - Additional Information (Detail)                         
48: R39         Classification of Compensation Expense Associated   HTML     34K 
                with Share-Based Payments (Detail)                               
49: R40         Assumptions Used in Estimating Fair Value of Stock  HTML     30K 
                Options Granted (Detail)                                         
50: R41         Summary of Option Activity (Detail)                 HTML     53K 
51: R42         Summary of Unvested Stock Option Activity (Detail)  HTML     38K 
52: R43         Cash Proceeds Along with Fair Value Disclosures     HTML     32K 
                Related to Grants, Exercises and Vested Options                  
                (Detail)                                                         
53: R44         Summary of Unvested Restricted Stock Units          HTML     44K 
                (Detail)                                                         
54: R45         Summary of Warrant Activity (Detail)                HTML     38K 
55: R46         Components of Inventory (Detail)                    HTML     31K 
56: R47         Inventory - Additional Information (Detail)         HTML     24K 
57: R48         Summary of Property, Plant, and Equipment (Detail)  HTML     45K 
58: R49         Property, Plant, and Equipment - Additional         HTML     24K 
                Information (Detail)                                             
59: R50         Intangible Assets and Goodwill - Additional         HTML     30K 
                Information (Detail)                                             
60: R51         Components of Accrued Liabilities (Detail)          HTML     45K 
61: R52         Changes in Initial Product Warranty Accrual and     HTML     36K 
                Expenses Under Initial and Extended Warranties                   
                (Detail)                                                         
62: R53         Accrued Liabilities - Additional Information        HTML     34K 
                (Detail)                                                         
63: R54         Debt - Summary of Principal Outstanding and         HTML     38K 
                Unamortized Discount (Detail)                                    
64: R55         Debt - Additional Information (Detail)              HTML    263K 
65: R56         Debt - Summary of Future Minimum Principal and      HTML     54K 
                Interest Payments (Detail)                                       
66: R57         Leases - Additional Information (Detail)            HTML     62K 
67: R58         Leases - Information related to Right-of-use        HTML     31K 
                Assets and Liabilities (Detail)                                  
68: R59         Leases - Schedule of Maturities of Lease            HTML     43K 
                Liabilities (Detail)                                             
69: R60         Leases - Future Minimum Rental Commitments Under    HTML     41K 
                Lease Agreements (Detail)                                        
70: R61         Commitments and Contingencies - Additional          HTML     52K 
                Information (Detail)                                             
71: R62         Segment Information - Additional Information        HTML     35K 
                (Detail)                                                         
72: R63         Summary of Net Revenue by Geographic Location       HTML     32K 
                (Detail)                                                         
73: R64         Summary of Property, Plant and Equipment by         HTML     29K 
                Geographic Location (Detail)                                     
74: R65         Concentrations - Summary of Net Revenue from        HTML     49K 
                Various Products (Detail)                                        
75: R66         Concentrations - Additional Information (Detail)    HTML     37K 
76: R67         Income Taxes - Additional Information (Detail)      HTML     33K 
77: R68         Subsequent Events - Additional Information          HTML     28K 
                (Detail)                                                         
79: XML         IDEA XML File -- Filing Summary                      XML    149K 
 9: XML         XBRL Instance -- biol-20210331_htm                   XML   2.13M 
78: EXCEL       IDEA Workbook of Financial Reports                  XLSX    101K 
 8: EX-101.CAL  XBRL Calculations -- biol-20210331_cal               XML    172K 
 5: EX-101.DEF  XBRL Definitions -- biol-20210331_def                XML    686K 
 7: EX-101.LAB  XBRL Labels -- biol-20210331_lab                     XML   1.63M 
 4: EX-101.PRE  XBRL Presentations -- biol-20210331_pre              XML   1.15M 
 6: EX-101.SCH  XBRL Schema -- biol-20210331                         XSD    236K 
80: JSON        XBRL Instance as JSON Data -- MetaLinks              420±   654K 
81: ZIP         XBRL Zipped Folder -- 0000950170-21-000226-xbrl      Zip    236K

‘JSON’   —   XBRL Instance as JSON Data — MetaLinks

This File is an XBRL Instance as JavaScript Object Notation (JSON) Data.


{
"instance":  {
    "biol-20210331.htm":  {
        "axisCustom":  0,
        "axisStandard":  26,
        "contextCount":  213,
        "dts":  {
            "calculationLink":  {
                "local":  [
                    "biol-20210331_cal.xml"
                    ]
                },
            "definitionLink":  {
                "local":  [
                    "biol-20210331_def.xml"
                    ],
                "remote":  [
                    "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml",
                    "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml"
                    ]
                },
            "inline":  {
                "local":  [
                    "biol-20210331.htm"
                    ]
                },
            "labelLink":  {
                "local":  [
                    "biol-20210331_lab.xml"
                    ],
                "remote":  [
                    "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-doc-2020-01-31.xml",
                    "https://xbrl.sec.gov/dei/2020/dei-doc-2020-01-31.xml"
                    ]
                },
            "presentationLink":  {
                "local":  [
                    "biol-20210331_pre.xml"
                    ]
                },
            "referenceLink":  {
                "remote":  [
                    "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-ref-2020-01-31.xml",
                    "https://xbrl.sec.gov/dei/2020/dei-ref-2020-01-31.xml"
                    ]
                },
            "schema":  {
                "local":  [
                    "biol-20210331.xsd"
                    ],
                "remote":  [
                    "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
                    "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
                    "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
                    "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
                    "http://www.xbrl.org/2005/xbrldt-2005.xsd",
                    "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd",
                    "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
                    "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
                    "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd",
                    "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd",
                    "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
                    "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd",
                    "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd",
                    "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd",
                    "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd",
                    "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd",
                    "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
                    "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
                    "http://xbrl.fasb.org/us-gaap/2020/elts/us-parts-codification-2020-01-31.xsd",
                    "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd"
                    ]
                }
            },
        "elementCount":  649,
        "entityCount":  1,
        "hidden":  {
            "http://fasb.org/us-gaap/2020-01-31":  11,
            "http://www.biolase.com/20210331":  1,
            "http://xbrl.sec.gov/dei/2020-01-31":  4,
            "total":  16
            },
        "keyCustom":  85,
        "keyStandard":  367,
        "memberCustom":  28,
        "memberStandard":  39,
        "nsprefix":  "biol",
        "nsuri":  "http://www.biolase.com/20210331",
        "report":  {
            "R1":  {
                "firstAnchor":  {
                    "ancestors":  [
                        "span",
                        "p",
                        "body",
                        "html"
                        ],
                    "baseRef":  "biol-20210331.htm",
                    "contextRef":  "C_46389777-7e99-4f67-8c76-d557afb20ab7",
                    "decimals":  null,
                    "first":  true,
                    "lang":  "en-US",
                    "name":  "dei:DocumentType",
                    "reportCount":  1,
                    "unique":  true,
                    "unitRef":  null,
                    "xsiNil":  "false"
                    },
                "groupType":  "document",
                "isDefault":  "true",
                "longName":  "100000 - Document - Document and Entity Information",
                "role":  "http://www.biolase.com/20210331/taxonomy/role/Role_DocumentDocumentAndEntityInformation",
                "shortName":  "Document and Entity Information",
                "subGroupType":  "",
                "uniqueAnchor":  {
                    "ancestors":  [
                        "span",
                        "p",
                        "body",
                        "html"
                        ],
                    "baseRef":  "biol-20210331.htm",
                    "contextRef":  "C_46389777-7e99-4f67-8c76-d557afb20ab7",
                    "decimals":  null,
                    "first":  true,
                    "lang":  "en-US",
                    "name":  "dei:DocumentType",
                    "reportCount":  1,
                    "unique":  true,
                    "unitRef":  null,
                    "xsiNil":  "false"
                    }
                },
            "R10":  {
                "firstAnchor":  {
                    "ancestors":  [
                        "div",
                        "body",
                        "html"
                        ],
                    "baseRef":  "biol-20210331.htm",
                    "contextRef":  "C_46389777-7e99-4f67-8c76-d557afb20ab7",
                    "decimals":  null,
                    "first":  true,
                    "lang":  "en-US",
                    "name":  "biol:TemporaryEquityAndStockholdersEquityNoteDisclosureTextBlock",
                    "reportCount":  1,
                    "unique":  true,
                    "unitRef":  null,
                    "xsiNil":  "false"
                    },
                "groupType":  "disclosure",
                "isDefault":  "false",
                "longName":  "100150 - Disclosure - Redeemable Preferred Stock and Stockholders' Equity",
                "role":  "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureRedeemablePreferredStockAndStockholdersEquity",
                "shortName":  "Redeemable Preferred Stock and Stockholders' Equity",
                "subGroupType":  "",
                "uniqueAnchor":  {
                    "ancestors":  [
                        "div",
                        "body",
                        "html"
                        ],
                    "baseRef":  "biol-20210331.htm",
                    "contextRef":  "C_46389777-7e99-4f67-8c76-d557afb20ab7",
                    "decimals":  null,
                    "first":  true,
                    "lang":  "en-US",
                    "name":  "biol:TemporaryEquityAndStockholdersEquityNoteDisclosureTextBlock",
                    "reportCount":  1,
                    "unique":  true,
                    "unitRef":  null,
                    "xsiNil":  "false"
                    }
                },
            "R11":  {
                "firstAnchor":  {
                    "ancestors":  [
                        "div",
                        "body",
                        "html"
                        ],
                    "baseRef":  "biol-20210331.htm",
                    "contextRef":  "C_46389777-7e99-4f67-8c76-d557afb20ab7",
                    "decimals":  null,
                    "first":  true,
                    "lang":  "en-US",
                    "name":  "us-gaap:InventoryDisclosureTextBlock",
                    "reportCount":  1,
                    "unique":  true,
                    "unitRef":  null,
                    "xsiNil":  "false"
                    },
                "groupType":  "disclosure",
                "isDefault":  "false",
                "longName":  "100160 - Disclosure - Inventory",
                "role":  "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureInventory",
                "shortName":  "Inventory",
                "subGroupType":  "",
                "uniqueAnchor":  {
                    "ancestors":  [
                        "div",
                        "body",
                        "html"
                        ],
                    "baseRef":  "biol-20210331.htm",
                    "contextRef":  "C_46389777-7e99-4f67-8c76-d557afb20ab7",
                    "decimals":  null,
                    "first":  true,
                    "lang":  "en-US",
                    "name":  "us-gaap:InventoryDisclosureTextBlock",
                    "reportCount":  1,
                    "unique":  true,
                    "unitRef":  null,
                    "xsiNil":  "false"
                    }
                },
            "R12":  {
                "firstAnchor":  {
                    "ancestors":  [
                        "div",
                        "body",
                        "html"
                        ],
                    "baseRef":  "biol-20210331.htm",
                    "contextRef":  "C_46389777-7e99-4f67-8c76-d557afb20ab7",
                    "decimals":  null,
                    "first":  true,
                    "lang":  "en-US",
                    "name":  "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
                    "reportCount":  1,
                    "unique":  true,
                    "unitRef":  null,
                    "xsiNil":  "false"
                    },
                "groupType":  "disclosure",
                "isDefault":  "false",
                "longName":  "100170 - Disclosure - Property, Plant, and Equipment",
                "role":  "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosurePropertyPlantAndEquipment",
                "shortName":  "Property, Plant, and Equipment",
                "subGroupType":  "",
                "uniqueAnchor":  {
                    "ancestors":  [
                        "div",
                        "body",
                        "html"
                        ],
                    "baseRef":  "biol-20210331.htm",
                    "contextRef":  "C_46389777-7e99-4f67-8c76-d557afb20ab7",
                    "decimals":  null,
                    "first":  true,
                    "lang":  "en-US",
                    "name":  "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
                    "reportCount":  1,
                    "unique":  true,
                    "unitRef":  null,
                    "xsiNil":  "false"
                    }
                },
            "R13":  {
                "firstAnchor":  {
                    "ancestors":  [
                        "div",
                        "body",
                        "html"
                        ],
                    "baseRef":  "biol-20210331.htm",
                    "contextRef":  "C_46389777-7e99-4f67-8c76-d557afb20ab7",
                    "decimals":  null,
                    "first":  true,
                    "lang":  "en-US",
                    "name":  "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
                    "reportCount":  1,
                    "unique":  true,
                    "unitRef":  null,
                    "xsiNil":  "false"
                    },
                "groupType":  "disclosure",
                "isDefault":  "false",
                "longName":  "100180 - Disclosure - Intangible Assets and Goodwill",
                "role":  "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureIntangibleAssetsAndGoodwill",
                "shortName":  "Intangible Assets and Goodwill",
                "subGroupType":  "",
                "uniqueAnchor":  {
                    "ancestors":  [
                        "div",
                        "body",
                        "html"
                        ],
                    "baseRef":  "biol-20210331.htm",
                    "contextRef":  "C_46389777-7e99-4f67-8c76-d557afb20ab7",
                    "decimals":  null,
                    "first":  true,
                    "lang":  "en-US",
                    "name":  "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
                    "reportCount":  1,
                    "unique":  true,
                    "unitRef":  null,
                    "xsiNil":  "false"
                    }
                },
            "R14":  {
                "firstAnchor":  {
                    "ancestors":  [
                        "div",
                        "body",
                        "html"
                        ],
                    "baseRef":  "biol-20210331.htm",
                    "contextRef":  "C_46389777-7e99-4f67-8c76-d557afb20ab7",
                    "decimals":  null,
                    "first":  true,
                    "lang":  "en-US",
                    "name":  "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
                    "reportCount":  1,
                    "unique":  true,
                    "unitRef":  null,
                    "xsiNil":  "false"
                    },
                "groupType":  "disclosure",
                "isDefault":  "false",
                "longName":  "100190 - Disclosure - Accrued Liabilities",
                "role":  "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureAccruedLiabilities",
                "shortName":  "Accrued Liabilities",
                "subGroupType":  "",
                "uniqueAnchor":  {
                    "ancestors":  [
                        "div",
                        "body",
                        "html"
                        ],
                    "baseRef":  "biol-20210331.htm",
                    "contextRef":  "C_46389777-7e99-4f67-8c76-d557afb20ab7",
                    "decimals":  null,
                    "first":  true,
                    "lang":  "en-US",
                    "name":  "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
                    "reportCount":  1,
                    "unique":  true,
                    "unitRef":  null,
                    "xsiNil":  "false"
                    }
                },
            "R15":  {
                "firstAnchor":  {
                    "ancestors":  [
                        "div",
                        "body",
                        "html"
                        ],
                    "baseRef":  "biol-20210331.htm",
                    "contextRef":  "C_46389777-7e99-4f67-8c76-d557afb20ab7",
                    "decimals":  null,
                    "first":  true,
                    "lang":  "en-US",
                    "name":  "us-gaap:DebtDisclosureTextBlock",
                    "reportCount":  1,
                    "unique":  true,
                    "unitRef":  null,
                    "xsiNil":  "false"
                    },
                "groupType":  "disclosure",
                "isDefault":  "false",
                "longName":  "100200 - Disclosure - Debt",
                "role":  "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureDebt",
                "shortName":  "Debt",
                "subGroupType":  "",
                "uniqueAnchor":  {
                    "ancestors":  [
                        "div",
                        "body",
                        "html"
                        ],
                    "baseRef":  "biol-20210331.htm",
                    "contextRef":  "C_46389777-7e99-4f67-8c76-d557afb20ab7",
                    "decimals":  null,
                    "first":  true,
                    "lang":  "en-US",
                    "name":  "us-gaap:DebtDisclosureTextBlock",
                    "reportCount":  1,
                    "unique":  true,
                    "unitRef":  null,
                    "xsiNil":  "false"
                    }
                },
            "R16":  {
                "firstAnchor":  {
                    "ancestors":  [
                        "div",
                        "body",
                        "html"
                        ],
                    "baseRef":  "biol-20210331.htm",
                    "contextRef":  "C_46389777-7e99-4f67-8c76-d557afb20ab7",
                    "decimals":  null,
                    "first":  true,
                    "lang":  "en-US",
                    "name":  "us-gaap:LesseeOperatingLeasesTextBlock",
                    "reportCount":  1,
                    "unique":  true,
                    "unitRef":  null,
                    "xsiNil":  "false"
                    },
                "groupType":  "disclosure",
                "isDefault":  "false",
                "longName":  "100210 - Disclosure - Leases",
                "role":  "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureLeases",
                "shortName":  "Leases",
                "subGroupType":  "",
                "uniqueAnchor":  {
                    "ancestors":  [
                        "div",
                        "body",
                        "html"
                        ],
                    "baseRef":  "biol-20210331.htm",
                    "contextRef":  "C_46389777-7e99-4f67-8c76-d557afb20ab7",
                    "decimals":  null,
                    "first":  true,
                    "lang":  "en-US",
                    "name":  "us-gaap:LesseeOperatingLeasesTextBlock",
                    "reportCount":  1,
                    "unique":  true,
                    "unitRef":  null,
                    "xsiNil":  "false"
                    }
                },
            "R17":  {
                "firstAnchor":  {
                    "ancestors":  [
                        "div",
                        "body",
                        "html"
                        ],
                    "baseRef":  "biol-20210331.htm",
                    "contextRef":  "C_46389777-7e99-4f67-8c76-d557afb20ab7",
                    "decimals":  null,
                    "first":  true,
                    "lang":  "en-US",
                    "name":  "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
                    "reportCount":  1,
                    "unique":  true,
                    "unitRef":  null,
                    "xsiNil":  "false"
                    },
                "groupType":  "disclosure",
                "isDefault":  "false",
                "longName":  "100220 - Disclosure - Commitments and Contingencies",
                "role":  "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureCommitmentsAndContingencies",
                "shortName":  "Commitments and Contingencies",
                "subGroupType":  "",
                "uniqueAnchor":  {
                    "ancestors":  [
                        "div",
                        "body",
                        "html"
                        ],
                    "baseRef":  "biol-20210331.htm",
                    "contextRef":  "C_46389777-7e99-4f67-8c76-d557afb20ab7",
                    "decimals":  null,
                    "first":  true,
                    "lang":  "en-US",
                    "name":  "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
                    "reportCount":  1,
                    "unique":  true,
                    "unitRef":  null,
                    "xsiNil":  "false"
                    }
                },
            "R18":  {
                "firstAnchor":  {
                    "ancestors":  [
                        "div",
                        "body",
                        "html"
                        ],
                    "baseRef":  "biol-20210331.htm",
                    "contextRef":  "C_46389777-7e99-4f67-8c76-d557afb20ab7",
                    "decimals":  null,
                    "first":  true,
                    "lang":  "en-US",
                    "name":  "us-gaap:SegmentReportingDisclosureTextBlock",
                    "reportCount":  1,
                    "unique":  true,
                    "unitRef":  null,
                    "xsiNil":  "false"
                    },
                "groupType":  "disclosure",
                "isDefault":  "false",
                "longName":  "100230 - Disclosure - Segment Information",
                "role":  "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureSegmentInformation",
                "shortName":  "Segment Information",
                "subGroupType":  "",
                "uniqueAnchor":  {
                    "ancestors":  [
                        "div",
                        "body",
                        "html"
                        ],
                    "baseRef":  "biol-20210331.htm",
                    "contextRef":  "C_46389777-7e99-4f67-8c76-d557afb20ab7",
                    "decimals":  null,
                    "first":  true,
                    "lang":  "en-US",
                    "name":  "us-gaap:SegmentReportingDisclosureTextBlock",
                    "reportCount":  1,
                    "unique":  true,
                    "unitRef":  null,
                    "xsiNil":  "false"
                    }
                },
            "R19":  {
                "firstAnchor":  {
                    "ancestors":  [
                        "div",
                        "body",
                        "html"
                        ],
                    "baseRef":  "biol-20210331.htm",
                    "contextRef":  "C_46389777-7e99-4f67-8c76-d557afb20ab7",
                    "decimals":  null,
                    "first":  true,
                    "lang":  "en-US",
                    "name":  "us-gaap:ConcentrationRiskDisclosureTextBlock",
                    "reportCount":  1,
                    "unique":  true,
                    "unitRef":  null,
                    "xsiNil":  "false"
                    },
                "groupType":  "disclosure",
                "isDefault":  "false",
                "longName":  "100240 - Disclosure - Concentrations",
                "role":  "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureConcentrations",
                "shortName":  "Concentrations",
                "subGroupType":  "",
                "uniqueAnchor":  {
                    "ancestors":  [
                        "div",
                        "body",
                        "html"
                        ],
                    "baseRef":  "biol-20210331.htm",
                    "contextRef":  "C_46389777-7e99-4f67-8c76-d557afb20ab7",
                    "decimals":  null,
                    "first":  true,
                    "lang":  "en-US",
                    "name":  "us-gaap:ConcentrationRiskDisclosureTextBlock",
                    "reportCount":  1,
                    "unique":  true,
                    "unitRef":  null,
                    "xsiNil":  "false"
                    }
                },
            "R2":  {
                "firstAnchor":  {
                    "ancestors":  [
                        "span",
                        "p",
                        "td",
                        "tr",
                        "table",
                        "body",
                        "html"
                        ],
                    "baseRef":  "biol-20210331.htm",
                    "contextRef":  "C_9f7ebf99-0e4f-4ef2-9ade-8fa1dcb53908",
                    "decimals":  "-3",
                    "first":  true,
                    "lang":  null,
                    "name":  "us-gaap:CashAndCashEquivalentsAtCarryingValue",
                    "reportCount":  1,
                    "unique":  true,
                    "unitRef":  "U_USD",
                    "xsiNil":  "false"
                    },
                "groupType":  "statement",
                "isDefault":  "false",
                "longName":  "100010 - Statement - Consolidated Balance Sheets (Unaudited)",
                "role":  "http://www.biolase.com/20210331/taxonomy/role/Role_StatementConsolidatedBalanceSheetsUnaudited",
                "shortName":  "Consolidated Balance Sheets (Unaudited)",
                "subGroupType":  "",
                "uniqueAnchor":  {
                    "ancestors":  [
                        "span",
                        "p",
                        "td",
                        "tr",
                        "table",
                        "body",
                        "html"
                        ],
                    "baseRef":  "biol-20210331.htm",
                    "contextRef":  "C_9f7ebf99-0e4f-4ef2-9ade-8fa1dcb53908",
                    "decimals":  "-3",
                    "first":  true,
                    "lang":  null,
                    "name":  "us-gaap:CashAndCashEquivalentsAtCarryingValue",
                    "reportCount":  1,
                    "unique":  true,
                    "unitRef":  "U_USD",
                    "xsiNil":  "false"
                    }
                },
            "R20":  {
                "firstAnchor":  {
                    "ancestors":  [
                        "div",
                        "body",
                        "html"
                        ],
                    "baseRef":  "biol-20210331.htm",
                    "contextRef":  "C_46389777-7e99-4f67-8c76-d557afb20ab7",
                    "decimals":  null,
                    "first":  true,
                    "lang":  "en-US",
                    "name":  "us-gaap:IncomeTaxDisclosureTextBlock",
                    "reportCount":  1,
                    "unique":  true,
                    "unitRef":  null,
                    "xsiNil":  "false"
                    },
                "groupType":  "disclosure",
                "isDefault":  "false",
                "longName":  "100250 - Disclosure - Income Taxes",
                "role":  "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureIncomeTaxes",
                "shortName":  "Income Taxes",
                "subGroupType":  "",
                "uniqueAnchor":  {
                    "ancestors":  [
                        "div",
                        "body",
                        "html"
                        ],
                    "baseRef":  "biol-20210331.htm",
                    "contextRef":  "C_46389777-7e99-4f67-8c76-d557afb20ab7",
                    "decimals":  null,
                    "first":  true,
                    "lang":  "en-US",
                    "name":  "us-gaap:IncomeTaxDisclosureTextBlock",
                    "reportCount":  1,
                    "unique":  true,
                    "unitRef":  null,
                    "xsiNil":  "false"
                    }
                },
            "R21":  {
                "firstAnchor":  {
                    "ancestors":  [
                        "div",
                        "body",
                        "html"
                        ],
                    "baseRef":  "biol-20210331.htm",
                    "contextRef":  "C_46389777-7e99-4f67-8c76-d557afb20ab7",
                    "decimals":  null,
                    "first":  true,
                    "lang":  "en-US",
                    "name":  "us-gaap:SubsequentEventsTextBlock",
                    "reportCount":  1,
                    "unique":  true,
                    "unitRef":  null,
                    "xsiNil":  "false"
                    },
                "groupType":  "disclosure",
                "isDefault":  "false",
                "longName":  "100260 - Disclosure - Subsequent Events",
                "role":  "http://www.biolase.com/20210331/taxonomy/role/DisclosureSubsequentEvents",
                "shortName":  "Subsequent Events",
                "subGroupType":  "",
                "uniqueAnchor":  {
                    "ancestors":  [
                        "div",
                        "body",
                        "html"
                        ],
                    "baseRef":  "biol-20210331.htm",
                    "contextRef":  "C_46389777-7e99-4f67-8c76-d557afb20ab7",
                    "decimals":  null,
                    "first":  true,
                    "lang":  "en-US",
                    "name":  "us-gaap:SubsequentEventsTextBlock",
                    "reportCount":  1,
                    "unique":  true,
                    "unitRef":  null,
                    "xsiNil":  "false"
                    }
                },
            "R22":  {
                "firstAnchor":  {
                    "ancestors":  [
                        "div",
                        "us-gaap:SignificantAccountingPoliciesTextBlock",
                        "div",
                        "body",
                        "html"
                        ],
                    "baseRef":  "biol-20210331.htm",
                    "contextRef":  "C_46389777-7e99-4f67-8c76-d557afb20ab7",
                    "decimals":  null,
                    "first":  true,
                    "lang":  "en-US",
                    "name":  "us-gaap:UseOfEstimates",
                    "reportCount":  1,
                    "unique":  true,
                    "unitRef":  null,
                    "xsiNil":  "false"
                    },
                "groupType":  "disclosure",
                "isDefault":  "false",
                "longName":  "100270 - Disclosure - Summary of Significant Accounting Policies (Policies)",
                "role":  "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies",
                "shortName":  "Summary of Significant Accounting Policies (Policies)",
                "subGroupType":  "policies",
                "uniqueAnchor":  {
                    "ancestors":  [
                        "div",
                        "us-gaap:SignificantAccountingPoliciesTextBlock",
                        "div",
                        "body",
                        "html"
                        ],
                    "baseRef":  "biol-20210331.htm",
                    "contextRef":  "C_46389777-7e99-4f67-8c76-d557afb20ab7",
                    "decimals":  null,
                    "first":  true,
                    "lang":  "en-US",
                    "name":  "us-gaap:UseOfEstimates",
                    "reportCount":  1,
                    "unique":  true,
                    "unitRef":  null,
                    "xsiNil":  "false"
                    }
                },
            "R23":  {
                "firstAnchor":  {
                    "ancestors":  [
                        "div",
                        "ix:continuation",
                        "div",
                        "us-gaap:RevenueFromContractWithCustomerTextBlock",
                        "div",
                        "body",
                        "html"
                        ],
                    "baseRef":  "biol-20210331.htm",
                    "contextRef":  "C_46389777-7e99-4f67-8c76-d557afb20ab7",
                    "decimals":  null,
                    "first":  true,
                    "lang":  "en-US",
                    "name":  "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock",
                    "reportCount":  1,
                    "unique":  true,
                    "unitRef":  null,
                    "xsiNil":  "false"
                    },
                "groupType":  "disclosure",
                "isDefault":  "false",
                "longName":  "100280 - Disclosure - Revenue Recognition (Tables)",
                "role":  "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureRevenueRecognitionTables",
                "shortName":  "Revenue Recognition (Tables)",
                "subGroupType":  "tables",
                "uniqueAnchor":  {
                    "ancestors":  [
                        "div",
                        "ix:continuation",
                        "div",
                        "us-gaap:RevenueFromContractWithCustomerTextBlock",
                        "div",
                        "body",
                        "html"
                        ],
                    "baseRef":  "biol-20210331.htm",
                    "contextRef":  "C_46389777-7e99-4f67-8c76-d557afb20ab7",
                    "decimals":  null,
                    "first":  true,
                    "lang":  "en-US",
                    "name":  "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock",
                    "reportCount":  1,
                    "unique":  true,
                    "unitRef":  null,
                    "xsiNil":  "false"
                    }
                },
            "R24":  {
                "firstAnchor":  {
                    "ancestors":  [
                        "div",
                        "biol:TemporaryEquityAndStockholdersEquityNoteDisclosureTextBlock",
                        "div",
                        "body",
                        "html"
                        ],
                    "baseRef":  "biol-20210331.htm",
                    "contextRef":  "C_46389777-7e99-4f67-8c76-d557afb20ab7",
                    "decimals":  null,
                    "first":  true,
                    "lang":  "en-US",
                    "name":  "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
                    "reportCount":  1,
                    "unique":  true,
                    "unitRef":  null,
                    "xsiNil":  "false"
                    },
                "groupType":  "disclosure",
                "isDefault":  "false",
                "longName":  "100290 - Disclosure - Redeemable Preferred Stock and Stockholders' Equity (Tables)",
                "role":  "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureRedeemablePreferredStockAndStockholdersEquityTables",
                "shortName":  "Redeemable Preferred Stock and Stockholders' Equity (Tables)",
                "subGroupType":  "tables",
                "uniqueAnchor":  {
                    "ancestors":  [
                        "div",
                        "biol:TemporaryEquityAndStockholdersEquityNoteDisclosureTextBlock",
                        "div",
                        "body",
                        "html"
                        ],
                    "baseRef":  "biol-20210331.htm",
                    "contextRef":  "C_46389777-7e99-4f67-8c76-d557afb20ab7",
                    "decimals":  null,
                    "first":  true,
                    "lang":  "en-US",
                    "name":  "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
                    "reportCount":  1,
                    "unique":  true,
                    "unitRef":  null,
                    "xsiNil":  "false"
                    }
                },
            "R25":  {
                "firstAnchor":  {
                    "ancestors":  [
                        "div",
                        "us-gaap:InventoryDisclosureTextBlock",
                        "div",
                        "body",
                        "html"
                        ],
                    "baseRef":  "biol-20210331.htm",
                    "contextRef":  "C_46389777-7e99-4f67-8c76-d557afb20ab7",
                    "decimals":  null,
                    "first":  true,
                    "lang":  "en-US",
                    "name":  "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
                    "reportCount":  1,
                    "unique":  true,
                    "unitRef":  null,
                    "xsiNil":  "false"
                    },
                "groupType":  "disclosure",
                "isDefault":  "false",
                "longName":  "100300 - Disclosure - Inventory (Tables)",
                "role":  "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureInventoryTables",
                "shortName":  "Inventory (Tables)",
                "subGroupType":  "tables",
                "uniqueAnchor":  {
                    "ancestors":  [
                        "div",
                        "us-gaap:InventoryDisclosureTextBlock",
                        "div",
                        "body",
                        "html"
                        ],
                    "baseRef":  "biol-20210331.htm",
                    "contextRef":  "C_46389777-7e99-4f67-8c76-d557afb20ab7",
                    "decimals":  null,
                    "first":  true,
                    "lang":  "en-US",
                    "name":  "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
                    "reportCount":  1,
                    "unique":  true,
                    "unitRef":  null,
                    "xsiNil":  "false"
                    }
                },
            "R26":  {
                "firstAnchor":  {
                    "ancestors":  [
                        "div",
                        "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
                        "div",
                        "body",
                        "html"
                        ],
                    "baseRef":  "biol-20210331.htm",
                    "contextRef":  "C_46389777-7e99-4f67-8c76-d557afb20ab7",
                    "decimals":  null,
                    "first":  true,
                    "lang":  "en-US",
                    "name":  "us-gaap:PropertyPlantAndEquipmentTextBlock",
                    "reportCount":  1,
                    "unique":  true,
                    "unitRef":  null,
                    "xsiNil":  "false"
                    },
                "groupType":  "disclosure",
                "isDefault":  "false",
                "longName":  "100310 - Disclosure - Property, Plant, and Equipment (Tables)",
                "role":  "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosurePropertyPlantAndEquipmentTables",
                "shortName":  "Property, Plant, and Equipment (Tables)",
                "subGroupType":  "tables",
                "uniqueAnchor":  {
                    "ancestors":  [
                        "div",
                        "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
                        "div",
                        "body",
                        "html"
                        ],
                    "baseRef":  "biol-20210331.htm",
                    "contextRef":  "C_46389777-7e99-4f67-8c76-d557afb20ab7",
                    "decimals":  null,
                    "first":  true,
                    "lang":  "en-US",
                    "name":  "us-gaap:PropertyPlantAndEquipmentTextBlock",
                    "reportCount":  1,
                    "unique":  true,
                    "unitRef":  null,
                    "xsiNil":  "false"
                    }
                },
            "R27":  {
                "firstAnchor":  {
                    "ancestors":  [
                        "div",
                        "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
                        "div",
                        "body",
                        "html"
                        ],
                    "baseRef":  "biol-20210331.htm",
                    "contextRef":  "C_46389777-7e99-4f67-8c76-d557afb20ab7",
                    "decimals":  null,
                    "first":  true,
                    "lang":  "en-US",
                    "name":  "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
                    "reportCount":  1,
                    "unique":  true,
                    "unitRef":  null,
                    "xsiNil":  "false"
                    },
                "groupType":  "disclosure",
                "isDefault":  "false",
                "longName":  "100320 - Disclosure - Accrued Liabilities (Tables)",
                "role":  "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureAccruedLiabilitiesTables",
                "shortName":  "Accrued Liabilities (Tables)",
                "subGroupType":  "tables",
                "uniqueAnchor":  {
                    "ancestors":  [
                        "div",
                        "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
                        "div",
                        "body",
                        "html"
                        ],
                    "baseRef":  "biol-20210331.htm",
                    "contextRef":  "C_46389777-7e99-4f67-8c76-d557afb20ab7",
                    "decimals":  null,
                    "first":  true,
                    "lang":  "en-US",
                    "name":  "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
                    "reportCount":  1,
                    "unique":  true,
                    "unitRef":  null,
                    "xsiNil":  "false"
                    }
                },
            "R28":  {
                "firstAnchor":  {
                    "ancestors":  [
                        "div",
                        "us-gaap:DebtDisclosureTextBlock",
                        "div",
                        "body",
                        "html"
                        ],
                    "baseRef":  "biol-20210331.htm",
                    "contextRef":  "C_46389777-7e99-4f67-8c76-d557afb20ab7",
                    "decimals":  null,
                    "first":  true,
                    "lang":  "en-US",
                    "name":  "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
                    "reportCount":  1,
                    "unique":  true,
                    "unitRef":  null,
                    "xsiNil":  "false"
                    },
                "groupType":  "disclosure",
                "isDefault":  "false",
                "longName":  "100330 - Disclosure - Debt (Tables)",
                "role":  "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureDebtTables",
                "shortName":  "Debt (Tables)",
                "subGroupType":  "tables",
                "uniqueAnchor":  {
                    "ancestors":  [
                        "div",
                        "us-gaap:DebtDisclosureTextBlock",
                        "div",
                        "body",
                        "html"
                        ],
                    "baseRef":  "biol-20210331.htm",
                    "contextRef":  "C_46389777-7e99-4f67-8c76-d557afb20ab7",
                    "decimals":  null,
                    "first":  true,
                    "lang":  "en-US",
                    "name":  "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
                    "reportCount":  1,
                    "unique":  true,
                    "unitRef":  null,
                    "xsiNil":  "false"
                    }
                },
            "R29":  {
                "firstAnchor":  {
                    "ancestors":  [
                        "div",
                        "us-gaap:LesseeOperatingLeasesTextBlock",
                        "div",
                        "body",
                        "html"
                        ],
                    "baseRef":  "biol-20210331.htm",
                    "contextRef":  "C_46389777-7e99-4f67-8c76-d557afb20ab7",
                    "decimals":  null,
                    "first":  true,
                    "lang":  "en-US",
                    "name":  "biol:InformationRelatedToOperatingRightOfUseAssetsAndRelatedLiabilitiesTableTextBlock",
                    "reportCount":  1,
                    "unique":  true,
                    "unitRef":  null,
                    "xsiNil":  "false"
                    },
                "groupType":  "disclosure",
                "isDefault":  "false",
                "longName":  "100340 - Disclosure - Leases (Tables)",
                "role":  "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureLeasesTables",
                "shortName":  "Leases (Tables)",
                "subGroupType":  "tables",
                "uniqueAnchor":  {
                    "ancestors":  [
                        "div",
                        "us-gaap:LesseeOperatingLeasesTextBlock",
                        "div",
                        "body",
                        "html"
                        ],
                    "baseRef":  "biol-20210331.htm",
                    "contextRef":  "C_46389777-7e99-4f67-8c76-d557afb20ab7",
                    "decimals":  null,
                    "first":  true,
                    "lang":  "en-US",
                    "name":  "biol:InformationRelatedToOperatingRightOfUseAssetsAndRelatedLiabilitiesTableTextBlock",
                    "reportCount":  1,
                    "unique":  true,
                    "unitRef":  null,
                    "xsiNil":  "false"
                    }
                },
            "R3":  {
                "firstAnchor":  {
                    "ancestors":  [
                        "span",
                        "p",
                        "td",
                        "tr",
                        "table",
                        "body",
                        "html"
                        ],
                    "baseRef":  "biol-20210331.htm",
                    "contextRef":  "C_9f7ebf99-0e4f-4ef2-9ade-8fa1dcb53908",
                    "decimals":  "-3",
                    "first":  true,
                    "lang":  null,
                    "name":  "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent",
                    "reportCount":  1,
                    "unique":  true,
                    "unitRef":  "U_USD",
                    "xsiNil":  "false"
                    },
                "groupType":  "statement",
                "isDefault":  "false",
                "longName":  "100060 - Statement - Consolidated Balance Sheets (Unaudited) (Parenthetical)",
                "role":  "http://www.biolase.com/20210331/taxonomy/role/Role_StatementConsolidatedBalanceSheetsUnauditedParenthetical",
                "shortName":  "Consolidated Balance Sheets (Unaudited) (Parenthetical)",
                "subGroupType":  "parenthetical",
                "uniqueAnchor":  {
                    "ancestors":  [
                        "span",
                        "p",
                        "td",
                        "tr",
                        "table",
                        "body",
                        "html"
                        ],
                    "baseRef":  "biol-20210331.htm",
                    "contextRef":  "C_9f7ebf99-0e4f-4ef2-9ade-8fa1dcb53908",
                    "decimals":  "-3",
                    "first":  true,
                    "lang":  null,
                    "name":  "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent",
                    "reportCount":  1,
                    "unique":  true,
                    "unitRef":  "U_USD",
                    "xsiNil":  "false"
                    }
                },
            "R30":  {
                "firstAnchor":  {
                    "ancestors":  [
                        "div",
                        "us-gaap:SegmentReportingDisclosureTextBlock",
                        "div",
                        "body",
                        "html"
                        ],
                    "baseRef":  "biol-20210331.htm",
                    "contextRef":  "C_46389777-7e99-4f67-8c76-d557afb20ab7",
                    "decimals":  null,
                    "first":  true,
                    "lang":  "en-US",
                    "name":  "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock",
                    "reportCount":  1,
                    "unique":  true,
                    "unitRef":  null,
                    "xsiNil":  "false"
                    },
                "groupType":  "disclosure",
                "isDefault":  "false",
                "longName":  "100350 - Disclosure - Segment Information (Tables)",
                "role":  "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureSegmentInformationTables",
                "shortName":  "Segment Information (Tables)",
                "subGroupType":  "tables",
                "uniqueAnchor":  {
                    "ancestors":  [
                        "div",
                        "us-gaap:SegmentReportingDisclosureTextBlock",
                        "div",
                        "body",
                        "html"
                        ],
                    "baseRef":  "biol-20210331.htm",
                    "contextRef":  "C_46389777-7e99-4f67-8c76-d557afb20ab7",
                    "decimals":  null,
                    "first":  true,
                    "lang":  "en-US",
                    "name":  "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock",
                    "reportCount":  1,
                    "unique":  true,
                    "unitRef":  null,
                    "xsiNil":  "false"
                    }
                },
            "R31":  {
                "firstAnchor":  {
                    "ancestors":  [
                        "div",
                        "us-gaap:ConcentrationRiskDisclosureTextBlock",
                        "div",
                        "body",
                        "html"
                        ],
                    "baseRef":  "biol-20210331.htm",
                    "contextRef":  "C_46389777-7e99-4f67-8c76-d557afb20ab7",
                    "decimals":  null,
                    "first":  true,
                    "lang":  "en-US",
                    "name":  "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
                    "reportCount":  1,
                    "unique":  true,
                    "unitRef":  null,
                    "xsiNil":  "false"
                    },
                "groupType":  "disclosure",
                "isDefault":  "false",
                "longName":  "100360 - Disclosure - Concentrations (Tables)",
                "role":  "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureConcentrationsTables",
                "shortName":  "Concentrations (Tables)",
                "subGroupType":  "tables",
                "uniqueAnchor":  {
                    "ancestors":  [
                        "div",
                        "us-gaap:ConcentrationRiskDisclosureTextBlock",
                        "div",
                        "body",
                        "html"
                        ],
                    "baseRef":  "biol-20210331.htm",
                    "contextRef":  "C_46389777-7e99-4f67-8c76-d557afb20ab7",
                    "decimals":  null,
                    "first":  true,
                    "lang":  "en-US",
                    "name":  "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
                    "reportCount":  1,
                    "unique":  true,
                    "unitRef":  null,
                    "xsiNil":  "false"
                    }
                },
            "R32":  {
                "firstAnchor":  {
                    "ancestors":  [
                        "us-gaap:PreferredStockSharesOutstanding",
                        "span",
                        "p",
                        "td",
                        "tr",
                        "table",
                        "body",
                        "html"
                        ],
                    "baseRef":  "biol-20210331.htm",
                    "contextRef":  "C_9f7ebf99-0e4f-4ef2-9ade-8fa1dcb53908",
                    "decimals":  "INF",
                    "first":  true,
                    "lang":  null,
                    "name":  "us-gaap:PreferredStockSharesIssued",
                    "reportCount":  1,
                    "unitRef":  "U_shares",
                    "xsiNil":  "false"
                    },
                "groupType":  "disclosure",
                "isDefault":  "false",
                "longName":  "100370 - Disclosure - Description of Business and Basis of Presentation - Additional Information (Detail)",
                "role":  "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureDescriptionOfBusinessAndBasisOfPresentationAdditionalInformationDetail",
                "shortName":  "Description of Business and Basis of Presentation - Additional Information (Detail)",
                "subGroupType":  "details",
                "uniqueAnchor":  {
                    "ancestors":  [
                        "span",
                        "p",
                        "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
                        "div",
                        "body",
                        "html"
                        ],
                    "baseRef":  "biol-20210331.htm",
                    "contextRef":  "C_5aa33e1c-1c13-4dc2-86f2-cff634c14e59",
                    "decimals":  "-5",
                    "lang":  null,
                    "name":  "us-gaap:ProceedsFromIssuanceOfCommonStock",
                    "reportCount":  1,
                    "unique":  true,
                    "unitRef":  "U_USD",
                    "xsiNil":  "false"
                    }
                },
            "R33":  {
                "firstAnchor":  {
                    "ancestors":  [
                        "span",
                        "p",
                        "ix:continuation",
                        "div",
                        "us-gaap:RevenueFromContractWithCustomerTextBlock",
                        "div",
                        "body",
                        "html"
                        ],
                    "baseRef":  "biol-20210331.htm",
                    "contextRef":  "C_46389777-7e99-4f67-8c76-d557afb20ab7",
                    "decimals":  "-5",
                    "first":  true,
                    "lang":  null,
                    "name":  "biol:ContractWithCustomerLiabilityRevenueRecognizedUndeliveredElements",
                    "reportCount":  1,
                    "unique":  true,
                    "unitRef":  "U_USD",
                    "xsiNil":  "false"
                    },
                "groupType":  "disclosure",
                "isDefault":  "false",
                "longName":  "100380 - Disclosure - Revenue Recognition - Additional Information (Detail)",
                "role":  "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureRevenueRecognitionAdditionalInformationDetail",
                "shortName":  "Revenue Recognition - Additional Information (Detail)",
                "subGroupType":  "details",
                "uniqueAnchor":  {
                    "ancestors":  [
                        "span",
                        "p",
                        "ix:continuation",
                        "div",
                        "us-gaap:RevenueFromContractWithCustomerTextBlock",
                        "div",
                        "body",
                        "html"
                        ],
                    "baseRef":  "biol-20210331.htm",
                    "contextRef":  "C_46389777-7e99-4f67-8c76-d557afb20ab7",
                    "decimals":  "-5",
                    "first":  true,
                    "lang":  null,
                    "name":  "biol:ContractWithCustomerLiabilityRevenueRecognizedUndeliveredElements",
                    "reportCount":  1,
                    "unique":  true,
                    "unitRef":  "U_USD",
                    "xsiNil":  "false"
                    }
                },
            "R34":  {
                "firstAnchor":  {
                    "ancestors":  [
                        "span",
                        "p",
                        "td",
                        "tr",
                        "table",
                        "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock",
                        "div",
                        "ix:continuation",
                        "div",
                        "us-gaap:RevenueFromContractWithCustomerTextBlock",
                        "div",
                        "body",
                        "html"
                        ],
                    "baseRef":  "biol-20210331.htm",
                    "contextRef":  "C_9f7ebf99-0e4f-4ef2-9ade-8fa1dcb53908",
                    "decimals":  "-3",
                    "first":  true,
                    "lang":  null,
                    "name":  "biol:ContractWithCustomerLiabilityInUndeliveredElements",
                    "reportCount":  1,
                    "unitRef":  "U_USD",
                    "xsiNil":  "false"
                    },
                "groupType":  "disclosure",
                "isDefault":  "false",
                "longName":  "100390 - Disclosure - Summary of Opening and Closing Balances of Contract Liabilities (Detail)",
                "role":  "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureSummaryOfOpeningAndClosingBalancesOfContractLiabilitiesDetail",
                "shortName":  "Summary of Opening and Closing Balances of Contract Liabilities (Detail)",
                "subGroupType":  "details",
                "uniqueAnchor":  {
                    "ancestors":  [
                        "span",
                        "p",
                        "td",
                        "tr",
                        "table",
                        "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock",
                        "div",
                        "ix:continuation",
                        "div",
                        "us-gaap:RevenueFromContractWithCustomerTextBlock",
                        "div",
                        "body",
                        "html"
                        ],
                    "baseRef":  "biol-20210331.htm",
                    "contextRef":  "C_9f7ebf99-0e4f-4ef2-9ade-8fa1dcb53908",
                    "decimals":  "-3",
                    "lang":  null,
                    "name":  "biol:ContractWithCustomerLiabilityInExtendedWarrantyContracts",
                    "reportCount":  1,
                    "unique":  true,
                    "unitRef":  "U_USD",
                    "xsiNil":  "false"
                    }
                },
            "R35":  {
                "firstAnchor":  {
                    "ancestors":  [
                        "span",
                        "p",
                        "td",
                        "tr",
                        "table",
                        "body",
                        "html"
                        ],
                    "baseRef":  "biol-20210331.htm",
                    "contextRef":  "C_46389777-7e99-4f67-8c76-d557afb20ab7",
                    "decimals":  "-3",
                    "first":  true,
                    "lang":  null,
                    "name":  "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
                    "reportCount":  1,
                    "unitRef":  "U_USD",
                    "xsiNil":  "false"
                    },
                "groupType":  "disclosure",
                "isDefault":  "false",
                "longName":  "100400 - Disclosure - Summary of Disaggregation of Revenues Related to Geographic Areas (Detail)",
                "role":  "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureSummaryOfDisaggregationOfRevenuesRelatedToGeographicAreasDetail",
                "shortName":  "Summary of Disaggregation of Revenues Related to Geographic Areas (Detail)",
                "subGroupType":  "details",
                "uniqueAnchor":  null
                },
            "R36":  {
                "firstAnchor":  {
                    "ancestors":  [
                        "span",
                        "p",
                        "td",
                        "tr",
                        "table",
                        "body",
                        "html"
                        ],
                    "baseRef":  "biol-20210331.htm",
                    "contextRef":  "C_46389777-7e99-4f67-8c76-d557afb20ab7",
                    "decimals":  "-3",
                    "first":  true,
                    "lang":  null,
                    "name":  "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
                    "reportCount":  1,
                    "unitRef":  "U_USD",
                    "xsiNil":  "false"
                    },
                "groupType":  "disclosure",
                "isDefault":  "false",
                "longName":  "100410 - Disclosure - Summary of Revenues Disaggregated by Timing of Goods and Services Transferred (Detail)",
                "role":  "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureSummaryOfRevenuesDisaggregatedByTimingOfGoodsAndServicesTransferredDetail",
                "shortName":  "Summary of Revenues Disaggregated by Timing of Goods and Services Transferred (Detail)",
                "subGroupType":  "details",
                "uniqueAnchor":  {
                    "ancestors":  [
                        "span",
                        "p",
                        "td",
                        "tr",
                        "table",
                        "biol:SummaryOfRevenuesDisaggregatedByTimingOfGoodsAndServicesTransferredTableTextBlock",
                        "div",
                        "ix:continuation",
                        "div",
                        "us-gaap:RevenueFromContractWithCustomerTextBlock",
                        "div",
                        "body",
                        "html"
                        ],
                    "baseRef":  "biol-20210331.htm",
                    "contextRef":  "C_9154dfaa-09e2-4871-b7ac-18947e2b0903",
                    "decimals":  "-3",
                    "lang":  null,
                    "name":  "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
                    "reportCount":  1,
                    "unique":  true,
                    "unitRef":  "U_USD",
                    "xsiNil":  "false"
                    }
                },
            "R37":  {
                "firstAnchor":  {
                    "ancestors":  [
                        "span",
                        "p",
                        "td",
                        "tr",
                        "table",
                        "body",
                        "html"
                        ],
                    "baseRef":  "biol-20210331.htm",
                    "contextRef":  "C_46389777-7e99-4f67-8c76-d557afb20ab7",
                    "decimals":  "-3",
                    "first":  true,
                    "lang":  null,
                    "name":  "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
                    "reportCount":  1,
                    "unitRef":  "U_USD",
                    "xsiNil":  "false"
                    },
                "groupType":  "disclosure",
                "isDefault":  "false",
                "longName":  "100420 - Disclosure - Summary of Sales by End Market (Detail)",
                "role":  "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureSummaryOfSalesByEndMarketDetail",
                "shortName":  "Summary of Sales by End Market (Detail)",
                "subGroupType":  "details",
                "uniqueAnchor":  {
                    "ancestors":  [
                        "span",
                        "p",
                        "td",
                        "tr",
                        "table",
                        "biol:SummaryOfSalesByEndMarketTableTextBlock",
                        "div",
                        "ix:continuation",
                        "div",
                        "us-gaap:RevenueFromContractWithCustomerTextBlock",
                        "div",
                        "body",
                        "html"
                        ],
                    "baseRef":  "biol-20210331.htm",
                    "contextRef":  "C_7f12ad07-c45d-4f92-823f-5fa4c425bd55",
                    "decimals":  "-3",
                    "lang":  null,
                    "name":  "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
                    "reportCount":  1,
                    "unique":  true,
                    "unitRef":  "U_USD",
                    "xsiNil":  "false"
                    }
                },
            "R38":  {
                "firstAnchor":  {
                    "ancestors":  [
                        "span",
                        "p",
                        "td",
                        "tr",
                        "table",
                        "body",
                        "html"
                        ],
                    "baseRef":  "biol-20210331.htm",
                    "contextRef":  "C_9f7ebf99-0e4f-4ef2-9ade-8fa1dcb53908",
                    "decimals":  "INF",
                    "first":  true,
                    "lang":  null,
                    "name":  "us-gaap:TemporaryEquitySharesAuthorized",
                    "reportCount":  1,
                    "unitRef":  "U_shares",
                    "xsiNil":  "false"
                    },
                "groupType":  "disclosure",
                "isDefault":  "false",
                "longName":  "100430 - Disclosure - Redeemable Preferred Stock and Stockholders' Equity - Additional Information (Detail)",
                "role":  "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureRedeemablePreferredStockAndStockholdersEquityAdditionalInformationDetail",
                "shortName":  "Redeemable Preferred Stock and Stockholders' Equity - Additional Information (Detail)",
                "subGroupType":  "details",
                "uniqueAnchor":  {
                    "ancestors":  [
                        "span",
                        "p",
                        "biol:TemporaryEquityAndStockholdersEquityNoteDisclosureTextBlock",
                        "div",
                        "body",
                        "html"
                        ],
                    "baseRef":  "biol-20210331.htm",
                    "contextRef":  "C_46389777-7e99-4f67-8c76-d557afb20ab7",
                    "decimals":  "-5",
                    "lang":  null,
                    "name":  "biol:ProceedsFromWarrantExercise",
                    "reportCount":  1,
                    "unique":  true,
                    "unitRef":  "U_USD",
                    "xsiNil":  "false"
                    }
                },
            "R39":  {
                "firstAnchor":  {
                    "ancestors":  [
                        "span",
                        "p",
                        "td",
                        "tr",
                        "table",
                        "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
                        "div",
                        "biol:TemporaryEquityAndStockholdersEquityNoteDisclosureTextBlock",
                        "div",
                        "body",
                        "html"
                        ],
                    "baseRef":  "biol-20210331.htm",
                    "contextRef":  "C_46389777-7e99-4f67-8c76-d557afb20ab7",
                    "decimals":  "-3",
                    "first":  true,
                    "lang":  null,
                    "name":  "us-gaap:AllocatedShareBasedCompensationExpense",
                    "reportCount":  1,
                    "unique":  true,
                    "unitRef":  "U_USD",
                    "xsiNil":  "false"
                    },
                "groupType":  "disclosure",
                "isDefault":  "false",
                "longName":  "100440 - Disclosure - Classification of Compensation Expense Associated with Share-Based Payments (Detail)",
                "role":  "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureClassificationOfCompensationExpenseAssociatedWithShareBasedPaymentsDetail",
                "shortName":  "Classification of Compensation Expense Associated with Share-Based Payments (Detail)",
                "subGroupType":  "details",
                "uniqueAnchor":  {
                    "ancestors":  [
                        "span",
                        "p",
                        "td",
                        "tr",
                        "table",
                        "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
                        "div",
                        "biol:TemporaryEquityAndStockholdersEquityNoteDisclosureTextBlock",
                        "div",
                        "body",
                        "html"
                        ],
                    "baseRef":  "biol-20210331.htm",
                    "contextRef":  "C_46389777-7e99-4f67-8c76-d557afb20ab7",
                    "decimals":  "-3",
                    "first":  true,
                    "lang":  null,
                    "name":  "us-gaap:AllocatedShareBasedCompensationExpense",
                    "reportCount":  1,
                    "unique":  true,
                    "unitRef":  "U_USD",
                    "xsiNil":  "false"
                    }
                },
            "R4":  {
                "firstAnchor":  {
                    "ancestors":  [
                        "span",
                        "p",
                        "td",
                        "tr",
                        "table",
                        "body",
                        "html"
                        ],
                    "baseRef":  "biol-20210331.htm",
                    "contextRef":  "C_46389777-7e99-4f67-8c76-d557afb20ab7",
                    "decimals":  "-3",
                    "first":  true,
                    "lang":  null,
                    "name":  "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
                    "reportCount":  1,
                    "unitRef":  "U_USD",
                    "xsiNil":  "false"
                    },
                "groupType":  "statement",
                "isDefault":  "false",
                "longName":  "100080 - Statement - Consolidated Statements Of Operations And Comprehensive Loss (Unaudited)",
                "role":  "http://www.biolase.com/20210331/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited",
                "shortName":  "Consolidated Statements Of Operations And Comprehensive Loss (Unaudited)",
                "subGroupType":  "",
                "uniqueAnchor":  {
                    "ancestors":  [
                        "span",
                        "p",
                        "td",
                        "tr",
                        "table",
                        "body",
                        "html"
                        ],
                    "baseRef":  "biol-20210331.htm",
                    "contextRef":  "C_46389777-7e99-4f67-8c76-d557afb20ab7",
                    "decimals":  "-3",
                    "lang":  null,
                    "name":  "us-gaap:CostOfRevenue",
                    "reportCount":  1,
                    "unique":  true,
                    "unitRef":  "U_USD",
                    "xsiNil":  "false"
                    }
                },
            "R40":  {
                "firstAnchor":  {
                    "ancestors":  [
                        "span",
                        "p",
                        "td",
                        "tr",
                        "table",
                        "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
                        "div",
                        "biol:TemporaryEquityAndStockholdersEquityNoteDisclosureTextBlock",
                        "div",
                        "body",
                        "html"
                        ],
                    "baseRef":  "biol-20210331.htm",
                    "contextRef":  "C_46389777-7e99-4f67-8c76-d557afb20ab7",
                    "decimals":  null,
                    "first":  true,
                    "lang":  "en-US",
                    "name":  "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
                    "reportCount":  1,
                    "unitRef":  null,
                    "xsiNil":  "false"
                    },
                "groupType":  "disclosure",
                "isDefault":  "false",
                "longName":  "100450 - Disclosure - Assumptions Used in Estimating Fair Value of Stock Options Granted (Detail)",
                "role":  "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureAssumptionsUsedInEstimatingFairValueOfStockOptionsGrantedDetail",
                "shortName":  "Assumptions Used in Estimating Fair Value of Stock Options Granted (Detail)",
                "subGroupType":  "details",
                "uniqueAnchor":  null
                },
            "R41":  {
                "firstAnchor":  {
                    "ancestors":  [
                        "span",
                        "p",
                        "td",
                        "tr",
                        "table",
                        "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
                        "div",
                        "biol:TemporaryEquityAndStockholdersEquityNoteDisclosureTextBlock",
                        "div",
                        "body",
                        "html"
                        ],
                    "baseRef":  "biol-20210331.htm",
                    "contextRef":  "C_0d14d282-ab11-49f1-8904-3aa28cfd1600",
                    "decimals":  "-3",
                    "first":  true,
                    "lang":  null,
                    "name":  "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
                    "reportCount":  1,
                    "unitRef":  "U_shares",
                    "xsiNil":  "false"
                    },
                "groupType":  "disclosure",
                "isDefault":  "false",
                "longName":  "100460 - Disclosure - Summary of Option Activity (Detail)",
                "role":  "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureSummaryOfOptionActivityDetail",
                "shortName":  "Summary of Option Activity (Detail)",
                "subGroupType":  "details",
                "uniqueAnchor":  {
                    "ancestors":  [
                        "span",
                        "p",
                        "td",
                        "tr",
                        "table",
                        "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
                        "div",
                        "biol:TemporaryEquityAndStockholdersEquityNoteDisclosureTextBlock",
                        "div",
                        "body",
                        "html"
                        ],
                    "baseRef":  "biol-20210331.htm",
                    "contextRef":  "C_46389777-7e99-4f67-8c76-d557afb20ab7",
                    "decimals":  "-3",
                    "lang":  null,
                    "name":  "biol:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAtFairMarketValue",
                    "reportCount":  1,
                    "unique":  true,
                    "unitRef":  "U_shares",
                    "xsiNil":  "false"
                    }
                },
            "R42":  {
                "firstAnchor":  {
                    "ancestors":  [
                        "span",
                        "p",
                        "td",
                        "tr",
                        "table",
                        "biol:CashProceedsAlongWithFairValueDisclosuresRelatedToGrantsExercisesAndVestingOptionsTableTextBlock",
                        "div",
                        "biol:TemporaryEquityAndStockholdersEquityNoteDisclosureTextBlock",
                        "div",
                        "body",
                        "html"
                        ],
                    "baseRef":  "biol-20210331.htm",
                    "contextRef":  "C_46389777-7e99-4f67-8c76-d557afb20ab7",
                    "decimals":  "2",
                    "first":  true,
                    "lang":  null,
                    "name":  "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
                    "reportCount":  1,
                    "unitRef":  "U_USDollarShare",
                    "xsiNil":  "false"
                    },
                "groupType":  "disclosure",
                "isDefault":  "false",
                "longName":  "100470 - Disclosure - Summary of Unvested Stock Option Activity (Detail)",
                "role":  "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureSummaryOfUnvestedStockOptionActivityDetail",
                "shortName":  "Summary of Unvested Stock Option Activity (Detail)",
                "subGroupType":  "details",
                "uniqueAnchor":  {
                    "ancestors":  [
                        "span",
                        "p",
                        "td",
                        "tr",
                        "table",
                        "us-gaap:ScheduleOfNonvestedShareActivityTableTextBlock",
                        "div",
                        "biol:TemporaryEquityAndStockholdersEquityNoteDisclosureTextBlock",
                        "div",
                        "body",
                        "html"
                        ],
                    "baseRef":  "biol-20210331.htm",
                    "contextRef":  "C_8356d243-15c9-48a8-96a1-cd06d9d51db9",
                    "decimals":  "-3",
                    "lang":  null,
                    "name":  "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares",
                    "reportCount":  1,
                    "unique":  true,
                    "unitRef":  "U_shares",
                    "xsiNil":  "false"
                    }
                },
            "R43":  {
                "firstAnchor":  {
                    "ancestors":  [
                        "span",
                        "p",
                        "td",
                        "tr",
                        "table",
                        "biol:CashProceedsAlongWithFairValueDisclosuresRelatedToGrantsExercisesAndVestingOptionsTableTextBlock",
                        "div",
                        "biol:TemporaryEquityAndStockholdersEquityNoteDisclosureTextBlock",
                        "div",
                        "body",
                        "html"
                        ],
                    "baseRef":  "biol-20210331.htm",
                    "contextRef":  "C_46389777-7e99-4f67-8c76-d557afb20ab7",
                    "decimals":  "-3",
                    "first":  true,
                    "lang":  null,
                    "name":  "us-gaap:ProceedsFromStockOptionsExercised",
                    "reportCount":  1,
                    "unique":  true,
                    "unitRef":  "U_USD",
                    "xsiNil":  "false"
                    },
                "groupType":  "disclosure",
                "isDefault":  "false",
                "longName":  "100480 - Disclosure - Cash Proceeds Along with Fair Value Disclosures Related to Grants, Exercises and Vested Options (Detail)",
                "role":  "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureCashProceedsAlongWithFairValueDisclosuresRelatedToGrantsExercisesAndVestedOptionsDetail",
                "shortName":  "Cash Proceeds Along with Fair Value Disclosures Related to Grants, Exercises and Vested Options (Detail)",
                "subGroupType":  "details",
                "uniqueAnchor":  {
                    "ancestors":  [
                        "span",
                        "p",
                        "td",
                        "tr",
                        "table",
                        "biol:CashProceedsAlongWithFairValueDisclosuresRelatedToGrantsExercisesAndVestingOptionsTableTextBlock",
                        "div",
                        "biol:TemporaryEquityAndStockholdersEquityNoteDisclosureTextBlock",
                        "div",
                        "body",
                        "html"
                        ],
                    "baseRef":  "biol-20210331.htm",
                    "contextRef":  "C_46389777-7e99-4f67-8c76-d557afb20ab7",
                    "decimals":  "-3",
                    "first":  true,
                    "lang":  null,
                    "name":  "us-gaap:ProceedsFromStockOptionsExercised",
                    "reportCount":  1,
                    "unique":  true,
                    "unitRef":  "U_USD",
                    "xsiNil":  "false"
                    }
                },
            "R44":  {
                "firstAnchor":  {
                    "ancestors":  [
                        "span",
                        "p",
                        "td",
                        "tr",
                        "table",
                        "us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock",
                        "div",
                        "biol:TemporaryEquityAndStockholdersEquityNoteDisclosureTextBlock",
                        "div",
                        "body",
                        "html"
                        ],
                    "baseRef":  "biol-20210331.htm",
                    "contextRef":  "C_e710a9d5-8afd-4054-adcb-9dab7fbd2892",
                    "decimals":  "-3",
                    "first":  true,
                    "lang":  null,
                    "name":  "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
                    "reportCount":  1,
                    "unique":  true,
                    "unitRef":  "U_shares",
                    "xsiNil":  "false"
                    },
                "groupType":  "disclosure",
                "isDefault":  "false",
                "longName":  "100490 - Disclosure - Summary of Unvested Restricted Stock Units (Detail)",
                "role":  "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureSummaryOfUnvestedRestrictedStockUnitsDetail",
                "shortName":  "Summary of Unvested Restricted Stock Units (Detail)",
                "subGroupType":  "details",
                "uniqueAnchor":  {
                    "ancestors":  [
                        "span",
                        "p",
                        "td",
                        "tr",
                        "table",
                        "us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock",
                        "div",
                        "biol:TemporaryEquityAndStockholdersEquityNoteDisclosureTextBlock",
                        "div",
                        "body",
                        "html"
                        ],
                    "baseRef":  "biol-20210331.htm",
                    "contextRef":  "C_e710a9d5-8afd-4054-adcb-9dab7fbd2892",
                    "decimals":  "-3",
                    "first":  true,
                    "lang":  null,
                    "name":  "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
                    "reportCount":  1,
                    "unique":  true,
                    "unitRef":  "U_shares",
                    "xsiNil":  "false"
                    }
                },
            "R45":  {
                "firstAnchor":  {
                    "ancestors":  [
                        "span",
                        "p",
                        "td",
                        "tr",
                        "table",
                        "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
                        "div",
                        "biol:TemporaryEquityAndStockholdersEquityNoteDisclosureTextBlock",
                        "div",
                        "body",
                        "html"
                        ],
                    "baseRef":  "biol-20210331.htm",
                    "contextRef":  "C_cf3b9076-a74f-463f-88c3-b425106d88bd",
                    "decimals":  "-3",
                    "first":  true,
                    "lang":  null,
                    "name":  "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
                    "reportCount":  1,
                    "unique":  true,
                    "unitRef":  "U_shares",
                    "xsiNil":  "false"
                    },
                "groupType":  "disclosure",
                "isDefault":  "false",
                "longName":  "100500 - Disclosure - Summary of Warrant Activity (Detail)",
                "role":  "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureSummaryOfWarrantActivityDetail",
                "shortName":  "Summary of Warrant Activity (Detail)",
                "subGroupType":  "details",
                "uniqueAnchor":  {
                    "ancestors":  [
                        "span",
                        "p",
                        "td",
                        "tr",
                        "table",
                        "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
                        "div",
                        "biol:TemporaryEquityAndStockholdersEquityNoteDisclosureTextBlock",
                        "div",
                        "body",
                        "html"
                        ],
                    "baseRef":  "biol-20210331.htm",
                    "contextRef":  "C_cf3b9076-a74f-463f-88c3-b425106d88bd",
                    "decimals":  "-3",
                    "first":  true,
                    "lang":  null,
                    "name":  "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
                    "reportCount":  1,
                    "unique":  true,
                    "unitRef":  "U_shares",
                    "xsiNil":  "false"
                    }
                },
            "R46":  {
                "firstAnchor":  {
                    "ancestors":  [
                        "span",
                        "p",
                        "td",
                        "tr",
                        "table",
                        "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
                        "div",
                        "us-gaap:InventoryDisclosureTextBlock",
                        "div",
                        "body",
                        "html"
                        ],
                    "baseRef":  "biol-20210331.htm",
                    "contextRef":  "C_9f7ebf99-0e4f-4ef2-9ade-8fa1dcb53908",
                    "decimals":  "-3",
                    "first":  true,
                    "lang":  null,
                    "name":  "us-gaap:InventoryRawMaterials",
                    "reportCount":  1,
                    "unique":  true,
                    "unitRef":  "U_USD",
                    "xsiNil":  "false"
                    },
                "groupType":  "disclosure",
                "isDefault":  "false",
                "longName":  "100510 - Disclosure - Components of Inventory (Detail)",
                "role":  "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureComponentsOfInventoryDetail",
                "shortName":  "Components of Inventory (Detail)",
                "subGroupType":  "details",
                "uniqueAnchor":  {
                    "ancestors":  [
                        "span",
                        "p",
                        "td",
                        "tr",
                        "table",
                        "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
                        "div",
                        "us-gaap:InventoryDisclosureTextBlock",
                        "div",
                        "body",
                        "html"
                        ],
                    "baseRef":  "biol-20210331.htm",
                    "contextRef":  "C_9f7ebf99-0e4f-4ef2-9ade-8fa1dcb53908",
                    "decimals":  "-3",
                    "first":  true,
                    "lang":  null,
                    "name":  "us-gaap:InventoryRawMaterials",
                    "reportCount":  1,
                    "unique":  true,
                    "unitRef":  "U_USD",
                    "xsiNil":  "false"
                    }
                },
            "R47":  {
                "firstAnchor":  {
                    "ancestors":  [
                        "span",
                        "ix:continuation",
                        "span",
                        "p",
                        "body",
                        "html"
                        ],
                    "baseRef":  "biol-20210331.htm",
                    "contextRef":  "C_9f7ebf99-0e4f-4ef2-9ade-8fa1dcb53908",
                    "decimals":  "-5",
                    "first":  true,
                    "lang":  null,
                    "name":  "us-gaap:InventoryValuationReserves",
                    "reportCount":  1,
                    "unique":  true,
                    "unitRef":  "U_USD",
                    "xsiNil":  "false"
                    },
                "groupType":  "disclosure",
                "isDefault":  "false",
                "longName":  "100520 - Disclosure - Inventory - Additional Information (Detail)",
                "role":  "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureInventoryAdditionalInformationDetail",
                "shortName":  "Inventory - Additional Information (Detail)",
                "subGroupType":  "details",
                "uniqueAnchor":  {
                    "ancestors":  [
                        "span",
                        "ix:continuation",
                        "span",
                        "p",
                        "body",
                        "html"
                        ],
                    "baseRef":  "biol-20210331.htm",
                    "contextRef":  "C_9f7ebf99-0e4f-4ef2-9ade-8fa1dcb53908",
                    "decimals":  "-5",
                    "first":  true,
                    "lang":  null,
                    "name":  "us-gaap:InventoryValuationReserves",
                    "reportCount":  1,
                    "unique":  true,
                    "unitRef":  "U_USD",
                    "xsiNil":  "false"
                    }
                },
            "R48":  {
                "firstAnchor":  {
                    "ancestors":  [
                        "span",
                        "p",
                        "td",
                        "tr",
                        "table",
                        "us-gaap:PropertyPlantAndEquipmentTextBlock",
                        "div",
                        "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
                        "div",
                        "body",
                        "html"
                        ],
                    "baseRef":  "biol-20210331.htm",
                    "contextRef":  "C_9f7ebf99-0e4f-4ef2-9ade-8fa1dcb53908",
                    "decimals":  "-3",
                    "first":  true,
                    "lang":  null,
                    "name":  "biol:PropertyPlantAndEquipmentGrossExcludingLand",
                    "reportCount":  1,
                    "unique":  true,
                    "unitRef":  "U_USD",
                    "xsiNil":  "false"
                    },
                "groupType":  "disclosure",
                "isDefault":  "false",
                "longName":  "100530 - Disclosure - Summary of Property, Plant, and Equipment (Detail)",
                "role":  "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureSummaryOfPropertyPlantAndEquipmentDetail",
                "shortName":  "Summary of Property, Plant, and Equipment (Detail)",
                "subGroupType":  "details",
                "uniqueAnchor":  {
                    "ancestors":  [
                        "span",
                        "p",
                        "td",
                        "tr",
                        "table",
                        "us-gaap:PropertyPlantAndEquipmentTextBlock",
                        "div",
                        "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
                        "div",
                        "body",
                        "html"
                        ],
                    "baseRef":  "biol-20210331.htm",
                    "contextRef":  "C_9f7ebf99-0e4f-4ef2-9ade-8fa1dcb53908",
                    "decimals":  "-3",
                    "first":  true,
                    "lang":  null,
                    "name":  "biol:PropertyPlantAndEquipmentGrossExcludingLand",
                    "reportCount":  1,
                    "unique":  true,
                    "unitRef":  "U_USD",
                    "xsiNil":  "false"
                    }
                },
            "R49":  {
                "firstAnchor":  {
                    "ancestors":  [
                        "span",
                        "ix:continuation",
                        "span",
                        "p",
                        "body",
                        "html"
                        ],
                    "baseRef":  "biol-20210331.htm",
                    "contextRef":  "C_46389777-7e99-4f67-8c76-d557afb20ab7",
                    "decimals":  "-5",
                    "first":  true,
                    "lang":  null,
                    "name":  "us-gaap:DepreciationAndAmortization",
                    "reportCount":  1,
                    "unique":  true,
                    "unitRef":  "U_USD",
                    "xsiNil":  "false"
                    },
                "groupType":  "disclosure",
                "isDefault":  "false",
                "longName":  "100540 - Disclosure - Property, Plant, and Equipment - Additional Information (Detail)",
                "role":  "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosurePropertyPlantAndEquipmentAdditionalInformationDetail",
                "shortName":  "Property, Plant, and Equipment - Additional Information (Detail)",
                "subGroupType":  "details",
                "uniqueAnchor":  {
                    "ancestors":  [
                        "span",
                        "ix:continuation",
                        "span",
                        "p",
                        "body",
                        "html"
                        ],
                    "baseRef":  "biol-20210331.htm",
                    "contextRef":  "C_46389777-7e99-4f67-8c76-d557afb20ab7",
                    "decimals":  "-5",
                    "first":  true,
                    "lang":  null,
                    "name":  "us-gaap:DepreciationAndAmortization",
                    "reportCount":  1,
                    "unique":  true,
                    "unitRef":  "U_USD",
                    "xsiNil":  "false"
                    }
                },
            "R5":  {
                "firstAnchor":  {
                    "ancestors":  [
                        "span",
                        "p",
                        "td",
                        "tr",
                        "table",
                        "body",
                        "html"
                        ],
                    "baseRef":  "biol-20210331.htm",
                    "contextRef":  "C_7d807172-8fa1-43e8-8912-c9f9bb46a357",
                    "decimals":  "-3",
                    "first":  true,
                    "lang":  null,
                    "name":  "us-gaap:StockholdersEquity",
                    "reportCount":  1,
                    "unique":  true,
                    "unitRef":  "U_USD",
                    "xsiNil":  "false"
                    },
                "groupType":  "statement",
                "isDefault":  "false",
                "longName":  "100090 - Statement - Consolidated Statements Of Redeemable Preferred Stock and Stockholders' Equity (Unaudited)",
                "role":  "http://www.biolase.com/20210331/taxonomy/role/Role_StatementConsolidatedStatementsOfRedeemablePreferredStockAndStockholdersEquityUnaudited",
                "shortName":  "Consolidated Statements Of Redeemable Preferred Stock and Stockholders' Equity (Unaudited)",
                "subGroupType":  "",
                "uniqueAnchor":  {
                    "ancestors":  [
                        "span",
                        "p",
                        "td",
                        "tr",
                        "table",
                        "body",
                        "html"
                        ],
                    "baseRef":  "biol-20210331.htm",
                    "contextRef":  "C_7d807172-8fa1-43e8-8912-c9f9bb46a357",
                    "decimals":  "-3",
                    "first":  true,
                    "lang":  null,
                    "name":  "us-gaap:StockholdersEquity",
                    "reportCount":  1,
                    "unique":  true,
                    "unitRef":  "U_USD",
                    "xsiNil":  "false"
                    }
                },
            "R50":  {
                "firstAnchor":  {
                    "ancestors":  [
                        "span",
                        "p",
                        "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
                        "div",
                        "body",
                        "html"
                        ],
                    "baseRef":  "biol-20210331.htm",
                    "contextRef":  "C_c19a4c6f-afa5-4c21-b525-f07e9af2788d",
                    "decimals":  "0",
                    "first":  true,
                    "lang":  null,
                    "name":  "us-gaap:GoodwillAndIntangibleAssetImpairment",
                    "reportCount":  1,
                    "unique":  true,
                    "unitRef":  "U_USD",
                    "xsiNil":  "false"
                    },
                "groupType":  "disclosure",
                "isDefault":  "false",
                "longName":  "100550 - Disclosure - Intangible Assets and Goodwill - Additional Information (Detail)",
                "role":  "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureIntangibleAssetsAndGoodwillAdditionalInformationDetail",
                "shortName":  "Intangible Assets and Goodwill - Additional Information (Detail)",
                "subGroupType":  "details",
                "uniqueAnchor":  {
                    "ancestors":  [
                        "span",
                        "p",
                        "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
                        "div",
                        "body",
                        "html"
                        ],
                    "baseRef":  "biol-20210331.htm",
                    "contextRef":  "C_c19a4c6f-afa5-4c21-b525-f07e9af2788d",
                    "decimals":  "0",
                    "first":  true,
                    "lang":  null,
                    "name":  "us-gaap:GoodwillAndIntangibleAssetImpairment",
                    "reportCount":  1,
                    "unique":  true,
                    "unitRef":  "U_USD",
                    "xsiNil":  "false"
                    }
                },
            "R51":  {
                "firstAnchor":  {
                    "ancestors":  [
                        "span",
                        "p",
                        "td",
                        "tr",
                        "table",
                        "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
                        "div",
                        "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
                        "div",
                        "body",
                        "html"
                        ],
                    "baseRef":  "biol-20210331.htm",
                    "contextRef":  "C_9f7ebf99-0e4f-4ef2-9ade-8fa1dcb53908",
                    "decimals":  "-3",
                    "first":  true,
                    "lang":  null,
                    "name":  "us-gaap:EmployeeRelatedLiabilitiesCurrent",
                    "reportCount":  1,
                    "unique":  true,
                    "unitRef":  "U_USD",
                    "xsiNil":  "false"
                    },
                "groupType":  "disclosure",
                "isDefault":  "false",
                "longName":  "100560 - Disclosure - Components of Accrued Liabilities (Detail)",
                "role":  "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureComponentsOfAccruedLiabilitiesDetail",
                "shortName":  "Components of Accrued Liabilities (Detail)",
                "subGroupType":  "details",
                "uniqueAnchor":  {
                    "ancestors":  [
                        "span",
                        "p",
                        "td",
                        "tr",
                        "table",
                        "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
                        "div",
                        "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
                        "div",
                        "body",
                        "html"
                        ],
                    "baseRef":  "biol-20210331.htm",
                    "contextRef":  "C_9f7ebf99-0e4f-4ef2-9ade-8fa1dcb53908",
                    "decimals":  "-3",
                    "first":  true,
                    "lang":  null,
                    "name":  "us-gaap:EmployeeRelatedLiabilitiesCurrent",
                    "reportCount":  1,
                    "unique":  true,
                    "unitRef":  "U_USD",
                    "xsiNil":  "false"
                    }
                },
            "R52":  {
                "firstAnchor":  {
                    "ancestors":  [
                        "span",
                        "p",
                        "td",
                        "tr",
                        "table",
                        "us-gaap:ScheduleOfProductWarrantyLiabilityTableTextBlock",
                        "div",
                        "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
                        "div",
                        "body",
                        "html"
                        ],
                    "baseRef":  "biol-20210331.htm",
                    "contextRef":  "C_0d14d282-ab11-49f1-8904-3aa28cfd1600",
                    "decimals":  "-3",
                    "first":  true,
                    "lang":  null,
                    "name":  "us-gaap:ProductWarrantyAccrual",
                    "reportCount":  1,
                    "unique":  true,
                    "unitRef":  "U_USD",
                    "xsiNil":  "false"
                    },
                "groupType":  "disclosure",
                "isDefault":  "false",
                "longName":  "100570 - Disclosure - Changes in Initial Product Warranty Accrual and Expenses Under Initial and Extended Warranties (Detail)",
                "role":  "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureChangesInInitialProductWarrantyAccrualAndExpensesUnderInitialAndExtendedWarrantiesDetail",
                "shortName":  "Changes in Initial Product Warranty Accrual and Expenses Under Initial and Extended Warranties (Detail)",
                "subGroupType":  "details",
                "uniqueAnchor":  {
                    "ancestors":  [
                        "span",
                        "p",
                        "td",
                        "tr",
                        "table",
                        "us-gaap:ScheduleOfProductWarrantyLiabilityTableTextBlock",
                        "div",
                        "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
                        "div",
                        "body",
                        "html"
                        ],
                    "baseRef":  "biol-20210331.htm",
                    "contextRef":  "C_0d14d282-ab11-49f1-8904-3aa28cfd1600",
                    "decimals":  "-3",
                    "first":  true,
                    "lang":  null,
                    "name":  "us-gaap:ProductWarrantyAccrual",
                    "reportCount":  1,
                    "unique":  true,
                    "unitRef":  "U_USD",
                    "xsiNil":  "false"
                    }
                },
            "R53":  {
                "firstAnchor":  {
                    "ancestors":  [
                        "span",
                        "p",
                        "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
                        "div",
                        "body",
                        "html"
                        ],
                    "baseRef":  "biol-20210331.htm",
                    "contextRef":  "C_9f7ebf99-0e4f-4ef2-9ade-8fa1dcb53908",
                    "decimals":  "-5",
                    "first":  true,
                    "lang":  null,
                    "name":  "us-gaap:DeferredTaxLiabilitiesDeferredExpense",
                    "reportCount":  1,
                    "unique":  true,
                    "unitRef":  "U_USD",
                    "xsiNil":  "false"
                    },
                "groupType":  "disclosure",
                "isDefault":  "false",
                "longName":  "100580 - Disclosure - Accrued Liabilities - Additional Information (Detail)",
                "role":  "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureAccruedLiabilitiesAdditionalInformationDetail",
                "shortName":  "Accrued Liabilities - Additional Information (Detail)",
                "subGroupType":  "details",
                "uniqueAnchor":  {
                    "ancestors":  [
                        "span",
                        "p",
                        "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
                        "div",
                        "body",
                        "html"
                        ],
                    "baseRef":  "biol-20210331.htm",
                    "contextRef":  "C_9f7ebf99-0e4f-4ef2-9ade-8fa1dcb53908",
                    "decimals":  "-5",
                    "first":  true,
                    "lang":  null,
                    "name":  "us-gaap:DeferredTaxLiabilitiesDeferredExpense",
                    "reportCount":  1,
                    "unique":  true,
                    "unitRef":  "U_USD",
                    "xsiNil":  "false"
                    }
                },
            "R54":  {
                "firstAnchor":  {
                    "ancestors":  [
                        "span",
                        "p",
                        "td",
                        "tr",
                        "table",
                        "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
                        "div",
                        "us-gaap:DebtDisclosureTextBlock",
                        "div",
                        "body",
                        "html"
                        ],
                    "baseRef":  "biol-20210331.htm",
                    "contextRef":  "C_9f7ebf99-0e4f-4ef2-9ade-8fa1dcb53908",
                    "decimals":  "-3",
                    "first":  true,
                    "lang":  null,
                    "name":  "us-gaap:LongTermDebt",
                    "reportCount":  1,
                    "unitRef":  "U_USD",
                    "xsiNil":  "false"
                    },
                "groupType":  "disclosure",
                "isDefault":  "false",
                "longName":  "100590 - Disclosure - Debt - Summary of Principal Outstanding and Unamortized Discount (Detail)",
                "role":  "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureDebtSummaryOfPrincipalOutstandingAndUnamortizedDiscountDetail",
                "shortName":  "Debt - Summary of Principal Outstanding and Unamortized Discount (Detail)",
                "subGroupType":  "details",
                "uniqueAnchor":  {
                    "ancestors":  [
                        "span",
                        "p",
                        "td",
                        "tr",
                        "table",
                        "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
                        "div",
                        "us-gaap:DebtDisclosureTextBlock",
                        "div",
                        "body",
                        "html"
                        ],
                    "baseRef":  "biol-20210331.htm",
                    "contextRef":  "C_9f7ebf99-0e4f-4ef2-9ade-8fa1dcb53908",
                    "decimals":  "-3",
                    "lang":  null,
                    "name":  "us-gaap:LongTermDebtCurrent",
                    "reportCount":  1,
                    "unique":  true,
                    "unitRef":  "U_USD",
                    "xsiNil":  "false"
                    }
                },
            "R55":  {
                "firstAnchor":  {
                    "ancestors":  [
                        "span",
                        "p",
                        "td",
                        "tr",
                        "table",
                        "body",
                        "html"
                        ],
                    "baseRef":  "biol-20210331.htm",
                    "contextRef":  "C_9f7ebf99-0e4f-4ef2-9ade-8fa1dcb53908",
                    "decimals":  "-3",
                    "first":  true,
                    "lang":  null,
                    "name":  "us-gaap:CommonStockValue",
                    "reportCount":  1,
                    "unitRef":  "U_USD",
                    "xsiNil":  "false"
                    },
                "groupType":  "disclosure",
                "isDefault":  "false",
                "longName":  "100600 - Disclosure - Debt - Additional Information (Detail)",
                "role":  "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetail",
                "shortName":  "Debt - Additional Information (Detail)",
                "subGroupType":  "details",
                "uniqueAnchor":  {
                    "ancestors":  [
                        "span",
                        "p",
                        "us-gaap:DebtDisclosureTextBlock",
                        "div",
                        "body",
                        "html"
                        ],
                    "baseRef":  "biol-20210331.htm",
                    "contextRef":  "C_46389777-7e99-4f67-8c76-d557afb20ab7",
                    "decimals":  "-5",
                    "lang":  null,
                    "name":  "us-gaap:InterestExpenseDebt",
                    "reportCount":  1,
                    "unique":  true,
                    "unitRef":  "U_USD",
                    "xsiNil":  "false"
                    }
                },
            "R56":  {
                "firstAnchor":  {
                    "ancestors":  [
                        "span",
                        "p",
                        "td",
                        "tr",
                        "table",
                        "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
                        "div",
                        "us-gaap:DebtDisclosureTextBlock",
                        "div",
                        "body",
                        "html"
                        ],
                    "baseRef":  "biol-20210331.htm",
                    "contextRef":  "C_9f7ebf99-0e4f-4ef2-9ade-8fa1dcb53908",
                    "decimals":  "-3",
                    "first":  true,
                    "lang":  null,
                    "name":  "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear",
                    "reportCount":  1,
                    "unique":  true,
                    "unitRef":  "U_USD",
                    "xsiNil":  "false"
                    },
                "groupType":  "disclosure",
                "isDefault":  "false",
                "longName":  "100610 - Disclosure - Debt - Summary of Future Minimum Principal and Interest Payments (Detail)",
                "role":  "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureDebtSummaryOfFutureMinimumPrincipalAndInterestPaymentsDetail",
                "shortName":  "Debt - Summary of Future Minimum Principal and Interest Payments (Detail)",
                "subGroupType":  "details",
                "uniqueAnchor":  {
                    "ancestors":  [
                        "span",
                        "p",
                        "td",
                        "tr",
                        "table",
                        "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
                        "div",
                        "us-gaap:DebtDisclosureTextBlock",
                        "div",
                        "body",
                        "html"
                        ],
                    "baseRef":  "biol-20210331.htm",
                    "contextRef":  "C_9f7ebf99-0e4f-4ef2-9ade-8fa1dcb53908",
                    "decimals":  "-3",
                    "first":  true,
                    "lang":  null,
                    "name":  "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear",
                    "reportCount":  1,
                    "unique":  true,
                    "unitRef":  "U_USD",
                    "xsiNil":  "false"
                    }
                },
            "R57":  {
                "firstAnchor":  {
                    "ancestors":  [
                        "span",
                        "p",
                        "us-gaap:LesseeOperatingLeasesTextBlock",
                        "div",
                        "body",
                        "html"
                        ],
                    "baseRef":  "biol-20210331.htm",
                    "contextRef":  "C_46389777-7e99-4f67-8c76-d557afb20ab7",
                    "decimals":  "-2",
                    "first":  true,
                    "lang":  null,
                    "name":  "us-gaap:PaymentsForRent",
                    "reportCount":  1,
                    "unique":  true,
                    "unitRef":  "U_USD",
                    "xsiNil":  "false"
                    },
                "groupType":  "disclosure",
                "isDefault":  "false",
                "longName":  "100620 - Disclosure - Leases - Additional Information (Detail)",
                "role":  "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail",
                "shortName":  "Leases - Additional Information (Detail)",
                "subGroupType":  "details",
                "uniqueAnchor":  {
                    "ancestors":  [
                        "span",
                        "p",
                        "us-gaap:LesseeOperatingLeasesTextBlock",
                        "div",
                        "body",
                        "html"
                        ],
                    "baseRef":  "biol-20210331.htm",
                    "contextRef":  "C_46389777-7e99-4f67-8c76-d557afb20ab7",
                    "decimals":  "-2",
                    "first":  true,
                    "lang":  null,
                    "name":  "us-gaap:PaymentsForRent",
                    "reportCount":  1,
                    "unique":  true,
                    "unitRef":  "U_USD",
                    "xsiNil":  "false"
                    }
                },
            "R58":  {
                "firstAnchor":  {
                    "ancestors":  [
                        "span",
                        "p",
                        "td",
                        "tr",
                        "table",
                        "biol:InformationRelatedToOperatingRightOfUseAssetsAndRelatedLiabilitiesTableTextBlock",
                        "div",
                        "us-gaap:LesseeOperatingLeasesTextBlock",
                        "div",
                        "body",
                        "html"
                        ],
                    "baseRef":  "biol-20210331.htm",
                    "contextRef":  "C_46389777-7e99-4f67-8c76-d557afb20ab7",
                    "decimals":  "-3",
                    "first":  true,
                    "lang":  null,
                    "name":  "us-gaap:OperatingLeasePayments",
                    "reportCount":  1,
                    "unique":  true,
                    "unitRef":  "U_USD",
                    "xsiNil":  "false"
                    },
                "groupType":  "disclosure",
                "isDefault":  "false",
                "longName":  "100630 - Disclosure - Leases - Information related to Right-of-use Assets and Liabilities (Detail)",
                "role":  "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureLeasesInformationRelatedToRightOfUseAssetsAndLiabilitiesDetail",
                "shortName":  "Leases - Information related to Right-of-use Assets and Liabilities (Detail)",
                "subGroupType":  "details",
                "uniqueAnchor":  {
                    "ancestors":  [
                        "span",
                        "p",
                        "td",
                        "tr",
                        "table",
                        "biol:InformationRelatedToOperatingRightOfUseAssetsAndRelatedLiabilitiesTableTextBlock",
                        "div",
                        "us-gaap:LesseeOperatingLeasesTextBlock",
                        "div",
                        "body",
                        "html"
                        ],
                    "baseRef":  "biol-20210331.htm",
                    "contextRef":  "C_46389777-7e99-4f67-8c76-d557afb20ab7",
                    "decimals":  "-3",
                    "first":  true,
                    "lang":  null,
                    "name":  "us-gaap:OperatingLeasePayments",
                    "reportCount":  1,
                    "unique":  true,
                    "unitRef":  "U_USD",
                    "xsiNil":  "false"
                    }
                },
            "R59":  {
                "firstAnchor":  {
                    "ancestors":  [
                        "span",
                        "p",
                        "td",
                        "tr",
                        "table",
                        "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
                        "div",
                        "us-gaap:LesseeOperatingLeasesTextBlock",
                        "div",
                        "body",
                        "html"
                        ],
                    "baseRef":  "biol-20210331.htm",
                    "contextRef":  "C_9f7ebf99-0e4f-4ef2-9ade-8fa1dcb53908",
                    "decimals":  "-3",
                    "first":  true,
                    "lang":  null,
                    "name":  "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
                    "reportCount":  1,
                    "unique":  true,
                    "unitRef":  "U_USD",
                    "xsiNil":  "false"
                    },
                "groupType":  "disclosure",
                "isDefault":  "false",
                "longName":  "100640 - Disclosure - Leases - Schedule of Maturities of Lease Liabilities (Detail)",
                "role":  "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetail",
                "shortName":  "Leases - Schedule of Maturities of Lease Liabilities (Detail)",
                "subGroupType":  "details",
                "uniqueAnchor":  {
                    "ancestors":  [
                        "span",
                        "p",
                        "td",
                        "tr",
                        "table",
                        "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
                        "div",
                        "us-gaap:LesseeOperatingLeasesTextBlock",
                        "div",
                        "body",
                        "html"
                        ],
                    "baseRef":  "biol-20210331.htm",
                    "contextRef":  "C_9f7ebf99-0e4f-4ef2-9ade-8fa1dcb53908",
                    "decimals":  "-3",
                    "first":  true,
                    "lang":  null,
                    "name":  "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
                    "reportCount":  1,
                    "unique":  true,
                    "unitRef":  "U_USD",
                    "xsiNil":  "false"
                    }
                },
            "R6":  {
                "firstAnchor":  {
                    "ancestors":  [
                        "span",
                        "p",
                        "td",
                        "tr",
                        "table",
                        "body",
                        "html"
                        ],
                    "baseRef":  "biol-20210331.htm",
                    "contextRef":  "C_46389777-7e99-4f67-8c76-d557afb20ab7",
                    "decimals":  "-3",
                    "first":  true,
                    "lang":  null,
                    "name":  "us-gaap:ProfitLoss",
                    "reportCount":  1,
                    "unique":  true,
                    "unitRef":  "U_USD",
                    "xsiNil":  "false"
                    },
                "groupType":  "statement",
                "isDefault":  "false",
                "longName":  "100110 - Statement - Consolidated Statements Of Cash Flows (Unaudited)",
                "role":  "http://www.biolase.com/20210331/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlowsUnaudited",
                "shortName":  "Consolidated Statements Of Cash Flows (Unaudited)",
                "subGroupType":  "",
                "uniqueAnchor":  {
                    "ancestors":  [
                        "span",
                        "p",
                        "td",
                        "tr",
                        "table",
                        "body",
                        "html"
                        ],
                    "baseRef":  "biol-20210331.htm",
                    "contextRef":  "C_46389777-7e99-4f67-8c76-d557afb20ab7",
                    "decimals":  "-3",
                    "first":  true,
                    "lang":  null,
                    "name":  "us-gaap:ProfitLoss",
                    "reportCount":  1,
                    "unique":  true,
                    "unitRef":  "U_USD",
                    "xsiNil":  "false"
                    }
                },
            "R60":  {
                "firstAnchor":  {
                    "ancestors":  [
                        "span",
                        "p",
                        "td",
                        "tr",
                        "table",
                        "us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock",
                        "div",
                        "us-gaap:LesseeOperatingLeasesTextBlock",
                        "div",
                        "body",
                        "html"
                        ],
                    "baseRef":  "biol-20210331.htm",
                    "contextRef":  "C_0d14d282-ab11-49f1-8904-3aa28cfd1600",
                    "decimals":  "-3",
                    "first":  true,
                    "lang":  null,
                    "name":  "us-gaap:OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear",
                    "reportCount":  1,
                    "unique":  true,
                    "unitRef":  "U_USD",
                    "xsiNil":  "false"
                    },
                "groupType":  "disclosure",
                "isDefault":  "false",
                "longName":  "100650 - Disclosure - Leases - Future Minimum Rental Commitments Under Lease Agreements (Detail)",
                "role":  "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureLeasesFutureMinimumRentalCommitmentsUnderLeaseAgreementsDetail",
                "shortName":  "Leases - Future Minimum Rental Commitments Under Lease Agreements (Detail)",
                "subGroupType":  "details",
                "uniqueAnchor":  {
                    "ancestors":  [
                        "span",
                        "p",
                        "td",
                        "tr",
                        "table",
                        "us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock",
                        "div",
                        "us-gaap:LesseeOperatingLeasesTextBlock",
                        "div",
                        "body",
                        "html"
                        ],
                    "baseRef":  "biol-20210331.htm",
                    "contextRef":  "C_0d14d282-ab11-49f1-8904-3aa28cfd1600",
                    "decimals":  "-3",
                    "first":  true,
                    "lang":  null,
                    "name":  "us-gaap:OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear",
                    "reportCount":  1,
                    "unique":  true,
                    "unitRef":  "U_USD",
                    "xsiNil":  "false"
                    }
                },
            "R61":  {
                "firstAnchor":  {
                    "ancestors":  [
                        "span",
                        "p",
                        "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
                        "div",
                        "body",
                        "html"
                        ],
                    "baseRef":  "biol-20210331.htm",
                    "contextRef":  "C_cda3b52e-3afc-4116-b524-2ab73e0aff3e",
                    "decimals":  "INF",
                    "first":  true,
                    "lang":  null,
                    "name":  "biol:LitigationSettlementSharesIssued",
                    "reportCount":  1,
                    "unique":  true,
                    "unitRef":  "U_shares",
                    "xsiNil":  "false"
                    },
                "groupType":  "disclosure",
                "isDefault":  "false",
                "longName":  "100660 - Disclosure - Commitments and Contingencies - Additional Information (Detail)",
                "role":  "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail",
                "shortName":  "Commitments and Contingencies - Additional Information (Detail)",
                "subGroupType":  "details",
                "uniqueAnchor":  {
                    "ancestors":  [
                        "span",
                        "p",
                        "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
                        "div",
                        "body",
                        "html"
                        ],
                    "baseRef":  "biol-20210331.htm",
                    "contextRef":  "C_cda3b52e-3afc-4116-b524-2ab73e0aff3e",
                    "decimals":  "INF",
                    "first":  true,
                    "lang":  null,
                    "name":  "biol:LitigationSettlementSharesIssued",
                    "reportCount":  1,
                    "unique":  true,
                    "unitRef":  "U_shares",
                    "xsiNil":  "false"
                    }
                },
            "R62":  {
                "firstAnchor":  {
                    "ancestors":  [
                        "span",
                        "p",
                        "us-gaap:SegmentReportingDisclosureTextBlock",
                        "div",
                        "body",
                        "html"
                        ],
                    "baseRef":  "biol-20210331.htm",
                    "contextRef":  "C_4211ef5e-5b74-4ebf-86e2-afad640bdaf6",
                    "decimals":  "2",
                    "first":  true,
                    "lang":  null,
                    "name":  "us-gaap:ConcentrationRiskPercentage1",
                    "reportCount":  1,
                    "unique":  true,
                    "unitRef":  "U_pure",
                    "xsiNil":  "false"
                    },
                "groupType":  "disclosure",
                "isDefault":  "false",
                "longName":  "100670 - Disclosure - Segment Information - Additional Information (Detail)",
                "role":  "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureSegmentInformationAdditionalInformationDetail",
                "shortName":  "Segment Information - Additional Information (Detail)",
                "subGroupType":  "details",
                "uniqueAnchor":  {
                    "ancestors":  [
                        "span",
                        "p",
                        "us-gaap:SegmentReportingDisclosureTextBlock",
                        "div",
                        "body",
                        "html"
                        ],
                    "baseRef":  "biol-20210331.htm",
                    "contextRef":  "C_4211ef5e-5b74-4ebf-86e2-afad640bdaf6",
                    "decimals":  "2",
                    "first":  true,
                    "lang":  null,
                    "name":  "us-gaap:ConcentrationRiskPercentage1",
                    "reportCount":  1,
                    "unique":  true,
                    "unitRef":  "U_pure",
                    "xsiNil":  "false"
                    }
                },
            "R63":  {
                "firstAnchor":  {
                    "ancestors":  [
                        "span",
                        "p",
                        "td",
                        "tr",
                        "table",
                        "body",
                        "html"
                        ],
                    "baseRef":  "biol-20210331.htm",
                    "contextRef":  "C_46389777-7e99-4f67-8c76-d557afb20ab7",
                    "decimals":  "-3",
                    "first":  true,
                    "lang":  null,
                    "name":  "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
                    "reportCount":  1,
                    "unitRef":  "U_USD",
                    "xsiNil":  "false"
                    },
                "groupType":  "disclosure",
                "isDefault":  "false",
                "longName":  "100680 - Disclosure - Summary of Net Revenue by Geographic Location (Detail)",
                "role":  "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureSummaryOfNetRevenueByGeographicLocationDetail",
                "shortName":  "Summary of Net Revenue by Geographic Location (Detail)",
                "subGroupType":  "details",
                "uniqueAnchor":  null
                },
            "R64":  {
                "firstAnchor":  {
                    "ancestors":  [
                        "span",
                        "p",
                        "td",
                        "tr",
                        "table",
                        "body",
                        "html"
                        ],
                    "baseRef":  "biol-20210331.htm",
                    "contextRef":  "C_9f7ebf99-0e4f-4ef2-9ade-8fa1dcb53908",
                    "decimals":  "-3",
                    "first":  true,
                    "lang":  null,
                    "name":  "us-gaap:PropertyPlantAndEquipmentNet",
                    "reportCount":  1,
                    "unitRef":  "U_USD",
                    "xsiNil":  "false"
                    },
                "groupType":  "disclosure",
                "isDefault":  "false",
                "longName":  "100690 - Disclosure - Summary of Property, Plant and Equipment by Geographic Location (Detail)",
                "role":  "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureSummaryOfPropertyPlantAndEquipmentByGeographicLocationDetail",
                "shortName":  "Summary of Property, Plant and Equipment by Geographic Location (Detail)",
                "subGroupType":  "details",
                "uniqueAnchor":  {
                    "ancestors":  [
                        "span",
                        "p",
                        "td",
                        "tr",
                        "table",
                        "us-gaap:LongLivedAssetsByGeographicAreasTableTextBlock",
                        "div",
                        "us-gaap:SegmentReportingDisclosureTextBlock",
                        "div",
                        "body",
                        "html"
                        ],
                    "baseRef":  "biol-20210331.htm",
                    "contextRef":  "C_4bfa4e3d-c937-43cf-b7ab-46e2fed45617",
                    "decimals":  "-3",
                    "lang":  null,
                    "name":  "us-gaap:PropertyPlantAndEquipmentNet",
                    "reportCount":  1,
                    "unique":  true,
                    "unitRef":  "U_USD",
                    "xsiNil":  "false"
                    }
                },
            "R65":  {
                "firstAnchor":  {
                    "ancestors":  [
                        "span",
                        "p",
                        "td",
                        "tr",
                        "table",
                        "body",
                        "html"
                        ],
                    "baseRef":  "biol-20210331.htm",
                    "contextRef":  "C_46389777-7e99-4f67-8c76-d557afb20ab7",
                    "decimals":  "-3",
                    "first":  true,
                    "lang":  null,
                    "name":  "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
                    "reportCount":  1,
                    "unitRef":  "U_USD",
                    "xsiNil":  "false"
                    },
                "groupType":  "disclosure",
                "isDefault":  "false",
                "longName":  "100700 - Disclosure - Concentrations - Summary of Net Revenue from Various Products (Detail)",
                "role":  "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureConcentrationsSummaryOfNetRevenueFromVariousProductsDetail",
                "shortName":  "Concentrations - Summary of Net Revenue from Various Products (Detail)",
                "subGroupType":  "details",
                "uniqueAnchor":  {
                    "ancestors":  [
                        "span",
                        "p",
                        "td",
                        "tr",
                        "table",
                        "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
                        "div",
                        "us-gaap:ConcentrationRiskDisclosureTextBlock",
                        "div",
                        "body",
                        "html"
                        ],
                    "baseRef":  "biol-20210331.htm",
                    "contextRef":  "C_2a2fe7c8-16b6-4901-b363-713e6bfcd4a7",
                    "decimals":  "-3",
                    "lang":  null,
                    "name":  "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
                    "reportCount":  1,
                    "unique":  true,
                    "unitRef":  "U_USD",
                    "xsiNil":  "false"
                    }
                },
            "R66":  {
                "firstAnchor":  {
                    "ancestors":  [
                        "span",
                        "p",
                        "us-gaap:ConcentrationRiskDisclosureTextBlock",
                        "div",
                        "body",
                        "html"
                        ],
                    "baseRef":  "biol-20210331.htm",
                    "contextRef":  "C_61aa133e-0e3e-4c0b-8b9e-97241f9ab852",
                    "decimals":  "INF",
                    "first":  true,
                    "lang":  null,
                    "name":  "biol:EntityWideRevenueMajorCustomerNumber",
                    "reportCount":  1,
                    "unique":  true,
                    "unitRef":  "U_Customer",
                    "xsiNil":  "false"
                    },
                "groupType":  "disclosure",
                "isDefault":  "false",
                "longName":  "100710 - Disclosure - Concentrations - Additional Information (Detail)",
                "role":  "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureConcentrationsAdditionalInformationDetail",
                "shortName":  "Concentrations - Additional Information (Detail)",
                "subGroupType":  "details",
                "uniqueAnchor":  {
                    "ancestors":  [
                        "span",
                        "p",
                        "us-gaap:ConcentrationRiskDisclosureTextBlock",
                        "div",
                        "body",
                        "html"
                        ],
                    "baseRef":  "biol-20210331.htm",
                    "contextRef":  "C_61aa133e-0e3e-4c0b-8b9e-97241f9ab852",
                    "decimals":  "INF",
                    "first":  true,
                    "lang":  null,
                    "name":  "biol:EntityWideRevenueMajorCustomerNumber",
                    "reportCount":  1,
                    "unique":  true,
                    "unitRef":  "U_Customer",
                    "xsiNil":  "false"
                    }
                },
            "R67":  {
                "firstAnchor":  {
                    "ancestors":  [
                        "span",
                        "p",
                        "us-gaap:IncomeTaxDisclosureTextBlock",
                        "div",
                        "body",
                        "html"
                        ],
                    "baseRef":  "biol-20210331.htm",
                    "contextRef":  "C_46389777-7e99-4f67-8c76-d557afb20ab7",
                    "decimals":  "INF",
                    "first":  true,
                    "lang":  null,
                    "name":  "us-gaap:UnrecognizedTaxBenefitsPeriodIncreaseDecrease",
                    "reportCount":  1,
                    "unique":  true,
                    "unitRef":  "U_USD",
                    "xsiNil":  "false"
                    },
                "groupType":  "disclosure",
                "isDefault":  "false",
                "longName":  "100720 - Disclosure - Income Taxes - Additional Information (Detail)",
                "role":  "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail",
                "shortName":  "Income Taxes - Additional Information (Detail)",
                "subGroupType":  "details",
                "uniqueAnchor":  {
                    "ancestors":  [
                        "span",
                        "p",
                        "us-gaap:IncomeTaxDisclosureTextBlock",
                        "div",
                        "body",
                        "html"
                        ],
                    "baseRef":  "biol-20210331.htm",
                    "contextRef":  "C_46389777-7e99-4f67-8c76-d557afb20ab7",
                    "decimals":  "INF",
                    "first":  true,
                    "lang":  null,
                    "name":  "us-gaap:UnrecognizedTaxBenefitsPeriodIncreaseDecrease",
                    "reportCount":  1,
                    "unique":  true,
                    "unitRef":  "U_USD",
                    "xsiNil":  "false"
                    }
                },
            "R68":  {
                "firstAnchor":  {
                    "ancestors":  [
                        "span",
                        "p",
                        "us-gaap:DebtDisclosureTextBlock",
                        "div",
                        "body",
                        "html"
                        ],
                    "baseRef":  "biol-20210331.htm",
                    "contextRef":  "C_c5779017-d50f-471c-b5c2-27b6596b8f9a",
                    "decimals":  null,
                    "first":  true,
                    "lang":  "en-US",
                    "name":  "us-gaap:DebtInstrumentFrequencyOfPeriodicPayment",
                    "reportCount":  1,
                    "unitRef":  null,
                    "xsiNil":  "false"
                    },
                "groupType":  "disclosure",
                "isDefault":  "false",
                "longName":  "100730 - Disclosure - Subsequent Events - Additional Information (Detail)",
                "role":  "http://www.biolase.com/20210331/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail",
                "shortName":  "Subsequent Events - Additional Information (Detail)",
                "subGroupType":  "details",
                "uniqueAnchor":  {
                    "ancestors":  [
                        "span",
                        "p",
                        "us-gaap:SubsequentEventsTextBlock",
                        "div",
                        "body",
                        "html"
                        ],
                    "baseRef":  "biol-20210331.htm",
                    "contextRef":  "C_4187b0fd-c7f8-4b40-8803-91036af90e2b",
                    "decimals":  null,
                    "lang":  "en-US",
                    "name":  "us-gaap:DebtInstrumentFrequencyOfPeriodicPayment",
                    "reportCount":  1,
                    "unique":  true,
                    "unitRef":  null,
                    "xsiNil":  "false"
                    }
                },
            "R7":  {
                "firstAnchor":  {
                    "ancestors":  [
                        "div",
                        "body",
                        "html"
                        ],
                    "baseRef":  "biol-20210331.htm",
                    "contextRef":  "C_46389777-7e99-4f67-8c76-d557afb20ab7",
                    "decimals":  null,
                    "first":  true,
                    "lang":  "en-US",
                    "name":  "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
                    "reportCount":  1,
                    "unique":  true,
                    "unitRef":  null,
                    "xsiNil":  "false"
                    },
                "groupType":  "disclosure",
                "isDefault":  "false",
                "longName":  "100120 - Disclosure - Description of Business and Basis of Presentation",
                "role":  "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureDescriptionOfBusinessAndBasisOfPresentation",
                "shortName":  "Description of Business and Basis of Presentation",
                "subGroupType":  "",
                "uniqueAnchor":  {
                    "ancestors":  [
                        "div",
                        "body",
                        "html"
                        ],
                    "baseRef":  "biol-20210331.htm",
                    "contextRef":  "C_46389777-7e99-4f67-8c76-d557afb20ab7",
                    "decimals":  null,
                    "first":  true,
                    "lang":  "en-US",
                    "name":  "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
                    "reportCount":  1,
                    "unique":  true,
                    "unitRef":  null,
                    "xsiNil":  "false"
                    }
                },
            "R8":  {
                "firstAnchor":  {
                    "ancestors":  [
                        "div",
                        "body",
                        "html"
                        ],
                    "baseRef":  "biol-20210331.htm",
                    "contextRef":  "C_46389777-7e99-4f67-8c76-d557afb20ab7",
                    "decimals":  null,
                    "first":  true,
                    "lang":  "en-US",
                    "name":  "us-gaap:SignificantAccountingPoliciesTextBlock",
                    "reportCount":  1,
                    "unique":  true,
                    "unitRef":  null,
                    "xsiNil":  "false"
                    },
                "groupType":  "disclosure",
                "isDefault":  "false",
                "longName":  "100130 - Disclosure - Summary of Significant Accounting Policies",
                "role":  "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies",
                "shortName":  "Summary of Significant Accounting Policies",
                "subGroupType":  "",
                "uniqueAnchor":  {
                    "ancestors":  [
                        "div",
                        "body",
                        "html"
                        ],
                    "baseRef":  "biol-20210331.htm",
                    "contextRef":  "C_46389777-7e99-4f67-8c76-d557afb20ab7",
                    "decimals":  null,
                    "first":  true,
                    "lang":  "en-US",
                    "name":  "us-gaap:SignificantAccountingPoliciesTextBlock",
                    "reportCount":  1,
                    "unique":  true,
                    "unitRef":  null,
                    "xsiNil":  "false"
                    }
                },
            "R9":  {
                "firstAnchor":  {
                    "ancestors":  [
                        "div",
                        "body",
                        "html"
                        ],
                    "baseRef":  "biol-20210331.htm",
                    "contextRef":  "C_46389777-7e99-4f67-8c76-d557afb20ab7",
                    "decimals":  null,
                    "first":  true,
                    "lang":  "en-US",
                    "name":  "us-gaap:RevenueFromContractWithCustomerTextBlock",
                    "reportCount":  1,
                    "unique":  true,
                    "unitRef":  null,
                    "xsiNil":  "false"
                    },
                "groupType":  "disclosure",
                "isDefault":  "false",
                "longName":  "100140 - Disclosure - Revenue Recognition",
                "role":  "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureRevenueRecognition",
                "shortName":  "Revenue Recognition",
                "subGroupType":  "",
                "uniqueAnchor":  {
                    "ancestors":  [
                        "div",
                        "body",
                        "html"
                        ],
                    "baseRef":  "biol-20210331.htm",
                    "contextRef":  "C_46389777-7e99-4f67-8c76-d557afb20ab7",
                    "decimals":  null,
                    "first":  true,
                    "lang":  "en-US",
                    "name":  "us-gaap:RevenueFromContractWithCustomerTextBlock",
                    "reportCount":  1,
                    "unique":  true,
                    "unitRef":  null,
                    "xsiNil":  "false"
                    }
                }
            },
        "segmentCount":  68,
        "tag":  {
            "biol_AccruedLiabilitiesLineItems":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Accrued liabilities.",
                            "label":  "Accrued Liabilities [Line Items]",
                            "terseLabel":  "Accrued Liabilities [Line Items]"
                            }
                        }
                    },
                "localname":  "AccruedLiabilitiesLineItems",
                "nsuri":  "http://www.biolase.com/20210331",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureAccruedLiabilitiesAdditionalInformationDetail"
                    ],
                "xbrltype":  "stringItemType"
                },
            "biol_AccruedLiabilitiesTable":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Accrued liabilities.",
                            "label":  "Accrued Liabilities [Table]",
                            "terseLabel":  "Accrued Liabilities [Table]"
                            }
                        }
                    },
                "localname":  "AccruedLiabilitiesTable",
                "nsuri":  "http://www.biolase.com/20210331",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureAccruedLiabilitiesAdditionalInformationDetail"
                    ],
                "xbrltype":  "stringItemType"
                },
            "biol_AdditionalClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Additional class of warrant or right number of securities called by warrants or rights.",
                            "label":  "Additional Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights",
                            "terseLabel":  "Additional Warrants issued to purchase shares of common stock"
                            }
                        }
                    },
                "localname":  "AdditionalClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
                "nsuri":  "http://www.biolase.com/20210331",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetail"
                    ],
                "xbrltype":  "sharesItemType"
                },
            "biol_AdditionalEquityFundingRequirementUntilMinimumLiquidityIsMet":  {
                "auth_ref":  [
                    ],
                "crdr":  "credit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Additional equity funding requirement until minimum liquidity is met.",
                            "label":  "Additional Equity Funding Requirement Until Minimum Liquidity Is Met",
                            "terseLabel":  "Additional equity or debt funding requirement until minimum liquidity is met"
                            }
                        }
                    },
                "localname":  "AdditionalEquityFundingRequirementUntilMinimumLiquidityIsMet",
                "nsuri":  "http://www.biolase.com/20210331",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetail"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "biol_AdditionalWarrantsToPurchaseCommonStockValue":  {
                "auth_ref":  [
                    ],
                "crdr":  "debit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Additional warrants to purchase common stock value.",
                            "label":  "Additional Warrants To Purchase Common Stock Value",
                            "terseLabel":  "Additional warrants to purchase common stock value"
                            }
                        }
                    },
                "localname":  "AdditionalWarrantsToPurchaseCommonStockValue",
                "nsuri":  "http://www.biolase.com/20210331",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetail"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "biol_AdjustedExercisePriceOfWarrants":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Adjusted exercise price of warrants.",
                            "label":  "Adjusted Exercise Price Of Warrants",
                            "terseLabel":  "Adjusted exercise price of warrants"
                            }
                        }
                    },
                "localname":  "AdjustedExercisePriceOfWarrants",
                "nsuri":  "http://www.biolase.com/20210331",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetail"
                    ],
                "xbrltype":  "perShareItemType"
                },
            "biol_AdjustmentForDeferredRent":  {
                "auth_ref":  [
                    ],
                "crdr":  "debit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Adjustment for deferred rent.",
                            "label":  "Adjustment For Deferred Rent",
                            "terseLabel":  "Adjustment for deferred rent"
                            }
                        }
                    },
                "localname":  "AdjustmentForDeferredRent",
                "nsuri":  "http://www.biolase.com/20210331",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "biol_AdjustmentsToAdditionalPaidInCapitalSettlementOfLiabilityAwards":  {
                "auth_ref":  [
                    ],
                "crdr":  "credit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Adjustments to Additional Paid in Capital Settlement of Liability Awards",
                            "label":  "Adjustments to Additional Paid in Capital Settlement of Liability Awards",
                            "terseLabel":  "Settlement of liability awards"
                            }
                        }
                    },
                "localname":  "AdjustmentsToAdditionalPaidInCapitalSettlementOfLiabilityAwards",
                "nsuri":  "http://www.biolase.com/20210331",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_StatementConsolidatedStatementsOfRedeemablePreferredStockAndStockholdersEquityUnaudited"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "biol_AdjustmentsToAdditionalPaidInCapitalSettlementOfLiabilityAwardsShares":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Adjustments to additional paid in capital settlement of liability awards, shares",
                            "label":  "Adjustments to Additional Paid in Capital Settlement of Liability Awards, Shares",
                            "terseLabel":  "Settlement of liability awards, shares"
                            }
                        }
                    },
                "localname":  "AdjustmentsToAdditionalPaidInCapitalSettlementOfLiabilityAwardsShares",
                "nsuri":  "http://www.biolase.com/20210331",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_StatementConsolidatedStatementsOfRedeemablePreferredStockAndStockholdersEquityUnaudited"
                    ],
                "xbrltype":  "sharesItemType"
                },
            "biol_AggregateNumberOfUnitsSold":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Aggregate number of units sold.",
                            "label":  "Aggregate Number Of Units Sold",
                            "terseLabel":  "Aggregate number of units sold"
                            }
                        }
                    },
                "localname":  "AggregateNumberOfUnitsSold",
                "nsuri":  "http://www.biolase.com/20210331",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureDescriptionOfBusinessAndBasisOfPresentationAdditionalInformationDetail"
                    ],
                "xbrltype":  "sharesItemType"
                },
            "biol_AllocatedShareBasedCompensationExpenseCredit":  {
                "auth_ref":  [
                    ],
                "crdr":  "debit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Allocated share-based compensation expense (credit).",
                            "label":  "Allocated Share Based Compensation Expense Credit",
                            "verboseLabel":  "Compensation expense related to stock options"
                            }
                        }
                    },
                "localname":  "AllocatedShareBasedCompensationExpenseCredit",
                "nsuri":  "http://www.biolase.com/20210331",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureRedeemablePreferredStockAndStockholdersEquityAdditionalInformationDetail"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "biol_AllocatedToWarrantsBasedUponFairValues":  {
                "auth_ref":  [
                    ],
                "crdr":  "debit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Allocated to the warrants based upon fair values.",
                            "label":  "Allocated To Warrants Based Upon Fair Values",
                            "terseLabel":  "Allocated to the warrants based upon fair values"
                            }
                        }
                    },
                "localname":  "AllocatedToWarrantsBasedUponFairValues",
                "nsuri":  "http://www.biolase.com/20210331",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureRedeemablePreferredStockAndStockholdersEquityAdditionalInformationDetail"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "biol_AllocationToCommonStockBeforeIssuanceCosts":  {
                "auth_ref":  [
                    ],
                "crdr":  "credit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Allocation to common stock before issuance costs.",
                            "label":  "Allocation To Common Stock Before Issuance Costs",
                            "terseLabel":  "Allocation to common stock and warrants before issuance costs"
                            }
                        }
                    },
                "localname":  "AllocationToCommonStockBeforeIssuanceCosts",
                "nsuri":  "http://www.biolase.com/20210331",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureRedeemablePreferredStockAndStockholdersEquityAdditionalInformationDetail"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "biol_AllocationToPreferredStockBeforeIssuanceCosts":  {
                "auth_ref":  [
                    ],
                "crdr":  "credit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Allocation to preferred stock before issuance costs.",
                            "label":  "Allocation To Preferred Stock Before Issuance Costs",
                            "terseLabel":  "Allocation to preferred stock and warrants before issuance costs"
                            }
                        }
                    },
                "localname":  "AllocationToPreferredStockBeforeIssuanceCosts",
                "nsuri":  "http://www.biolase.com/20210331",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureRedeemablePreferredStockAndStockholdersEquityAdditionalInformationDetail"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "biol_AllocationToWarrantsBeforeIssuanceCosts":  {
                "auth_ref":  [
                    ],
                "crdr":  "credit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Allocation to warrants before issuance costs.",
                            "label":  "Allocation To Warrants Before Issuance Costs",
                            "terseLabel":  "Allocation to preferred stock and warrants before issuance costs"
                            }
                        }
                    },
                "localname":  "AllocationToWarrantsBeforeIssuanceCosts",
                "nsuri":  "http://www.biolase.com/20210331",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureRedeemablePreferredStockAndStockholdersEquityAdditionalInformationDetail"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "biol_BasisOfPresentationLineItems":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Basis of presentation.",
                            "label":  "Basis Of Presentation [Line Items]",
                            "terseLabel":  "Basis Of Presentation [Line Items]"
                            }
                        }
                    },
                "localname":  "BasisOfPresentationLineItems",
                "nsuri":  "http://www.biolase.com/20210331",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureDescriptionOfBusinessAndBasisOfPresentationAdditionalInformationDetail"
                    ],
                "xbrltype":  "stringItemType"
                },
            "biol_BasisOfPresentationTable":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Basis of presentation.",
                            "label":  "Basis Of Presentation [Table]",
                            "terseLabel":  "Basis Of Presentation [Table]"
                            }
                        }
                    },
                "localname":  "BasisOfPresentationTable",
                "nsuri":  "http://www.biolase.com/20210331",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureDescriptionOfBusinessAndBasisOfPresentationAdditionalInformationDetail"
                    ],
                "xbrltype":  "stringItemType"
                },
            "biol_BusinessFinancingAgreementMember":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Business financing agreement.",
                            "label":  "Business Financing Agreement [Member]",
                            "terseLabel":  "Business Financing Agreement"
                            }
                        }
                    },
                "localname":  "BusinessFinancingAgreementMember",
                "nsuri":  "http://www.biolase.com/20210331",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetail"
                    ],
                "xbrltype":  "domainItemType"
                },
            "biol_CashPaidForOperatingLeases":  {
                "auth_ref":  [
                    ],
                "crdr":  "credit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Cash paid for operating leases.",
                            "label":  "Cash Paid For Operating Leases",
                            "terseLabel":  "Cash paid for operating leases"
                            }
                        }
                    },
                "localname":  "CashPaidForOperatingLeases",
                "nsuri":  "http://www.biolase.com/20210331",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlowsUnaudited"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "biol_CashProceedsAlongWithFairValueDisclosuresRelatedToGrantsExercisesAndVestingOptionsTableTextBlock":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Cash proceeds along with fair value disclosures related to grants, exercises and vesting options.",
                            "label":  "Cash Proceeds Along With Fair Value Disclosures Related To Grants Exercises And Vesting Options Table [Text Block]",
                            "terseLabel":  "Cash Proceeds, Along With Fair Value Disclosures Related to Grants, Exercises and Vesting Options"
                            }
                        }
                    },
                "localname":  "CashProceedsAlongWithFairValueDisclosuresRelatedToGrantsExercisesAndVestingOptionsTableTextBlock",
                "nsuri":  "http://www.biolase.com/20210331",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureRedeemablePreferredStockAndStockholdersEquityTables"
                    ],
                "xbrltype":  "textBlockItemType"
                },
            "biol_ClassOfWarrantOrRightExpirationDate":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Class of warrant or right expiration date.",
                            "label":  "Class Of Warrant Or Right Expiration Date",
                            "terseLabel":  "Warrants expire date"
                            }
                        }
                    },
                "localname":  "ClassOfWarrantOrRightExpirationDate",
                "nsuri":  "http://www.biolase.com/20210331",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetail"
                    ],
                "xbrltype":  "dateItemType"
                },
            "biol_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsValue":  {
                "auth_ref":  [
                    ],
                "crdr":  "credit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Class of warrant or right, number of securities called by warrants or rights, value.",
                            "label":  "Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights Value",
                            "terseLabel":  "Warrants issued to purchase shares of common stock equal value"
                            }
                        }
                    },
                "localname":  "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsValue",
                "nsuri":  "http://www.biolase.com/20210331",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetail"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "biol_ClassOfWarrantOrRightsExpirationDate":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Class of warrant or rights expiration date.",
                            "label":  "Class Of Warrant Or Rights Expiration Date",
                            "terseLabel":  "Warrants expire date"
                            }
                        }
                    },
                "localname":  "ClassOfWarrantOrRightsExpirationDate",
                "nsuri":  "http://www.biolase.com/20210331",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetail"
                    ],
                "xbrltype":  "dateItemType"
                },
            "biol_ClosingPriceOfCommonStock":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Closing price of common stock.",
                            "label":  "Closing Price Of Common Stock",
                            "terseLabel":  "Closing price of common stock"
                            }
                        }
                    },
                "localname":  "ClosingPriceOfCommonStock",
                "nsuri":  "http://www.biolase.com/20210331",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureRedeemablePreferredStockAndStockholdersEquityAdditionalInformationDetail"
                    ],
                "xbrltype":  "perShareItemType"
                },
            "biol_CombinedPurchasePricePerShareAndWarrant":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Combined purchase price per share and warrant.",
                            "label":  "Combined Purchase Price Per Share And Warrant",
                            "terseLabel":  "Combined purchase price of share and warrant"
                            }
                        }
                    },
                "localname":  "CombinedPurchasePricePerShareAndWarrant",
                "nsuri":  "http://www.biolase.com/20210331",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureRedeemablePreferredStockAndStockholdersEquityAdditionalInformationDetail"
                    ],
                "xbrltype":  "perShareItemType"
                },
            "biol_CommitmentAndContingenciesLineItems":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Commitment and contingencies.",
                            "label":  "Commitment And Contingencies [Line Items]",
                            "terseLabel":  "Commitment And Contingencies [Line Items]"
                            }
                        }
                    },
                "localname":  "CommitmentAndContingenciesLineItems",
                "nsuri":  "http://www.biolase.com/20210331",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
                    ],
                "xbrltype":  "stringItemType"
                },
            "biol_CommitmentAndContingenciesTable":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Commitment and contingencies.",
                            "label":  "Commitment And Contingencies [Table]",
                            "terseLabel":  "Commitment And Contingencies [Table]"
                            }
                        }
                    },
                "localname":  "CommitmentAndContingenciesTable",
                "nsuri":  "http://www.biolase.com/20210331",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
                    ],
                "xbrltype":  "stringItemType"
                },
            "biol_CommonStockIssuedPursuantToOptionsExercised":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Common stock issued pursuant to options exercised.",
                            "label":  "Common Stock Issued Pursuant To Options Exercised",
                            "terseLabel":  "Common stock issued pursuant to options exercised"
                            }
                        }
                    },
                "localname":  "CommonStockIssuedPursuantToOptionsExercised",
                "nsuri":  "http://www.biolase.com/20210331",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureRedeemablePreferredStockAndStockholdersEquityAdditionalInformationDetail"
                    ],
                "xbrltype":  "sharesItemType"
                },
            "biol_ComponentsOfInventoryAbstract":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Components of inventory.",
                            "label":  "Components Of Inventory [Abstract]",
                            "terseLabel":  "Components of inventory, net of allowances"
                            }
                        }
                    },
                "localname":  "ComponentsOfInventoryAbstract",
                "nsuri":  "http://www.biolase.com/20210331",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureComponentsOfInventoryDetail"
                    ],
                "xbrltype":  "stringItemType"
                },
            "biol_ConsumableAndOtherMember":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Consumable and other.",
                            "label":  "Consumable And Other [Member]",
                            "terseLabel":  "Consumables and other"
                            }
                        }
                    },
                "localname":  "ConsumableAndOtherMember",
                "nsuri":  "http://www.biolase.com/20210331",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureConcentrationsSummaryOfNetRevenueFromVariousProductsDetail"
                    ],
                "xbrltype":  "domainItemType"
                },
            "biol_ContractWithCustomerLiabilityInExtendedWarrantyContracts":  {
                "auth_ref":  [
                    ],
                "calculation":  {
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureSummaryOfOpeningAndClosingBalancesOfContractLiabilitiesDetail":  {
                        "order":  1.0,
                        "parentTag":  "us-gaap_ContractWithCustomerLiability",
                        "weight":  1.0
                        }
                    },
                "crdr":  "credit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Contract with customer liability in extended warranty contracts.",
                            "label":  "Contract With Customer Liability In Extended Warranty Contracts",
                            "terseLabel":  "Extended warranty contracts"
                            }
                        }
                    },
                "localname":  "ContractWithCustomerLiabilityInExtendedWarrantyContracts",
                "nsuri":  "http://www.biolase.com/20210331",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureSummaryOfOpeningAndClosingBalancesOfContractLiabilitiesDetail"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "biol_ContractWithCustomerLiabilityInUndeliveredElements":  {
                "auth_ref":  [
                    ],
                "calculation":  {
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureSummaryOfOpeningAndClosingBalancesOfContractLiabilitiesDetail":  {
                        "order":  0.0,
                        "parentTag":  "us-gaap_ContractWithCustomerLiability",
                        "weight":  1.0
                        }
                    },
                "crdr":  "credit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Contract with customer liability in undelivered elements.",
                            "label":  "Contract With Customer Liability In Undelivered Elements",
                            "terseLabel":  "Undelivered elements (training, installation, product and support services)",
                            "verboseLabel":  "Undelivered elements (product training, installation, product and support services)"
                            }
                        }
                    },
                "localname":  "ContractWithCustomerLiabilityInUndeliveredElements",
                "nsuri":  "http://www.biolase.com/20210331",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureRevenueRecognitionAdditionalInformationDetail",
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureSummaryOfOpeningAndClosingBalancesOfContractLiabilitiesDetail"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "biol_ContractWithCustomerLiabilityRevenueRecognizedExtendedWarranty":  {
                "auth_ref":  [
                    ],
                "crdr":  "credit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Contract with customer liability, revenue recognized, extended warranty.",
                            "label":  "Contract With Customer Liability Revenue Recognized Extended Warranty"
                            }
                        }
                    },
                "localname":  "ContractWithCustomerLiabilityRevenueRecognizedExtendedWarranty",
                "nsuri":  "http://www.biolase.com/20210331",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureRevenueRecognitionAdditionalInformationDetail"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "biol_ContractWithCustomerLiabilityRevenueRecognizedUndeliveredElements":  {
                "auth_ref":  [
                    ],
                "crdr":  "credit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Contract with customer liability, revenue recognized, undelivered elements.",
                            "label":  "Contract With Customer Liability Revenue Recognized Undelivered Elements",
                            "terseLabel":  "Revenue recognized from contract liability"
                            }
                        }
                    },
                "localname":  "ContractWithCustomerLiabilityRevenueRecognizedUndeliveredElements",
                "nsuri":  "http://www.biolase.com/20210331",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureRevenueRecognitionAdditionalInformationDetail"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "biol_ConvertiblePreferredStockAndWarrantsIssuanceCost":  {
                "auth_ref":  [
                    ],
                "crdr":  "debit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Convertible preferred stock and warrants issuance cost.",
                            "label":  "Convertible Preferred Stock And Warrants Issuance Cost",
                            "terseLabel":  "Convertible preferred stock in right offering, issuance cost"
                            }
                        }
                    },
                "localname":  "ConvertiblePreferredStockAndWarrantsIssuanceCost",
                "nsuri":  "http://www.biolase.com/20210331",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_StatementConsolidatedStatementsOfRedeemablePreferredStockAndShareholdersEquityParenthetical"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "biol_CoronaMember":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Corona.",
                            "label":  "Corona [Member]",
                            "terseLabel":  "Corona Lease [Member]"
                            }
                        }
                    },
                "localname":  "CoronaMember",
                "nsuri":  "http://www.biolase.com/20210331",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail"
                    ],
                "xbrltype":  "domainItemType"
                },
            "biol_CreditAgreementFifthAmendmentMember":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Credit agreement, fifth amendment.",
                            "label":  "Credit Agreement Fifth Amendment [Member]",
                            "terseLabel":  "Credit Agreement, Fifth Amendment"
                            }
                        }
                    },
                "localname":  "CreditAgreementFifthAmendmentMember",
                "nsuri":  "http://www.biolase.com/20210331",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetail"
                    ],
                "xbrltype":  "domainItemType"
                },
            "biol_CreditAgreementFirstAmendmentMember":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Credit agreement, first amendment.",
                            "label":  "Credit Agreement First Amendment [Member]",
                            "terseLabel":  "Credit Agreement, First Amendment"
                            }
                        }
                    },
                "localname":  "CreditAgreementFirstAmendmentMember",
                "nsuri":  "http://www.biolase.com/20210331",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetail"
                    ],
                "xbrltype":  "domainItemType"
                },
            "biol_CreditAgreementSecondAmendmentMember":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Credit agreement second amendment.",
                            "label":  "Credit Agreement Second Amendment [Member]",
                            "terseLabel":  "Credit Agreement, Second Amendment"
                            }
                        }
                    },
                "localname":  "CreditAgreementSecondAmendmentMember",
                "nsuri":  "http://www.biolase.com/20210331",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetail"
                    ],
                "xbrltype":  "domainItemType"
                },
            "biol_CreditAgreementSeventhAmendmentMember":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Credit agreement seventh amendment.",
                            "label":  "Credit Agreement Seventh Amendment [Member]",
                            "terseLabel":  "Credit Agreement, Seventh Amendment"
                            }
                        }
                    },
                "localname":  "CreditAgreementSeventhAmendmentMember",
                "nsuri":  "http://www.biolase.com/20210331",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetail"
                    ],
                "xbrltype":  "domainItemType"
                },
            "biol_CreditAgreementSixthAmendmentMember":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Credit Agreement, Sixth Amendment [Member]",
                            "label":  "Credit Agreement Sixth Amendment [Member]",
                            "terseLabel":  "Credit Agreement, Sixth Amendment"
                            }
                        }
                    },
                "localname":  "CreditAgreementSixthAmendmentMember",
                "nsuri":  "http://www.biolase.com/20210331",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetail"
                    ],
                "xbrltype":  "domainItemType"
                },
            "biol_CumulativeEffectOnRetainedEarnings":  {
                "auth_ref":  [
                    ],
                "crdr":  "debit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Cumulative effect on retained earnings.",
                            "label":  "Cumulative Effect On Retained Earnings",
                            "terseLabel":  "Cumulative-effect adjustment to retained earnings"
                            }
                        }
                    },
                "localname":  "CumulativeEffectOnRetainedEarnings",
                "nsuri":  "http://www.biolase.com/20210331",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "biol_DealPartnersGroupWarrantsMember":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Deal partners group warrants.",
                            "label":  "Deal Partners Group Warrants [Member]",
                            "terseLabel":  "DPG Warrants"
                            }
                        }
                    },
                "localname":  "DealPartnersGroupWarrantsMember",
                "nsuri":  "http://www.biolase.com/20210331",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetail"
                    ],
                "xbrltype":  "domainItemType"
                },
            "biol_DebtInstrumentAdditionalFindersFee":  {
                "auth_ref":  [
                    ],
                "crdr":  "debit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Debt instrument additional finders fee.",
                            "label":  "Debt Instrument Additional Finders Fee",
                            "terseLabel":  "Additional finders fee"
                            }
                        }
                    },
                "localname":  "DebtInstrumentAdditionalFindersFee",
                "nsuri":  "http://www.biolase.com/20210331",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetail"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "biol_DebtInstrumentCovenantsUnencumberedLiquidAssets":  {
                "auth_ref":  [
                    ],
                "crdr":  "debit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Debt instrument covenants unencumbered liquid assets.",
                            "label":  "Debt Instrument Covenants Unencumbered Liquid Assets",
                            "verboseLabel":  "Debt instrument covenants unencumbered liquid assets"
                            }
                        }
                    },
                "localname":  "DebtInstrumentCovenantsUnencumberedLiquidAssets",
                "nsuri":  "http://www.biolase.com/20210331",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetail"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "biol_DebtInstrumentFeeAndOtherFeePayable":  {
                "auth_ref":  [
                    ],
                "crdr":  "debit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Debt instrument fee and other fee payable.",
                            "label":  "Debt Instrument Fee And Other Fee Payable",
                            "terseLabel":  "Loan origination and other fees to be paid"
                            }
                        }
                    },
                "localname":  "DebtInstrumentFeeAndOtherFeePayable",
                "nsuri":  "http://www.biolase.com/20210331",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetail"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "biol_DebtInstrumentFinancialCovenantAdditionalBorrowings":  {
                "auth_ref":  [
                    ],
                "crdr":  "credit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Debt instrument financial covenant additional borrowings.",
                            "label":  "Debt Instrument Financial Covenant Additional Borrowings",
                            "terseLabel":  "Financial covenant additional borrowings"
                            }
                        }
                    },
                "localname":  "DebtInstrumentFinancialCovenantAdditionalBorrowings",
                "nsuri":  "http://www.biolase.com/20210331",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetail"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "biol_DebtInstrumentFinancialCovenantsIncreaseInMinimumLiquidityRequirement":  {
                "auth_ref":  [
                    ],
                "crdr":  "debit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Debt instrument financial covenants increase in minimum liquidity requirement.",
                            "label":  "Debt Instrument Financial Covenants Increase In Minimum Liquidity Requirement",
                            "terseLabel":  "Increase in minimum liquidity requirement if aggregate minimum revenue and EBITDA levels are not achieved"
                            }
                        }
                    },
                "localname":  "DebtInstrumentFinancialCovenantsIncreaseInMinimumLiquidityRequirement",
                "nsuri":  "http://www.biolase.com/20210331",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetail"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "biol_DebtInstrumentFinancialCovenantsMinimumLiquidityAmount":  {
                "auth_ref":  [
                    ],
                "crdr":  "debit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Debt instrument financial covenants minimum liquidity amount.",
                            "label":  "Debt Instrument Financial Covenants Minimum Liquidity Amount",
                            "terseLabel":  "Minimum level of liquidity financial covenant"
                            }
                        }
                    },
                "localname":  "DebtInstrumentFinancialCovenantsMinimumLiquidityAmount",
                "nsuri":  "http://www.biolase.com/20210331",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetail"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "biol_DebtInstrumentFindersFee":  {
                "auth_ref":  [
                    ],
                "crdr":  "debit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Debt instrument finder's fee.",
                            "label":  "Debt Instrument Finders Fee",
                            "terseLabel":  "Finder's fee"
                            }
                        }
                    },
                "localname":  "DebtInstrumentFindersFee",
                "nsuri":  "http://www.biolase.com/20210331",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetail"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "biol_DebtInstrumentLegalAndOtherFees":  {
                "auth_ref":  [
                    ],
                "crdr":  "debit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Debt instrument legal and other fees.",
                            "label":  "Debt Instrument Legal And Other Fees",
                            "terseLabel":  "Legal and other fees"
                            }
                        }
                    },
                "localname":  "DebtInstrumentLegalAndOtherFees",
                "nsuri":  "http://www.biolase.com/20210331",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetail"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "biol_DebtInstrumentMaximumAggregateOfferingPrice":  {
                "auth_ref":  [
                    ],
                "crdr":  "credit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Debt instrument, maximum aggregate offering price.",
                            "label":  "Debt Instrument Maximum Aggregate Offering Price",
                            "terseLabel":  "Maximum aggregate offering price"
                            }
                        }
                    },
                "localname":  "DebtInstrumentMaximumAggregateOfferingPrice",
                "nsuri":  "http://www.biolase.com/20210331",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetail"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "biol_DebtInstrumentNotePrepaymentPenalties":  {
                "auth_ref":  [
                    ],
                "crdr":  "debit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Debt instrument note prepayment penalties.",
                            "label":  "Debt Instrument Note Prepayment Penalties",
                            "terseLabel":  "Note prepayment penalties"
                            }
                        }
                    },
                "localname":  "DebtInstrumentNotePrepaymentPenalties",
                "nsuri":  "http://www.biolase.com/20210331",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetail"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "biol_DebtInstrumentPrincipalRepaymentsTermMaturityYear":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Debt instrument, principal repayments maturity term.",
                            "label":  "Debt Instrument Principal Repayments Term Maturity Year",
                            "terseLabel":  "Debt instrument, maturity term"
                            }
                        }
                    },
                "localname":  "DebtInstrumentPrincipalRepaymentsTermMaturityYear",
                "nsuri":  "http://www.biolase.com/20210331",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetail"
                    ],
                "xbrltype":  "gYearItemType"
                },
            "biol_DebtInstrumentPrincipalRepaymentsTermStartYear":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Debt instrument principal repayments term start year.",
                            "label":  "Debt Instrument Principal Repayments Term Start Year",
                            "terseLabel":  "Debt instrument, principal repayments beginning term"
                            }
                        }
                    },
                "localname":  "DebtInstrumentPrincipalRepaymentsTermStartYear",
                "nsuri":  "http://www.biolase.com/20210331",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetail"
                    ],
                "xbrltype":  "gYearItemType"
                },
            "biol_DebtInstrumentRepaymentOfInterestOnlyOnLoanPeriod":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Debt instrument repayment of interest only on loan period.",
                            "label":  "Debt Instrument Repayment Of Interest Only On Loan Period",
                            "terseLabel":  "Debt instrument, repayment of interest-only on loan period"
                            }
                        }
                    },
                "localname":  "DebtInstrumentRepaymentOfInterestOnlyOnLoanPeriod",
                "nsuri":  "http://www.biolase.com/20210331",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetail"
                    ],
                "xbrltype":  "durationItemType"
                },
            "biol_DeemedDividendOnConvertiblePreferredStock":  {
                "auth_ref":  [
                    ],
                "calculation":  {
                    "http://www.biolase.com/20210331/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited2":  {
                        "order":  1.0,
                        "parentTag":  "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
                        "weight":  -1.0
                        }
                    },
                "crdr":  "debit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Deemed dividend on convertible preferred stock",
                            "label":  "Deemed Dividend on Convertible Preferred Stock"
                            }
                        }
                    },
                "localname":  "DeemedDividendOnConvertiblePreferredStock",
                "nsuri":  "http://www.biolase.com/20210331",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited",
                    "http://www.biolase.com/20210331/taxonomy/role/Role_StatementConsolidatedStatementsOfRedeemablePreferredStockAndStockholdersEquityUnaudited"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "biol_DeferredRoyalties":  {
                "auth_ref":  [
                    ],
                "crdr":  "credit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Deferred Royalties",
                            "label":  "Deferred Royalties",
                            "terseLabel":  "Deferred royalties"
                            }
                        }
                    },
                "localname":  "DeferredRoyalties",
                "nsuri":  "http://www.biolase.com/20210331",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureRevenueRecognitionAdditionalInformationDetail"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "biol_DiodeSystemsMember":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Diode systems.",
                            "label":  "Diode Systems [Member]",
                            "terseLabel":  "Diode Systems"
                            }
                        }
                    },
                "localname":  "DiodeSystemsMember",
                "nsuri":  "http://www.biolase.com/20210331",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureAccruedLiabilitiesAdditionalInformationDetail"
                    ],
                "xbrltype":  "domainItemType"
                },
            "biol_EIDLLoanMember":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "EIDL loan.",
                            "label":  "E I D L Loan [Member]",
                            "terseLabel":  "EIDL Loan"
                            }
                        }
                    },
                "localname":  "EIDLLoanMember",
                "nsuri":  "http://www.biolase.com/20210331",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail",
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetail",
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureDebtSummaryOfPrincipalOutstandingAndUnamortizedDiscountDetail"
                    ],
                "xbrltype":  "domainItemType"
                },
            "biol_EngineeringAndDevelopmentMember":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Engineering and development.",
                            "label":  "Engineering And Development [Member]",
                            "terseLabel":  "Engineering and Development"
                            }
                        }
                    },
                "localname":  "EngineeringAndDevelopmentMember",
                "nsuri":  "http://www.biolase.com/20210331",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureClassificationOfCompensationExpenseAssociatedWithShareBasedPaymentsDetail"
                    ],
                "xbrltype":  "domainItemType"
                },
            "biol_EntityWideAccountsReceivableMajorCustomerNumber":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Entity wide accounts receivable, major customer, number.",
                            "label":  "Entity Wide Accounts Receivable Major Customer Number",
                            "terseLabel":  "Number of customers which represented more than 10% of the Company's accounts receivable"
                            }
                        }
                    },
                "localname":  "EntityWideAccountsReceivableMajorCustomerNumber",
                "nsuri":  "http://www.biolase.com/20210331",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureConcentrationsAdditionalInformationDetail"
                    ],
                "xbrltype":  "integerItemType"
                },
            "biol_EntityWideRevenueMajorCustomerNumber":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Entity wide revenue, major customer, number.",
                            "label":  "Entity Wide Revenue Major Customer Number",
                            "terseLabel":  "Number of customers which represented more than 10% of the Company's revenue"
                            }
                        }
                    },
                "localname":  "EntityWideRevenueMajorCustomerNumber",
                "nsuri":  "http://www.biolase.com/20210331",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureConcentrationsAdditionalInformationDetail",
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureSegmentInformationAdditionalInformationDetail"
                    ],
                "xbrltype":  "integerItemType"
                },
            "biol_EximBankMember":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Exim Bank.",
                            "label":  "Exim Bank [Member]",
                            "terseLabel":  "Exim Bank"
                            }
                        }
                    },
                "localname":  "EximBankMember",
                "nsuri":  "http://www.biolase.com/20210331",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetail"
                    ],
                "xbrltype":  "domainItemType"
                },
            "biol_FoothillRanchMember":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Foothill ranch.",
                            "label":  "Foothill Ranch [Member]",
                            "terseLabel":  "Foothill Ranch [Member]"
                            }
                        }
                    },
                "localname":  "FoothillRanchMember",
                "nsuri":  "http://www.biolase.com/20210331",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail"
                    ],
                "xbrltype":  "domainItemType"
                },
            "biol_ImagingSystemMember":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Imaging system.",
                            "label":  "Imaging System [Member]",
                            "terseLabel":  "Imaging systems"
                            }
                        }
                    },
                "localname":  "ImagingSystemMember",
                "nsuri":  "http://www.biolase.com/20210331",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureConcentrationsSummaryOfNetRevenueFromVariousProductsDetail"
                    ],
                "xbrltype":  "domainItemType"
                },
            "biol_IncrementalAmendmentFee":  {
                "auth_ref":  [
                    ],
                "crdr":  "debit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Incremental amendment fee",
                            "label":  "Incremental Amendment Fee",
                            "terseLabel":  "Incremental amendment fee"
                            }
                        }
                    },
                "localname":  "IncrementalAmendmentFee",
                "nsuri":  "http://www.biolase.com/20210331",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetail"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "biol_InformationRelatedToOperatingRightOfUseAssetsAndRelatedLiabilitiesTableTextBlock":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Information related to operating right-of-use assets and related liabilities.",
                            "label":  "Information Related To Operating Right Of Use Assets And Related Liabilities Table [Text Block]",
                            "terseLabel":  "Information related to Right-of-use Assets and Liabilities"
                            }
                        }
                    },
                "localname":  "InformationRelatedToOperatingRightOfUseAssetsAndRelatedLiabilitiesTableTextBlock",
                "nsuri":  "http://www.biolase.com/20210331",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureLeasesTables"
                    ],
                "xbrltype":  "textBlockItemType"
                },
            "biol_IssuanceOfCommonStockForSettlementOfLiability":  {
                "auth_ref":  [
                    ],
                "crdr":  "credit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Issuance Of Common Stock For Settlement Of Liability",
                            "label":  "Issuance Of Common Stock For Settlement Of Liability",
                            "terseLabel":  "Issuance of common stock for settlement of liability"
                            }
                        }
                    },
                "localname":  "IssuanceOfCommonStockForSettlementOfLiability",
                "nsuri":  "http://www.biolase.com/20210331",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_StatementConsolidatedStatementsOfRedeemablePreferredStockAndStockholdersEquityUnaudited"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "biol_IssuanceOfCommonStockForSettlementOfLiabilityShares":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Issuance Of Common Stock For Settlement Of Liability Shares",
                            "label":  "Issuance Of Common Stock For Settlement Of Liability Shares",
                            "terseLabel":  "Issuance of common stock for settlement of liability, Shares"
                            }
                        }
                    },
                "localname":  "IssuanceOfCommonStockForSettlementOfLiabilityShares",
                "nsuri":  "http://www.biolase.com/20210331",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_StatementConsolidatedStatementsOfRedeemablePreferredStockAndStockholdersEquityUnaudited"
                    ],
                "xbrltype":  "sharesItemType"
                },
            "biol_JulyTwoThousandTwentyWarrantsMember":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "July two thousand twenty warrants.",
                            "label":  "July Two Thousand Twenty Warrants [Member]",
                            "terseLabel":  "July 2020 Warrants"
                            }
                        }
                    },
                "localname":  "JulyTwoThousandTwentyWarrantsMember",
                "nsuri":  "http://www.biolase.com/20210331",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureRedeemablePreferredStockAndStockholdersEquityAdditionalInformationDetail"
                    ],
                "xbrltype":  "domainItemType"
                },
            "biol_June2020WarrantsMember":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "June 2020 Warrants [Member].",
                            "label":  "June2020 Warrants [Member]",
                            "terseLabel":  "June 2020 Warrants"
                            }
                        }
                    },
                "localname":  "June2020WarrantsMember",
                "nsuri":  "http://www.biolase.com/20210331",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureRedeemablePreferredStockAndStockholdersEquityAdditionalInformationDetail"
                    ],
                "xbrltype":  "domainItemType"
                },
            "biol_LaserSystemsMember":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Laser systems.",
                            "label":  "Laser Systems [Member]",
                            "terseLabel":  "Laser systems"
                            }
                        }
                    },
                "localname":  "LaserSystemsMember",
                "nsuri":  "http://www.biolase.com/20210331",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureConcentrationsSummaryOfNetRevenueFromVariousProductsDetail"
                    ],
                "xbrltype":  "domainItemType"
                },
            "biol_LeaseCommencementDate":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Lease Commencement Date",
                            "label":  "Lease Commencement Date"
                            }
                        }
                    },
                "localname":  "LeaseCommencementDate",
                "nsuri":  "http://www.biolase.com/20210331",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail"
                    ],
                "xbrltype":  "dateItemType"
                },
            "biol_LeaseFacilityArea":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Lease facility area.",
                            "label":  "Lease Facility Area",
                            "terseLabel":  "Lease facility area"
                            }
                        }
                    },
                "localname":  "LeaseFacilityArea",
                "nsuri":  "http://www.biolase.com/20210331",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail"
                    ],
                "xbrltype":  "areaItemType"
                },
            "biol_LesseeOperatingLeaseInitialTermOfContract":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Lessee operating lease initial term of contract.",
                            "label":  "Lessee Operating Lease Initial Term Of Contract",
                            "terseLabel":  "Lease initial term of contract"
                            }
                        }
                    },
                "localname":  "LesseeOperatingLeaseInitialTermOfContract",
                "nsuri":  "http://www.biolase.com/20210331",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail"
                    ],
                "xbrltype":  "durationItemType"
                },
            "biol_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour":  {
                "auth_ref":  [
                    ],
                "crdr":  "credit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Lessee Operating Lease Liability Payments Due After Year Four",
                            "label":  "Lessee Operating Lease Liability Payments Due After Year Four",
                            "terseLabel":  "2026 and thereafter"
                            }
                        }
                    },
                "localname":  "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour",
                "nsuri":  "http://www.biolase.com/20210331",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetail"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "biol_LicenseFeesAndRoyaltiesMember":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "License fees and royalties.",
                            "label":  "License Fees And Royalties [Member]",
                            "terseLabel":  "License fees and royalties"
                            }
                        }
                    },
                "localname":  "LicenseFeesAndRoyaltiesMember",
                "nsuri":  "http://www.biolase.com/20210331",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureConcentrationsSummaryOfNetRevenueFromVariousProductsDetail"
                    ],
                "xbrltype":  "domainItemType"
                },
            "biol_LineOfCreditFacilityAnnualFee":  {
                "auth_ref":  [
                    ],
                "crdr":  "debit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Line of credit facility annual fee.",
                            "label":  "Line Of Credit Facility Annual Fee",
                            "terseLabel":  "Annual fee"
                            }
                        }
                    },
                "localname":  "LineOfCreditFacilityAnnualFee",
                "nsuri":  "http://www.biolase.com/20210331",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetail"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "biol_LineOfCreditFacilityCovenantUnrestrictedCashAmountDepositedWithLenders":  {
                "auth_ref":  [
                    ],
                "crdr":  "debit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Line of credit facility, covenant, unrestricted cash amount deposited with lender.",
                            "label":  "Line Of Credit Facility Covenant Unrestricted Cash Amount Deposited With Lenders",
                            "terseLabel":  "Company maintains unrestricted cash"
                            }
                        }
                    },
                "localname":  "LineOfCreditFacilityCovenantUnrestrictedCashAmountDepositedWithLenders",
                "nsuri":  "http://www.biolase.com/20210331",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetail"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "biol_LineOfCreditFacilityInitialAndAnnualFee":  {
                "auth_ref":  [
                    ],
                "crdr":  "debit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Line of credit facility initial and annual fee.",
                            "label":  "Line of Credit Facility Initial and Annual Fee",
                            "terseLabel":  "Line of credit facility initial and annual fee"
                            }
                        }
                    },
                "localname":  "LineOfCreditFacilityInitialAndAnnualFee",
                "nsuri":  "http://www.biolase.com/20210331",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetail"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "biol_LineOfCreditFacilityMaximumBorrowingPercentageOfEligibleAccounts":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Line of credit facility maximum borrowing percentage of eligible accounts.",
                            "label":  "Line Of Credit Facility Maximum Borrowing Percentage Of Eligible Accounts",
                            "terseLabel":  "Maximum borrowing base percentage of eligible accounts"
                            }
                        }
                    },
                "localname":  "LineOfCreditFacilityMaximumBorrowingPercentageOfEligibleAccounts",
                "nsuri":  "http://www.biolase.com/20210331",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetail"
                    ],
                "xbrltype":  "percentItemType"
                },
            "biol_LineOfCreditFacilityMaximumBorrowingPercentageOfEligibleInventory":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Line of credit facility maximum borrowing percentage of eligible accounts inventory.",
                            "label":  "Line Of Credit Facility Maximum Borrowing Percentage Of Eligible Inventory",
                            "terseLabel":  "Maximum borrowing base percentage of eligible inventory"
                            }
                        }
                    },
                "localname":  "LineOfCreditFacilityMaximumBorrowingPercentageOfEligibleInventory",
                "nsuri":  "http://www.biolase.com/20210331",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetail"
                    ],
                "xbrltype":  "percentItemType"
                },
            "biol_LineOfCreditTerminationFee":  {
                "auth_ref":  [
                    ],
                "crdr":  "debit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Line of credit termination fee.",
                            "label":  "Line Of Credit Termination Fee",
                            "terseLabel":  "Termination fee"
                            }
                        }
                    },
                "localname":  "LineOfCreditTerminationFee",
                "nsuri":  "http://www.biolase.com/20210331",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetail"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "biol_LiquidityAndManagementPlansPolicyTextBlock":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Liquidity and management plans.",
                            "label":  "Liquidity And Management Plans Policy [Text Block]",
                            "terseLabel":  "Liquidity and Management's Plans"
                            }
                        }
                    },
                "localname":  "LiquidityAndManagementPlansPolicyTextBlock",
                "nsuri":  "http://www.biolase.com/20210331",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
                    ],
                "xbrltype":  "textBlockItemType"
                },
            "biol_LitigationSettlementAmountInCashEqualToDifferenceBetweenValueOfStockConsideration":  {
                "auth_ref":  [
                    ],
                "crdr":  "credit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Litigation settlement amount in cash equal to difference between value of stock consideration.",
                            "label":  "Litigation Settlement Amount In Cash Equal To Difference Between Value Of Stock Consideration",
                            "terseLabel":  "Litigation settlement amount in cash equal to difference between value of stock consideration"
                            }
                        }
                    },
                "localname":  "LitigationSettlementAmountInCashEqualToDifferenceBetweenValueOfStockConsideration",
                "nsuri":  "http://www.biolase.com/20210331",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "biol_LitigationSettlementSharesIssued":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Litigation settlement shares issued.",
                            "label":  "Litigation Settlement Shares Issued",
                            "terseLabel":  "Litigation settlement share issued"
                            }
                        }
                    },
                "localname":  "LitigationSettlementSharesIssued",
                "nsuri":  "http://www.biolase.com/20210331",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
                    ],
                "xbrltype":  "sharesItemType"
                },
            "biol_LoanAgreementMember":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Loan agreement.",
                            "label":  "Loan Agreement [Member]",
                            "terseLabel":  "Loan Agreement"
                            }
                        }
                    },
                "localname":  "LoanAgreementMember",
                "nsuri":  "http://www.biolase.com/20210331",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetail"
                    ],
                "xbrltype":  "domainItemType"
                },
            "biol_LoanForgivenessDescriptionOfPeriod":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Loan forgiveness description of period.",
                            "label":  "Loan Forgiveness Description Of Period",
                            "terseLabel":  "Loan forgiveness description of period"
                            }
                        }
                    },
                "localname":  "LoanForgivenessDescriptionOfPeriod",
                "nsuri":  "http://www.biolase.com/20210331",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetail"
                    ],
                "xbrltype":  "stringItemType"
                },
            "biol_LongTermDebtMaturitiesRepaymentsOfInterest":  {
                "auth_ref":  [
                    ],
                "calculation":  {
                    "http://www.biolase.com/20210331/taxonomy/role/DisclosureDebtSummaryOfFutureMinimumPrincipalAndInterestPaymentsDetail2":  {
                        "order":  null,
                        "parentTag":  null,
                        "root":  true,
                        "weight":  null
                        }
                    },
                "crdr":  "credit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Long term debt maturities repayments of interest.",
                            "label":  "Long Term Debt Maturities Repayments Of Interest",
                            "totalLabel":  "Total future payments"
                            }
                        }
                    },
                "localname":  "LongTermDebtMaturitiesRepaymentsOfInterest",
                "nsuri":  "http://www.biolase.com/20210331",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureDebtSummaryOfFutureMinimumPrincipalAndInterestPaymentsDetail"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "biol_LongTermDebtMaturitiesRepaymentsOfInterestInNextTwelveMonths":  {
                "auth_ref":  [
                    ],
                "calculation":  {
                    "http://www.biolase.com/20210331/taxonomy/role/DisclosureDebtSummaryOfFutureMinimumPrincipalAndInterestPaymentsDetail2":  {
                        "order":  1.0,
                        "parentTag":  "biol_LongTermDebtMaturitiesRepaymentsOfInterest",
                        "weight":  1.0
                        }
                    },
                "crdr":  "credit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Long term debt maturities repayments of interest in next twelve months.",
                            "label":  "Long Term Debt Maturities Repayments of Interest in Next Twelve Months",
                            "terseLabel":  "2022"
                            }
                        }
                    },
                "localname":  "LongTermDebtMaturitiesRepaymentsOfInterestInNextTwelveMonths",
                "nsuri":  "http://www.biolase.com/20210331",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureDebtSummaryOfFutureMinimumPrincipalAndInterestPaymentsDetail"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "biol_LongTermDebtMaturitiesRepaymentsOfInterestInYearAfterFive":  {
                "auth_ref":  [
                    ],
                "calculation":  {
                    "http://www.biolase.com/20210331/taxonomy/role/DisclosureDebtSummaryOfFutureMinimumPrincipalAndInterestPaymentsDetail2":  {
                        "order":  5.0,
                        "parentTag":  "biol_LongTermDebtMaturitiesRepaymentsOfInterest",
                        "weight":  1.0
                        }
                    },
                "crdr":  "credit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Long term debt maturities repayments of interest in year after five.",
                            "label":  "Long Term Debt Maturities Repayments Of Interest In Year After Five",
                            "terseLabel":  "2025 and thereafter",
                            "verboseLabel":  "2026 and thereafter"
                            }
                        }
                    },
                "localname":  "LongTermDebtMaturitiesRepaymentsOfInterestInYearAfterFive",
                "nsuri":  "http://www.biolase.com/20210331",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureDebtSummaryOfFutureMinimumPrincipalAndInterestPaymentsDetail"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "biol_LongTermDebtMaturitiesRepaymentsOfInterestInYearFour":  {
                "auth_ref":  [
                    ],
                "calculation":  {
                    "http://www.biolase.com/20210331/taxonomy/role/DisclosureDebtSummaryOfFutureMinimumPrincipalAndInterestPaymentsDetail2":  {
                        "order":  4.0,
                        "parentTag":  "biol_LongTermDebtMaturitiesRepaymentsOfInterest",
                        "weight":  1.0
                        }
                    },
                "crdr":  "credit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Long term debt maturities repayments of interest in year four.",
                            "label":  "Long Term Debt Maturities Repayments Of Interest In Year Four",
                            "terseLabel":  "2023",
                            "verboseLabel":  "2025"
                            }
                        }
                    },
                "localname":  "LongTermDebtMaturitiesRepaymentsOfInterestInYearFour",
                "nsuri":  "http://www.biolase.com/20210331",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureDebtSummaryOfFutureMinimumPrincipalAndInterestPaymentsDetail"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "biol_LongTermDebtMaturitiesRepaymentsOfInterestInYearThree":  {
                "auth_ref":  [
                    ],
                "calculation":  {
                    "http://www.biolase.com/20210331/taxonomy/role/DisclosureDebtSummaryOfFutureMinimumPrincipalAndInterestPaymentsDetail2":  {
                        "order":  3.0,
                        "parentTag":  "biol_LongTermDebtMaturitiesRepaymentsOfInterest",
                        "weight":  1.0
                        }
                    },
                "crdr":  "credit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Long term debt maturities repayments of interest in year three.",
                            "label":  "Long Term Debt Maturities Repayments Of Interest In Year Three",
                            "terseLabel":  "2022",
                            "verboseLabel":  "2024"
                            }
                        }
                    },
                "localname":  "LongTermDebtMaturitiesRepaymentsOfInterestInYearThree",
                "nsuri":  "http://www.biolase.com/20210331",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureDebtSummaryOfFutureMinimumPrincipalAndInterestPaymentsDetail"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "biol_LongTermDebtMaturitiesRepaymentsOfInterestInYearTwo":  {
                "auth_ref":  [
                    ],
                "calculation":  {
                    "http://www.biolase.com/20210331/taxonomy/role/DisclosureDebtSummaryOfFutureMinimumPrincipalAndInterestPaymentsDetail2":  {
                        "order":  2.0,
                        "parentTag":  "biol_LongTermDebtMaturitiesRepaymentsOfInterest",
                        "weight":  1.0
                        }
                    },
                "crdr":  "credit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Long-term debt maturities repayments of interest in year two.",
                            "label":  "Long Term Debt Maturities Repayments Of Interest In Year Two",
                            "terseLabel":  "2021",
                            "verboseLabel":  "2023"
                            }
                        }
                    },
                "localname":  "LongTermDebtMaturitiesRepaymentsOfInterestInYearTwo",
                "nsuri":  "http://www.biolase.com/20210331",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureDebtSummaryOfFutureMinimumPrincipalAndInterestPaymentsDetail"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "biol_LongTermDebtMaturitiesRepaymentsOfInterestRemainderOfFiscalYear":  {
                "auth_ref":  [
                    ],
                "calculation":  {
                    "http://www.biolase.com/20210331/taxonomy/role/DisclosureDebtSummaryOfFutureMinimumPrincipalAndInterestPaymentsDetail2":  {
                        "order":  0.0,
                        "parentTag":  "biol_LongTermDebtMaturitiesRepaymentsOfInterest",
                        "weight":  1.0
                        }
                    },
                "crdr":  "credit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Long term debt maturities repayments of interest remainder of fiscal year.",
                            "label":  "Long Term Debt Maturities Repayments Of Interest Remainder Of Fiscal Year",
                            "terseLabel":  "2020 (nine months)",
                            "verboseLabel":  "2021 (nine months)"
                            }
                        }
                    },
                "localname":  "LongTermDebtMaturitiesRepaymentsOfInterestRemainderOfFiscalYear",
                "nsuri":  "http://www.biolase.com/20210331",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureDebtSummaryOfFutureMinimumPrincipalAndInterestPaymentsDetail"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "biol_MezzanineEquityMember":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Mezzanine equity.",
                            "label":  "Mezzanine Equity [Member]",
                            "terseLabel":  "Mezzanine Equity"
                            }
                        }
                    },
                "localname":  "MezzanineEquityMember",
                "nsuri":  "http://www.biolase.com/20210331",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_StatementConsolidatedStatementsOfRedeemablePreferredStockAndStockholdersEquityUnaudited"
                    ],
                "xbrltype":  "domainItemType"
                },
            "biol_NonCashSettlementOfPerformanceAwardLiability":  {
                "auth_ref":  [
                    ],
                "crdr":  "credit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Non-cash settlement of performance award liability.",
                            "label":  "Non Cash Settlement Of Performance Award Liability",
                            "terseLabel":  "Non-cash settlement of liability"
                            }
                        }
                    },
                "localname":  "NonCashSettlementOfPerformanceAwardLiability",
                "nsuri":  "http://www.biolase.com/20210331",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlowsUnaudited"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "biol_NonPayrollCostsPercentageRateForLoanForgivness":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Non-payroll costs percentage rate for loan forgivness.",
                            "label":  "Non Payroll Costs Percentage Rate For Loan Forgivness",
                            "terseLabel":  "Nonpayroll costs eligible for loan forgiveness percentage"
                            }
                        }
                    },
                "localname":  "NonPayrollCostsPercentageRateForLoanForgivness",
                "nsuri":  "http://www.biolase.com/20210331",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetail"
                    ],
                "xbrltype":  "percentItemType"
                },
            "biol_NumberOfDaysLitigationSettlementSharesToBeIssued":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Number of days litigation settlement shares to be issued.",
                            "label":  "Number Of Days Litigation Settlement Shares To Be Issued",
                            "terseLabel":  "Number of days litigation settlement shares to be issued"
                            }
                        }
                    },
                "localname":  "NumberOfDaysLitigationSettlementSharesToBeIssued",
                "nsuri":  "http://www.biolase.com/20210331",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
                    ],
                "xbrltype":  "durationItemType"
                },
            "biol_NumberOfDaysLitigationSettlementToBePaidInCash":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Number of days litigation settlement to be paid in cash.",
                            "label":  "Number Of Days Litigation Settlement To Be Paid In Cash",
                            "terseLabel":  "Number of days litigation settlement to be paid in cash"
                            }
                        }
                    },
                "localname":  "NumberOfDaysLitigationSettlementToBePaidInCash",
                "nsuri":  "http://www.biolase.com/20210331",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
                    ],
                "xbrltype":  "durationItemType"
                },
            "biol_NumberOfDaysLitigationSettlementToBePaidInValueOfStockConsideration":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Number of days litigation settlement to be paid in value of stock consideration.",
                            "label":  "Number Of Days Litigation Settlement To Be Paid In Value Of Stock Consideration",
                            "terseLabel":  "Number of days litigation settlement to be paid in value of stock consideration"
                            }
                        }
                    },
                "localname":  "NumberOfDaysLitigationSettlementToBePaidInValueOfStockConsideration",
                "nsuri":  "http://www.biolase.com/20210331",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
                    ],
                "xbrltype":  "durationItemType"
                },
            "biol_NumberOfNewRealPropertyLeases":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Number of new real property leases.",
                            "label":  "Number Of New Real Property Leases",
                            "terseLabel":  "Number of new real property leases"
                            }
                        }
                    },
                "localname":  "NumberOfNewRealPropertyLeases",
                "nsuri":  "http://www.biolase.com/20210331",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail"
                    ],
                "xbrltype":  "integerItemType"
                },
            "biol_NumberOfTradingDays":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Number of trading days.",
                            "label":  "Number Of Trading Days",
                            "terseLabel":  "Number of trading days of average closing price of common stock"
                            }
                        }
                    },
                "localname":  "NumberOfTradingDays",
                "nsuri":  "http://www.biolase.com/20210331",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetail"
                    ],
                "xbrltype":  "integerItemType"
                },
            "biol_OfferingOfCommonStock":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Offering of common stock.",
                            "label":  "Offering Of Common Stock",
                            "terseLabel":  "Common stock offered"
                            }
                        }
                    },
                "localname":  "OfferingOfCommonStock",
                "nsuri":  "http://www.biolase.com/20210331",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureRedeemablePreferredStockAndStockholdersEquityAdditionalInformationDetail"
                    ],
                "xbrltype":  "sharesItemType"
                },
            "biol_OperatingLeaseWeightedAverageRemainingLeaseTerms":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Operating Lease, Weighted Average Remaining Lease Terms.",
                            "label":  "Operating Lease Weighted Average Remaining Lease Terms",
                            "terseLabel":  "Weighted-average remaining lease term"
                            }
                        }
                    },
                "localname":  "OperatingLeaseWeightedAverageRemainingLeaseTerms",
                "nsuri":  "http://www.biolase.com/20210331",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureLeasesInformationRelatedToRightOfUseAssetsAndLiabilitiesDetail"
                    ],
                "xbrltype":  "durationItemType"
                },
            "biol_OriginalPaymentDefermentPeriod":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Original payment deferment period.",
                            "label":  "Original Payment Deferment Period",
                            "terseLabel":  "Original payment deferment period"
                            }
                        }
                    },
                "localname":  "OriginalPaymentDefermentPeriod",
                "nsuri":  "http://www.biolase.com/20210331",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetail"
                    ],
                "xbrltype":  "durationItemType"
                },
            "biol_OriginalWesternAllianceWarrantMember":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Original western alliance warrant.",
                            "label":  "Original Western Alliance Warrant [Member]",
                            "terseLabel":  "Original Western Alliance Warrant"
                            }
                        }
                    },
                "localname":  "OriginalWesternAllianceWarrantMember",
                "nsuri":  "http://www.biolase.com/20210331",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetail"
                    ],
                "xbrltype":  "domainItemType"
                },
            "biol_OtherOfferingExpenses":  {
                "auth_ref":  [
                    ],
                "crdr":  "debit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Other offering expenses.",
                            "label":  "Other Offering Expenses",
                            "terseLabel":  "Other offering expenses"
                            }
                        }
                    },
                "localname":  "OtherOfferingExpenses",
                "nsuri":  "http://www.biolase.com/20210331",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureRedeemablePreferredStockAndStockholdersEquityAdditionalInformationDetail"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "biol_PacificMercantileBankMember":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Pacific Mercantile Bank.",
                            "label":  "Pacific Mercantile Bank [Member]",
                            "terseLabel":  "Pacific Mercantile Bank"
                            }
                        }
                    },
                "localname":  "PacificMercantileBankMember",
                "nsuri":  "http://www.biolase.com/20210331",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetail",
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureDescriptionOfBusinessAndBasisOfPresentationAdditionalInformationDetail"
                    ],
                "xbrltype":  "domainItemType"
                },
            "biol_PatentLitigationMarkToMarket":  {
                "auth_ref":  [
                    ],
                "calculation":  {
                    "http://www.biolase.com/20210331/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlowsUnaudited":  {
                        "order":  7.0,
                        "parentTag":  "us-gaap_NetCashProvidedByUsedInOperatingActivities",
                        "weight":  1.0
                        }
                    },
                "crdr":  "debit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Patent litigation mark-to-market.",
                            "label":  "Patent Litigation Mark-to-Market",
                            "terseLabel":  "Patent litigation mark-to-market"
                            }
                        }
                    },
                "localname":  "PatentLitigationMarkToMarket",
                "nsuri":  "http://www.biolase.com/20210331",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlowsUnaudited"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "biol_PatentLitigationMember":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Patent litigation.",
                            "label":  "Patent Litigation [Member]",
                            "terseLabel":  "Patent Litigation"
                            }
                        }
                    },
                "localname":  "PatentLitigationMember",
                "nsuri":  "http://www.biolase.com/20210331",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
                    ],
                "xbrltype":  "domainItemType"
                },
            "biol_PaycheckProtectionProgramLoanMember":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Paycheck protection program loan.",
                            "label":  "Paycheck Protection Program Loan [Member]",
                            "terseLabel":  "PPP Loan"
                            }
                        }
                    },
                "localname":  "PaycheckProtectionProgramLoanMember",
                "nsuri":  "http://www.biolase.com/20210331",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetail",
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureDebtSummaryOfPrincipalOutstandingAndUnamortizedDiscountDetail"
                    ],
                "xbrltype":  "domainItemType"
                },
            "biol_PerformanceBasedAwardsMember":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Performance Based Awards.",
                            "label":  "Performance Based Awards Member",
                            "terseLabel":  "Performance-Based Awards"
                            }
                        }
                    },
                "localname":  "PerformanceBasedAwardsMember",
                "nsuri":  "http://www.biolase.com/20210331",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureRedeemablePreferredStockAndStockholdersEquityAdditionalInformationDetail"
                    ],
                "xbrltype":  "domainItemType"
                },
            "biol_ProceedsAllocatedToWarrantsBasedUponFairValues":  {
                "auth_ref":  [
                    ],
                "crdr":  "debit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Proceeds allocated to the warrants based upon fair values.",
                            "label":  "Proceeds Allocated To Warrants Based Upon Fair Values",
                            "terseLabel":  "Proceeds allocated to the warrants based upon fair values"
                            }
                        }
                    },
                "localname":  "ProceedsAllocatedToWarrantsBasedUponFairValues",
                "nsuri":  "http://www.biolase.com/20210331",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureRedeemablePreferredStockAndStockholdersEquityAdditionalInformationDetail"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "biol_ProceedsFromCommonStockAndWarrants":  {
                "auth_ref":  [
                    ],
                "crdr":  "debit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Proceeds from common stock and warrants.",
                            "label":  "Proceeds From Common Stock And Warrants",
                            "terseLabel":  "Proceeds of common stock and warrants"
                            }
                        }
                    },
                "localname":  "ProceedsFromCommonStockAndWarrants",
                "nsuri":  "http://www.biolase.com/20210331",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureRedeemablePreferredStockAndStockholdersEquityAdditionalInformationDetail"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "biol_ProceedsFromSubordinatedDebtThresholdLimit":  {
                "auth_ref":  [
                    ],
                "crdr":  "debit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Proceeds from subordinated debt threshold limit.",
                            "label":  "Proceeds From Subordinated Debt Threshold Limit",
                            "terseLabel":  "Gross proceeds from subordinated debt threshold limit"
                            }
                        }
                    },
                "localname":  "ProceedsFromSubordinatedDebtThresholdLimit",
                "nsuri":  "http://www.biolase.com/20210331",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetail"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "biol_ProceedsFromWarrantExercise":  {
                "auth_ref":  [
                    ],
                "crdr":  "debit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "The cash inflow associated with the amount received from holder exercising their stock warrant.",
                            "label":  "Proceeds from Warrant Exercise"
                            }
                        }
                    },
                "localname":  "ProceedsFromWarrantExercise",
                "nsuri":  "http://www.biolase.com/20210331",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureRedeemablePreferredStockAndStockholdersEquityAdditionalInformationDetail"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "biol_ProductWarrantTerm":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Product warrant term.",
                            "label":  "Product Warrant Term",
                            "terseLabel":  "Product warrant period"
                            }
                        }
                    },
                "localname":  "ProductWarrantTerm",
                "nsuri":  "http://www.biolase.com/20210331",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureAccruedLiabilitiesAdditionalInformationDetail"
                    ],
                "xbrltype":  "durationItemType"
                },
            "biol_PropertyPlantAndEquipmentGrossExcludingLand":  {
                "auth_ref":  [
                    ],
                "calculation":  {
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureSummaryOfPropertyPlantAndEquipmentDetail":  {
                        "order":  0.0,
                        "parentTag":  "biol_PropertyPlantAndEquipmentNetExcludingLand",
                        "weight":  1.0
                        }
                    },
                "crdr":  "debit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Gross amount of long-lived physical assets used in the normal conduct of business and not intended for resale.  Examples include, but are not limited to, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
                            "label":  "Property Plant And Equipment Gross Excluding Land",
                            "terseLabel":  "Property, plant, and equipment gross, excluding land"
                            }
                        }
                    },
                "localname":  "PropertyPlantAndEquipmentGrossExcludingLand",
                "nsuri":  "http://www.biolase.com/20210331",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureSummaryOfPropertyPlantAndEquipmentDetail"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "biol_PropertyPlantAndEquipmentNetExcludingLand":  {
                "auth_ref":  [
                    ],
                "calculation":  {
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureSummaryOfPropertyPlantAndEquipmentDetail":  {
                        "order":  0.0,
                        "parentTag":  "us-gaap_PropertyPlantAndEquipmentNet",
                        "weight":  1.0
                        }
                    },
                "crdr":  "debit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Property plant and equipment net, excluding land.",
                            "label":  "Property Plant And Equipment Net Excluding Land",
                            "totalLabel":  "Property, plant, and equipment, net before land"
                            }
                        }
                    },
                "localname":  "PropertyPlantAndEquipmentNetExcludingLand",
                "nsuri":  "http://www.biolase.com/20210331",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureSummaryOfPropertyPlantAndEquipmentDetail"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "biol_ProvisionForSalesReturns":  {
                "auth_ref":  [
                    ],
                "calculation":  {
                    "http://www.biolase.com/20210331/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlowsUnaudited":  {
                        "order":  3.0,
                        "parentTag":  "us-gaap_NetCashProvidedByUsedInOperatingActivities",
                        "weight":  1.0
                        }
                    },
                "crdr":  "debit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Provision for sales returns.",
                            "label":  "Provision For Sales Returns",
                            "terseLabel":  "Provision for sales returns"
                            }
                        }
                    },
                "localname":  "ProvisionForSalesReturns",
                "nsuri":  "http://www.biolase.com/20210331",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlowsUnaudited"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "biol_RevenueFromProductsAndServicesTransferredToCustomersPercentage":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Revenue from products and services transferred to customers at a single point in time, percentage.",
                            "label":  "Revenue From Products And Services Transferred To Customers Percentage",
                            "terseLabel":  "Revenue from products and services transferred to customers, percentage"
                            }
                        }
                    },
                "localname":  "RevenueFromProductsAndServicesTransferredToCustomersPercentage",
                "nsuri":  "http://www.biolase.com/20210331",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureRevenueRecognitionAdditionalInformationDetail"
                    ],
                "xbrltype":  "percentItemType"
                },
            "biol_RevenueFromServicesTransferredToCustomersOverTimePercentage":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Revenue from services transferred to customers over time, percentage.",
                            "label":  "Revenue From Services Transferred To Customers Over Time Percentage",
                            "terseLabel":  "Revenue from services transferred to customers over time, percentage"
                            }
                        }
                    },
                "localname":  "RevenueFromServicesTransferredToCustomersOverTimePercentage",
                "nsuri":  "http://www.biolase.com/20210331",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureRevenueRecognitionAdditionalInformationDetail"
                    ],
                "xbrltype":  "percentItemType"
                },
            "biol_SWKWarrantsAndDealPartnersGroupWarrantsMember":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "SWK warrants and Deal partners group warrants.",
                            "label":  "S W K Warrants And Deal Partners Group Warrants [Member]",
                            "terseLabel":  "SWK Warrants and DPG Warrants"
                            }
                        }
                    },
                "localname":  "SWKWarrantsAndDealPartnersGroupWarrantsMember",
                "nsuri":  "http://www.biolase.com/20210331",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetail"
                    ],
                "xbrltype":  "domainItemType"
                },
            "biol_SWKWarrantsMember":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "SWK warrants.",
                            "label":  "S W K Warrants [Member]",
                            "terseLabel":  "SWK Warrants"
                            }
                        }
                    },
                "localname":  "SWKWarrantsMember",
                "nsuri":  "http://www.biolase.com/20210331",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetail"
                    ],
                "xbrltype":  "domainItemType"
                },
            "biol_SeriesFConvertiblePreferredStockMember":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Series F convertible preferred stock.",
                            "label":  "Series F Convertible Preferred Stock [Member]",
                            "terseLabel":  "Series F Convertible Preferred Stock"
                            }
                        }
                    },
                "localname":  "SeriesFConvertiblePreferredStockMember",
                "nsuri":  "http://www.biolase.com/20210331",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureDescriptionOfBusinessAndBasisOfPresentationAdditionalInformationDetail"
                    ],
                "xbrltype":  "domainItemType"
                },
            "biol_SeriesFPreferredStockAndJulyTwoThousandTwentyAmendmentMember":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Series F preferred stock and july two thousand twenty amendment.",
                            "label":  "Series F Preferred Stock And July Two Thousand Twenty Amendment [Member]",
                            "terseLabel":  "Series F Preferred Stock and July Two Thousand Twenty Amendment"
                            }
                        }
                    },
                "localname":  "SeriesFPreferredStockAndJulyTwoThousandTwentyAmendmentMember",
                "nsuri":  "http://www.biolase.com/20210331",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureRedeemablePreferredStockAndStockholdersEquityAdditionalInformationDetail"
                    ],
                "xbrltype":  "domainItemType"
                },
            "biol_SeriesFPreferredStockAndJulyTwoThousandTwentyMember":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Series F preferred stock and july two thousand twenty.",
                            "label":  "Series F Preferred Stock And July Two Thousand Twenty [Member]",
                            "terseLabel":  "Series F Convertible Preferred Stock and July 2020 Warrants"
                            }
                        }
                    },
                "localname":  "SeriesFPreferredStockAndJulyTwoThousandTwentyMember",
                "nsuri":  "http://www.biolase.com/20210331",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureRedeemablePreferredStockAndStockholdersEquityAdditionalInformationDetail"
                    ],
                "xbrltype":  "domainItemType"
                },
            "biol_SettlementLiabilityAccrualClassifiedCurrent":  {
                "auth_ref":  [
                    ],
                "crdr":  "credit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Settlement Liability Accrual Classified Current",
                            "label":  "Settlement Liability Accrual Classified Current",
                            "terseLabel":  "Settlement accrual"
                            }
                        }
                    },
                "localname":  "SettlementLiabilityAccrualClassifiedCurrent",
                "nsuri":  "http://www.biolase.com/20210331",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureComponentsOfAccruedLiabilitiesDetail"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "biol_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCanceledInPeriod":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "The number of equity-based payment instruments, excluding stock (or unit) options, that were canceled during the reporting period.",
                            "label":  "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Canceled In Period",
                            "terseLabel":  "Cancelled RSU due to non achievement of performance targets"
                            }
                        }
                    },
                "localname":  "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCanceledInPeriod",
                "nsuri":  "http://www.biolase.com/20210331",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureRedeemablePreferredStockAndStockholdersEquityAdditionalInformationDetail"
                    ],
                "xbrltype":  "sharesItemType"
                },
            "biol_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableNumber":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Share based compensation arrangement by share based payment award equity instruments other than options exercisable number.",
                            "label":  "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Exercisable Number",
                            "terseLabel":  "Warrants exercisable at September 30, 2020",
                            "verboseLabel":  "Warrants exercisable at March 31, 2021"
                            }
                        }
                    },
                "localname":  "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableNumber",
                "nsuri":  "http://www.biolase.com/20210331",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureSummaryOfWarrantActivityDetail"
                    ],
                "xbrltype":  "sharesItemType"
                },
            "biol_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageExercisePrice":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Share based compensation arrangement by share based payment award equity instruments other than options exercisable weighted average exercise price.",
                            "label":  "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Exercisable Weighted Average Exercise Price",
                            "terseLabel":  "Warrants exercisable at September 30, 2020",
                            "verboseLabel":  "Warrants exercisable at March 31, 2021"
                            }
                        }
                    },
                "localname":  "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageExercisePrice",
                "nsuri":  "http://www.biolase.com/20210331",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureSummaryOfWarrantActivityDetail"
                    ],
                "xbrltype":  "perShareItemType"
                },
            "biol_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Sharebased compensation arrangement by sharebased payment award equity instruments other than options expired in period.",
                            "label":  "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Expired In Period",
                            "terseLabel":  "Vested warrants expired during the period ended September 30, 2020",
                            "verboseLabel":  "Vested warrants expired during the period ended March 31, 2021"
                            }
                        }
                    },
                "localname":  "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod",
                "nsuri":  "http://www.biolase.com/20210331",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureSummaryOfWarrantActivityDetail"
                    ],
                "xbrltype":  "sharesItemType"
                },
            "biol_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriodWeightedAverageGrantDateFairValue":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Share based compensation arrangement by share based payment award equity instruments other than options expired in period weighted average grant date fair value.",
                            "label":  "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Expired In Period Weighted Average Grant Date Fair Value",
                            "terseLabel":  "Vested warrants expired during the period ended September 30, 2020",
                            "verboseLabel":  "Vested warrants expired during the period ended March 31, 2021"
                            }
                        }
                    },
                "localname":  "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriodWeightedAverageGrantDateFairValue",
                "nsuri":  "http://www.biolase.com/20210331",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureSummaryOfWarrantActivityDetail"
                    ],
                "xbrltype":  "perShareItemType"
                },
            "biol_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedCancelledAndExpiredInPeriodWeightedAverageGrantDateFairValue":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Share based compensation arrangement by share based payment award equity instruments other than options forfeited, cancelled or expired in period weighted average grant date fair value.",
                            "label":  "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited Cancelled And Expired In Period Weighted Average Grant Date Fair Value",
                            "terseLabel":  "Forfeited, cancelled, or expired"
                            }
                        }
                    },
                "localname":  "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedCancelledAndExpiredInPeriodWeightedAverageGrantDateFairValue",
                "nsuri":  "http://www.biolase.com/20210331",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureSummaryOfWarrantActivityDetail"
                    ],
                "xbrltype":  "perShareItemType"
                },
            "biol_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePrice":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Share based compensation arrangement by share based payment award equity instruments other than options weighted average exercise price.",
                            "label":  "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Weighted Average Exercise Price",
                            "periodEndLabel":  "Ending Balance",
                            "periodStartLabel":  "Beginning Balance"
                            }
                        }
                    },
                "localname":  "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePrice",
                "nsuri":  "http://www.biolase.com/20210331",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureSummaryOfWarrantActivityDetail"
                    ],
                "xbrltype":  "perShareItemType"
                },
            "biol_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividend":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Share based compensation arrangement by share based payment award fair value assumptions expected dividend.",
                            "label":  "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend",
                            "terseLabel":  "Annual dividend per share"
                            }
                        }
                    },
                "localname":  "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividend",
                "nsuri":  "http://www.biolase.com/20210331",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureAssumptionsUsedInEstimatingFairValueOfStockOptionsGrantedDetail"
                    ],
                "xbrltype":  "perShareItemType"
                },
            "biol_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRestrictedStockUnitsOutstandingNumber":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Share based compensation arrangement by share based payment award options and restricted stock units outstanding number.",
                            "label":  "Share Based Compensation Arrangement By Share Based Payment Award Options And Restricted Stock Units Outstanding Number",
                            "terseLabel":  "Options and restricted stock units outstanding"
                            }
                        }
                    },
                "localname":  "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRestrictedStockUnitsOutstandingNumber",
                "nsuri":  "http://www.biolase.com/20210331",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureRedeemablePreferredStockAndStockholdersEquityAdditionalInformationDetail"
                    ],
                "xbrltype":  "sharesItemType"
                },
            "biol_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAtFairMarketValue":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Share based compensation arrangement by share based payment award options grants in period at fair market value.",
                            "label":  "Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period At Fair Market Value",
                            "terseLabel":  "Granted at fair market value"
                            }
                        }
                    },
                "localname":  "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAtFairMarketValue",
                "nsuri":  "http://www.biolase.com/20210331",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureSummaryOfOptionActivityDetail"
                    ],
                "xbrltype":  "sharesItemType"
                },
            "biol_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Share based compensation arrangement by share based payment award options weighted average remaining contractual term.",
                            "label":  "Share Based Compensation Arrangement By Share Based Payment Award Options Weighted Average Remaining Contractual Term [Abstract]",
                            "terseLabel":  "Weighted-Average Remaining Contractual Term (Years)"
                            }
                        }
                    },
                "localname":  "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract",
                "nsuri":  "http://www.biolase.com/20210331",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureSummaryOfOptionActivityDetail"
                    ],
                "xbrltype":  "stringItemType"
                },
            "biol_ShareBasedCompensationArrangementByShareBasedPaymentAwardRecognizedWeightedAverageExpectedDate":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Share-based Compensation Arrangement by Share-based Payment Award, Recognized Weighted Average Expected date",
                            "label":  "Share-based Compensation Arrangement by Share-based Payment Award, Recognized Weighted Average Expected date",
                            "terseLabel":  "Share-based compensation arrangement by share-based payment award, recognized weighted average expected date"
                            }
                        }
                    },
                "localname":  "ShareBasedCompensationArrangementByShareBasedPaymentAwardRecognizedWeightedAverageExpectedDate",
                "nsuri":  "http://www.biolase.com/20210331",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureRedeemablePreferredStockAndStockholdersEquityAdditionalInformationDetail"
                    ],
                "xbrltype":  "gYearMonthItemType"
                },
            "biol_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestedOptionsExpirationsInPeriod":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Share based compensation arrangement by share based payment award vested options expirations in period.",
                            "label":  "Share Based Compensation Arrangement By Share Based Payment Award Vested Options Expirations In Period",
                            "terseLabel":  "Vested options expired during the period ended September 30, 2020",
                            "verboseLabel":  "Vested options expired during the period ended March 31, 2021"
                            }
                        }
                    },
                "localname":  "ShareBasedCompensationArrangementByShareBasedPaymentAwardVestedOptionsExpirationsInPeriod",
                "nsuri":  "http://www.biolase.com/20210331",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureSummaryOfOptionActivityDetail"
                    ],
                "xbrltype":  "sharesItemType"
                },
            "biol_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestedOptionsExpirationsInPeriodWeightedAverageExercisePrice":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Share based compensation arrangement by share based payment award vested options expirations in period weighted average exercise price.",
                            "label":  "Share Based Compensation Arrangement By Share Based Payment Award Vested Options Expirations In Period Weighted Average Exercise Price",
                            "terseLabel":  "Vested options expired during the period ended September 30, 2020",
                            "verboseLabel":  "Vested options expired during the period ended March 31, 2021"
                            }
                        }
                    },
                "localname":  "ShareBasedCompensationArrangementByShareBasedPaymentAwardVestedOptionsExpirationsInPeriodWeightedAverageExercisePrice",
                "nsuri":  "http://www.biolase.com/20210331",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureSummaryOfOptionActivityDetail"
                    ],
                "xbrltype":  "perShareItemType"
                },
            "biol_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePriceAtFairMarketValue":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Share based compensation arrangements by share based payment award options grants in period weighted average exercise price at fair market value.",
                            "label":  "Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price At Fair Market Value",
                            "terseLabel":  "Granted at fair market value"
                            }
                        }
                    },
                "localname":  "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePriceAtFairMarketValue",
                "nsuri":  "http://www.biolase.com/20210331",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureSummaryOfOptionActivityDetail"
                    ],
                "xbrltype":  "perShareItemType"
                },
            "biol_StockIssuedDuringPeriodSharesCommonStockWarrantsExercised":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Stock issued during period shares common stock warrants exercised.",
                            "label":  "Stock Issued During Period Shares Common Stock Warrants Exercised",
                            "terseLabel":  "Exercise of common stock warrants, shares"
                            }
                        }
                    },
                "localname":  "StockIssuedDuringPeriodSharesCommonStockWarrantsExercised",
                "nsuri":  "http://www.biolase.com/20210331",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_StatementConsolidatedStatementsOfRedeemablePreferredStockAndStockholdersEquityUnaudited"
                    ],
                "xbrltype":  "sharesItemType"
                },
            "biol_StockIssuedDuringPeriodValueCommonStockWarrantsExercised":  {
                "auth_ref":  [
                    ],
                "crdr":  "credit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Stock issued during period value common stock warrants exercised.",
                            "label":  "Stock Issued During Period Value Common Stock Warrants Exercised",
                            "terseLabel":  "Exercise of common stock warrants"
                            }
                        }
                    },
                "localname":  "StockIssuedDuringPeriodValueCommonStockWarrantsExercised",
                "nsuri":  "http://www.biolase.com/20210331",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_StatementConsolidatedStatementsOfRedeemablePreferredStockAndStockholdersEquityUnaudited"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "biol_SummaryOfRevenuesDisaggregatedByTimingOfGoodsAndServicesTransferredTableTextBlock":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Summary of revenues disaggregated by timing of goods and services transferred.",
                            "label":  "Summary Of Revenues Disaggregated By Timing Of Goods And Services Transferred Table [Text Block]",
                            "terseLabel":  "Summary of Revenues Disaggregated by Timing of Goods and Services Transferred"
                            }
                        }
                    },
                "localname":  "SummaryOfRevenuesDisaggregatedByTimingOfGoodsAndServicesTransferredTableTextBlock",
                "nsuri":  "http://www.biolase.com/20210331",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureRevenueRecognitionTables"
                    ],
                "xbrltype":  "textBlockItemType"
                },
            "biol_SummaryOfSalesByEndMarketTableTextBlock":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Summary of sales by end market.",
                            "label":  "Summary Of Sales By End Market Table [Text Block]",
                            "terseLabel":  "Summary of Sales by End Market"
                            }
                        }
                    },
                "localname":  "SummaryOfSalesByEndMarketTableTextBlock",
                "nsuri":  "http://www.biolase.com/20210331",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureRevenueRecognitionTables"
                    ],
                "xbrltype":  "textBlockItemType"
                },
            "biol_SwkFundingLlcMember":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "SWK Funding LLC.",
                            "label":  "Swk Funding Llc [Member]",
                            "terseLabel":  "SWK Loan"
                            }
                        }
                    },
                "localname":  "SwkFundingLlcMember",
                "nsuri":  "http://www.biolase.com/20210331",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetail",
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureDebtSummaryOfPrincipalOutstandingAndUnamortizedDiscountDetail",
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureDescriptionOfBusinessAndBasisOfPresentationAdditionalInformationDetail"
                    ],
                "xbrltype":  "domainItemType"
                },
            "biol_TemporaryEquityAndEquityAbstract":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Temporary equity and equity.",
                            "label":  "Temporary Equity And Equity [Abstract]"
                            }
                        }
                    },
                "localname":  "TemporaryEquityAndEquityAbstract",
                "nsuri":  "http://www.biolase.com/20210331",
                "xbrltype":  "stringItemType"
                },
            "biol_TemporaryEquityAndStockholdersEquityLineItems":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Temporary equity and stockholders equity.",
                            "label":  "Temporary Equity And Stockholders Equity [Line Items]",
                            "terseLabel":  "Temporary Equity And Stockholders Equity [Line Items]"
                            }
                        }
                    },
                "localname":  "TemporaryEquityAndStockholdersEquityLineItems",
                "nsuri":  "http://www.biolase.com/20210331",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureRedeemablePreferredStockAndStockholdersEquityAdditionalInformationDetail"
                    ],
                "xbrltype":  "stringItemType"
                },
            "biol_TemporaryEquityAndStockholdersEquityNoteDisclosureTextBlock":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Temporary equity and Stockholders equity note disclosure.",
                            "label":  "Temporary Equity And Stockholders Equity Note Disclosure [Text Block]",
                            "terseLabel":  "Redeemable Preferred Stock and Stockholders' Equity"
                            }
                        }
                    },
                "localname":  "TemporaryEquityAndStockholdersEquityNoteDisclosureTextBlock",
                "nsuri":  "http://www.biolase.com/20210331",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureRedeemablePreferredStockAndStockholdersEquity"
                    ],
                "xbrltype":  "textBlockItemType"
                },
            "biol_TemporaryEquityAndStockholdersEquityTable":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Temporary equity and stockholders equity.",
                            "label":  "Temporary Equity And Stockholders Equity [Table]",
                            "terseLabel":  "Temporary Equity And Stockholders Equity [Table]"
                            }
                        }
                    },
                "localname":  "TemporaryEquityAndStockholdersEquityTable",
                "nsuri":  "http://www.biolase.com/20210331",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureRedeemablePreferredStockAndStockholdersEquityAdditionalInformationDetail"
                    ],
                "xbrltype":  "stringItemType"
                },
            "biol_TemporaryEquityConversionOfPreferredStockIntoCommonStock":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Temporary equity conversion of preferred stock into common stock.",
                            "label":  "Temporary Equity Conversion Of Preferred Stock Into Common Stock",
                            "terseLabel":  "Conversion of preferred stock into common stock"
                            }
                        }
                    },
                "localname":  "TemporaryEquityConversionOfPreferredStockIntoCommonStock",
                "nsuri":  "http://www.biolase.com/20210331",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureRedeemablePreferredStockAndStockholdersEquityAdditionalInformationDetail"
                    ],
                "xbrltype":  "sharesItemType"
                },
            "biol_TemporaryEquityNetProceedsFromConversionToCommonStock":  {
                "auth_ref":  [
                    ],
                "crdr":  "debit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Temporary equity net proceeds from conversion to common stock.",
                            "label":  "Temporary Equity Net Proceeds From Conversion To Common Stock",
                            "terseLabel":  "Temporary equity net proceeds from conversion to common stock"
                            }
                        }
                    },
                "localname":  "TemporaryEquityNetProceedsFromConversionToCommonStock",
                "nsuri":  "http://www.biolase.com/20210331",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureRedeemablePreferredStockAndStockholdersEquityAdditionalInformationDetail"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "biol_TemporaryEquityNumbersOfSharesSold":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Temporary equity numbers of shares sold.",
                            "label":  "Temporary Equity Numbers Of Shares Sold",
                            "terseLabel":  "Temporary equity numbers of shares sold"
                            }
                        }
                    },
                "localname":  "TemporaryEquityNumbersOfSharesSold",
                "nsuri":  "http://www.biolase.com/20210331",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureRedeemablePreferredStockAndStockholdersEquityAdditionalInformationDetail"
                    ],
                "xbrltype":  "sharesItemType"
                },
            "biol_TwoThousandEighteenLongTermIncentivePlanMember":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "2018 Long-Term Incentive Plan.",
                            "label":  "Two Thousand Eighteen Long Term Incentive Plan [Member]",
                            "terseLabel":  "2018 Long-Term Incentive Plan"
                            }
                        }
                    },
                "localname":  "TwoThousandEighteenLongTermIncentivePlanMember",
                "nsuri":  "http://www.biolase.com/20210331",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureRedeemablePreferredStockAndStockholdersEquityAdditionalInformationDetail"
                    ],
                "xbrltype":  "domainItemType"
                },
            "biol_TwoThousandTwoStockIncentivePlanMember":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "2002 stock incentive plan.",
                            "label":  "Two Thousand Two Stock Incentive Plan [Member]",
                            "terseLabel":  "2002 Stock Incentive Plan"
                            }
                        }
                    },
                "localname":  "TwoThousandTwoStockIncentivePlanMember",
                "nsuri":  "http://www.biolase.com/20210331",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureRedeemablePreferredStockAndStockholdersEquityAdditionalInformationDetail"
                    ],
                "xbrltype":  "domainItemType"
                },
            "biol_WarrantExpirationDate":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Warrant expiration date.",
                            "label":  "Warrant Expiration Date",
                            "terseLabel":  "Warrant expiration date"
                            }
                        }
                    },
                "localname":  "WarrantExpirationDate",
                "nsuri":  "http://www.biolase.com/20210331",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureRedeemablePreferredStockAndStockholdersEquityAdditionalInformationDetail"
                    ],
                "xbrltype":  "dateItemType"
                },
            "biol_WarrantsAdjustedExercisePrice":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Warrants adjusted exercise price.",
                            "label":  "Warrants Adjusted Exercise Price",
                            "terseLabel":  "Warrants adjusted exercise price"
                            }
                        }
                    },
                "localname":  "WarrantsAdjustedExercisePrice",
                "nsuri":  "http://www.biolase.com/20210331",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetail"
                    ],
                "xbrltype":  "perShareItemType"
                },
            "biol_WarrantsAdjustedStrikePrice":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Warrants adjusted strike price.",
                            "label":  "Warrants Adjusted Strike Price",
                            "terseLabel":  "Warrants adjusted strike price"
                            }
                        }
                    },
                "localname":  "WarrantsAdjustedStrikePrice",
                "nsuri":  "http://www.biolase.com/20210331",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetail"
                    ],
                "xbrltype":  "perShareItemType"
                },
            "biol_WarrantsEffectiveInterestMethodAmortizationPeriod":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Warrants effective interest-method amortization period.",
                            "label":  "Warrants Effective Interest Method Amortization Period",
                            "terseLabel":  "Warrants effective-interest method amortization period"
                            }
                        }
                    },
                "localname":  "WarrantsEffectiveInterestMethodAmortizationPeriod",
                "nsuri":  "http://www.biolase.com/20210331",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetail"
                    ],
                "xbrltype":  "durationItemType"
                },
            "biol_WarrantsFairValueAssumptionsAnnualDividendPerShare":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Warrants fair value assumptions annual dividend per share.",
                            "label":  "Warrants Fair Value Assumptions Annual Dividend Per Share",
                            "terseLabel":  "Warrants fair value assumptions annual dividend per share"
                            }
                        }
                    },
                "localname":  "WarrantsFairValueAssumptionsAnnualDividendPerShare",
                "nsuri":  "http://www.biolase.com/20210331",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetail"
                    ],
                "xbrltype":  "perShareItemType"
                },
            "biol_WarrantsFairValueAssumptionsExpectedTerm":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Warrants fair value assumptions expected term.",
                            "label":  "Warrants Fair Value Assumptions Expected Term",
                            "terseLabel":  "Warrants expiration period"
                            }
                        }
                    },
                "localname":  "WarrantsFairValueAssumptionsExpectedTerm",
                "nsuri":  "http://www.biolase.com/20210331",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetail"
                    ],
                "xbrltype":  "durationItemType"
                },
            "biol_WarrantsFairValueAssumptionsExpectedVolatilityRate":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Warrants, fair value assumptions, expected volatility rate.",
                            "label":  "Warrants Fair Value Assumptions Expected Volatility Rate",
                            "terseLabel":  "Warrants fair value assumptions, expected volatility rate"
                            }
                        }
                    },
                "localname":  "WarrantsFairValueAssumptionsExpectedVolatilityRate",
                "nsuri":  "http://www.biolase.com/20210331",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetail"
                    ],
                "xbrltype":  "percentItemType"
                },
            "biol_WarrantsFairValueAssumptionsRiskFreeInterestRate":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Warrants, fair value assumptions, risk free interest rate.",
                            "label":  "Warrants Fair Value Assumptions Risk Free Interest Rate",
                            "terseLabel":  "Warrants fair value assumptions, risk-free interest rate"
                            }
                        }
                    },
                "localname":  "WarrantsFairValueAssumptionsRiskFreeInterestRate",
                "nsuri":  "http://www.biolase.com/20210331",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetail"
                    ],
                "xbrltype":  "percentItemType"
                },
            "biol_WarrantsIssuedOnMayTwoThousandNineteenMember":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Warrants issued on may two thousand nineteen.",
                            "label":  "Warrants Issued On May Two Thousand Nineteen [Member]",
                            "terseLabel":  "Warrants Issued on May, 2019"
                            }
                        }
                    },
                "localname":  "WarrantsIssuedOnMayTwoThousandNineteenMember",
                "nsuri":  "http://www.biolase.com/20210331",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetail"
                    ],
                "xbrltype":  "domainItemType"
                },
            "biol_WarrantsIssuedOnNovemberNineTwoThousandEighteenMember":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Warrants issued on november nine two thousand eighteen.",
                            "label":  "Warrants Issued On November Nine Two Thousand Eighteen [Member]",
                            "terseLabel":  "Warrants Issued on November 9, 2018"
                            }
                        }
                    },
                "localname":  "WarrantsIssuedOnNovemberNineTwoThousandEighteenMember",
                "nsuri":  "http://www.biolase.com/20210331",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetail"
                    ],
                "xbrltype":  "domainItemType"
                },
            "biol_WaterlaseLaserSystemsMember":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Waterlase laser systems.",
                            "label":  "Waterlase Laser Systems [Member]",
                            "terseLabel":  "Waterlase Laser Systems"
                            }
                        }
                    },
                "localname":  "WaterlaseLaserSystemsMember",
                "nsuri":  "http://www.biolase.com/20210331",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureAccruedLiabilitiesAdditionalInformationDetail"
                    ],
                "xbrltype":  "domainItemType"
                },
            "biol_WaterlaseSystemsAndDiodeSystemsMember":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Waterlase Systems And Diode Systems [Member]",
                            "label":  "Waterlase Systems And Diode Systems"
                            }
                        }
                    },
                "localname":  "WaterlaseSystemsAndDiodeSystemsMember",
                "nsuri":  "http://www.biolase.com/20210331",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureAccruedLiabilitiesAdditionalInformationDetail"
                    ],
                "xbrltype":  "domainItemType"
                },
            "biol_WesternAllianceMember":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Western alliance.",
                            "label":  "Western Alliance [Member]",
                            "terseLabel":  "Western Alliance"
                            }
                        }
                    },
                "localname":  "WesternAllianceMember",
                "nsuri":  "http://www.biolase.com/20210331",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetail"
                    ],
                "xbrltype":  "domainItemType"
                },
            "biol_WesternAllianceWarrantMember":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Western alliance warrant.",
                            "label":  "Western Alliance Warrant [Member]",
                            "terseLabel":  "Western Alliance Warrant"
                            }
                        }
                    },
                "localname":  "WesternAllianceWarrantMember",
                "nsuri":  "http://www.biolase.com/20210331",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetail"
                    ],
                "xbrltype":  "domainItemType"
                },
            "biol_WorkingCapital":  {
                "auth_ref":  [
                    ],
                "crdr":  "debit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "A financial calculation subtracting current liabilities from current assets.",
                            "label":  "Working Capital",
                            "terseLabel":  "Working capital"
                            }
                        }
                    },
                "localname":  "WorkingCapital",
                "nsuri":  "http://www.biolase.com/20210331",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureDescriptionOfBusinessAndBasisOfPresentationAdditionalInformationDetail"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "country_US":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "label":  "UNITED STATES",
                            "terseLabel":  "United States"
                            }
                        }
                    },
                "localname":  "US",
                "nsuri":  "http://xbrl.sec.gov/country/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureAccruedLiabilitiesAdditionalInformationDetail",
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureSegmentInformationAdditionalInformationDetail",
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureSummaryOfDisaggregationOfRevenuesRelatedToGeographicAreasDetail",
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureSummaryOfNetRevenueByGeographicLocationDetail",
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureSummaryOfPropertyPlantAndEquipmentByGeographicLocationDetail"
                    ],
                "xbrltype":  "domainItemType"
                },
            "dei_AmendmentFlag":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
                            "label":  "Amendment Flag",
                            "verboseLabel":  "Amendment Flag"
                            }
                        }
                    },
                "localname":  "AmendmentFlag",
                "nsuri":  "http://xbrl.sec.gov/dei/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
                    ],
                "xbrltype":  "booleanItemType"
                },
            "dei_CityAreaCode":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Area code of city",
                            "label":  "City Area Code",
                            "terseLabel":  "City Area Code"
                            }
                        }
                    },
                "localname":  "CityAreaCode",
                "nsuri":  "http://xbrl.sec.gov/dei/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
                    ],
                "xbrltype":  "normalizedStringItemType"
                },
            "dei_CoverAbstract":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Cover page.",
                            "label":  "Cover [Abstract]"
                            }
                        }
                    },
                "localname":  "CoverAbstract",
                "nsuri":  "http://xbrl.sec.gov/dei/2020-01-31",
                "xbrltype":  "stringItemType"
                },
            "dei_CurrentFiscalYearEndDate":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "End date of current fiscal year in the format --MM-DD.",
                            "label":  "Current Fiscal Year End Date",
                            "terseLabel":  "Current Fiscal Year End Date"
                            }
                        }
                    },
                "localname":  "CurrentFiscalYearEndDate",
                "nsuri":  "http://xbrl.sec.gov/dei/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
                    ],
                "xbrltype":  "gMonthDayItemType"
                },
            "dei_DocumentFiscalPeriodFocus":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
                            "label":  "Document Fiscal Period Focus",
                            "terseLabel":  "Document Fiscal Period Focus"
                            }
                        }
                    },
                "localname":  "DocumentFiscalPeriodFocus",
                "nsuri":  "http://xbrl.sec.gov/dei/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
                    ],
                "xbrltype":  "fiscalPeriodItemType"
                },
            "dei_DocumentFiscalYearFocus":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "This is focus fiscal year of the document report in YYYY format.  For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus.  Example: 2006.",
                            "label":  "Document Fiscal Year Focus",
                            "verboseLabel":  "Document Fiscal Year Focus"
                            }
                        }
                    },
                "localname":  "DocumentFiscalYearFocus",
                "nsuri":  "http://xbrl.sec.gov/dei/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
                    ],
                "xbrltype":  "gYearItemType"
                },
            "dei_DocumentPeriodEndDate":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "The end date of the period reflected on the cover page if a periodic report.  For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date.  The format of the date is YYYY-MM-DD.",
                            "label":  "Document Period End Date",
                            "terseLabel":  "Document Period End Date"
                            }
                        }
                    },
                "localname":  "DocumentPeriodEndDate",
                "nsuri":  "http://xbrl.sec.gov/dei/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
                    ],
                "xbrltype":  "dateItemType"
                },
            "dei_DocumentQuarterlyReport":  {
                "auth_ref":  [
                    "r503"
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Boolean flag that is true only for a form used as an quarterly report.",
                            "label":  "Document Quarterly Report",
                            "terseLabel":  "Document Quarterly Report"
                            }
                        }
                    },
                "localname":  "DocumentQuarterlyReport",
                "nsuri":  "http://xbrl.sec.gov/dei/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
                    ],
                "xbrltype":  "booleanItemType"
                },
            "dei_DocumentTransitionReport":  {
                "auth_ref":  [
                    "r504"
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Boolean flag that is true only for a form used as a transition report.",
                            "label":  "Document Transition Report",
                            "terseLabel":  "Document Transition Report"
                            }
                        }
                    },
                "localname":  "DocumentTransitionReport",
                "nsuri":  "http://xbrl.sec.gov/dei/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
                    ],
                "xbrltype":  "booleanItemType"
                },
            "dei_DocumentType":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc).  The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
                            "label":  "Document Type",
                            "verboseLabel":  "Document Type"
                            }
                        }
                    },
                "localname":  "DocumentType",
                "nsuri":  "http://xbrl.sec.gov/dei/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
                    ],
                "xbrltype":  "submissionTypeItemType"
                },
            "dei_EntityAddressAddressLine1":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Address Line 1 such as Attn, Building Name, Street Name",
                            "label":  "Entity Address Address Line1",
                            "terseLabel":  "Entity Address, Address Line One"
                            }
                        }
                    },
                "localname":  "EntityAddressAddressLine1",
                "nsuri":  "http://xbrl.sec.gov/dei/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
                    ],
                "xbrltype":  "normalizedStringItemType"
                },
            "dei_EntityAddressAddressLine2":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Address Line 2 such as Street or Suite number",
                            "label":  "Entity Address Address Line2",
                            "terseLabel":  "Entity Address, Address Line Two"
                            }
                        }
                    },
                "localname":  "EntityAddressAddressLine2",
                "nsuri":  "http://xbrl.sec.gov/dei/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
                    ],
                "xbrltype":  "normalizedStringItemType"
                },
            "dei_EntityAddressCityOrTown":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Name of the City or Town",
                            "label":  "Entity Address City Or Town",
                            "terseLabel":  "Entity Address, City or Town"
                            }
                        }
                    },
                "localname":  "EntityAddressCityOrTown",
                "nsuri":  "http://xbrl.sec.gov/dei/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
                    ],
                "xbrltype":  "normalizedStringItemType"
                },
            "dei_EntityAddressPostalZipCode":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Code for the postal or zip code",
                            "label":  "Entity Address Postal Zip Code",
                            "terseLabel":  "Entity Address, Postal Zip Code"
                            }
                        }
                    },
                "localname":  "EntityAddressPostalZipCode",
                "nsuri":  "http://xbrl.sec.gov/dei/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
                    ],
                "xbrltype":  "normalizedStringItemType"
                },
            "dei_EntityAddressStateOrProvince":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Name of the state or province.",
                            "label":  "Entity Address State Or Province",
                            "terseLabel":  "Entity Address, State or Province"
                            }
                        }
                    },
                "localname":  "EntityAddressStateOrProvince",
                "nsuri":  "http://xbrl.sec.gov/dei/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
                    ],
                "xbrltype":  "stateOrProvinceItemType"
                },
            "dei_EntityCentralIndexKey":  {
                "auth_ref":  [
                    "r505"
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC.  It is commonly abbreviated as CIK.",
                            "label":  "Entity Central Index Key",
                            "terseLabel":  "Entity Central Index Key"
                            }
                        }
                    },
                "localname":  "EntityCentralIndexKey",
                "nsuri":  "http://xbrl.sec.gov/dei/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
                    ],
                "xbrltype":  "centralIndexKeyItemType"
                },
            "dei_EntityCommonStockSharesOutstanding":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report.  Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
                            "label":  "Entity Common Stock Shares Outstanding",
                            "verboseLabel":  "Entity Common Stock, Shares Outstanding"
                            }
                        }
                    },
                "localname":  "EntityCommonStockSharesOutstanding",
                "nsuri":  "http://xbrl.sec.gov/dei/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
                    ],
                "xbrltype":  "sharesItemType"
                },
            "dei_EntityCurrentReportingStatus":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days.  This information should be based on the registrant's current or most recent filing containing the related disclosure.",
                            "label":  "Entity Current Reporting Status",
                            "terseLabel":  "Entity Current Reporting Status"
                            }
                        }
                    },
                "localname":  "EntityCurrentReportingStatus",
                "nsuri":  "http://xbrl.sec.gov/dei/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
                    ],
                "xbrltype":  "yesNoItemType"
                },
            "dei_EntityEmergingGrowthCompany":  {
                "auth_ref":  [
                    "r505"
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Indicate if registrant meets the emerging growth company criteria.",
                            "label":  "Entity Emerging Growth Company",
                            "terseLabel":  "Entity Emerging Growth Company"
                            }
                        }
                    },
                "localname":  "EntityEmergingGrowthCompany",
                "nsuri":  "http://xbrl.sec.gov/dei/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
                    ],
                "xbrltype":  "booleanItemType"
                },
            "dei_EntityFileNumber":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Commission file number.  The field allows up to 17 characters.  The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
                            "label":  "Entity File Number",
                            "terseLabel":  "Entity File Number"
                            }
                        }
                    },
                "localname":  "EntityFileNumber",
                "nsuri":  "http://xbrl.sec.gov/dei/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
                    ],
                "xbrltype":  "fileNumberItemType"
                },
            "dei_EntityFilerCategory":  {
                "auth_ref":  [
                    "r505"
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Indicate whether the registrant is one of the following:  Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer.  Definitions of these categories are stated in Rule 12b-2 of the Exchange Act.  This information should be based on the registrant's current or most recent filing containing the related disclosure.",
                            "label":  "Entity Filer Category",
                            "terseLabel":  "Entity Filer Category"
                            }
                        }
                    },
                "localname":  "EntityFilerCategory",
                "nsuri":  "http://xbrl.sec.gov/dei/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
                    ],
                "xbrltype":  "filerCategoryItemType"
                },
            "dei_EntityIncorporationStateCountryCode":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Two-character EDGAR code representing the state or country of incorporation.",
                            "label":  "Entity Incorporation State Country Code",
                            "terseLabel":  "Entity Incorporation, State or Country Code"
                            }
                        }
                    },
                "localname":  "EntityIncorporationStateCountryCode",
                "nsuri":  "http://xbrl.sec.gov/dei/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
                    ],
                "xbrltype":  "edgarStateCountryItemType"
                },
            "dei_EntityInteractiveDataCurrent":  {
                "auth_ref":  [
                    "r506"
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
                            "label":  "Entity Interactive Data Current",
                            "terseLabel":  "Entity Interactive Data Current"
                            }
                        }
                    },
                "localname":  "EntityInteractiveDataCurrent",
                "nsuri":  "http://xbrl.sec.gov/dei/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
                    ],
                "xbrltype":  "yesNoItemType"
                },
            "dei_EntityRegistrantName":  {
                "auth_ref":  [
                    "r505"
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
                            "label":  "Entity Registrant Name",
                            "terseLabel":  "Entity Registrant Name"
                            }
                        }
                    },
                "localname":  "EntityRegistrantName",
                "nsuri":  "http://xbrl.sec.gov/dei/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
                    ],
                "xbrltype":  "normalizedStringItemType"
                },
            "dei_EntityShellCompany":  {
                "auth_ref":  [
                    "r505"
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
                            "label":  "Entity Shell Company",
                            "terseLabel":  "Entity Shell Company"
                            }
                        }
                    },
                "localname":  "EntityShellCompany",
                "nsuri":  "http://xbrl.sec.gov/dei/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
                    ],
                "xbrltype":  "booleanItemType"
                },
            "dei_EntitySmallBusiness":  {
                "auth_ref":  [
                    "r505"
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Indicates that the company is a Smaller Reporting Company (SRC).",
                            "label":  "Entity Small Business",
                            "terseLabel":  "Entity Small Business"
                            }
                        }
                    },
                "localname":  "EntitySmallBusiness",
                "nsuri":  "http://xbrl.sec.gov/dei/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
                    ],
                "xbrltype":  "booleanItemType"
                },
            "dei_EntityTaxIdentificationNumber":  {
                "auth_ref":  [
                    "r505"
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
                            "label":  "Entity Tax Identification Number",
                            "terseLabel":  "Entity Tax Identification Number"
                            }
                        }
                    },
                "localname":  "EntityTaxIdentificationNumber",
                "nsuri":  "http://xbrl.sec.gov/dei/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
                    ],
                "xbrltype":  "employerIdItemType"
                },
            "dei_LocalPhoneNumber":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Local phone number for entity.",
                            "label":  "Local Phone Number",
                            "terseLabel":  "Local Phone Number"
                            }
                        }
                    },
                "localname":  "LocalPhoneNumber",
                "nsuri":  "http://xbrl.sec.gov/dei/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
                    ],
                "xbrltype":  "normalizedStringItemType"
                },
            "dei_Security12bTitle":  {
                "auth_ref":  [
                    "r501"
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Title of a 12(b) registered security.",
                            "label":  "Security12b Title",
                            "terseLabel":  "Title of 12(b) Security"
                            }
                        }
                    },
                "localname":  "Security12bTitle",
                "nsuri":  "http://xbrl.sec.gov/dei/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
                    ],
                "xbrltype":  "securityTitleItemType"
                },
            "dei_SecurityExchangeName":  {
                "auth_ref":  [
                    "r502"
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Name of the Exchange on which a security is registered.",
                            "label":  "Security Exchange Name",
                            "terseLabel":  "Security Exchange Name"
                            }
                        }
                    },
                "localname":  "SecurityExchangeName",
                "nsuri":  "http://xbrl.sec.gov/dei/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
                    ],
                "xbrltype":  "edgarExchangeCodeItemType"
                },
            "dei_TradingSymbol":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Trading symbol of an instrument as listed on an exchange.",
                            "label":  "Trading Symbol",
                            "terseLabel":  "Trading Symbol"
                            }
                        }
                    },
                "localname":  "TradingSymbol",
                "nsuri":  "http://xbrl.sec.gov/dei/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
                    ],
                "xbrltype":  "tradingSymbolItemType"
                },
            "srt_MaximumMember":  {
                "auth_ref":  [
                    "r291",
                    "r292",
                    "r425",
                    "r426",
                    "r427",
                    "r428",
                    "r429",
                    "r430",
                    "r431",
                    "r470",
                    "r473"
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "label":  "Maximum [Member]",
                            "terseLabel":  "Maximum"
                            }
                        }
                    },
                "localname":  "MaximumMember",
                "nsuri":  "http://fasb.org/srt/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureAccruedLiabilitiesAdditionalInformationDetail",
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureConcentrationsAdditionalInformationDetail",
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetail",
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail",
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureRedeemablePreferredStockAndStockholdersEquityAdditionalInformationDetail"
                    ],
                "xbrltype":  "domainItemType"
                },
            "srt_MinimumMember":  {
                "auth_ref":  [
                    "r291",
                    "r292",
                    "r425",
                    "r426",
                    "r427",
                    "r428",
                    "r429",
                    "r430",
                    "r431",
                    "r470",
                    "r473"
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "label":  "Minimum [Member]",
                            "terseLabel":  "Minimum"
                            }
                        }
                    },
                "localname":  "MinimumMember",
                "nsuri":  "http://fasb.org/srt/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureConcentrationsAdditionalInformationDetail",
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetail",
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail",
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureRedeemablePreferredStockAndStockholdersEquityAdditionalInformationDetail"
                    ],
                "xbrltype":  "domainItemType"
                },
            "srt_ProductOrServiceAxis":  {
                "auth_ref":  [
                    "r193",
                    "r279",
                    "r282",
                    "r432",
                    "r469",
                    "r471"
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "label":  "Product Or Service [Axis]",
                            "terseLabel":  "Product and Service"
                            }
                        }
                    },
                "localname":  "ProductOrServiceAxis",
                "nsuri":  "http://fasb.org/srt/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureAccruedLiabilitiesAdditionalInformationDetail",
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureConcentrationsSummaryOfNetRevenueFromVariousProductsDetail"
                    ],
                "xbrltype":  "stringItemType"
                },
            "srt_ProductsAndServicesDomain":  {
                "auth_ref":  [
                    "r193",
                    "r279",
                    "r282",
                    "r432",
                    "r469",
                    "r471"
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "label":  "Products And Services [Domain]",
                            "terseLabel":  "Product and Service"
                            }
                        }
                    },
                "localname":  "ProductsAndServicesDomain",
                "nsuri":  "http://fasb.org/srt/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureAccruedLiabilitiesAdditionalInformationDetail",
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureConcentrationsSummaryOfNetRevenueFromVariousProductsDetail"
                    ],
                "xbrltype":  "domainItemType"
                },
            "srt_RangeAxis":  {
                "auth_ref":  [
                    "r290",
                    "r291",
                    "r292",
                    "r425",
                    "r426",
                    "r427",
                    "r428",
                    "r429",
                    "r430",
                    "r431",
                    "r470",
                    "r473"
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "label":  "Range [Axis]",
                            "terseLabel":  "Statistical Measurement"
                            }
                        }
                    },
                "localname":  "RangeAxis",
                "nsuri":  "http://fasb.org/srt/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureAccruedLiabilitiesAdditionalInformationDetail",
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureConcentrationsAdditionalInformationDetail",
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetail",
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail",
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureRedeemablePreferredStockAndStockholdersEquityAdditionalInformationDetail"
                    ],
                "xbrltype":  "stringItemType"
                },
            "srt_RangeMember":  {
                "auth_ref":  [
                    "r290",
                    "r291",
                    "r292",
                    "r425",
                    "r426",
                    "r427",
                    "r428",
                    "r429",
                    "r430",
                    "r431",
                    "r470",
                    "r473"
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "label":  "Range [Member]",
                            "terseLabel":  "Statistical Measurement"
                            }
                        }
                    },
                "localname":  "RangeMember",
                "nsuri":  "http://fasb.org/srt/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureAccruedLiabilitiesAdditionalInformationDetail",
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureConcentrationsAdditionalInformationDetail",
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetail",
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail",
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureRedeemablePreferredStockAndStockholdersEquityAdditionalInformationDetail"
                    ],
                "xbrltype":  "domainItemType"
                },
            "srt_SegmentGeographicalDomain":  {
                "auth_ref":  [
                    "r194",
                    "r195",
                    "r279",
                    "r283",
                    "r472",
                    "r491",
                    "r492",
                    "r493",
                    "r494",
                    "r495",
                    "r496",
                    "r497",
                    "r498"
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "label":  "Segment Geographical [Domain]",
                            "terseLabel":  "Geographical"
                            }
                        }
                    },
                "localname":  "SegmentGeographicalDomain",
                "nsuri":  "http://fasb.org/srt/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureAccruedLiabilitiesAdditionalInformationDetail",
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureSegmentInformationAdditionalInformationDetail",
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureSummaryOfDisaggregationOfRevenuesRelatedToGeographicAreasDetail",
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureSummaryOfNetRevenueByGeographicLocationDetail",
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureSummaryOfPropertyPlantAndEquipmentByGeographicLocationDetail"
                    ],
                "xbrltype":  "domainItemType"
                },
            "srt_StatementGeographicalAxis":  {
                "auth_ref":  [
                    "r194",
                    "r195",
                    "r279",
                    "r283",
                    "r472",
                    "r487",
                    "r491",
                    "r492",
                    "r493",
                    "r494",
                    "r495",
                    "r496",
                    "r497",
                    "r498",
                    "r499"
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "label":  "Statement Geographical [Axis]",
                            "terseLabel":  "Geographical"
                            }
                        }
                    },
                "localname":  "StatementGeographicalAxis",
                "nsuri":  "http://fasb.org/srt/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureAccruedLiabilitiesAdditionalInformationDetail",
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureSegmentInformationAdditionalInformationDetail",
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureSummaryOfDisaggregationOfRevenuesRelatedToGeographicAreasDetail",
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureSummaryOfNetRevenueByGeographicLocationDetail",
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureSummaryOfPropertyPlantAndEquipmentByGeographicLocationDetail"
                    ],
                "xbrltype":  "stringItemType"
                },
            "us-gaap_AccountingPoliciesAbstract":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "label":  "Accounting Policies [Abstract]"
                            }
                        }
                    },
                "localname":  "AccountingPoliciesAbstract",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "xbrltype":  "stringItemType"
                },
            "us-gaap_AccountingStandardsUpdate201602Member":  {
                "auth_ref":  [
                    "r407"
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Accounting Standards Update 2016-02 Leases (Topic 842).",
                            "label":  "Accounting Standards Update201602 [Member]",
                            "terseLabel":  "ASU 2016-02"
                            }
                        }
                    },
                "localname":  "AccountingStandardsUpdate201602Member",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail"
                    ],
                "xbrltype":  "domainItemType"
                },
            "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock":  {
                "auth_ref":  [
                    "r43"
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.",
                            "label":  "Accounts Payable And Accrued Liabilities Disclosure [Text Block]",
                            "terseLabel":  "Accrued Liabilities"
                            }
                        }
                    },
                "localname":  "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureAccruedLiabilities"
                    ],
                "xbrltype":  "textBlockItemType"
                },
            "us-gaap_AccountsPayableCurrent":  {
                "auth_ref":  [
                    "r42"
                    ],
                "calculation":  {
                    "http://www.biolase.com/20210331/taxonomy/role/Role_StatementConsolidatedBalanceSheetsUnaudited":  {
                        "order":  0.0,
                        "parentTag":  "us-gaap_LiabilitiesCurrent",
                        "weight":  1.0
                        }
                    },
                "crdr":  "credit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.  Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
                            "label":  "Accounts Payable Current",
                            "terseLabel":  "Accounts payable",
                            "totalLabel":  "Accounts Payable, Current, Total"
                            }
                        }
                    },
                "localname":  "AccountsPayableCurrent",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_StatementConsolidatedBalanceSheetsUnaudited"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "us-gaap_AccountsReceivableMember":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Due from customers or clients for goods or services that have been delivered or sold.",
                            "label":  "Accounts Receivable [Member]",
                            "terseLabel":  "Account Receivable"
                            }
                        }
                    },
                "localname":  "AccountsReceivableMember",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureConcentrationsAdditionalInformationDetail"
                    ],
                "xbrltype":  "domainItemType"
                },
            "us-gaap_AccountsReceivableNetCurrent":  {
                "auth_ref":  [
                    "r4",
                    "r23",
                    "r201",
                    "r202"
                    ],
                "calculation":  {
                    "http://www.biolase.com/20210331/taxonomy/role/Role_StatementConsolidatedBalanceSheetsUnaudited":  {
                        "order":  2.0,
                        "parentTag":  "us-gaap_AssetsCurrent",
                        "weight":  1.0
                        }
                    },
                "crdr":  "debit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
                            "label":  "Accounts Receivable Net Current",
                            "terseLabel":  "Accounts receivable, less allowance of $3,908 and $4,017 in 2021 and 2020, respectively",
                            "totalLabel":  "Accounts Receivable, after Allowance for Credit Loss, Current, Total",
                            "verboseLabel":  "Accounts receivable, net"
                            }
                        }
                    },
                "localname":  "AccountsReceivableNetCurrent",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureDescriptionOfBusinessAndBasisOfPresentationAdditionalInformationDetail",
                    "http://www.biolase.com/20210331/taxonomy/role/Role_StatementConsolidatedBalanceSheetsUnaudited"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "us-gaap_AccruedInsuranceCurrent":  {
                "auth_ref":  [
                    "r8",
                    "r9",
                    "r47"
                    ],
                "calculation":  {
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureComponentsOfAccruedLiabilitiesDetail":  {
                        "order":  4.0,
                        "parentTag":  "us-gaap_AccruedLiabilitiesCurrent",
                        "weight":  1.0
                        }
                    },
                "crdr":  "credit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Carrying value as of the balance sheet date of obligations incurred through that date and payable to insurance entities to mitigate potential loss from various risks or to satisfy a promise to provide certain coverage's to employees.  Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
                            "label":  "Accrued Insurance Current",
                            "terseLabel":  "Accrued insurance premium"
                            }
                        }
                    },
                "localname":  "AccruedInsuranceCurrent",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureComponentsOfAccruedLiabilitiesDetail"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "us-gaap_AccruedLiabilitiesCurrent":  {
                "auth_ref":  [
                    "r47"
                    ],
                "calculation":  {
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureComponentsOfAccruedLiabilitiesDetail":  {
                        "order":  null,
                        "parentTag":  null,
                        "root":  true,
                        "weight":  null
                        },
                    "http://www.biolase.com/20210331/taxonomy/role/Role_StatementConsolidatedBalanceSheetsUnaudited":  {
                        "order":  1.0,
                        "parentTag":  "us-gaap_LiabilitiesCurrent",
                        "weight":  1.0
                        }
                    },
                "crdr":  "credit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered.  Examples include taxes, interest, rent and utilities.  Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
                            "label":  "Accrued Liabilities Current",
                            "terseLabel":  "Accrued liabilities",
                            "totalLabel":  "Accrued liabilities",
                            "verboseLabel":  "Accrued liability"
                            }
                        }
                    },
                "localname":  "AccruedLiabilitiesCurrent",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail",
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureComponentsOfAccruedLiabilitiesDetail",
                    "http://www.biolase.com/20210331/taxonomy/role/Role_StatementConsolidatedBalanceSheetsUnaudited"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "us-gaap_AccruedProfessionalFeesCurrent":  {
                "auth_ref":  [
                    "r8",
                    "r9",
                    "r47"
                    ],
                "calculation":  {
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureComponentsOfAccruedLiabilitiesDetail":  {
                        "order":  3.0,
                        "parentTag":  "us-gaap_AccruedLiabilitiesCurrent",
                        "weight":  1.0
                        }
                    },
                "crdr":  "credit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received.  Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
                            "label":  "Accrued Professional Fees Current",
                            "terseLabel":  "Accrued professional services"
                            }
                        }
                    },
                "localname":  "AccruedProfessionalFeesCurrent",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureComponentsOfAccruedLiabilitiesDetail"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment":  {
                "auth_ref":  [
                    "r40",
                    "r226"
                    ],
                "calculation":  {
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureSummaryOfPropertyPlantAndEquipmentDetail":  {
                        "order":  1.0,
                        "parentTag":  "biol_PropertyPlantAndEquipmentNetExcludingLand",
                        "weight":  -1.0
                        }
                    },
                "crdr":  "credit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
                            "label":  "Accumulated Depreciation Depletion And Amortization Property Plant And Equipment",
                            "negatedLabel":  "Accumulated depreciation and amortization",
                            "periodEndLabel":  "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Ending Balance",
                            "periodStartLabel":  "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Beginning Balance",
                            "totalLabel":  "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Total"
                            }
                        }
                    },
                "localname":  "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureSummaryOfPropertyPlantAndEquipmentDetail"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax":  {
                "auth_ref":  [
                    "r26",
                    "r65",
                    "r66",
                    "r67",
                    "r458",
                    "r481",
                    "r485"
                    ],
                "calculation":  {
                    "http://www.biolase.com/20210331/taxonomy/role/Role_StatementConsolidatedBalanceSheetsUnaudited":  {
                        "order":  3.0,
                        "parentTag":  "us-gaap_StockholdersEquity",
                        "weight":  1.0
                        }
                    },
                "crdr":  "credit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end.  Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.  Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
                            "label":  "Accumulated Other Comprehensive Income Loss Net Of Tax",
                            "terseLabel":  "Accumulated other comprehensive loss",
                            "totalLabel":  "Accumulated Other Comprehensive Income (Loss), Net of Tax, Total"
                            }
                        }
                    },
                "localname":  "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_StatementConsolidatedBalanceSheetsUnaudited"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "us-gaap_AccumulatedOtherComprehensiveIncomeMember":  {
                "auth_ref":  [
                    "r64",
                    "r67",
                    "r68",
                    "r121",
                    "r122",
                    "r123",
                    "r372",
                    "r476",
                    "r477"
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent.  Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
                            "label":  "Accumulated Other Comprehensive Income [Member]",
                            "terseLabel":  "Accumulated Other Comprehensive Loss"
                            }
                        }
                    },
                "localname":  "AccumulatedOtherComprehensiveIncomeMember",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_StatementConsolidatedStatementsOfRedeemablePreferredStockAndStockholdersEquityUnaudited"
                    ],
                "xbrltype":  "domainItemType"
                },
            "us-gaap_AdditionalPaidInCapitalCommonStock":  {
                "auth_ref":  [
                    "r24"
                    ],
                "calculation":  {
                    "http://www.biolase.com/20210331/taxonomy/role/Role_StatementConsolidatedBalanceSheetsUnaudited":  {
                        "order":  2.0,
                        "parentTag":  "us-gaap_StockholdersEquity",
                        "weight":  1.0
                        }
                    },
                "crdr":  "credit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions.  Includes only common stock transactions (excludes preferred stock transactions).  May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.",
                            "label":  "Additional Paid In Capital Common Stock",
                            "periodEndLabel":  "Additional Paid in Capital, Common Stock, Ending Balance",
                            "periodStartLabel":  "Additional Paid in Capital, Common Stock, Beginning Balance",
                            "terseLabel":  "Additional paid-in-capital"
                            }
                        }
                    },
                "localname":  "AdditionalPaidInCapitalCommonStock",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_StatementConsolidatedBalanceSheetsUnaudited"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "us-gaap_AdditionalPaidInCapitalMember":  {
                "auth_ref":  [
                    "r121",
                    "r122",
                    "r123",
                    "r333",
                    "r334",
                    "r335"
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
                            "label":  "Additional Paid In Capital [Member]",
                            "terseLabel":  "Additional Paid-in Capital"
                            }
                        }
                    },
                "localname":  "AdditionalPaidInCapitalMember",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_StatementConsolidatedStatementsOfRedeemablePreferredStockAndStockholdersEquityUnaudited"
                    ],
                "xbrltype":  "domainItemType"
                },
            "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis":  {
                "auth_ref":  [
                    "r124",
                    "r125",
                    "r126",
                    "r127",
                    "r206",
                    "r207",
                    "r208",
                    "r209",
                    "r210",
                    "r211",
                    "r329",
                    "r330",
                    "r331",
                    "r332",
                    "r333",
                    "r334",
                    "r335",
                    "r336",
                    "r351",
                    "r352",
                    "r353",
                    "r354",
                    "r433",
                    "r434",
                    "r435",
                    "r474",
                    "r475",
                    "r476",
                    "r477",
                    "r478",
                    "r479",
                    "r480",
                    "r481",
                    "r482",
                    "r483",
                    "r484",
                    "r485"
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Information by amendment to accounting standards.",
                            "label":  "Adjustments For New Accounting Pronouncements [Axis]",
                            "terseLabel":  "Accounting Standards Update"
                            }
                        }
                    },
                "localname":  "AdjustmentsForNewAccountingPronouncementsAxis",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail"
                    ],
                "xbrltype":  "stringItemType"
                },
            "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue":  {
                "auth_ref":  [
                    "r293",
                    "r295",
                    "r339",
                    "r340"
                    ],
                "crdr":  "credit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
                            "label":  "Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value",
                            "terseLabel":  "Stock-based compensation",
                            "totalLabel":  "APIC, Share-based Payment Arrangement, Increase for Cost Recognition, Total"
                            }
                        }
                    },
                "localname":  "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_StatementConsolidatedStatementsOfRedeemablePreferredStockAndStockholdersEquityUnaudited"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "label":  "Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities [Abstract]",
                            "terseLabel":  "Adjustments to reconcile net loss to net cash and cash equivalents used in operating activities:"
                            }
                        }
                    },
                "localname":  "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlowsUnaudited"
                    ],
                "xbrltype":  "stringItemType"
                },
            "us-gaap_AllocatedShareBasedCompensationExpense":  {
                "auth_ref":  [
                    "r295",
                    "r325",
                    "r338"
                    ],
                "crdr":  "debit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Amount of expense for award under share-based payment arrangement.  Excludes amount capitalized.",
                            "label":  "Allocated Share Based Compensation Expense",
                            "terseLabel":  "Allocated Share-based Compensation Expense"
                            }
                        }
                    },
                "localname":  "AllocatedShareBasedCompensationExpense",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureClassificationOfCompensationExpenseAssociatedWithShareBasedPaymentsDetail"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent":  {
                "auth_ref":  [
                    "r30",
                    "r203",
                    "r212"
                    ],
                "crdr":  "credit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Amount of allowance for credit loss on accounts receivable, classified as current.",
                            "label":  "Allowance For Doubtful Accounts Receivable Current",
                            "terseLabel":  "Allowance for accounts receivable"
                            }
                        }
                    },
                "localname":  "AllowanceForDoubtfulAccountsReceivableCurrent",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_StatementConsolidatedBalanceSheetsUnauditedParenthetical"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "us-gaap_AmortizationOfDebtDiscountPremium":  {
                "auth_ref":  [
                    "r87",
                    "r102",
                    "r400"
                    ],
                "calculation":  {
                    "http://www.biolase.com/20210331/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlowsUnaudited":  {
                        "order":  5.0,
                        "parentTag":  "us-gaap_NetCashProvidedByUsedInOperatingActivities",
                        "weight":  1.0
                        }
                    },
                "crdr":  "debit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments.  Excludes amortization of financing costs.  Alternate captions include noncash interest expense.",
                            "label":  "Amortization Of Debt Discount Premium",
                            "terseLabel":  "Amortization of discounts on lines of credit"
                            }
                        }
                    },
                "localname":  "AmortizationOfDebtDiscountPremium",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlowsUnaudited"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "us-gaap_AmortizationOfFinancingCosts":  {
                "auth_ref":  [
                    "r81",
                    "r102",
                    "r402"
                    ],
                "calculation":  {
                    "http://www.biolase.com/20210331/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlowsUnaudited":  {
                        "order":  6.0,
                        "parentTag":  "us-gaap_NetCashProvidedByUsedInOperatingActivities",
                        "weight":  1.0
                        }
                    },
                "crdr":  "debit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Amount of amortization expense attributable to debt issuance costs.",
                            "label":  "Amortization Of Financing Costs",
                            "terseLabel":  "Amortization of debt issuance costs"
                            }
                        }
                    },
                "localname":  "AmortizationOfFinancingCosts",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlowsUnaudited"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "us-gaap_AmortizationOfIntangibleAssets":  {
                "auth_ref":  [
                    "r102",
                    "r221",
                    "r222"
                    ],
                "crdr":  "debit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets.  As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.",
                            "label":  "Amortization Of Intangible Assets",
                            "terseLabel":  "Amortization expense",
                            "totalLabel":  "Amortization of Intangible Assets, Total"
                            }
                        }
                    },
                "localname":  "AmortizationOfIntangibleAssets",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureIntangibleAssetsAndGoodwillAdditionalInformationDetail"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount":  {
                "auth_ref":  [
                    "r147"
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
                            "label":  "Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount",
                            "terseLabel":  "Outstanding stock options, RSUs and warrants excluded from diluted loss per share"
                            }
                        }
                    },
                "localname":  "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureRedeemablePreferredStockAndStockholdersEquityAdditionalInformationDetail"
                    ],
                "xbrltype":  "sharesItemType"
                },
            "us-gaap_Assets":  {
                "auth_ref":  [
                    "r114",
                    "r177",
                    "r182",
                    "r189",
                    "r205",
                    "r367",
                    "r373",
                    "r387",
                    "r438",
                    "r455"
                    ],
                "calculation":  {
                    "http://www.biolase.com/20210331/taxonomy/role/Role_StatementConsolidatedBalanceSheetsUnaudited":  {
                        "order":  null,
                        "parentTag":  null,
                        "root":  true,
                        "weight":  null
                        }
                    },
                "crdr":  "debit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized.  Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
                            "label":  "Assets",
                            "totalLabel":  "Total assets"
                            }
                        }
                    },
                "localname":  "Assets",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_StatementConsolidatedBalanceSheetsUnaudited"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "us-gaap_AssetsAbstract":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "label":  "Assets [Abstract]",
                            "terseLabel":  "ASSETS"
                            }
                        }
                    },
                "localname":  "AssetsAbstract",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_StatementConsolidatedBalanceSheetsUnaudited"
                    ],
                "xbrltype":  "stringItemType"
                },
            "us-gaap_AssetsCurrent":  {
                "auth_ref":  [
                    "r5",
                    "r6",
                    "r62",
                    "r114",
                    "r205",
                    "r367",
                    "r373",
                    "r387"
                    ],
                "calculation":  {
                    "http://www.biolase.com/20210331/taxonomy/role/Role_StatementConsolidatedBalanceSheetsUnaudited":  {
                        "order":  0.0,
                        "parentTag":  "us-gaap_Assets",
                        "weight":  1.0
                        }
                    },
                "crdr":  "debit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer).  Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
                            "label":  "Assets Current",
                            "totalLabel":  "Total current assets"
                            }
                        }
                    },
                "localname":  "AssetsCurrent",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_StatementConsolidatedBalanceSheetsUnaudited"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "us-gaap_AssetsCurrentAbstract":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "label":  "Assets Current [Abstract]",
                            "terseLabel":  "Current assets:"
                            }
                        }
                    },
                "localname":  "AssetsCurrentAbstract",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_StatementConsolidatedBalanceSheetsUnaudited"
                    ],
                "xbrltype":  "stringItemType"
                },
            "us-gaap_AwardTypeAxis":  {
                "auth_ref":  [
                    "r296",
                    "r327"
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Information by type of award under share-based payment arrangement.",
                            "label":  "Award Type [Axis]",
                            "terseLabel":  "Award Type"
                            }
                        }
                    },
                "localname":  "AwardTypeAxis",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureRedeemablePreferredStockAndStockholdersEquityAdditionalInformationDetail",
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureSummaryOfUnvestedRestrictedStockUnitsDetail",
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureSummaryOfUnvestedStockOptionActivityDetail"
                    ],
                "xbrltype":  "stringItemType"
                },
            "us-gaap_BasisOfAccountingPolicyPolicyTextBlock":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
                            "label":  "Basis Of Accounting Policy Policy [Text Block]",
                            "terseLabel":  "Critical Accounting Policies"
                            }
                        }
                    },
                "localname":  "BasisOfAccountingPolicyPolicyTextBlock",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
                    ],
                "xbrltype":  "textBlockItemType"
                },
            "us-gaap_BuildingMember":  {
                "auth_ref":  [
                    "r225"
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Facility held for productive use including, but not limited to, office, production, storage and distribution facilities.",
                            "label":  "Building [Member]",
                            "terseLabel":  "Building"
                            }
                        }
                    },
                "localname":  "BuildingMember",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureSummaryOfPropertyPlantAndEquipmentDetail"
                    ],
                "xbrltype":  "domainItemType"
                },
            "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock":  {
                "auth_ref":  [
                    "r1",
                    "r120",
                    "r169"
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "The entire disclosure for the business description and basis of presentation concepts.  Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity.  Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
                            "label":  "Business Description And Basis Of Presentation [Text Block]",
                            "terseLabel":  "Description of Business and Basis of Presentation"
                            }
                        }
                    },
                "localname":  "BusinessDescriptionAndBasisOfPresentationTextBlock",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureDescriptionOfBusinessAndBasisOfPresentation"
                    ],
                "xbrltype":  "textBlockItemType"
                },
            "us-gaap_CapitalExpendituresIncurredButNotYetPaid":  {
                "auth_ref":  [
                    "r106",
                    "r107",
                    "r108"
                    ],
                "crdr":  "credit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Future cash outflow to pay for purchases of fixed assets that have occurred.",
                            "label":  "Capital Expenditures Incurred But Not Yet Paid",
                            "terseLabel":  "Non-cash accrual for capital expenditures"
                            }
                        }
                    },
                "localname":  "CapitalExpendituresIncurredButNotYetPaid",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlowsUnaudited"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "us-gaap_CashAndCashEquivalentsAtCarryingValue":  {
                "auth_ref":  [
                    "r2",
                    "r38",
                    "r104"
                    ],
                "calculation":  {
                    "http://www.biolase.com/20210331/taxonomy/role/Role_StatementConsolidatedBalanceSheetsUnaudited":  {
                        "order":  0.0,
                        "parentTag":  "us-gaap_AssetsCurrent",
                        "weight":  1.0
                        }
                    },
                "crdr":  "debit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Amount of currency on hand as well as demand deposits with banks or financial institutions.  Includes other kinds of accounts that have the general characteristics of demand deposits.  Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.  Excludes cash and cash equivalents within disposal group and discontinued operation.",
                            "label":  "Cash And Cash Equivalents At Carrying Value",
                            "periodEndLabel":  "Cash and Cash Equivalents, at Carrying Value, Ending Balance",
                            "periodStartLabel":  "Cash and Cash Equivalents, at Carrying Value, Beginning Balance",
                            "terseLabel":  "Cash and cash equivalents",
                            "totalLabel":  "Cash and Cash Equivalents, at Carrying Value, Total"
                            }
                        }
                    },
                "localname":  "CashAndCashEquivalentsAtCarryingValue",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_StatementConsolidatedBalanceSheetsUnaudited"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents":  {
                "auth_ref":  [
                    "r97",
                    "r104",
                    "r109"
                    ],
                "crdr":  "debit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage.  Excludes amount for disposal group and discontinued operations.  Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.  Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
                            "label":  "Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents",
                            "periodEndLabel":  "Cash, cash equivalents and restricted cash, end of period",
                            "periodStartLabel":  "Cash, cash equivalents and restricted cash, beginning of period",
                            "terseLabel":  "Cash, cash equivalents, and restricted cash",
                            "totalLabel":  "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Total",
                            "verboseLabel":  "Cash and cash equivalents, including restricted cash"
                            }
                        }
                    },
                "localname":  "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureDescriptionOfBusinessAndBasisOfPresentationAdditionalInformationDetail",
                    "http://www.biolase.com/20210331/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlowsUnaudited"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect":  {
                "auth_ref":  [
                    "r97",
                    "r392"
                    ],
                "calculation":  {
                    "http://www.biolase.com/20210331/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlowsUnaudited":  {
                        "order":  null,
                        "parentTag":  null,
                        "root":  true,
                        "weight":  null
                        }
                    },
                "crdr":  "debit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change.  Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.  Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
                            "label":  "Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect",
                            "totalLabel":  "Increase (decrease) in cash, cash equivalents and restricted cash"
                            }
                        }
                    },
                "localname":  "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlowsUnaudited"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "us-gaap_ClassOfStockDomain":  {
                "auth_ref":  [
                    "r113",
                    "r114",
                    "r139",
                    "r140",
                    "r141",
                    "r144",
                    "r146",
                    "r151",
                    "r152",
                    "r153",
                    "r205",
                    "r387"
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Share of stock differentiated by the voting rights the holder receives.  Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
                            "label":  "Class Of Stock [Domain]",
                            "terseLabel":  "Class of Stock"
                            }
                        }
                    },
                "localname":  "ClassOfStockDomain",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetail",
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureDescriptionOfBusinessAndBasisOfPresentationAdditionalInformationDetail",
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureRedeemablePreferredStockAndStockholdersEquityAdditionalInformationDetail",
                    "http://www.biolase.com/20210331/taxonomy/role/Role_StatementConsolidatedStatementsOfRedeemablePreferredStockAndShareholdersEquityParenthetical",
                    "http://www.biolase.com/20210331/taxonomy/role/Role_StatementConsolidatedStatementsOfRedeemablePreferredStockAndStockholdersEquityUnaudited"
                    ],
                "xbrltype":  "domainItemType"
                },
            "us-gaap_ClassOfWarrantOrRightAxis":  {
                "auth_ref":  [
                    "r267",
                    "r294"
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Information by type of warrant or right issued.",
                            "label":  "Class Of Warrant Or Right [Axis]",
                            "terseLabel":  "Class of Warrant or Right"
                            }
                        }
                    },
                "localname":  "ClassOfWarrantOrRightAxis",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetail"
                    ],
                "xbrltype":  "stringItemType"
                },
            "us-gaap_ClassOfWarrantOrRightDomain":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Name of the class or type of warrant or right outstanding.  Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame.  Warrants are often included in a new debt issue to entice investors by a higher return potential.  The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company.  Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months.",
                            "label":  "Class Of Warrant Or Right [Domain]",
                            "terseLabel":  "Class of Warrant or Right"
                            }
                        }
                    },
                "localname":  "ClassOfWarrantOrRightDomain",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetail"
                    ],
                "xbrltype":  "domainItemType"
                },
            "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1":  {
                "auth_ref":  [
                    "r261"
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Exercise price per share or per unit of warrants or rights outstanding.",
                            "label":  "Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1",
                            "terseLabel":  "Exercise price of warrants",
                            "verboseLabel":  "Initial exercise price of warrants"
                            }
                        }
                    },
                "localname":  "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetail",
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureRedeemablePreferredStockAndStockholdersEquityAdditionalInformationDetail"
                    ],
                "xbrltype":  "perShareItemType"
                },
            "us-gaap_ClassOfWarrantOrRightLineItems":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Line items represent financial concepts included in a table.  These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
                            "label":  "Class Of Warrant Or Right [Line Items]",
                            "terseLabel":  "Class Of Warrant Or Right [Line Items]"
                            }
                        }
                    },
                "localname":  "ClassOfWarrantOrRightLineItems",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureSummaryOfWarrantActivityDetail"
                    ],
                "xbrltype":  "stringItemType"
                },
            "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights":  {
                "auth_ref":  [
                    "r261"
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Number of securities into which the class of warrant or right may be converted.  For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.",
                            "label":  "Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights",
                            "terseLabel":  "Warrant issued",
                            "verboseLabel":  "Warrants issued to purchase shares of common stock"
                            }
                        }
                    },
                "localname":  "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetail",
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureDescriptionOfBusinessAndBasisOfPresentationAdditionalInformationDetail"
                    ],
                "xbrltype":  "sharesItemType"
                },
            "us-gaap_ClassOfWarrantOrRightOutstanding":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Number of warrants or rights outstanding.",
                            "label":  "Class Of Warrant Or Right Outstanding",
                            "terseLabel":  "Warrant issued"
                            }
                        }
                    },
                "localname":  "ClassOfWarrantOrRightOutstanding",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureRedeemablePreferredStockAndStockholdersEquityAdditionalInformationDetail"
                    ],
                "xbrltype":  "sharesItemType"
                },
            "us-gaap_ClassOfWarrantOrRightTable":  {
                "auth_ref":  [
                    "r267",
                    "r294"
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Disclosure for warrants or rights issued, which includes the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.",
                            "label":  "Class Of Warrant Or Right [Table]",
                            "terseLabel":  "Class Of Warrant Or Right [Table]"
                            }
                        }
                    },
                "localname":  "ClassOfWarrantOrRightTable",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureSummaryOfWarrantActivityDetail"
                    ],
                "xbrltype":  "stringItemType"
                },
            "us-gaap_CommitmentsAndContingencies":  {
                "auth_ref":  [
                    "r56",
                    "r233",
                    "r443",
                    "r462"
                    ],
                "calculation":  {
                    "http://www.biolase.com/20210331/taxonomy/role/Role_StatementConsolidatedBalanceSheetsUnaudited":  {
                        "order":  3.0,
                        "parentTag":  "us-gaap_LiabilitiesAndStockholdersEquity",
                        "weight":  1.0
                        }
                    },
                "crdr":  "credit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
                            "label":  "Commitments And Contingencies",
                            "terseLabel":  "Commitments and contingencies \u2014 Note 11"
                            }
                        }
                    },
                "localname":  "CommitmentsAndContingencies",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_StatementConsolidatedBalanceSheetsUnaudited"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "us-gaap_CommitmentsAndContingenciesDisclosureAbstract":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "label":  "Commitments And Contingencies Disclosure [Abstract]"
                            }
                        }
                    },
                "localname":  "CommitmentsAndContingenciesDisclosureAbstract",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "xbrltype":  "stringItemType"
                },
            "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock":  {
                "auth_ref":  [
                    "r230",
                    "r231",
                    "r232",
                    "r242"
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "The entire disclosure for commitments and contingencies.",
                            "label":  "Commitments And Contingencies Disclosure [Text Block]",
                            "terseLabel":  "Commitments and Contingencies"
                            }
                        }
                    },
                "localname":  "CommitmentsAndContingenciesDisclosureTextBlock",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureCommitmentsAndContingencies"
                    ],
                "xbrltype":  "textBlockItemType"
                },
            "us-gaap_CommonStockMember":  {
                "auth_ref":  [
                    "r121",
                    "r122"
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Stock that is subordinate to all other stock of the issuer.",
                            "label":  "Common Stock [Member]",
                            "terseLabel":  "Common Stock"
                            }
                        }
                    },
                "localname":  "CommonStockMember",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureRedeemablePreferredStockAndStockholdersEquityAdditionalInformationDetail",
                    "http://www.biolase.com/20210331/taxonomy/role/Role_StatementConsolidatedStatementsOfRedeemablePreferredStockAndStockholdersEquityUnaudited"
                    ],
                "xbrltype":  "domainItemType"
                },
            "us-gaap_CommonStockParOrStatedValuePerShare":  {
                "auth_ref":  [
                    "r22"
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Face amount or stated value per share of common stock.",
                            "label":  "Common Stock Par Or Stated Value Per Share",
                            "terseLabel":  "Common stock, par value"
                            }
                        }
                    },
                "localname":  "CommonStockParOrStatedValuePerShare",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_StatementConsolidatedBalanceSheetsUnauditedParenthetical"
                    ],
                "xbrltype":  "perShareItemType"
                },
            "us-gaap_CommonStockSharesAuthorized":  {
                "auth_ref":  [
                    "r22"
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
                            "label":  "Common Stock Shares Authorized",
                            "terseLabel":  "Common stock, shares authorized"
                            }
                        }
                    },
                "localname":  "CommonStockSharesAuthorized",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureRedeemablePreferredStockAndStockholdersEquityAdditionalInformationDetail",
                    "http://www.biolase.com/20210331/taxonomy/role/Role_StatementConsolidatedBalanceSheetsUnauditedParenthetical"
                    ],
                "xbrltype":  "sharesItemType"
                },
            "us-gaap_CommonStockSharesIssued":  {
                "auth_ref":  [
                    "r22"
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury).  These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized.  Shares issued include shares outstanding and shares held in the treasury.",
                            "label":  "Common Stock Shares Issued",
                            "periodEndLabel":  "Balance (in shares)",
                            "periodStartLabel":  "Balance (in shares)",
                            "terseLabel":  "Common stock, shares issued",
                            "totalLabel":  "Common Stock, Shares, Issued, Total"
                            }
                        }
                    },
                "localname":  "CommonStockSharesIssued",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureRedeemablePreferredStockAndStockholdersEquityAdditionalInformationDetail",
                    "http://www.biolase.com/20210331/taxonomy/role/Role_StatementConsolidatedBalanceSheetsUnauditedParenthetical",
                    "http://www.biolase.com/20210331/taxonomy/role/Role_StatementConsolidatedStatementsOfRedeemablePreferredStockAndStockholdersEquityUnaudited"
                    ],
                "xbrltype":  "sharesItemType"
                },
            "us-gaap_CommonStockSharesOutstanding":  {
                "auth_ref":  [
                    "r22",
                    "r260"
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Number of shares of common stock outstanding.  Common stock represent the ownership interest in a corporation.",
                            "label":  "Common Stock Shares Outstanding",
                            "periodEndLabel":  "Common Stock, Shares, Outstanding, Ending Balance",
                            "periodStartLabel":  "Common Stock, Shares, Outstanding, Beginning Balance",
                            "terseLabel":  "Common stock, shares outstanding"
                            }
                        }
                    },
                "localname":  "CommonStockSharesOutstanding",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_StatementConsolidatedBalanceSheetsUnauditedParenthetical"
                    ],
                "xbrltype":  "sharesItemType"
                },
            "us-gaap_CommonStockValue":  {
                "auth_ref":  [
                    "r22"
                    ],
                "calculation":  {
                    "http://www.biolase.com/20210331/taxonomy/role/Role_StatementConsolidatedBalanceSheetsUnaudited":  {
                        "order":  1.0,
                        "parentTag":  "us-gaap_StockholdersEquity",
                        "weight":  1.0
                        }
                    },
                "crdr":  "credit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer).  This item includes treasury stock repurchased by the entity.  Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
                            "label":  "Common Stock Value",
                            "periodEndLabel":  "Common Stock, Value, Issued, Ending Balance",
                            "periodStartLabel":  "Common Stock, Value, Issued, Beginning Balance",
                            "terseLabel":  "Common stock, par value $0.001 per share; 180,000 shares authorized, 149,427 and 97,709 shares issued and 149,382 and 97,663 outstanding as of March 31, 2021 and December 31, 2020, respectively",
                            "totalLabel":  "Common Stock, Value, Issued, Total",
                            "verboseLabel":  "Common stock value"
                            }
                        }
                    },
                "localname":  "CommonStockValue",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetail",
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureRedeemablePreferredStockAndStockholdersEquityAdditionalInformationDetail",
                    "http://www.biolase.com/20210331/taxonomy/role/Role_StatementConsolidatedBalanceSheetsUnaudited"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "us-gaap_ComprehensiveIncomeNetOfTax":  {
                "auth_ref":  [
                    "r70",
                    "r72",
                    "r73",
                    "r77",
                    "r446",
                    "r464"
                    ],
                "calculation":  {
                    "http://www.biolase.com/20210331/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited":  {
                        "order":  null,
                        "parentTag":  null,
                        "root":  true,
                        "weight":  null
                        }
                    },
                "crdr":  "credit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity.  Excludes changes in equity resulting from investments by owners and distributions to owners.",
                            "label":  "Comprehensive Income Net Of Tax",
                            "totalLabel":  "Comprehensive loss"
                            }
                        }
                    },
                "localname":  "ComprehensiveIncomeNetOfTax",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "us-gaap_ComputerEquipmentMember":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems.",
                            "label":  "Computer Equipment [Member]",
                            "terseLabel":  "Equipment and Computers"
                            }
                        }
                    },
                "localname":  "ComputerEquipmentMember",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureSummaryOfPropertyPlantAndEquipmentDetail"
                    ],
                "xbrltype":  "domainItemType"
                },
            "us-gaap_ConcentrationRiskBenchmarkDomain":  {
                "auth_ref":  [
                    "r163",
                    "r164",
                    "r199",
                    "r384",
                    "r385"
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "The denominator in a calculation of a disclosed concentration risk percentage.",
                            "label":  "Concentration Risk Benchmark [Domain]",
                            "terseLabel":  "Concentration Risk Benchmark"
                            }
                        }
                    },
                "localname":  "ConcentrationRiskBenchmarkDomain",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureConcentrationsAdditionalInformationDetail",
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureConcentrationsSummaryOfNetRevenueFromVariousProductsDetail",
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureSegmentInformationAdditionalInformationDetail"
                    ],
                "xbrltype":  "domainItemType"
                },
            "us-gaap_ConcentrationRiskByBenchmarkAxis":  {
                "auth_ref":  [
                    "r163",
                    "r164",
                    "r199",
                    "r384",
                    "r385",
                    "r486"
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Information by benchmark of concentration risk.",
                            "label":  "Concentration Risk By Benchmark [Axis]",
                            "terseLabel":  "Concentration Risk Benchmark"
                            }
                        }
                    },
                "localname":  "ConcentrationRiskByBenchmarkAxis",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureConcentrationsAdditionalInformationDetail",
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureConcentrationsSummaryOfNetRevenueFromVariousProductsDetail",
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureSegmentInformationAdditionalInformationDetail"
                    ],
                "xbrltype":  "stringItemType"
                },
            "us-gaap_ConcentrationRiskByTypeAxis":  {
                "auth_ref":  [
                    "r163",
                    "r164",
                    "r199",
                    "r384",
                    "r385",
                    "r486"
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.",
                            "label":  "Concentration Risk By Type [Axis]",
                            "terseLabel":  "Concentration Risk Type"
                            }
                        }
                    },
                "localname":  "ConcentrationRiskByTypeAxis",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureConcentrationsAdditionalInformationDetail",
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureConcentrationsSummaryOfNetRevenueFromVariousProductsDetail",
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureSegmentInformationAdditionalInformationDetail"
                    ],
                "xbrltype":  "stringItemType"
                },
            "us-gaap_ConcentrationRiskCreditRisk":  {
                "auth_ref":  [
                    "r156",
                    "r453"
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Disclosure of accounting policy for credit risk.",
                            "label":  "Concentration Risk Credit Risk",
                            "terseLabel":  "Concentration of Credit Risk, Interest Rate Risk and Foreign Currency Exchange Rate"
                            }
                        }
                    },
                "localname":  "ConcentrationRiskCreditRisk",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
                    ],
                "xbrltype":  "textBlockItemType"
                },
            "us-gaap_ConcentrationRiskDisclosureTextBlock":  {
                "auth_ref":  [
                    "r169"
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "The entire disclosure for any concentrations existing at the date of the financial statements that make an entity vulnerable to a reasonably possible, near-term, severe impact.  This disclosure informs financial statement users about the general nature of the risk associated with the concentration, and may indicate the percentage of concentration risk as of the balance sheet date.",
                            "label":  "Concentration Risk Disclosure [Text Block]",
                            "terseLabel":  "Concentrations"
                            }
                        }
                    },
                "localname":  "ConcentrationRiskDisclosureTextBlock",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureConcentrations"
                    ],
                "xbrltype":  "textBlockItemType"
                },
            "us-gaap_ConcentrationRiskLineItems":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Line items represent financial concepts included in a table.  These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
                            "label":  "Concentration Risk [Line Items]",
                            "terseLabel":  "Concentration Risk [Line Items]"
                            }
                        }
                    },
                "localname":  "ConcentrationRiskLineItems",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureConcentrationsAdditionalInformationDetail",
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureConcentrationsSummaryOfNetRevenueFromVariousProductsDetail"
                    ],
                "xbrltype":  "stringItemType"
                },
            "us-gaap_ConcentrationRiskPercentage1":  {
                "auth_ref":  [
                    "r163",
                    "r164",
                    "r199",
                    "r384",
                    "r385"
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.",
                            "label":  "Concentration Risk Percentage1",
                            "terseLabel":  "Percentage of sales",
                            "verboseLabel":  "Concentration Risk Percentage"
                            }
                        }
                    },
                "localname":  "ConcentrationRiskPercentage1",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureConcentrationsAdditionalInformationDetail",
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureConcentrationsSummaryOfNetRevenueFromVariousProductsDetail",
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureSegmentInformationAdditionalInformationDetail"
                    ],
                "xbrltype":  "percentItemType"
                },
            "us-gaap_ConcentrationRiskTable":  {
                "auth_ref":  [
                    "r159",
                    "r163",
                    "r164",
                    "r165",
                    "r384",
                    "r386"
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Describes the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.",
                            "label":  "Concentration Risk [Table]",
                            "terseLabel":  "Concentration Risk [Table]"
                            }
                        }
                    },
                "localname":  "ConcentrationRiskTable",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureConcentrationsAdditionalInformationDetail",
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureConcentrationsSummaryOfNetRevenueFromVariousProductsDetail"
                    ],
                "xbrltype":  "stringItemType"
                },
            "us-gaap_ConcentrationRiskTypeDomain":  {
                "auth_ref":  [
                    "r163",
                    "r164",
                    "r199",
                    "r384",
                    "r385"
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.",
                            "label":  "Concentration Risk Type [Domain]",
                            "terseLabel":  "Concentration Risk Type"
                            }
                        }
                    },
                "localname":  "ConcentrationRiskTypeDomain",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureConcentrationsAdditionalInformationDetail",
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureConcentrationsSummaryOfNetRevenueFromVariousProductsDetail",
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureSegmentInformationAdditionalInformationDetail"
                    ],
                "xbrltype":  "domainItemType"
                },
            "us-gaap_ConsolidationPolicyTextBlock":  {
                "auth_ref":  [
                    "r110",
                    "r369"
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.",
                            "label":  "Consolidation Policy [Text Block]",
                            "terseLabel":  "Basis of Presentation"
                            }
                        }
                    },
                "localname":  "ConsolidationPolicyTextBlock",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
                    ],
                "xbrltype":  "textBlockItemType"
                },
            "us-gaap_ConstructionInProgressMember":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Structure or a modification to a structure under construction.  Includes recently completed structures or modifications to structures that have not been placed into service.",
                            "label":  "Construction In Progress [Member]",
                            "terseLabel":  "Construction in Progress"
                            }
                        }
                    },
                "localname":  "ConstructionInProgressMember",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureSummaryOfPropertyPlantAndEquipmentDetail"
                    ],
                "xbrltype":  "domainItemType"
                },
            "us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock":  {
                "auth_ref":  [
                    "r270"
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Tabular disclosure of receivable, contract asset, and contract liability from contract with customer.  Includes, but is not limited to, change in contract asset and contract liability.",
                            "label":  "Contract With Customer Asset And Liability Table [Text Block]",
                            "terseLabel":  "Summary of Opening and Closing Balances of Contract Liabilities"
                            }
                        }
                    },
                "localname":  "ContractWithCustomerAssetAndLiabilityTableTextBlock",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureRevenueRecognitionTables"
                    ],
                "xbrltype":  "textBlockItemType"
                },
            "us-gaap_ContractWithCustomerLiability":  {
                "auth_ref":  [
                    "r268",
                    "r269",
                    "r280"
                    ],
                "calculation":  {
                    "http://www.biolase.com/20210331/taxonomy/role/DisclosureSummaryOfOpeningAndClosingBalancesOfContractLiabilitiesDetail2":  {
                        "order":  null,
                        "parentTag":  null,
                        "root":  true,
                        "weight":  null
                        },
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureSummaryOfOpeningAndClosingBalancesOfContractLiabilitiesDetail":  {
                        "order":  null,
                        "parentTag":  null,
                        "root":  true,
                        "weight":  null
                        }
                    },
                "crdr":  "credit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.",
                            "label":  "Contract With Customer Liability",
                            "totalLabel":  "Total deferred revenue"
                            }
                        }
                    },
                "localname":  "ContractWithCustomerLiability",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureSummaryOfOpeningAndClosingBalancesOfContractLiabilitiesDetail"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "us-gaap_ContractWithCustomerLiabilityCurrent":  {
                "auth_ref":  [
                    "r268",
                    "r269",
                    "r280"
                    ],
                "calculation":  {
                    "http://www.biolase.com/20210331/taxonomy/role/DisclosureSummaryOfOpeningAndClosingBalancesOfContractLiabilitiesDetail2":  {
                        "order":  1.0,
                        "parentTag":  "us-gaap_ContractWithCustomerLiability",
                        "weight":  1.0
                        }
                    },
                "crdr":  "credit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.",
                            "label":  "Contract With Customer Liability Current",
                            "terseLabel":  "Deferred revenue \u2014 current",
                            "totalLabel":  "Contract With Customer Liability Current, Total"
                            }
                        }
                    },
                "localname":  "ContractWithCustomerLiabilityCurrent",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureSummaryOfOpeningAndClosingBalancesOfContractLiabilitiesDetail"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "us-gaap_ContractWithCustomerLiabilityNoncurrent":  {
                "auth_ref":  [
                    "r268",
                    "r269",
                    "r280"
                    ],
                "calculation":  {
                    "http://www.biolase.com/20210331/taxonomy/role/DisclosureSummaryOfOpeningAndClosingBalancesOfContractLiabilitiesDetail2":  {
                        "order":  0.0,
                        "parentTag":  "us-gaap_ContractWithCustomerLiability",
                        "weight":  1.0
                        }
                    },
                "crdr":  "credit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.",
                            "label":  "Contract With Customer Liability Noncurrent",
                            "negatedLabel":  "Less long-term portion of deferred revenue",
                            "terseLabel":  "Less long-term portion of deferred revenue"
                            }
                        }
                    },
                "localname":  "ContractWithCustomerLiabilityNoncurrent",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureSummaryOfOpeningAndClosingBalancesOfContractLiabilitiesDetail"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "us-gaap_ContractWithCustomerSalesChannelAxis":  {
                "auth_ref":  [
                    "r279",
                    "r288"
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Information by sales channel for delivery of good or service in contract with customer.",
                            "label":  "Contract With Customer Sales Channel [Axis]",
                            "terseLabel":  "Contract with Customer, Sales Channel"
                            }
                        }
                    },
                "localname":  "ContractWithCustomerSalesChannelAxis",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureSummaryOfSalesByEndMarketDetail"
                    ],
                "xbrltype":  "stringItemType"
                },
            "us-gaap_ContractWithCustomerSalesChannelDomain":  {
                "auth_ref":  [
                    "r279",
                    "r288"
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Sales channel for delivery of good or service in contract with customer.  Includes, but is not limited to, directly to consumer and through intermediary.",
                            "label":  "Contract With Customer Sales Channel [Domain]",
                            "terseLabel":  "Contract with Customer, Sales Channel"
                            }
                        }
                    },
                "localname":  "ContractWithCustomerSalesChannelDomain",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureSummaryOfSalesByEndMarketDetail"
                    ],
                "xbrltype":  "domainItemType"
                },
            "us-gaap_ConvertiblePreferredStockMember":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Preferred stock that may be exchanged into common shares or other types of securities at the owner's option.",
                            "label":  "Convertible Preferred Stock [Member]",
                            "terseLabel":  "Series F Convertible Preferred Stock"
                            }
                        }
                    },
                "localname":  "ConvertiblePreferredStockMember",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureRedeemablePreferredStockAndStockholdersEquityAdditionalInformationDetail"
                    ],
                "xbrltype":  "domainItemType"
                },
            "us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion":  {
                "auth_ref":  [
                    "r20",
                    "r21",
                    "r261",
                    "r262"
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Number of shares issued for each share of convertible preferred stock that is converted.",
                            "label":  "Convertible Preferred Stock, Shares Issued upon Conversion",
                            "terseLabel":  "Convertible preferred stock, Common shares issued upon conversion"
                            }
                        }
                    },
                "localname":  "ConvertiblePreferredStockSharesIssuedUponConversion",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureRedeemablePreferredStockAndStockholdersEquityAdditionalInformationDetail"
                    ],
                "xbrltype":  "sharesItemType"
                },
            "us-gaap_CostOfRevenue":  {
                "auth_ref":  [
                    "r83",
                    "r114",
                    "r205",
                    "r387"
                    ],
                "calculation":  {
                    "http://www.biolase.com/20210331/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited":  {
                        "order":  1.0,
                        "parentTag":  "us-gaap_GrossProfit",
                        "weight":  -1.0
                        }
                    },
                "crdr":  "debit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "The aggregate cost of goods produced and sold and services rendered during the reporting period.",
                            "label":  "Cost Of Revenue",
                            "terseLabel":  "Cost of revenue",
                            "totalLabel":  "Cost of Revenue, Total"
                            }
                        }
                    },
                "localname":  "CostOfRevenue",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "us-gaap_CostOfSalesMember":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Primary financial statement caption encompassing cost of sales.",
                            "label":  "Cost Of Sales [Member]",
                            "terseLabel":  "Cost of Revenue"
                            }
                        }
                    },
                "localname":  "CostOfSalesMember",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureClassificationOfCompensationExpenseAssociatedWithShareBasedPaymentsDetail"
                    ],
                "xbrltype":  "domainItemType"
                },
            "us-gaap_CreditFacilityAxis":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Information by type of credit facility.  Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
                            "label":  "Credit Facility [Axis]",
                            "terseLabel":  "Credit Facility"
                            }
                        }
                    },
                "localname":  "CreditFacilityAxis",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetail"
                    ],
                "xbrltype":  "stringItemType"
                },
            "us-gaap_CreditFacilityDomain":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Type of credit facility.  Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
                            "label":  "Credit Facility [Domain]",
                            "terseLabel":  "Credit Facility"
                            }
                        }
                    },
                "localname":  "CreditFacilityDomain",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetail"
                    ],
                "xbrltype":  "domainItemType"
                },
            "us-gaap_CustomerConcentrationRiskMember":  {
                "auth_ref":  [
                    "r160",
                    "r199"
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues.  The risk is the materially adverse effects of loss of a significant customer.",
                            "label":  "Customer Concentration Risk [Member]",
                            "terseLabel":  "Customer Concentration Risk"
                            }
                        }
                    },
                "localname":  "CustomerConcentrationRiskMember",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureSegmentInformationAdditionalInformationDetail"
                    ],
                "xbrltype":  "domainItemType"
                },
            "us-gaap_DebtDisclosureAbstract":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "label":  "Debt Disclosure [Abstract]"
                            }
                        }
                    },
                "localname":  "DebtDisclosureAbstract",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "xbrltype":  "stringItemType"
                },
            "us-gaap_DebtDisclosureTextBlock":  {
                "auth_ref":  [
                    "r257"
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
                            "label":  "Debt Disclosure [Text Block]",
                            "terseLabel":  "Debt"
                            }
                        }
                    },
                "localname":  "DebtDisclosureTextBlock",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureDebt"
                    ],
                "xbrltype":  "textBlockItemType"
                },
            "us-gaap_DebtInstrumentAxis":  {
                "auth_ref":  [
                    "r16",
                    "r17",
                    "r18",
                    "r439",
                    "r440",
                    "r454"
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
                            "label":  "Debt Instrument [Axis]",
                            "terseLabel":  "Debt Instrument"
                            }
                        }
                    },
                "localname":  "DebtInstrumentAxis",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail",
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetail",
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureDebtSummaryOfPrincipalOutstandingAndUnamortizedDiscountDetail"
                    ],
                "xbrltype":  "stringItemType"
                },
            "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Percentage points added to the reference rate to compute the variable rate on the debt instrument.",
                            "label":  "Debt Instrument Basis Spread On Variable Rate1",
                            "terseLabel":  "Line of credit facility bearing floating interest rate per annum"
                            }
                        }
                    },
                "localname":  "DebtInstrumentBasisSpreadOnVariableRate1",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetail"
                    ],
                "xbrltype":  "percentItemType"
                },
            "us-gaap_DebtInstrumentCarryingAmount":  {
                "auth_ref":  [
                    "r18",
                    "r253",
                    "r440",
                    "r454"
                    ],
                "calculation":  {
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureDebtSummaryOfFutureMinimumPrincipalAndInterestPaymentsDetail":  {
                        "order":  null,
                        "parentTag":  null,
                        "root":  true,
                        "weight":  null
                        }
                    },
                "crdr":  "credit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt.  Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.",
                            "label":  "Debt Instrument Carrying Amount",
                            "totalLabel":  "Total future payments"
                            }
                        }
                    },
                "localname":  "DebtInstrumentCarryingAmount",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureDebtSummaryOfFutureMinimumPrincipalAndInterestPaymentsDetail"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "us-gaap_DebtInstrumentCovenantDescription":  {
                "auth_ref":  [
                    "r18",
                    "r450"
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Description of minimum financial levels (for example, tangible net worth and working capital) and achievement of certain financial ratios (for example, working capital ratio and debt service coverage ratio), and adherence to certain clauses which generally require or restrict certain actions (for example, entering into a debt arrangement with equal or greater seniority, and selling or discontinuing a certain business segment or material subsidiary) to be in compliance with the covenant clauses of the debt agreement.  May also include a discussion of the adverse consequences that would result if the entity violates or fails to satisfy the covenants.",
                            "label":  "Debt Instrument Covenant Description",
                            "terseLabel":  "Debt instrument covenant description"
                            }
                        }
                    },
                "localname":  "DebtInstrumentCovenantDescription",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetail"
                    ],
                "xbrltype":  "stringItemType"
                },
            "us-gaap_DebtInstrumentDescriptionOfVariableRateBasis":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "The reference rate for the variable rate of the debt instrument, such as LIBOR or the US Treasury rate and the maturity of the reference rate used, such as three months or six months LIBOR.",
                            "label":  "Debt Instrument Description Of Variable Rate Basis",
                            "terseLabel":  "Line of credit facility interest rate description"
                            }
                        }
                    },
                "localname":  "DebtInstrumentDescriptionOfVariableRateBasis",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetail"
                    ],
                "xbrltype":  "stringItemType"
                },
            "us-gaap_DebtInstrumentFrequencyOfPeriodicPayment":  {
                "auth_ref":  [
                    "r54",
                    "r449"
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Description of the frequency of periodic payments (monthly, quarterly, annual).",
                            "label":  "Debt Instrument Frequency Of Periodic Payment",
                            "terseLabel":  "Loan periodic payment terms"
                            }
                        }
                    },
                "localname":  "DebtInstrumentFrequencyOfPeriodicPayment",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail",
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetail"
                    ],
                "xbrltype":  "stringItemType"
                },
            "us-gaap_DebtInstrumentInterestRateStatedPercentage":  {
                "auth_ref":  [
                    "r49"
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Contractual interest rate for funds borrowed, under the debt agreement.",
                            "label":  "Debt Instrument Interest Rate Stated Percentage",
                            "terseLabel":  "Note interest rate per annum",
                            "verboseLabel":  "Loan interest rate per annum"
                            }
                        }
                    },
                "localname":  "DebtInstrumentInterestRateStatedPercentage",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetail"
                    ],
                "xbrltype":  "percentItemType"
                },
            "us-gaap_DebtInstrumentIssuanceDate1":  {
                "auth_ref":  [
                    "r52"
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Date the debt instrument was issued, in CCYY-MM-DD format.",
                            "label":  "Debt Instrument Issuance Date1",
                            "terseLabel":  "Note issued date"
                            }
                        }
                    },
                "localname":  "DebtInstrumentIssuanceDate1",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetail"
                    ],
                "xbrltype":  "dateItemType"
                },
            "us-gaap_DebtInstrumentLineItems":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Line items represent financial concepts included in a table.  These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
                            "label":  "Debt Instrument [Line Items]",
                            "terseLabel":  "Debt Instrument [Line Items]"
                            }
                        }
                    },
                "localname":  "DebtInstrumentLineItems",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetail",
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureDebtSummaryOfPrincipalOutstandingAndUnamortizedDiscountDetail"
                    ],
                "xbrltype":  "stringItemType"
                },
            "us-gaap_DebtInstrumentMaturityDate":  {
                "auth_ref":  [
                    "r50",
                    "r378"
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Date when the debt instrument is scheduled to be fully repaid, in CCYY-MM-DD format.",
                            "label":  "Debt Instrument Maturity Date",
                            "terseLabel":  "Note maturity date"
                            }
                        }
                    },
                "localname":  "DebtInstrumentMaturityDate",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetail"
                    ],
                "xbrltype":  "dateItemType"
                },
            "us-gaap_DebtInstrumentNameDomain":  {
                "auth_ref":  [
                    "r54"
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
                            "label":  "Debt Instrument Name [Domain]",
                            "terseLabel":  "Debt Instrument, Name"
                            }
                        }
                    },
                "localname":  "DebtInstrumentNameDomain",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail",
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetail",
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureDebtSummaryOfPrincipalOutstandingAndUnamortizedDiscountDetail"
                    ],
                "xbrltype":  "domainItemType"
                },
            "us-gaap_DebtInstrumentPaymentTerms":  {
                "auth_ref":  [
                    "r51",
                    "r449"
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Description of the payment terms of the debt instrument (for example, whether periodic payments include principal and frequency of payments) and discussion about any contingencies associated with the payment.",
                            "label":  "Debt Instrument Payment Terms",
                            "terseLabel":  "Loan balance payment terms"
                            }
                        }
                    },
                "localname":  "DebtInstrumentPaymentTerms",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetail"
                    ],
                "xbrltype":  "stringItemType"
                },
            "us-gaap_DebtInstrumentPeriodicPayment":  {
                "auth_ref":  [
                    "r54",
                    "r449"
                    ],
                "crdr":  "debit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Amount of the required periodic payments including both interest and principal payments.",
                            "label":  "Debt Instrument Periodic Payment",
                            "terseLabel":  "Loan periodic payment",
                            "totalLabel":  "Debt Instrument, Periodic Payment, Total"
                            }
                        }
                    },
                "localname":  "DebtInstrumentPeriodicPayment",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetail"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "us-gaap_DebtInstrumentRedemptionPeriodStartDate":  {
                "auth_ref":  [
                    "r451"
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Start date of debt instrument redemption period, in CCYY-MM-DD format.",
                            "label":  "Debt Instrument Redemption Period Start Date",
                            "terseLabel":  "Note payable commencing date"
                            }
                        }
                    },
                "localname":  "DebtInstrumentRedemptionPeriodStartDate",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetail"
                    ],
                "xbrltype":  "dateItemType"
                },
            "us-gaap_DebtInstrumentTable":  {
                "auth_ref":  [
                    "r54",
                    "r116",
                    "r261",
                    "r263",
                    "r264",
                    "r265",
                    "r400",
                    "r401",
                    "r403",
                    "r452"
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation.  These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
                            "label":  "Debt Instrument [Table]",
                            "terseLabel":  "Debt Instrument [Table]"
                            }
                        }
                    },
                "localname":  "DebtInstrumentTable",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetail",
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureDebtSummaryOfPrincipalOutstandingAndUnamortizedDiscountDetail"
                    ],
                "xbrltype":  "stringItemType"
                },
            "us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet":  {
                "auth_ref":  [
                    "r254",
                    "r402"
                    ],
                "crdr":  "debit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Amount of unamortized debt discount (premium) and debt issuance costs.",
                            "label":  "Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net",
                            "negatedLabel":  "Discount and debt issuance costs on SWK Loan",
                            "totalLabel":  "Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net, Total"
                            }
                        }
                    },
                "localname":  "DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureDebtSummaryOfPrincipalOutstandingAndUnamortizedDiscountDetail"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "us-gaap_DebtInstrumentUnusedBorrowingCapacityAmount":  {
                "auth_ref":  [
                    "r53"
                    ],
                "crdr":  "credit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Amount of unused borrowing capacity under the long-term financing arrangement that is available to the entity as of the balance sheet date.",
                            "label":  "Debt Instrument Unused Borrowing Capacity Amount",
                            "terseLabel":  "Line of credit facility, unused availability"
                            }
                        }
                    },
                "localname":  "DebtInstrumentUnusedBorrowingCapacityAmount",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetail"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "us-gaap_DebtWeightedAverageInterestRate":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Weighted average interest rate of debt outstanding.",
                            "label":  "Debt Weighted Average Interest Rate",
                            "terseLabel":  "Weighted-average interest rate"
                            }
                        }
                    },
                "localname":  "DebtWeightedAverageInterestRate",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetail"
                    ],
                "xbrltype":  "percentItemType"
                },
            "us-gaap_DeferredCompensationShareBasedArrangementsLiabilityCurrent":  {
                "auth_ref":  [
                    "r47"
                    ],
                "crdr":  "credit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Aggregate carrying value as of the balance sheet date of the liabilities for stock option plans and other equity-based compensation arrangements payable within one year (or the operating cycle, if longer).",
                            "label":  "Deferred Compensation Share-based Arrangements, Liability, Current",
                            "terseLabel":  "Stock Compensation Liability"
                            }
                        }
                    },
                "localname":  "DeferredCompensationShareBasedArrangementsLiabilityCurrent",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureRedeemablePreferredStockAndStockholdersEquityAdditionalInformationDetail"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "us-gaap_DeferredIncomeTaxExpenseBenefit":  {
                "auth_ref":  [
                    "r102",
                    "r115",
                    "r350",
                    "r357",
                    "r358",
                    "r359"
                    ],
                "calculation":  {
                    "http://www.biolase.com/20210331/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlowsUnaudited":  {
                        "order":  9.0,
                        "parentTag":  "us-gaap_NetCashProvidedByUsedInOperatingActivities",
                        "weight":  1.0
                        }
                    },
                "crdr":  "debit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.",
                            "label":  "Deferred Income Tax Expense Benefit",
                            "terseLabel":  "Deferred income taxes",
                            "totalLabel":  "Deferred Income Tax Expense (Benefit), Total"
                            }
                        }
                    },
                "localname":  "DeferredIncomeTaxExpenseBenefit",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlowsUnaudited"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "us-gaap_DeferredRevenueCurrent":  {
                "auth_ref":  [
                    "r31"
                    ],
                "calculation":  {
                    "http://www.biolase.com/20210331/taxonomy/role/Role_StatementConsolidatedBalanceSheetsUnaudited":  {
                        "order":  2.0,
                        "parentTag":  "us-gaap_LiabilitiesCurrent",
                        "weight":  1.0
                        }
                    },
                "crdr":  "credit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current.",
                            "label":  "Deferred Revenue Current",
                            "terseLabel":  "Deferred revenue, current portion",
                            "totalLabel":  "Deferred Revenue, Current, Total"
                            }
                        }
                    },
                "localname":  "DeferredRevenueCurrent",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_StatementConsolidatedBalanceSheetsUnaudited"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "us-gaap_DeferredRevenueNoncurrent":  {
                "auth_ref":  [
                    "r31"
                    ],
                "calculation":  {
                    "http://www.biolase.com/20210331/taxonomy/role/Role_StatementConsolidatedBalanceSheetsUnaudited":  {
                        "order":  1.0,
                        "parentTag":  "us-gaap_Liabilities",
                        "weight":  1.0
                        }
                    },
                "crdr":  "credit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as noncurrent.",
                            "label":  "Deferred Revenue Noncurrent",
                            "terseLabel":  "Deferred revenue",
                            "totalLabel":  "Deferred Revenue, Noncurrent, Total"
                            }
                        }
                    },
                "localname":  "DeferredRevenueNoncurrent",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_StatementConsolidatedBalanceSheetsUnaudited"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "us-gaap_DeferredTaxLiabilitiesDeferredExpense":  {
                "auth_ref":  [
                    "r348",
                    "r349"
                    ],
                "crdr":  "credit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Amount of deferred tax liability attributable to taxable temporary differences from capitalized costs.",
                            "label":  "Deferred Liability",
                            "totalLabel":  "Deferred Tax Liabilities, Deferred Expense, Total"
                            }
                        }
                    },
                "localname":  "DeferredTaxLiabilitiesDeferredExpense",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureAccruedLiabilitiesAdditionalInformationDetail"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "us-gaap_DepreciationAndAmortization":  {
                "auth_ref":  [
                    "r102",
                    "r224"
                    ],
                "crdr":  "debit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.",
                            "label":  "Depreciation And Amortization",
                            "terseLabel":  "Depreciation and amortization expenses",
                            "totalLabel":  "Depreciation, Depletion and Amortization, Nonproduction, Total"
                            }
                        }
                    },
                "localname":  "DepreciationAndAmortization",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosurePropertyPlantAndEquipmentAdditionalInformationDetail"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "us-gaap_DepreciationDepletionAndAmortization":  {
                "auth_ref":  [
                    "r102",
                    "r175"
                    ],
                "calculation":  {
                    "http://www.biolase.com/20210331/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlowsUnaudited":  {
                        "order":  1.0,
                        "parentTag":  "us-gaap_NetCashProvidedByUsedInOperatingActivities",
                        "weight":  1.0
                        }
                    },
                "crdr":  "debit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
                            "label":  "Depreciation Depletion And Amortization",
                            "terseLabel":  "Depreciation and amortization",
                            "totalLabel":  "Depreciation, Depletion and Amortization, Total"
                            }
                        }
                    },
                "localname":  "DepreciationDepletionAndAmortization",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlowsUnaudited"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "us-gaap_DisaggregationOfRevenueLineItems":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Line items represent financial concepts included in a table.  These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
                            "label":  "Disaggregation Of Revenue [Line Items]",
                            "terseLabel":  "Disaggregation Of Revenue [Line Items]"
                            }
                        }
                    },
                "localname":  "DisaggregationOfRevenueLineItems",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureSummaryOfDisaggregationOfRevenuesRelatedToGeographicAreasDetail",
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureSummaryOfRevenuesDisaggregatedByTimingOfGoodsAndServicesTransferredDetail",
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureSummaryOfSalesByEndMarketDetail"
                    ],
                "xbrltype":  "stringItemType"
                },
            "us-gaap_DisaggregationOfRevenueTable":  {
                "auth_ref":  [
                    "r279",
                    "r282",
                    "r283",
                    "r284",
                    "r285",
                    "r286",
                    "r287",
                    "r288"
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
                            "label":  "Disaggregation Of Revenue [Table]",
                            "terseLabel":  "Disaggregation Of Revenue [Table]"
                            }
                        }
                    },
                "localname":  "DisaggregationOfRevenueTable",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureSummaryOfDisaggregationOfRevenuesRelatedToGeographicAreasDetail",
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureSummaryOfRevenuesDisaggregatedByTimingOfGoodsAndServicesTransferredDetail",
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureSummaryOfSalesByEndMarketDetail"
                    ],
                "xbrltype":  "stringItemType"
                },
            "us-gaap_DisaggregationOfRevenueTableTextBlock":  {
                "auth_ref":  [
                    "r279"
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
                            "label":  "Disaggregation Of Revenue Table [Text Block]",
                            "terseLabel":  "Summary of Disaggregation of Revenues Related to Geographic Areas"
                            }
                        }
                    },
                "localname":  "DisaggregationOfRevenueTableTextBlock",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureRevenueRecognitionTables"
                    ],
                "xbrltype":  "textBlockItemType"
                },
            "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "label":  "Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]"
                            }
                        }
                    },
                "localname":  "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "xbrltype":  "stringItemType"
                },
            "us-gaap_EarningsPerShareAbstract":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "label":  "Earnings Per Share [Abstract]",
                            "terseLabel":  "Net loss per share attributable to common stockholders:"
                            }
                        }
                    },
                "localname":  "EarningsPerShareAbstract",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited"
                    ],
                "xbrltype":  "stringItemType"
                },
            "us-gaap_EarningsPerShareBasic":  {
                "auth_ref":  [
                    "r78",
                    "r128",
                    "r129",
                    "r130",
                    "r131",
                    "r132",
                    "r136",
                    "r139",
                    "r144",
                    "r145",
                    "r146",
                    "r148",
                    "r149",
                    "r447",
                    "r465"
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
                            "label":  "Earnings Per Share Basic",
                            "terseLabel":  "Basic",
                            "totalLabel":  "Earnings Per Share, Basic, Total"
                            }
                        }
                    },
                "localname":  "EarningsPerShareBasic",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited"
                    ],
                "xbrltype":  "perShareItemType"
                },
            "us-gaap_EarningsPerShareDiluted":  {
                "auth_ref":  [
                    "r78",
                    "r128",
                    "r129",
                    "r130",
                    "r131",
                    "r132",
                    "r139",
                    "r144",
                    "r145",
                    "r146",
                    "r148",
                    "r149",
                    "r447",
                    "r465"
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
                            "label":  "Earnings Per Share Diluted",
                            "terseLabel":  "Diluted",
                            "totalLabel":  "Earnings Per Share, Diluted, Total"
                            }
                        }
                    },
                "localname":  "EarningsPerShareDiluted",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited"
                    ],
                "xbrltype":  "perShareItemType"
                },
            "us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents":  {
                "auth_ref":  [
                    "r392"
                    ],
                "calculation":  {
                    "http://www.biolase.com/20210331/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlowsUnaudited":  {
                        "order":  0.0,
                        "parentTag":  "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
                        "weight":  1.0
                        }
                    },
                "crdr":  "debit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Amount of increase (decrease) from the effect of exchange rate changes on cash and cash equivalent balances held in foreign currencies.",
                            "label":  "Effect Of Exchange Rate On Cash And Cash Equivalents",
                            "terseLabel":  "Effect of exchange rate changes",
                            "totalLabel":  "Effect of Exchange Rate on Cash and Cash Equivalents, Total"
                            }
                        }
                    },
                "localname":  "EffectOfExchangeRateOnCashAndCashEquivalents",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlowsUnaudited"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "us-gaap_EffectiveIncomeTaxRateContinuingOperations":  {
                "auth_ref":  [
                    "r343"
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
                            "label":  "Effective Income Tax Rate Continuing Operations",
                            "terseLabel":  "Projected annual effective tax rate",
                            "totalLabel":  "Effective Income Tax Rate Reconciliation, Percent, Total"
                            }
                        }
                    },
                "localname":  "EffectiveIncomeTaxRateContinuingOperations",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
                    ],
                "xbrltype":  "percentItemType"
                },
            "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate":  {
                "auth_ref":  [
                    "r343",
                    "r360"
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).",
                            "label":  "Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate",
                            "terseLabel":  "Statutory tax rate"
                            }
                        }
                    },
                "localname":  "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
                    ],
                "xbrltype":  "percentItemType"
                },
            "us-gaap_EmployeeRelatedLiabilitiesCurrent":  {
                "auth_ref":  [
                    "r47"
                    ],
                "calculation":  {
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureComponentsOfAccruedLiabilitiesDetail":  {
                        "order":  0.0,
                        "parentTag":  "us-gaap_AccruedLiabilitiesCurrent",
                        "weight":  1.0
                        }
                    },
                "crdr":  "credit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.  Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
                            "label":  "Employee Related Liabilities Current",
                            "terseLabel":  "Payroll and benefits",
                            "totalLabel":  "Employee-related Liabilities, Current, Total"
                            }
                        }
                    },
                "localname":  "EmployeeRelatedLiabilitiesCurrent",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureComponentsOfAccruedLiabilitiesDetail"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized":  {
                "auth_ref":  [
                    "r326"
                    ],
                "crdr":  "debit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.",
                            "label":  "Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized",
                            "terseLabel":  "Total unrecognized compensation expense",
                            "totalLabel":  "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total"
                            }
                        }
                    },
                "localname":  "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureRedeemablePreferredStockAndStockholdersEquityAdditionalInformationDetail"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1":  {
                "auth_ref":  [
                    "r326"
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
                            "label":  "Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1",
                            "terseLabel":  "Unrecognized share based compensation expense to be recognized over weighted-average period"
                            }
                        }
                    },
                "localname":  "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureRedeemablePreferredStockAndStockholdersEquityAdditionalInformationDetail"
                    ],
                "xbrltype":  "durationItemType"
                },
            "us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions":  {
                "auth_ref":  [
                    "r328"
                    ],
                "crdr":  "credit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Amount of tax benefit from exercise of option under share-based payment arrangement.",
                            "label":  "Employee Service Share Based Compensation Tax Benefit From Exercise Of Stock Options",
                            "terseLabel":  "Tax benefit related to stock options exercised"
                            }
                        }
                    },
                "localname":  "EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureCashProceedsAlongWithFairValueDisclosuresRelatedToGrantsExercisesAndVestedOptionsDetail"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "us-gaap_EmployeeStockOptionMember":  {
                "auth_ref":  [
                    "r323"
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
                            "label":  "Employee Stock Option [Member]",
                            "terseLabel":  "Stock Options"
                            }
                        }
                    },
                "localname":  "EmployeeStockOptionMember",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureSummaryOfUnvestedStockOptionActivityDetail"
                    ],
                "xbrltype":  "domainItemType"
                },
            "us-gaap_EquityAbstract":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "label":  "Equity [Abstract]"
                            }
                        }
                    },
                "localname":  "EquityAbstract",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "xbrltype":  "stringItemType"
                },
            "us-gaap_EquityComponentDomain":  {
                "auth_ref":  [
                    "r121",
                    "r122",
                    "r123",
                    "r125",
                    "r133",
                    "r135",
                    "r150",
                    "r209",
                    "r260",
                    "r266",
                    "r333",
                    "r334",
                    "r335",
                    "r353",
                    "r354",
                    "r393",
                    "r394",
                    "r395",
                    "r396",
                    "r397",
                    "r398",
                    "r476",
                    "r477",
                    "r478"
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
                            "label":  "Equity Component [Domain]",
                            "terseLabel":  "Equity Component"
                            }
                        }
                    },
                "localname":  "EquityComponentDomain",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetail",
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureRedeemablePreferredStockAndStockholdersEquityAdditionalInformationDetail",
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureSummaryOfWarrantActivityDetail",
                    "http://www.biolase.com/20210331/taxonomy/role/Role_StatementConsolidatedStatementsOfRedeemablePreferredStockAndStockholdersEquityUnaudited"
                    ],
                "xbrltype":  "domainItemType"
                },
            "us-gaap_FairValueAdjustmentOfWarrants":  {
                "auth_ref":  [
                    "r102",
                    "r258"
                    ],
                "crdr":  "debit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Amount of expense (income) related to adjustment to fair value of warrant liability.",
                            "label":  "Fair Value Adjustment Of Warrants",
                            "terseLabel":  "Change in fair value of warrants",
                            "verboseLabel":  "Warrants, estimated fair value"
                            }
                        }
                    },
                "localname":  "FairValueAdjustmentOfWarrants",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetail",
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureRedeemablePreferredStockAndStockholdersEquityAdditionalInformationDetail"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain":  {
                "auth_ref":  [
                    "r379"
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Class of asset.",
                            "label":  "Fair Value Assets Measured On Recurring Basis Unobservable Input Reconciliation By Asset Class [Domain]",
                            "terseLabel":  "Asset Class"
                            }
                        }
                    },
                "localname":  "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureRedeemablePreferredStockAndStockholdersEquityAdditionalInformationDetail"
                    ],
                "xbrltype":  "domainItemType"
                },
            "us-gaap_FairValueByAssetClassAxis":  {
                "auth_ref":  [
                    "r377",
                    "r380"
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Information by class of asset.",
                            "label":  "Fair Value By Asset Class [Axis]",
                            "terseLabel":  "Asset Class"
                            }
                        }
                    },
                "localname":  "FairValueByAssetClassAxis",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureRedeemablePreferredStockAndStockholdersEquityAdditionalInformationDetail"
                    ],
                "xbrltype":  "stringItemType"
                },
            "us-gaap_FairValueOfFinancialInstrumentsPolicy":  {
                "auth_ref":  [
                    "r110",
                    "r381",
                    "r382"
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Disclosure of accounting policy for determining the fair value of financial instruments.",
                            "label":  "Fair Value Of Financial Instruments Policy",
                            "terseLabel":  "Fair Value of Financial Instruments"
                            }
                        }
                    },
                "localname":  "FairValueOfFinancialInstrumentsPolicy",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
                    ],
                "xbrltype":  "textBlockItemType"
                },
            "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax":  {
                "auth_ref":  [
                    "r388",
                    "r389",
                    "r390",
                    "r391"
                    ],
                "calculation":  {
                    "http://www.biolase.com/20210331/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited":  {
                        "order":  2.0,
                        "parentTag":  "us-gaap_NonoperatingIncomeExpense",
                        "weight":  1.0
                        }
                    },
                "crdr":  "credit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.",
                            "label":  "Foreign Currency Transaction Gain Loss Before Tax",
                            "negatedLabel":  "Loss on foreign currency transactions",
                            "totalLabel":  "Foreign Currency Transaction Gain (Loss), before Tax, Total"
                            }
                        }
                    },
                "localname":  "ForeignCurrencyTransactionGainLossBeforeTax",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "us-gaap_FurnitureAndFixturesMember":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities.  Examples include, but are not limited to, desks, chairs, tables, and bookcases.",
                            "label":  "Furniture And Fixtures [Member]",
                            "terseLabel":  "Furniture and Fixtures"
                            }
                        }
                    },
                "localname":  "FurnitureAndFixturesMember",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureSummaryOfPropertyPlantAndEquipmentDetail"
                    ],
                "xbrltype":  "domainItemType"
                },
            "us-gaap_GainLossRelatedToLitigationSettlement":  {
                "auth_ref":  [
                    "r233"
                    ],
                "crdr":  "credit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Amount of gain (loss) recognized in settlement of litigation and insurance claims.  Excludes claims within an insurance entity's normal claims settlement process.",
                            "label":  "Gain Loss Related To Litigation Settlement",
                            "totalLabel":  "Gain (Loss) Related to Litigation Settlement, Total",
                            "verboseLabel":  "Contingent loss on patent litigation settlement"
                            }
                        }
                    },
                "localname":  "GainLossRelatedToLitigationSettlement",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "us-gaap_GeneralAndAdministrativeExpense":  {
                "auth_ref":  [
                    "r84"
                    ],
                "calculation":  {
                    "http://www.biolase.com/20210331/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited":  {
                        "order":  1.0,
                        "parentTag":  "us-gaap_OperatingExpenses",
                        "weight":  1.0
                        }
                    },
                "crdr":  "debit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
                            "label":  "General And Administrative Expense",
                            "terseLabel":  "General and administrative",
                            "totalLabel":  "General and Administrative Expense, Total"
                            }
                        }
                    },
                "localname":  "GeneralAndAdministrativeExpense",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "us-gaap_GeneralAndAdministrativeExpenseMember":  {
                "auth_ref":  [
                    "r79"
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Primary financial statement caption encompassing general and administrative expense.",
                            "label":  "General And Administrative Expense [Member]",
                            "terseLabel":  "General and Administrative"
                            }
                        }
                    },
                "localname":  "GeneralAndAdministrativeExpenseMember",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureClassificationOfCompensationExpenseAssociatedWithShareBasedPaymentsDetail"
                    ],
                "xbrltype":  "domainItemType"
                },
            "us-gaap_GeographicConcentrationRiskMember":  {
                "auth_ref":  [
                    "r162"
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Reflects the percentage that a specified dollar value on the balance sheet or income statement in the period from one or more specified geographic areas is to a corresponding consolidated, segment, or product line amount.  Risk is the materially adverse effects of economic decline or antagonistic political actions resulting in loss of assets, sales volume, labor supply, or source of materials and supplies in a US state or a specified country, continent, or region such as EMEA (Europe, Middle East, Africa).",
                            "label":  "Geographic Concentration Risk [Member]",
                            "terseLabel":  "Geographic Concentration Risk"
                            }
                        }
                    },
                "localname":  "GeographicConcentrationRiskMember",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureSegmentInformationAdditionalInformationDetail"
                    ],
                "xbrltype":  "domainItemType"
                },
            "us-gaap_Goodwill":  {
                "auth_ref":  [
                    "r218",
                    "r219",
                    "r437"
                    ],
                "calculation":  {
                    "http://www.biolase.com/20210331/taxonomy/role/Role_StatementConsolidatedBalanceSheetsUnaudited":  {
                        "order":  2.0,
                        "parentTag":  "us-gaap_Assets",
                        "weight":  1.0
                        }
                    },
                "crdr":  "debit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
                            "label":  "Goodwill",
                            "periodEndLabel":  "Goodwill, Ending Balance",
                            "periodStartLabel":  "Goodwill, Beginning Balance",
                            "terseLabel":  "Goodwill",
                            "totalLabel":  "Goodwill, Total"
                            }
                        }
                    },
                "localname":  "Goodwill",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureIntangibleAssetsAndGoodwillAdditionalInformationDetail",
                    "http://www.biolase.com/20210331/taxonomy/role/Role_StatementConsolidatedBalanceSheetsUnaudited"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "us-gaap_GoodwillAndIntangibleAssetImpairment":  {
                "auth_ref":  [
                    ],
                "crdr":  "debit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Total loss recognized during the period from the impairment of goodwill plus the loss recognized in the period resulting from the impairment of the carrying amount of intangible assets, other than goodwill.",
                            "label":  "Goodwill And Intangible Asset Impairment",
                            "terseLabel":  "Intangible assets and goodwill impairment",
                            "totalLabel":  "Goodwill and Intangible Asset Impairment, Total"
                            }
                        }
                    },
                "localname":  "GoodwillAndIntangibleAssetImpairment",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureIntangibleAssetsAndGoodwillAdditionalInformationDetail"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "label":  "Goodwill And Intangible Assets Disclosure [Abstract]"
                            }
                        }
                    },
                "localname":  "GoodwillAndIntangibleAssetsDisclosureAbstract",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "xbrltype":  "stringItemType"
                },
            "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock":  {
                "auth_ref":  [
                    "r223"
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "The entire disclosure for goodwill and intangible assets.",
                            "label":  "Goodwill And Intangible Assets Disclosure [Text Block]",
                            "terseLabel":  "Intangible Assets And Goodwill"
                            }
                        }
                    },
                "localname":  "GoodwillAndIntangibleAssetsDisclosureTextBlock",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureIntangibleAssetsAndGoodwill"
                    ],
                "xbrltype":  "textBlockItemType"
                },
            "us-gaap_GrossProfit":  {
                "auth_ref":  [
                    "r82",
                    "r114",
                    "r177",
                    "r181",
                    "r185",
                    "r188",
                    "r191",
                    "r205",
                    "r387"
                    ],
                "calculation":  {
                    "http://www.biolase.com/20210331/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited":  {
                        "order":  1.0,
                        "parentTag":  "us-gaap_OperatingIncomeLoss",
                        "weight":  1.0
                        }
                    },
                "crdr":  "credit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.",
                            "label":  "Gross Profit",
                            "totalLabel":  "Gross profit"
                            }
                        }
                    },
                "localname":  "GrossProfit",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest":  {
                "auth_ref":  [
                    "r75",
                    "r177",
                    "r181",
                    "r185",
                    "r188",
                    "r191",
                    "r436",
                    "r444",
                    "r448",
                    "r466"
                    ],
                "calculation":  {
                    "http://www.biolase.com/20210331/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited":  {
                        "order":  1.0,
                        "parentTag":  "us-gaap_NetIncomeLoss",
                        "weight":  1.0
                        }
                    },
                "crdr":  "credit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
                            "label":  "Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest",
                            "totalLabel":  "Loss before income tax provision"
                            }
                        }
                    },
                "localname":  "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "us-gaap_IncomeStatementAbstract":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "label":  "Income Statement [Abstract]"
                            }
                        }
                    },
                "localname":  "IncomeStatementAbstract",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "xbrltype":  "stringItemType"
                },
            "us-gaap_IncomeStatementLocationAxis":  {
                "auth_ref":  [
                    "r228"
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Information by location in the income statement.",
                            "label":  "Income Statement Location [Axis]",
                            "terseLabel":  "Income Statement Location"
                            }
                        }
                    },
                "localname":  "IncomeStatementLocationAxis",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureClassificationOfCompensationExpenseAssociatedWithShareBasedPaymentsDetail"
                    ],
                "xbrltype":  "stringItemType"
                },
            "us-gaap_IncomeStatementLocationDomain":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Location in the income statement.",
                            "label":  "Income Statement Location [Domain]",
                            "terseLabel":  "Income Statement Location"
                            }
                        }
                    },
                "localname":  "IncomeStatementLocationDomain",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureClassificationOfCompensationExpenseAssociatedWithShareBasedPaymentsDetail"
                    ],
                "xbrltype":  "domainItemType"
                },
            "us-gaap_IncomeTaxDisclosureAbstract":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "label":  "Income Tax Disclosure [Abstract]"
                            }
                        }
                    },
                "localname":  "IncomeTaxDisclosureAbstract",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "xbrltype":  "stringItemType"
                },
            "us-gaap_IncomeTaxDisclosureTextBlock":  {
                "auth_ref":  [
                    "r344",
                    "r346",
                    "r347",
                    "r355",
                    "r361",
                    "r363",
                    "r364",
                    "r365"
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "The entire disclosure for income taxes.  Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
                            "label":  "Income Tax Disclosure [Text Block]",
                            "terseLabel":  "Income Taxes"
                            }
                        }
                    },
                "localname":  "IncomeTaxDisclosureTextBlock",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureIncomeTaxes"
                    ],
                "xbrltype":  "textBlockItemType"
                },
            "us-gaap_IncomeTaxExpenseBenefit":  {
                "auth_ref":  [
                    "r115",
                    "r134",
                    "r135",
                    "r176",
                    "r342",
                    "r356",
                    "r362",
                    "r467"
                    ],
                "calculation":  {
                    "http://www.biolase.com/20210331/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited":  {
                        "order":  0.0,
                        "parentTag":  "us-gaap_NetIncomeLoss",
                        "weight":  -1.0
                        }
                    },
                "crdr":  "debit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
                            "label":  "Income Tax Expense Benefit",
                            "terseLabel":  "Income tax provision (benefit)",
                            "totalLabel":  "Income Tax Expense (Benefit), Total",
                            "verboseLabel":  "Income tax provision (benefit)"
                            }
                        }
                    },
                "localname":  "IncomeTaxExpenseBenefit",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail",
                    "http://www.biolase.com/20210331/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "us-gaap_IncomeTaxUncertaintiesPolicy":  {
                "auth_ref":  [
                    "r110"
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Disclosure of accounting policy for tax positions taken in the tax return filed or to be filed for which it is more likely than not that the tax position will not be sustained upon examination by taxing authorities and other types of contingencies related to income taxes.",
                            "label":  "Income Tax Uncertainties Policy",
                            "terseLabel":  "Income Tax Uncertainties"
                            }
                        }
                    },
                "localname":  "IncomeTaxUncertaintiesPolicy",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
                    ],
                "xbrltype":  "textBlockItemType"
                },
            "us-gaap_IncomeTaxesPaidNet":  {
                "auth_ref":  [
                    "r105"
                    ],
                "crdr":  "credit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.",
                            "label":  "Income Taxes Paid Net",
                            "terseLabel":  "Cash paid for income taxes",
                            "totalLabel":  "Income Taxes Paid, Net, Total"
                            }
                        }
                    },
                "localname":  "IncomeTaxesPaidNet",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlowsUnaudited"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities":  {
                "auth_ref":  [
                    "r101"
                    ],
                "calculation":  {
                    "http://www.biolase.com/20210331/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlowsUnaudited":  {
                        "order":  13.0,
                        "parentTag":  "us-gaap_NetCashProvidedByUsedInOperatingActivities",
                        "weight":  1.0
                        }
                    },
                "crdr":  "debit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.",
                            "label":  "Increase Decrease In Accounts Payable And Accrued Liabilities",
                            "terseLabel":  "Accounts payable and accrued liabilities",
                            "totalLabel":  "Increase (Decrease) in Accounts Payable and Accrued Liabilities, Total"
                            }
                        }
                    },
                "localname":  "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlowsUnaudited"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "us-gaap_IncreaseDecreaseInAccountsReceivable":  {
                "auth_ref":  [
                    "r101"
                    ],
                "calculation":  {
                    "http://www.biolase.com/20210331/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlowsUnaudited":  {
                        "order":  10.0,
                        "parentTag":  "us-gaap_NetCashProvidedByUsedInOperatingActivities",
                        "weight":  -1.0
                        }
                    },
                "crdr":  "credit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
                            "label":  "Increase Decrease In Accounts Receivable",
                            "negatedLabel":  "Accounts receivable"
                            }
                        }
                    },
                "localname":  "IncreaseDecreaseInAccountsReceivable",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlowsUnaudited"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "us-gaap_IncreaseDecreaseInContractWithCustomerLiability":  {
                "auth_ref":  [
                    "r101"
                    ],
                "calculation":  {
                    "http://www.biolase.com/20210331/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlowsUnaudited":  {
                        "order":  14.0,
                        "parentTag":  "us-gaap_NetCashProvidedByUsedInOperatingActivities",
                        "weight":  1.0
                        }
                    },
                "crdr":  "debit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.",
                            "label":  "Increase Decrease In Contract With Customer Liability",
                            "terseLabel":  "Deferred revenue"
                            }
                        }
                    },
                "localname":  "IncreaseDecreaseInContractWithCustomerLiability",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlowsUnaudited"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "us-gaap_IncreaseDecreaseInInventories":  {
                "auth_ref":  [
                    "r101"
                    ],
                "calculation":  {
                    "http://www.biolase.com/20210331/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlowsUnaudited":  {
                        "order":  11.0,
                        "parentTag":  "us-gaap_NetCashProvidedByUsedInOperatingActivities",
                        "weight":  -1.0
                        }
                    },
                "crdr":  "credit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.",
                            "label":  "Increase Decrease In Inventories",
                            "negatedLabel":  "Inventory",
                            "totalLabel":  "Increase (Decrease) in Inventories, Total"
                            }
                        }
                    },
                "localname":  "IncreaseDecreaseInInventories",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlowsUnaudited"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "label":  "Increase Decrease In Operating Capital [Abstract]",
                            "terseLabel":  "Changes in operating assets and liabilities:"
                            }
                        }
                    },
                "localname":  "IncreaseDecreaseInOperatingCapitalAbstract",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlowsUnaudited"
                    ],
                "xbrltype":  "stringItemType"
                },
            "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets":  {
                "auth_ref":  [
                    "r101"
                    ],
                "calculation":  {
                    "http://www.biolase.com/20210331/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlowsUnaudited":  {
                        "order":  12.0,
                        "parentTag":  "us-gaap_NetCashProvidedByUsedInOperatingActivities",
                        "weight":  -1.0
                        }
                    },
                "crdr":  "credit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
                            "label":  "Increase Decrease In Prepaid Deferred Expense And Other Assets",
                            "negatedLabel":  "Prepaid expenses and other current assets",
                            "totalLabel":  "Increase (Decrease) in Prepaid Expense and Other Assets, Total"
                            }
                        }
                    },
                "localname":  "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlowsUnaudited"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "us-gaap_InterestExpenseDebt":  {
                "auth_ref":  [
                    "r87",
                    "r256"
                    ],
                "crdr":  "debit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Amount of the cost of borrowed funds accounted for as interest expense for debt.",
                            "label":  "Interest Expense Debt",
                            "terseLabel":  "Interest expense",
                            "totalLabel":  "Interest Expense, Debt, Total"
                            }
                        }
                    },
                "localname":  "InterestExpenseDebt",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetail"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "us-gaap_InterestIncomeExpenseNonoperatingNet":  {
                "auth_ref":  [
                    ],
                "calculation":  {
                    "http://www.biolase.com/20210331/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited":  {
                        "order":  1.0,
                        "parentTag":  "us-gaap_NonoperatingIncomeExpense",
                        "weight":  1.0
                        }
                    },
                "crdr":  "credit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "The net amount of nonoperating interest income (expense).",
                            "label":  "Interest Income Expense Nonoperating Net",
                            "negatedLabel":  "Interest expense, net"
                            }
                        }
                    },
                "localname":  "InterestIncomeExpenseNonoperatingNet",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "us-gaap_InterestPaidNet":  {
                "auth_ref":  [
                    "r95",
                    "r98",
                    "r105"
                    ],
                "crdr":  "credit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity.  Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
                            "label":  "Interest Paid Net",
                            "terseLabel":  "Cash paid for interest"
                            }
                        }
                    },
                "localname":  "InterestPaidNet",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlowsUnaudited"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "us-gaap_InventoryDisclosureAbstract":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "label":  "Inventory Disclosure [Abstract]"
                            }
                        }
                    },
                "localname":  "InventoryDisclosureAbstract",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "xbrltype":  "stringItemType"
                },
            "us-gaap_InventoryDisclosureTextBlock":  {
                "auth_ref":  [
                    "r217"
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "The entire disclosure for inventory.  Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.",
                            "label":  "Inventory Disclosure [Text Block]",
                            "terseLabel":  "Inventory"
                            }
                        }
                    },
                "localname":  "InventoryDisclosureTextBlock",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureInventory"
                    ],
                "xbrltype":  "textBlockItemType"
                },
            "us-gaap_InventoryFinishedGoodsNetOfReserves":  {
                "auth_ref":  [
                    "r32",
                    "r216"
                    ],
                "calculation":  {
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureComponentsOfInventoryDetail":  {
                        "order":  2.0,
                        "parentTag":  "us-gaap_InventoryNet",
                        "weight":  1.0
                        }
                    },
                "crdr":  "debit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.",
                            "label":  "Inventory Finished Goods Net Of Reserves",
                            "terseLabel":  "Finished goods"
                            }
                        }
                    },
                "localname":  "InventoryFinishedGoodsNetOfReserves",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureComponentsOfInventoryDetail"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "us-gaap_InventoryNet":  {
                "auth_ref":  [
                    "r3",
                    "r61"
                    ],
                "calculation":  {
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureComponentsOfInventoryDetail":  {
                        "order":  null,
                        "parentTag":  null,
                        "root":  true,
                        "weight":  null
                        },
                    "http://www.biolase.com/20210331/taxonomy/role/Role_StatementConsolidatedBalanceSheetsUnaudited":  {
                        "order":  3.0,
                        "parentTag":  "us-gaap_AssetsCurrent",
                        "weight":  1.0
                        }
                    },
                "crdr":  "debit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
                            "label":  "Inventory Net",
                            "terseLabel":  "Inventory",
                            "totalLabel":  "Inventory"
                            }
                        }
                    },
                "localname":  "InventoryNet",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureComponentsOfInventoryDetail",
                    "http://www.biolase.com/20210331/taxonomy/role/Role_StatementConsolidatedBalanceSheetsUnaudited"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "us-gaap_InventoryRawMaterials":  {
                "auth_ref":  [
                    "r60"
                    ],
                "calculation":  {
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureComponentsOfInventoryDetail":  {
                        "order":  0.0,
                        "parentTag":  "us-gaap_InventoryNet",
                        "weight":  1.0
                        }
                    },
                "crdr":  "debit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.",
                            "label":  "Inventory Raw Materials",
                            "terseLabel":  "Raw materials",
                            "totalLabel":  "Inventory, Raw Materials, Gross, Total"
                            }
                        }
                    },
                "localname":  "InventoryRawMaterials",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureComponentsOfInventoryDetail"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "us-gaap_InventoryValuationReserves":  {
                "auth_ref":  [
                    "r61",
                    "r119",
                    "r215"
                    ],
                "crdr":  "credit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Amount of valuation reserve for inventory.",
                            "label":  "Inventory Valuation Reserves",
                            "periodEndLabel":  "Inventory Valuation Reserves, Ending Balance",
                            "periodStartLabel":  "Inventory Valuation Reserves, Beginning Balance",
                            "terseLabel":  "Inventory reduced by estimate for excess and obsolete amount"
                            }
                        }
                    },
                "localname":  "InventoryValuationReserves",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureInventoryAdditionalInformationDetail"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "us-gaap_InventoryWorkInProcess":  {
                "auth_ref":  [
                    "r59"
                    ],
                "calculation":  {
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureComponentsOfInventoryDetail":  {
                        "order":  1.0,
                        "parentTag":  "us-gaap_InventoryNet",
                        "weight":  1.0
                        }
                    },
                "crdr":  "debit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.",
                            "label":  "Inventory Work In Process",
                            "terseLabel":  "Work-in-process"
                            }
                        }
                    },
                "localname":  "InventoryWorkInProcess",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureComponentsOfInventoryDetail"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "us-gaap_InventoryWriteDown":  {
                "auth_ref":  [
                    "r214"
                    ],
                "calculation":  {
                    "http://www.biolase.com/20210331/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlowsUnaudited":  {
                        "order":  4.0,
                        "parentTag":  "us-gaap_NetCashProvidedByUsedInOperatingActivities",
                        "weight":  1.0
                        }
                    },
                "crdr":  "debit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels.",
                            "label":  "Inventory Write-down",
                            "terseLabel":  "Inventory write-offs and disposals"
                            }
                        }
                    },
                "localname":  "InventoryWriteDown",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlowsUnaudited"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims":  {
                "auth_ref":  [
                    "r102"
                    ],
                "crdr":  "debit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims.",
                            "label":  "Issuance Of Stock And Warrants For Services Or Claims",
                            "terseLabel":  "Issuance costs for common stock warrants"
                            }
                        }
                    },
                "localname":  "IssuanceOfStockAndWarrantsForServicesOrClaims",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureRedeemablePreferredStockAndStockholdersEquityAdditionalInformationDetail"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "us-gaap_Land":  {
                "auth_ref":  [
                    "r7",
                    "r39"
                    ],
                "calculation":  {
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureSummaryOfPropertyPlantAndEquipmentDetail":  {
                        "order":  1.0,
                        "parentTag":  "us-gaap_PropertyPlantAndEquipmentNet",
                        "weight":  1.0
                        }
                    },
                "crdr":  "debit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Amount before accumulated depletion of real estate held for productive use, excluding land held for sale.",
                            "label":  "Land",
                            "terseLabel":  "Land"
                            }
                        }
                    },
                "localname":  "Land",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureSummaryOfPropertyPlantAndEquipmentDetail"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "us-gaap_LeaseContractualTermAxis":  {
                "auth_ref":  [
                    "r415"
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Information by contractual term of lease arrangement.",
                            "label":  "Lease Contractual Term [Axis]",
                            "terseLabel":  "Lease Contractual Term"
                            }
                        }
                    },
                "localname":  "LeaseContractualTermAxis",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail"
                    ],
                "xbrltype":  "stringItemType"
                },
            "us-gaap_LeaseContractualTermDomain":  {
                "auth_ref":  [
                    "r415"
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Contractual term of lease arrangement.",
                            "label":  "Lease Contractual Term [Domain]",
                            "terseLabel":  "Lease Contractual Term"
                            }
                        }
                    },
                "localname":  "LeaseContractualTermDomain",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail"
                    ],
                "xbrltype":  "domainItemType"
                },
            "us-gaap_LeaseExpirationDate1":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Date which lease or group of leases is set to expire, in CCYY-MM-DD format.",
                            "label":  "Lease Expiration Date"
                            }
                        }
                    },
                "localname":  "LeaseExpirationDate1",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail"
                    ],
                "xbrltype":  "dateItemType"
                },
            "us-gaap_LeaseholdImprovementsMember":  {
                "auth_ref":  [
                    "r225"
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Additions or improvements to assets held under a lease arrangement.",
                            "label":  "Leasehold Improvements [Member]",
                            "terseLabel":  "Leasehold Improvements"
                            }
                        }
                    },
                "localname":  "LeaseholdImprovementsMember",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureSummaryOfPropertyPlantAndEquipmentDetail"
                    ],
                "xbrltype":  "domainItemType"
                },
            "us-gaap_LeasesAbstract":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "label":  "Leases [Abstract]"
                            }
                        }
                    },
                "localname":  "LeasesAbstract",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "xbrltype":  "stringItemType"
                },
            "us-gaap_LesseeLeaseDescriptionLineItems":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Line items represent financial concepts included in a table.  These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
                            "label":  "Lessee Lease Description [Line Items]",
                            "terseLabel":  "Lessee Lease Description [Line Items]"
                            }
                        }
                    },
                "localname":  "LesseeLeaseDescriptionLineItems",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail"
                    ],
                "xbrltype":  "stringItemType"
                },
            "us-gaap_LesseeLeaseDescriptionTable":  {
                "auth_ref":  [
                    "r415"
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Disclosure of information about lessee's leases.",
                            "label":  "Lessee Lease Description [Table]",
                            "terseLabel":  "Lessee Lease Description [Table]"
                            }
                        }
                    },
                "localname":  "LesseeLeaseDescriptionTable",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail"
                    ],
                "xbrltype":  "stringItemType"
                },
            "us-gaap_LesseeOperatingLeaseDiscountRate":  {
                "auth_ref":  [
                    "r414"
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Discount rate used by lessee to determine present value of operating lease payments.",
                            "label":  "Lessee Operating Lease Discount Rate",
                            "terseLabel":  "Lessee, operating lease incremental borrowing rate"
                            }
                        }
                    },
                "localname":  "LesseeOperatingLeaseDiscountRate",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail"
                    ],
                "xbrltype":  "percentItemType"
                },
            "us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend":  {
                "auth_ref":  [
                    "r412"
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Indicates (true false) whether lessee has option to extend operating lease.",
                            "label":  "Lessee Operating Lease Existence Of Option To Extend",
                            "terseLabel":  "Lessee, Operating Lease, Existence of Option to Extend [true false]"
                            }
                        }
                    },
                "localname":  "LesseeOperatingLeaseExistenceOfOptionToExtend",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail"
                    ],
                "xbrltype":  "booleanItemType"
                },
            "us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedDescription":  {
                "auth_ref":  [
                    "r413"
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Description of lessee's operating lease that has not yet commenced.  Including, but not limited to, nature of involvement with construction or design of underlying asset for lease.",
                            "label":  "Lessee Operating Lease Lease Not Yet Commenced Description",
                            "terseLabel":  "Operating lease, lease not yet commenced, description"
                            }
                        }
                    },
                "localname":  "LesseeOperatingLeaseLeaseNotYetCommencedDescription",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail"
                    ],
                "xbrltype":  "stringItemType"
                },
            "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock":  {
                "auth_ref":  [
                    "r419"
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability.  Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
                            "label":  "Lessee Operating Lease Liability Maturity Table [Text Block]",
                            "terseLabel":  "Schedule of Maturities of Lease Liabilities"
                            }
                        }
                    },
                "localname":  "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureLeasesTables"
                    ],
                "xbrltype":  "textBlockItemType"
                },
            "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue":  {
                "auth_ref":  [
                    "r419"
                    ],
                "calculation":  {
                    "http://www.biolase.com/20210331/taxonomy/role/DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetail2":  {
                        "order":  null,
                        "parentTag":  null,
                        "root":  true,
                        "weight":  null
                        },
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetail":  {
                        "order":  null,
                        "parentTag":  null,
                        "root":  true,
                        "weight":  null
                        }
                    },
                "crdr":  "credit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
                            "label":  "Lessee Operating Lease Liability Payments Due",
                            "totalLabel":  "Total operating lease liability",
                            "verboseLabel":  "Total future minimum lease obligations"
                            }
                        }
                    },
                "localname":  "LesseeOperatingLeaseLiabilityPaymentsDue",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetail"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths":  {
                "auth_ref":  [
                    "r419"
                    ],
                "calculation":  {
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetail":  {
                        "order":  0.0,
                        "parentTag":  "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
                        "weight":  1.0
                        }
                    },
                "crdr":  "credit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year.  Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
                            "label":  "Lessee Operating Lease Liability Payments Due Next Twelve Months",
                            "terseLabel":  "2022"
                            }
                        }
                    },
                "localname":  "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetail"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour":  {
                "auth_ref":  [
                    "r419"
                    ],
                "calculation":  {
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetail":  {
                        "order":  3.0,
                        "parentTag":  "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
                        "weight":  1.0
                        }
                    },
                "crdr":  "credit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year.  Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
                            "label":  "Lessee Operating Lease Liability Payments Due Year Four",
                            "terseLabel":  "2025"
                            }
                        }
                    },
                "localname":  "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetail"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree":  {
                "auth_ref":  [
                    "r419"
                    ],
                "calculation":  {
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetail":  {
                        "order":  2.0,
                        "parentTag":  "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
                        "weight":  1.0
                        }
                    },
                "crdr":  "credit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year.  Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
                            "label":  "Lessee Operating Lease Liability Payments Due Year Three",
                            "terseLabel":  "2024"
                            }
                        }
                    },
                "localname":  "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetail"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo":  {
                "auth_ref":  [
                    "r419"
                    ],
                "calculation":  {
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetail":  {
                        "order":  1.0,
                        "parentTag":  "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
                        "weight":  1.0
                        }
                    },
                "crdr":  "credit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year.  Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
                            "label":  "Lessee Operating Lease Liability Payments Due Year Two",
                            "terseLabel":  "2023"
                            }
                        }
                    },
                "localname":  "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetail"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount":  {
                "auth_ref":  [
                    "r419"
                    ],
                "calculation":  {
                    "http://www.biolase.com/20210331/taxonomy/role/DisclosureLeasesFutureMinimumRentalCommitmentsUnderLeaseAgreementsDetail2":  {
                        "order":  1.0,
                        "parentTag":  "us-gaap_OperatingLeaseLiability",
                        "weight":  1.0
                        },
                    "http://www.biolase.com/20210331/taxonomy/role/DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetail2":  {
                        "order":  0.0,
                        "parentTag":  "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
                        "weight":  1.0
                        }
                    },
                "crdr":  "credit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
                            "label":  "Lessee Operating Lease Liability Undiscounted Excess Amount",
                            "negatedTerseLabel":  "Less imputed interest",
                            "terseLabel":  "Less imputed interest"
                            }
                        }
                    },
                "localname":  "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureLeasesFutureMinimumRentalCommitmentsUnderLeaseAgreementsDetail",
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetail"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "us-gaap_LesseeOperatingLeaseRenewalTerm":  {
                "auth_ref":  [
                    "r412"
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
                            "label":  "Lessee Operating Lease Renewal Term",
                            "terseLabel":  "Operating lease, options to renew term"
                            }
                        }
                    },
                "localname":  "LesseeOperatingLeaseRenewalTerm",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail"
                    ],
                "xbrltype":  "durationItemType"
                },
            "us-gaap_LesseeOperatingLeaseTermOfContract":  {
                "auth_ref":  [
                    "r412"
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
                            "label":  "Lessee Operating Lease Term Of Contract",
                            "terseLabel":  "Lease term"
                            }
                        }
                    },
                "localname":  "LesseeOperatingLeaseTermOfContract",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail"
                    ],
                "xbrltype":  "durationItemType"
                },
            "us-gaap_LesseeOperatingLeasesTextBlock":  {
                "auth_ref":  [
                    "r421"
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "The entire disclosure for operating leases of lessee.  Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.",
                            "label":  "Lessee Operating Leases [Text Block]",
                            "terseLabel":  "Leases"
                            }
                        }
                    },
                "localname":  "LesseeOperatingLeasesTextBlock",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureLeases"
                    ],
                "xbrltype":  "textBlockItemType"
                },
            "us-gaap_Liabilities":  {
                "auth_ref":  [
                    "r46",
                    "r114",
                    "r183",
                    "r205",
                    "r368",
                    "r373",
                    "r374",
                    "r387"
                    ],
                "calculation":  {
                    "http://www.biolase.com/20210331/taxonomy/role/Role_StatementConsolidatedBalanceSheetsUnaudited":  {
                        "order":  1.0,
                        "parentTag":  "us-gaap_LiabilitiesAndStockholdersEquity",
                        "weight":  1.0
                        }
                    },
                "crdr":  "credit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized.  Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
                            "label":  "Liabilities",
                            "totalLabel":  "Total liabilities"
                            }
                        }
                    },
                "localname":  "Liabilities",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_StatementConsolidatedBalanceSheetsUnaudited"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "us-gaap_LiabilitiesAndStockholdersEquity":  {
                "auth_ref":  [
                    "r29",
                    "r114",
                    "r205",
                    "r387",
                    "r441",
                    "r460"
                    ],
                "calculation":  {
                    "http://www.biolase.com/20210331/taxonomy/role/Role_StatementConsolidatedBalanceSheetsUnaudited":  {
                        "order":  null,
                        "parentTag":  null,
                        "root":  true,
                        "weight":  null
                        }
                    },
                "crdr":  "credit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
                            "label":  "Liabilities And Stockholders Equity",
                            "totalLabel":  "Total liabilities, redeemable preferred stock and stockholders' equity"
                            }
                        }
                    },
                "localname":  "LiabilitiesAndStockholdersEquity",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_StatementConsolidatedBalanceSheetsUnaudited"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "us-gaap_LiabilitiesAndStockholdersEquityAbstract":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "label":  "Liabilities And Stockholders Equity [Abstract]",
                            "terseLabel":  "LIABILITIES, REDEEMABLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY"
                            }
                        }
                    },
                "localname":  "LiabilitiesAndStockholdersEquityAbstract",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_StatementConsolidatedBalanceSheetsUnaudited"
                    ],
                "xbrltype":  "stringItemType"
                },
            "us-gaap_LiabilitiesCurrent":  {
                "auth_ref":  [
                    "r48",
                    "r114",
                    "r205",
                    "r368",
                    "r373",
                    "r374",
                    "r387"
                    ],
                "calculation":  {
                    "http://www.biolase.com/20210331/taxonomy/role/Role_StatementConsolidatedBalanceSheetsUnaudited":  {
                        "order":  0.0,
                        "parentTag":  "us-gaap_Liabilities",
                        "weight":  1.0
                        }
                    },
                "crdr":  "credit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
                            "label":  "Liabilities Current",
                            "totalLabel":  "Total current liabilities"
                            }
                        }
                    },
                "localname":  "LiabilitiesCurrent",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_StatementConsolidatedBalanceSheetsUnaudited"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "us-gaap_LiabilitiesCurrentAbstract":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "label":  "Liabilities Current [Abstract]",
                            "terseLabel":  "Current liabilities:"
                            }
                        }
                    },
                "localname":  "LiabilitiesCurrentAbstract",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_StatementConsolidatedBalanceSheetsUnaudited"
                    ],
                "xbrltype":  "stringItemType"
                },
            "us-gaap_LineOfCredit":  {
                "auth_ref":  [
                    "r18",
                    "r440",
                    "r454"
                    ],
                "crdr":  "credit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount.  Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line.  Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.",
                            "label":  "Line Of Credit",
                            "terseLabel":  "Line of credit, outstanding borrowings",
                            "totalLabel":  "Long-term Line of Credit, Total"
                            }
                        }
                    },
                "localname":  "LineOfCredit",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetail"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "us-gaap_LineOfCreditFacilityAxis":  {
                "auth_ref":  [
                    "r44",
                    "r116"
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Information by name of lender, which may be a single entity (for example, but not limited to, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit.",
                            "label":  "Line Of Credit Facility [Axis]",
                            "terseLabel":  "Lender Name"
                            }
                        }
                    },
                "localname":  "LineOfCreditFacilityAxis",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetail",
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureDebtSummaryOfPrincipalOutstandingAndUnamortizedDiscountDetail",
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureDescriptionOfBusinessAndBasisOfPresentationAdditionalInformationDetail"
                    ],
                "xbrltype":  "stringItemType"
                },
            "us-gaap_LineOfCreditFacilityDescription":  {
                "auth_ref":  [
                    "r44"
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Description of the terms of a credit facility arrangement.  Terms typically include interest rate, collateral required, guarantees required, repayment requirements, and restrictions on use of assets and activities of the entity.",
                            "label":  "Line Of Credit Facility Description",
                            "terseLabel":  "Line of credit facility description"
                            }
                        }
                    },
                "localname":  "LineOfCreditFacilityDescription",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetail"
                    ],
                "xbrltype":  "stringItemType"
                },
            "us-gaap_LineOfCreditFacilityExpirationDate1":  {
                "auth_ref":  [
                    "r44"
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Date the credit facility terminates, in CCYY-MM-DD format.",
                            "label":  "Line Of Credit Facility Expiration Date1",
                            "terseLabel":  "Line of credit facility expiration date"
                            }
                        }
                    },
                "localname":  "LineOfCreditFacilityExpirationDate1",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetail"
                    ],
                "xbrltype":  "dateItemType"
                },
            "us-gaap_LineOfCreditFacilityExpirationPeriod":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Period remaining on line of credit facility before it terminates, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
                            "label":  "Line Of Credit Facility Expiration Period",
                            "terseLabel":  "Line of credit facility term"
                            }
                        }
                    },
                "localname":  "LineOfCreditFacilityExpirationPeriod",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetail"
                    ],
                "xbrltype":  "durationItemType"
                },
            "us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding":  {
                "auth_ref":  [
                    "r383"
                    ],
                "crdr":  "credit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Fair value of the amount outstanding under the credit facility.",
                            "label":  "Line Of Credit Facility Fair Value Of Amount Outstanding",
                            "terseLabel":  "Available balance"
                            }
                        }
                    },
                "localname":  "LineOfCreditFacilityFairValueOfAmountOutstanding",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureDescriptionOfBusinessAndBasisOfPresentationAdditionalInformationDetail"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd":  {
                "auth_ref":  [
                    "r44"
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "The effective interest rate at the end of the reporting period.",
                            "label":  "Line Of Credit Facility Interest Rate At Period End",
                            "terseLabel":  "Interest rate"
                            }
                        }
                    },
                "localname":  "LineOfCreditFacilityInterestRateAtPeriodEnd",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetail"
                    ],
                "xbrltype":  "percentItemType"
                },
            "us-gaap_LineOfCreditFacilityLenderDomain":  {
                "auth_ref":  [
                    "r44"
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Identification of the lender, which may be a single entity (for example, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit, including a letter of credit facility.",
                            "label":  "Line Of Credit Facility Lender [Domain]",
                            "terseLabel":  "Line of Credit Facility, Lender"
                            }
                        }
                    },
                "localname":  "LineOfCreditFacilityLenderDomain",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetail",
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureDebtSummaryOfPrincipalOutstandingAndUnamortizedDiscountDetail",
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureDescriptionOfBusinessAndBasisOfPresentationAdditionalInformationDetail"
                    ],
                "xbrltype":  "domainItemType"
                },
            "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity":  {
                "auth_ref":  [
                    "r44"
                    ],
                "crdr":  "credit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.",
                            "label":  "Line Of Credit Facility Maximum Borrowing Capacity",
                            "terseLabel":  "Line of credit facility, maximum borrowing capacity"
                            }
                        }
                    },
                "localname":  "LineOfCreditFacilityMaximumBorrowingCapacity",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetail"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "us-gaap_LitigationSettlementAmountAwardedToOtherParty":  {
                "auth_ref":  [
                    ],
                "crdr":  "credit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Amount awarded to other party in judgment or settlement of litigation.",
                            "label":  "Litigation Settlement Amount Awarded To Other Party",
                            "terseLabel":  "Litigation settlement in cash"
                            }
                        }
                    },
                "localname":  "LitigationSettlementAmountAwardedToOtherParty",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "us-gaap_LitigationStatusAxis":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Information by status of pending, threatened, or settled litigation.",
                            "label":  "Litigation Status [Axis]",
                            "terseLabel":  "Litigation Status"
                            }
                        }
                    },
                "localname":  "LitigationStatusAxis",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
                    ],
                "xbrltype":  "stringItemType"
                },
            "us-gaap_LitigationStatusDomain":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Status of pending, threatened, or settled litigation.",
                            "label":  "Litigation Status [Domain]",
                            "terseLabel":  "Litigation Status"
                            }
                        }
                    },
                "localname":  "LitigationStatusDomain",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
                    ],
                "xbrltype":  "domainItemType"
                },
            "us-gaap_LoanProcessingFee":  {
                "auth_ref":  [
                    ],
                "crdr":  "debit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Expenses paid for obtaining loans which includes expenses such as application and origination fees.",
                            "label":  "Loan Processing Fee",
                            "terseLabel":  "Loan origination fee"
                            }
                        }
                    },
                "localname":  "LoanProcessingFee",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetail"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "us-gaap_LondonInterbankOfferedRateLIBORMember":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Interest rate at which a bank borrows funds from other banks in the London interbank market.",
                            "label":  "London Interbank Offered Rate L I B O R [Member]",
                            "terseLabel":  "LIBOR"
                            }
                        }
                    },
                "localname":  "LondonInterbankOfferedRateLIBORMember",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetail"
                    ],
                "xbrltype":  "domainItemType"
                },
            "us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock":  {
                "auth_ref":  [
                    "r197"
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Tabular disclosure of long-lived assets, excluding financial instruments, long-term customer relationships of a financial institution, mortgage rights, deferred policy acquisition costs, and deferred tax assets, by geographic areas located in the entity's country of domicile and foreign countries in which the entity holds assets.",
                            "label":  "Long Lived Assets By Geographic Areas Table [Text Block]",
                            "terseLabel":  "Summary of Property, Plant and Equipment by Geographic Location"
                            }
                        }
                    },
                "localname":  "LongLivedAssetsByGeographicAreasTableTextBlock",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureSegmentInformationTables"
                    ],
                "xbrltype":  "textBlockItemType"
                },
            "us-gaap_LongTermDebt":  {
                "auth_ref":  [
                    "r18",
                    "r255",
                    "r440",
                    "r457"
                    ],
                "crdr":  "credit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt.  Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper.  Excludes capital lease obligations.",
                            "label":  "Long Term Debt",
                            "terseLabel":  "Non current term loans",
                            "totalLabel":  "Long-term Debt, Total"
                            }
                        }
                    },
                "localname":  "LongTermDebt",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetail",
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureDebtSummaryOfPrincipalOutstandingAndUnamortizedDiscountDetail"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "us-gaap_LongTermDebtCurrent":  {
                "auth_ref":  [
                    "r45"
                    ],
                "crdr":  "credit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current.  Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper.  Excludes capital lease obligations.",
                            "label":  "Long Term Debt Current",
                            "terseLabel":  "Term loan, net of discount",
                            "totalLabel":  "Long-term Debt, Current Maturities, Total"
                            }
                        }
                    },
                "localname":  "LongTermDebtCurrent",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureDebtSummaryOfPrincipalOutstandingAndUnamortizedDiscountDetail"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive":  {
                "auth_ref":  [
                    "r118",
                    "r252"
                    ],
                "calculation":  {
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureDebtSummaryOfFutureMinimumPrincipalAndInterestPaymentsDetail":  {
                        "order":  6.0,
                        "parentTag":  "us-gaap_DebtInstrumentCarryingAmount",
                        "weight":  1.0
                        }
                    },
                "crdr":  "credit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing after fifth fiscal year following current fiscal year.  Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
                            "label":  "Long Term Debt Maturities Repayments Of Principal After Year Five",
                            "terseLabel":  "2025 and thereafter",
                            "verboseLabel":  "2026 and thereafter"
                            }
                        }
                    },
                "localname":  "LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureDebtSummaryOfFutureMinimumPrincipalAndInterestPaymentsDetail"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths":  {
                "auth_ref":  [
                    "r118",
                    "r252"
                    ],
                "calculation":  {
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureDebtSummaryOfFutureMinimumPrincipalAndInterestPaymentsDetail":  {
                        "order":  1.0,
                        "parentTag":  "us-gaap_DebtInstrumentCarryingAmount",
                        "weight":  1.0
                        }
                    },
                "crdr":  "credit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year.  Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
                            "label":  "Long-Term Debt, Maturity, Year One",
                            "terseLabel":  "2022"
                            }
                        }
                    },
                "localname":  "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureDebtSummaryOfFutureMinimumPrincipalAndInterestPaymentsDetail"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour":  {
                "auth_ref":  [
                    "r118",
                    "r252"
                    ],
                "calculation":  {
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureDebtSummaryOfFutureMinimumPrincipalAndInterestPaymentsDetail":  {
                        "order":  4.0,
                        "parentTag":  "us-gaap_DebtInstrumentCarryingAmount",
                        "weight":  1.0
                        }
                    },
                "crdr":  "credit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year.  Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
                            "label":  "Long Term Debt Maturities Repayments Of Principal In Year Four",
                            "terseLabel":  "2023",
                            "verboseLabel":  "2025"
                            }
                        }
                    },
                "localname":  "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureDebtSummaryOfFutureMinimumPrincipalAndInterestPaymentsDetail"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree":  {
                "auth_ref":  [
                    "r118",
                    "r252"
                    ],
                "calculation":  {
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureDebtSummaryOfFutureMinimumPrincipalAndInterestPaymentsDetail":  {
                        "order":  3.0,
                        "parentTag":  "us-gaap_DebtInstrumentCarryingAmount",
                        "weight":  1.0
                        }
                    },
                "crdr":  "credit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year.  Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
                            "label":  "Long Term Debt Maturities Repayments Of Principal In Year Three",
                            "terseLabel":  "2022",
                            "verboseLabel":  "2024"
                            }
                        }
                    },
                "localname":  "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureDebtSummaryOfFutureMinimumPrincipalAndInterestPaymentsDetail"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo":  {
                "auth_ref":  [
                    "r118",
                    "r252"
                    ],
                "calculation":  {
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureDebtSummaryOfFutureMinimumPrincipalAndInterestPaymentsDetail":  {
                        "order":  2.0,
                        "parentTag":  "us-gaap_DebtInstrumentCarryingAmount",
                        "weight":  1.0
                        }
                    },
                "crdr":  "credit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year.  Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
                            "label":  "Long Term Debt Maturities Repayments Of Principal In Year Two",
                            "terseLabel":  "2021",
                            "verboseLabel":  "2023"
                            }
                        }
                    },
                "localname":  "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureDebtSummaryOfFutureMinimumPrincipalAndInterestPaymentsDetail"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear":  {
                "auth_ref":  [
                    "r118"
                    ],
                "calculation":  {
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureDebtSummaryOfFutureMinimumPrincipalAndInterestPaymentsDetail":  {
                        "order":  0.0,
                        "parentTag":  "us-gaap_DebtInstrumentCarryingAmount",
                        "weight":  1.0
                        }
                    },
                "crdr":  "credit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in remainder of current fiscal year.",
                            "label":  "Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year",
                            "terseLabel":  "2020 (Nine months)",
                            "verboseLabel":  "2021 (nine months)"
                            }
                        }
                    },
                "localname":  "LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureDebtSummaryOfFutureMinimumPrincipalAndInterestPaymentsDetail"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "us-gaap_LongTermDebtNoncurrent":  {
                "auth_ref":  [
                    "r54"
                    ],
                "crdr":  "credit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer.  Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper.  Excludes capital lease obligations.",
                            "label":  "Long Term Debt Noncurrent",
                            "terseLabel":  "Non current term loans, net of discount",
                            "totalLabel":  "Long-term Debt, Excluding Current Maturities, Total"
                            }
                        }
                    },
                "localname":  "LongTermDebtNoncurrent",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureDebtSummaryOfPrincipalOutstandingAndUnamortizedDiscountDetail"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "us-gaap_LongTermLoansFromBank":  {
                "auth_ref":  [
                    "r18",
                    "r440",
                    "r456"
                    ],
                "crdr":  "credit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Carrying value as of the balance sheet date of loans from a bank with maturities initially due after one year or beyond the operating cycle if longer, excluding current portion.",
                            "label":  "Long Term Loans From Bank",
                            "terseLabel":  "Loan granted amount from bank"
                            }
                        }
                    },
                "localname":  "LongTermLoansFromBank",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetail"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "us-gaap_LongTermNotesAndLoans":  {
                "auth_ref":  [
                    "r54"
                    ],
                "crdr":  "credit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Carrying value as of the balance sheet date of all notes and loans payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.",
                            "label":  "Long Term Notes And Loans",
                            "terseLabel":  "Loan principal amount",
                            "totalLabel":  "Notes and Loans, Noncurrent, Total"
                            }
                        }
                    },
                "localname":  "LongTermNotesAndLoans",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetail"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "us-gaap_LossContingenciesByNatureOfContingencyAxis":  {
                "auth_ref":  [
                    "r233",
                    "r234",
                    "r235",
                    "r237",
                    "r238",
                    "r239",
                    "r241",
                    "r244",
                    "r245"
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Information by type of existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur.",
                            "label":  "Loss Contingencies By Nature Of Contingency [Axis]",
                            "terseLabel":  "Loss Contingency Nature"
                            }
                        }
                    },
                "localname":  "LossContingenciesByNatureOfContingencyAxis",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
                    ],
                "xbrltype":  "stringItemType"
                },
            "us-gaap_LossContingencyNatureDomain":  {
                "auth_ref":  [
                    "r233",
                    "r234",
                    "r235",
                    "r237",
                    "r238",
                    "r239",
                    "r241",
                    "r244",
                    "r245"
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "An existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur.  Resolution of the uncertainty may confirm the incurrence of a loss or impairment of an asset or the incurrence of a liability.",
                            "label":  "Loss Contingency Nature [Domain]",
                            "terseLabel":  "Loss Contingency, Nature"
                            }
                        }
                    },
                "localname":  "LossContingencyNatureDomain",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
                    ],
                "xbrltype":  "domainItemType"
                },
            "us-gaap_LossContingencySettlementAgreementDate":  {
                "auth_ref":  [
                    "r233",
                    "r236",
                    "r240"
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "The effective date of a duly executed litigation settlement agreement.",
                            "label":  "Loss Contingency Settlement Agreement Date",
                            "terseLabel":  "Settlement agreement date"
                            }
                        }
                    },
                "localname":  "LossContingencySettlementAgreementDate",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
                    ],
                "xbrltype":  "stringItemType"
                },
            "us-gaap_LossContingencySettlementAgreementTerms":  {
                "auth_ref":  [
                    "r233",
                    "r236",
                    "r240"
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Description of the terms of a settlement agreement which resolved the legal matter, including the nature of the consideration, timing of payment, and the nature of rights obtained or lost (for example, but not limited to, patent, trademark, copyright, license and franchise rights).",
                            "label":  "Loss Contingency Settlement Agreement Terms",
                            "terseLabel":  "Settlement agreement, terms"
                            }
                        }
                    },
                "localname":  "LossContingencySettlementAgreementTerms",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
                    ],
                "xbrltype":  "stringItemType"
                },
            "us-gaap_MediumtermNotesNoncurrent":  {
                "auth_ref":  [
                    "r18",
                    "r440",
                    "r456"
                    ],
                "calculation":  {
                    "http://www.biolase.com/20210331/taxonomy/role/Role_StatementConsolidatedBalanceSheetsUnaudited":  {
                        "order":  3.0,
                        "parentTag":  "us-gaap_Liabilities",
                        "weight":  1.0
                        }
                    },
                "crdr":  "credit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Carrying value at the balance sheet date of the noncurrent portion of a financial instrument used to receive debt funding on a regular basis with original maturities ranging from 5-10 years.",
                            "label":  "Mediumterm Notes Noncurrent",
                            "terseLabel":  "Non current term loans, net of discount"
                            }
                        }
                    },
                "localname":  "MediumtermNotesNoncurrent",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_StatementConsolidatedBalanceSheetsUnaudited"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "us-gaap_MovementInStandardProductWarrantyAccrualRollForward":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
                            "label":  "Movement In Standard Product Warranty Accrual [Roll Forward]",
                            "terseLabel":  "Movement in Standard Product Warranty Accrual"
                            }
                        }
                    },
                "localname":  "MovementInStandardProductWarrantyAccrualRollForward",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureChangesInInitialProductWarrantyAccrualAndExpensesUnderInitialAndExtendedWarrantiesDetail"
                    ],
                "xbrltype":  "stringItemType"
                },
            "us-gaap_NetCashProvidedByUsedInFinancingActivities":  {
                "auth_ref":  [
                    "r97"
                    ],
                "calculation":  {
                    "http://www.biolase.com/20210331/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlowsUnaudited":  {
                        "order":  1.0,
                        "parentTag":  "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
                        "weight":  1.0
                        }
                    },
                "crdr":  "debit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Amount of cash inflow (outflow) from financing activities, including discontinued operations.  Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
                            "label":  "Net Cash Provided By Used In Financing Activities",
                            "totalLabel":  "Net cash and cash equivalents provided by (used in) financing activities"
                            }
                        }
                    },
                "localname":  "NetCashProvidedByUsedInFinancingActivities",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlowsUnaudited"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "label":  "Net Cash Provided By Used In Financing Activities [Abstract]",
                            "terseLabel":  "Cash Flows from Financing Activities:"
                            }
                        }
                    },
                "localname":  "NetCashProvidedByUsedInFinancingActivitiesAbstract",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlowsUnaudited"
                    ],
                "xbrltype":  "stringItemType"
                },
            "us-gaap_NetCashProvidedByUsedInInvestingActivities":  {
                "auth_ref":  [
                    "r97"
                    ],
                "calculation":  {
                    "http://www.biolase.com/20210331/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlowsUnaudited":  {
                        "order":  2.0,
                        "parentTag":  "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
                        "weight":  1.0
                        }
                    },
                "crdr":  "debit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Amount of cash inflow (outflow) from investing activities, including discontinued operations.  Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
                            "label":  "Net Cash Provided By Used In Investing Activities",
                            "totalLabel":  "Net cash and cash equivalents used in investing activities"
                            }
                        }
                    },
                "localname":  "NetCashProvidedByUsedInInvestingActivities",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlowsUnaudited"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "label":  "Net Cash Provided By Used In Investing Activities [Abstract]",
                            "terseLabel":  "Cash Flows from Investing Activities:"
                            }
                        }
                    },
                "localname":  "NetCashProvidedByUsedInInvestingActivitiesAbstract",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlowsUnaudited"
                    ],
                "xbrltype":  "stringItemType"
                },
            "us-gaap_NetCashProvidedByUsedInOperatingActivities":  {
                "auth_ref":  [
                    "r97",
                    "r100",
                    "r103"
                    ],
                "calculation":  {
                    "http://www.biolase.com/20210331/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlowsUnaudited":  {
                        "order":  3.0,
                        "parentTag":  "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
                        "weight":  1.0
                        }
                    },
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Amount of cash inflow (outflow) from operating activities, including discontinued operations.  Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
                            "label":  "Net Cash Provided By Used In Operating Activities",
                            "totalLabel":  "Net cash and cash equivalents used in operating activities"
                            }
                        }
                    },
                "localname":  "NetCashProvidedByUsedInOperatingActivities",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlowsUnaudited"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "label":  "Net Cash Provided By Used In Operating Activities [Abstract]",
                            "terseLabel":  "Cash Flows from Operating Activities:"
                            }
                        }
                    },
                "localname":  "NetCashProvidedByUsedInOperatingActivitiesAbstract",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlowsUnaudited"
                    ],
                "xbrltype":  "stringItemType"
                },
            "us-gaap_NetIncomeLoss":  {
                "auth_ref":  [
                    "r0",
                    "r69",
                    "r71",
                    "r76",
                    "r103",
                    "r114",
                    "r124",
                    "r128",
                    "r129",
                    "r130",
                    "r131",
                    "r134",
                    "r135",
                    "r142",
                    "r177",
                    "r181",
                    "r185",
                    "r188",
                    "r191",
                    "r205",
                    "r387",
                    "r445",
                    "r463"
                    ],
                "calculation":  {
                    "http://www.biolase.com/20210331/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited":  {
                        "order":  1.0,
                        "parentTag":  "us-gaap_ComprehensiveIncomeNetOfTax",
                        "weight":  1.0
                        },
                    "http://www.biolase.com/20210331/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited2":  {
                        "order":  0.0,
                        "parentTag":  "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
                        "weight":  1.0
                        }
                    },
                "crdr":  "credit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
                            "label":  "Net Income Loss",
                            "terseLabel":  "Net loss",
                            "totalLabel":  "Net loss",
                            "verboseLabel":  "Net loss"
                            }
                        }
                    },
                "localname":  "NetIncomeLoss",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited",
                    "http://www.biolase.com/20210331/taxonomy/role/Role_StatementConsolidatedStatementsOfRedeemablePreferredStockAndStockholdersEquityUnaudited"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic":  {
                "auth_ref":  [
                    "r128",
                    "r129",
                    "r130",
                    "r131",
                    "r136",
                    "r137",
                    "r143",
                    "r146",
                    "r177",
                    "r181",
                    "r185",
                    "r188",
                    "r191"
                    ],
                "calculation":  {
                    "http://www.biolase.com/20210331/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited2":  {
                        "order":  null,
                        "parentTag":  null,
                        "root":  true,
                        "weight":  null
                        }
                    },
                "crdr":  "credit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.",
                            "label":  "Net Income (Loss) Available to Common Stockholders, Basic",
                            "terseLabel":  "Net loss attributable to common stockholders",
                            "totalLabel":  "Net Income (Loss) Available to Common Stockholders, Basic, Total"
                            }
                        }
                    },
                "localname":  "NetIncomeLossAvailableToCommonStockholdersBasic",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting.  Includes, but is not limited to, quantification of the expected or actual impact.",
                            "label":  "New Accounting Pronouncements Policy Policy [Text Block]",
                            "terseLabel":  "Recent Accounting Pronouncements"
                            }
                        }
                    },
                "localname":  "NewAccountingPronouncementsPolicyPolicyTextBlock",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
                    ],
                "xbrltype":  "textBlockItemType"
                },
            "us-gaap_NonUsMember":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Countries excluding the United States of America (US).",
                            "label":  "Non Us [Member]",
                            "terseLabel":  "International"
                            }
                        }
                    },
                "localname":  "NonUsMember",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureAccruedLiabilitiesAdditionalInformationDetail",
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureSegmentInformationAdditionalInformationDetail",
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureSummaryOfDisaggregationOfRevenuesRelatedToGeographicAreasDetail",
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureSummaryOfNetRevenueByGeographicLocationDetail",
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureSummaryOfPropertyPlantAndEquipmentByGeographicLocationDetail"
                    ],
                "xbrltype":  "domainItemType"
                },
            "us-gaap_NonoperatingIncomeExpense":  {
                "auth_ref":  [
                    "r86"
                    ],
                "calculation":  {
                    "http://www.biolase.com/20210331/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited":  {
                        "order":  0.0,
                        "parentTag":  "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
                        "weight":  1.0
                        }
                    },
                "crdr":  "credit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
                            "label":  "Nonoperating Income Expense",
                            "totalLabel":  "Non-operating loss, net"
                            }
                        }
                    },
                "localname":  "NonoperatingIncomeExpense",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "us-gaap_OperatingExpenses":  {
                "auth_ref":  [
                    ],
                "calculation":  {
                    "http://www.biolase.com/20210331/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited":  {
                        "order":  0.0,
                        "parentTag":  "us-gaap_OperatingIncomeLoss",
                        "weight":  -1.0
                        }
                    },
                "crdr":  "debit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services.  Includes selling, general and administrative expense.",
                            "label":  "Operating Expenses",
                            "totalLabel":  "Total operating expenses"
                            }
                        }
                    },
                "localname":  "OperatingExpenses",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "us-gaap_OperatingExpensesAbstract":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "label":  "Operating Expenses [Abstract]",
                            "terseLabel":  "Operating expenses:"
                            }
                        }
                    },
                "localname":  "OperatingExpensesAbstract",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited"
                    ],
                "xbrltype":  "stringItemType"
                },
            "us-gaap_OperatingIncomeLoss":  {
                "auth_ref":  [
                    "r177",
                    "r181",
                    "r185",
                    "r188",
                    "r191"
                    ],
                "calculation":  {
                    "http://www.biolase.com/20210331/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited":  {
                        "order":  1.0,
                        "parentTag":  "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
                        "weight":  1.0
                        }
                    },
                "crdr":  "credit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "The net result for the period of deducting operating expenses from operating revenues.",
                            "label":  "Operating Income Loss",
                            "totalLabel":  "Loss from operations",
                            "verboseLabel":  "EBITDA target"
                            }
                        }
                    },
                "localname":  "OperatingIncomeLoss",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetail",
                    "http://www.biolase.com/20210331/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "us-gaap_OperatingLeaseLiability":  {
                "auth_ref":  [
                    "r409"
                    ],
                "calculation":  {
                    "http://www.biolase.com/20210331/taxonomy/role/DisclosureLeasesFutureMinimumRentalCommitmentsUnderLeaseAgreementsDetail2":  {
                        "order":  null,
                        "parentTag":  null,
                        "root":  true,
                        "weight":  null
                        },
                    "http://www.biolase.com/20210331/taxonomy/role/DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetail2":  {
                        "order":  1.0,
                        "parentTag":  "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
                        "weight":  1.0
                        }
                    },
                "crdr":  "credit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Present value of lessee's discounted obligation for lease payments from operating lease.",
                            "label":  "Operating Lease Liability",
                            "totalLabel":  "Total lease liabilities",
                            "verboseLabel":  "Operating lease, liability"
                            }
                        }
                    },
                "localname":  "OperatingLeaseLiability",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail",
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureLeasesFutureMinimumRentalCommitmentsUnderLeaseAgreementsDetail",
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetail"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "us-gaap_OperatingLeaseLiabilityCurrent":  {
                "auth_ref":  [
                    "r409"
                    ],
                "calculation":  {
                    "http://www.biolase.com/20210331/taxonomy/role/DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetail2":  {
                        "order":  1.0,
                        "parentTag":  "us-gaap_OperatingLeaseLiability",
                        "weight":  1.0
                        },
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureComponentsOfAccruedLiabilitiesDetail":  {
                        "order":  5.0,
                        "parentTag":  "us-gaap_AccruedLiabilitiesCurrent",
                        "weight":  1.0
                        }
                    },
                "crdr":  "credit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
                            "label":  "Operating Lease Liability Current",
                            "terseLabel":  "Lease liability",
                            "verboseLabel":  "Current operating lease liabilities"
                            }
                        }
                    },
                "localname":  "OperatingLeaseLiabilityCurrent",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureComponentsOfAccruedLiabilitiesDetail",
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetail"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "us-gaap_OperatingLeaseLiabilityNoncurrent":  {
                "auth_ref":  [
                    "r409"
                    ],
                "calculation":  {
                    "http://www.biolase.com/20210331/taxonomy/role/DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetail2":  {
                        "order":  0.0,
                        "parentTag":  "us-gaap_OperatingLeaseLiability",
                        "weight":  1.0
                        },
                    "http://www.biolase.com/20210331/taxonomy/role/Role_StatementConsolidatedBalanceSheetsUnaudited":  {
                        "order":  4.0,
                        "parentTag":  "us-gaap_Liabilities",
                        "weight":  1.0
                        }
                    },
                "crdr":  "credit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
                            "label":  "Operating Lease Liability Noncurrent",
                            "terseLabel":  "Non current operating lease liability"
                            }
                        }
                    },
                "localname":  "OperatingLeaseLiabilityNoncurrent",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetail",
                    "http://www.biolase.com/20210331/taxonomy/role/Role_StatementConsolidatedBalanceSheetsUnaudited"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList":  {
                "auth_ref":  [
                    "r410"
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Indicates line item in statement of financial position that includes operating lease liability.",
                            "label":  "Operating Lease Liability Statement Of Financial Position [Extensible List]",
                            "terseLabel":  "Operating Lease, Liability, Statement of Financial Position [Extensible List]"
                            }
                        }
                    },
                "localname":  "OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail"
                    ],
                "xbrltype":  "extensibleListItemType"
                },
            "us-gaap_OperatingLeasePayments":  {
                "auth_ref":  [
                    "r411",
                    "r416"
                    ],
                "crdr":  "credit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
                            "label":  "Operating Lease Payments",
                            "verboseLabel":  "Cash paid for operating lease liabilities"
                            }
                        }
                    },
                "localname":  "OperatingLeasePayments",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureLeasesInformationRelatedToRightOfUseAssetsAndLiabilitiesDetail"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "us-gaap_OperatingLeaseRightOfUseAsset":  {
                "auth_ref":  [
                    "r408"
                    ],
                "calculation":  {
                    "http://www.biolase.com/20210331/taxonomy/role/Role_StatementConsolidatedBalanceSheetsUnaudited":  {
                        "order":  3.0,
                        "parentTag":  "us-gaap_Assets",
                        "weight":  1.0
                        }
                    },
                "crdr":  "debit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Amount of lessee's right to use underlying asset under operating lease.",
                            "label":  "Operating Lease Right Of Use Asset",
                            "terseLabel":  "Right of use asset",
                            "verboseLabel":  "Operating lease, right-of-use asset"
                            }
                        }
                    },
                "localname":  "OperatingLeaseRightOfUseAsset",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail",
                    "http://www.biolase.com/20210331/taxonomy/role/Role_StatementConsolidatedBalanceSheetsUnaudited"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList":  {
                "auth_ref":  [
                    "r410"
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Indicates line item in statement of financial position that includes operating lease right-of-use asset.",
                            "label":  "Operating Lease Right Of Use Asset Statement Of Financial Position [Extensible List]",
                            "terseLabel":  "Operating Lease Right Of Use Asset Statement Of Financial Position [Extensible List]"
                            }
                        }
                    },
                "localname":  "OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail"
                    ],
                "xbrltype":  "extensibleListItemType"
                },
            "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent":  {
                "auth_ref":  [
                    "r418",
                    "r420"
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Weighted average discount rate for operating lease calculated at point in time.",
                            "label":  "Operating Lease Weighted Average Discount Rate Percent",
                            "terseLabel":  "Weighted-average discount rate"
                            }
                        }
                    },
                "localname":  "OperatingLeaseWeightedAverageDiscountRatePercent",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureLeasesInformationRelatedToRightOfUseAssetsAndLiabilitiesDetail"
                    ],
                "xbrltype":  "percentItemType"
                },
            "us-gaap_OperatingLeasesFutureMinimumPaymentsDue":  {
                "auth_ref":  [
                    "r404",
                    "r405"
                    ],
                "calculation":  {
                    "http://www.biolase.com/20210331/taxonomy/role/DisclosureLeasesFutureMinimumRentalCommitmentsUnderLeaseAgreementsDetail2":  {
                        "order":  0.0,
                        "parentTag":  "us-gaap_OperatingLeaseLiability",
                        "weight":  1.0
                        }
                    },
                "crdr":  "credit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Amount of required minimum rental payments for leases having an initial or remaining non-cancelable letter-terms in excess of one year.",
                            "label":  "Operating Leases Future Minimum Payments Due",
                            "totalLabel":  "Total future minimum lease obligations"
                            }
                        }
                    },
                "localname":  "OperatingLeasesFutureMinimumPaymentsDue",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureLeasesFutureMinimumRentalCommitmentsUnderLeaseAgreementsDetail"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears":  {
                "auth_ref":  [
                    "r404",
                    "r405"
                    ],
                "calculation":  {
                    "http://www.biolase.com/20210331/taxonomy/role/DisclosureLeasesFutureMinimumRentalCommitmentsUnderLeaseAgreementsDetail2":  {
                        "order":  4.0,
                        "parentTag":  "us-gaap_OperatingLeasesFutureMinimumPaymentsDue",
                        "weight":  1.0
                        }
                    },
                "crdr":  "credit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fifth fiscal year following the latest fiscal year.  Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
                            "label":  "Operating Leases Future Minimum Payments Due In Five Years",
                            "terseLabel":  "2024",
                            "verboseLabel":  "2025"
                            }
                        }
                    },
                "localname":  "OperatingLeasesFutureMinimumPaymentsDueInFiveYears",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureLeasesFutureMinimumRentalCommitmentsUnderLeaseAgreementsDetail"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears":  {
                "auth_ref":  [
                    "r404",
                    "r405"
                    ],
                "calculation":  {
                    "http://www.biolase.com/20210331/taxonomy/role/DisclosureLeasesFutureMinimumRentalCommitmentsUnderLeaseAgreementsDetail2":  {
                        "order":  3.0,
                        "parentTag":  "us-gaap_OperatingLeasesFutureMinimumPaymentsDue",
                        "weight":  1.0
                        }
                    },
                "crdr":  "credit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fourth fiscal year following the latest fiscal year.  Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
                            "label":  "Operating Leases Future Minimum Payments Due In Four Years",
                            "terseLabel":  "2023",
                            "verboseLabel":  "2024"
                            }
                        }
                    },
                "localname":  "OperatingLeasesFutureMinimumPaymentsDueInFourYears",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureLeasesFutureMinimumRentalCommitmentsUnderLeaseAgreementsDetail"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears":  {
                "auth_ref":  [
                    "r404",
                    "r405"
                    ],
                "calculation":  {
                    "http://www.biolase.com/20210331/taxonomy/role/DisclosureLeasesFutureMinimumRentalCommitmentsUnderLeaseAgreementsDetail2":  {
                        "order":  2.0,
                        "parentTag":  "us-gaap_OperatingLeasesFutureMinimumPaymentsDue",
                        "weight":  1.0
                        }
                    },
                "crdr":  "credit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the third fiscal year following the latest fiscal year.  Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
                            "label":  "Operating Leases Future Minimum Payments Due In Three Years",
                            "terseLabel":  "2022",
                            "verboseLabel":  "2023"
                            }
                        }
                    },
                "localname":  "OperatingLeasesFutureMinimumPaymentsDueInThreeYears",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureLeasesFutureMinimumRentalCommitmentsUnderLeaseAgreementsDetail"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears":  {
                "auth_ref":  [
                    "r404",
                    "r405"
                    ],
                "calculation":  {
                    "http://www.biolase.com/20210331/taxonomy/role/DisclosureLeasesFutureMinimumRentalCommitmentsUnderLeaseAgreementsDetail2":  {
                        "order":  1.0,
                        "parentTag":  "us-gaap_OperatingLeasesFutureMinimumPaymentsDue",
                        "weight":  1.0
                        }
                    },
                "crdr":  "credit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the second fiscal year following the latest fiscal year.  Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
                            "label":  "Operating Leases Future Minimum Payments Due In Two Years",
                            "terseLabel":  "2021",
                            "verboseLabel":  "2022"
                            }
                        }
                    },
                "localname":  "OperatingLeasesFutureMinimumPaymentsDueInTwoYears",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureLeasesFutureMinimumRentalCommitmentsUnderLeaseAgreementsDetail"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear":  {
                "auth_ref":  [
                    ],
                "calculation":  {
                    "http://www.biolase.com/20210331/taxonomy/role/DisclosureLeasesFutureMinimumRentalCommitmentsUnderLeaseAgreementsDetail2":  {
                        "order":  0.0,
                        "parentTag":  "us-gaap_OperatingLeasesFutureMinimumPaymentsDue",
                        "weight":  1.0
                        }
                    },
                "crdr":  "credit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the remainder of the fiscal year following the latest fiscal year.  Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
                            "label":  "Operating Leases Future Minimum Payments Remainder Of Fiscal Year",
                            "terseLabel":  "2020 (three months)",
                            "verboseLabel":  "2021 (nine months)"
                            }
                        }
                    },
                "localname":  "OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureLeasesFutureMinimumRentalCommitmentsUnderLeaseAgreementsDetail"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "us-gaap_OtherAccruedLiabilitiesCurrent":  {
                "auth_ref":  [
                    "r8",
                    "r9",
                    "r10",
                    "r47"
                    ],
                "calculation":  {
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureComponentsOfAccruedLiabilitiesDetail":  {
                        "order":  6.0,
                        "parentTag":  "us-gaap_AccruedLiabilitiesCurrent",
                        "weight":  1.0
                        }
                    },
                "crdr":  "credit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
                            "label":  "Other Accrued Liabilities Current",
                            "terseLabel":  "Other"
                            }
                        }
                    },
                "localname":  "OtherAccruedLiabilitiesCurrent",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureComponentsOfAccruedLiabilitiesDetail"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "us-gaap_OtherAssetsNoncurrent":  {
                "auth_ref":  [
                    "r41"
                    ],
                "calculation":  {
                    "http://www.biolase.com/20210331/taxonomy/role/Role_StatementConsolidatedBalanceSheetsUnaudited":  {
                        "order":  4.0,
                        "parentTag":  "us-gaap_Assets",
                        "weight":  1.0
                        }
                    },
                "crdr":  "debit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Amount of noncurrent assets classified as other.",
                            "label":  "Other Assets Noncurrent",
                            "terseLabel":  "Other assets",
                            "totalLabel":  "Other Assets, Noncurrent, Total"
                            }
                        }
                    },
                "localname":  "OtherAssetsNoncurrent",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_StatementConsolidatedBalanceSheetsUnaudited"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax":  {
                "auth_ref":  [
                    "r63"
                    ],
                "calculation":  {
                    "http://www.biolase.com/20210331/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited":  {
                        "order":  0.0,
                        "parentTag":  "us-gaap_ComprehensiveIncomeNetOfTax",
                        "weight":  1.0
                        }
                    },
                "crdr":  "credit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.",
                            "label":  "Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax",
                            "terseLabel":  "Foreign currency translation adjustments",
                            "totalLabel":  "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Total"
                            }
                        }
                    },
                "localname":  "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited",
                    "http://www.biolase.com/20210331/taxonomy/role/Role_StatementConsolidatedStatementsOfRedeemablePreferredStockAndStockholdersEquityUnaudited"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "label":  "Other Comprehensive Income Loss Net Of Tax Period Increase Decrease [Abstract]",
                            "terseLabel":  "Other comprehensive loss items:"
                            }
                        }
                    },
                "localname":  "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited"
                    ],
                "xbrltype":  "stringItemType"
                },
            "us-gaap_OtherExpenses":  {
                "auth_ref":  [
                    "r85",
                    "r468"
                    ],
                "crdr":  "debit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Amount of expense classified as other.",
                            "label":  "Other Expenses",
                            "terseLabel":  "Broker fees and related expenses",
                            "totalLabel":  "Other Expenses, Total"
                            }
                        }
                    },
                "localname":  "OtherExpenses",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureRedeemablePreferredStockAndStockholdersEquityAdditionalInformationDetail"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "us-gaap_OtherLiabilitiesNoncurrent":  {
                "auth_ref":  [
                    "r55"
                    ],
                "calculation":  {
                    "http://www.biolase.com/20210331/taxonomy/role/Role_StatementConsolidatedBalanceSheetsUnaudited":  {
                        "order":  5.0,
                        "parentTag":  "us-gaap_Liabilities",
                        "weight":  1.0
                        }
                    },
                "crdr":  "credit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
                            "label":  "Other Liabilities Noncurrent",
                            "terseLabel":  "Other liabilities",
                            "totalLabel":  "Other Liabilities, Noncurrent, Total"
                            }
                        }
                    },
                "localname":  "OtherLiabilitiesNoncurrent",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_StatementConsolidatedBalanceSheetsUnaudited"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "us-gaap_PayablesAndAccrualsAbstract":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "label":  "Payables And Accruals [Abstract]"
                            }
                        }
                    },
                "localname":  "PayablesAndAccrualsAbstract",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "xbrltype":  "stringItemType"
                },
            "us-gaap_PaymentsForLegalSettlements":  {
                "auth_ref":  [
                    "r99"
                    ],
                "crdr":  "credit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "The amount of cash paid for the settlement of litigation or for other legal issues during the period.",
                            "label":  "Payments For Legal Settlements",
                            "terseLabel":  "Payment for litigation settlement in cash"
                            }
                        }
                    },
                "localname":  "PaymentsForLegalSettlements",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "us-gaap_PaymentsForRent":  {
                "auth_ref":  [
                    "r99"
                    ],
                "crdr":  "credit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Cash payments to lessor's for use of assets under operating leases.",
                            "label":  "Payments for Rent",
                            "terseLabel":  "Rent expense"
                            }
                        }
                    },
                "localname":  "PaymentsForRent",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "us-gaap_PaymentsOfDebtIssuanceCosts":  {
                "auth_ref":  [
                    "r92"
                    ],
                "crdr":  "credit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.",
                            "label":  "Payments Of Debt Issuance Costs",
                            "terseLabel":  "Debt issuance costs"
                            }
                        }
                    },
                "localname":  "PaymentsOfDebtIssuanceCosts",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetail"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "us-gaap_PaymentsOfStockIssuanceCosts":  {
                "auth_ref":  [
                    "r93"
                    ],
                "calculation":  {
                    "http://www.biolase.com/20210331/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlowsUnaudited":  {
                        "order":  1.0,
                        "parentTag":  "us-gaap_NetCashProvidedByUsedInFinancingActivities",
                        "weight":  -1.0
                        }
                    },
                "crdr":  "credit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "The cash outflow for cost incurred directly with the issuance of an equity security.",
                            "label":  "Payments Of Stock Issuance Costs",
                            "negatedLabel":  "Payments of equity offering costs"
                            }
                        }
                    },
                "localname":  "PaymentsOfStockIssuanceCosts",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlowsUnaudited"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment":  {
                "auth_ref":  [
                    "r88"
                    ],
                "calculation":  {
                    "http://www.biolase.com/20210331/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlowsUnaudited":  {
                        "order":  0.0,
                        "parentTag":  "us-gaap_NetCashProvidedByUsedInInvestingActivities",
                        "weight":  -1.0
                        }
                    },
                "crdr":  "credit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
                            "label":  "Payments To Acquire Property Plant And Equipment",
                            "negatedLabel":  "Purchases of property, plant, and equipment",
                            "totalLabel":  "Payments to Acquire Property, Plant, and Equipment, Total"
                            }
                        }
                    },
                "localname":  "PaymentsToAcquirePropertyPlantAndEquipment",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlowsUnaudited"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "us-gaap_PlanNameAxis":  {
                "auth_ref":  [
                    "r296",
                    "r327"
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Information by plan name for share-based payment arrangement.",
                            "label":  "Plan Name [Axis]",
                            "terseLabel":  "Plan Name"
                            }
                        }
                    },
                "localname":  "PlanNameAxis",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureRedeemablePreferredStockAndStockholdersEquityAdditionalInformationDetail"
                    ],
                "xbrltype":  "stringItemType"
                },
            "us-gaap_PlanNameDomain":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Plan name for share-based payment arrangement.",
                            "label":  "Plan Name [Domain]",
                            "terseLabel":  "Plan Name"
                            }
                        }
                    },
                "localname":  "PlanNameDomain",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureRedeemablePreferredStockAndStockholdersEquityAdditionalInformationDetail"
                    ],
                "xbrltype":  "domainItemType"
                },
            "us-gaap_PreferredStockConvertibleConversionPriceIncrease":  {
                "auth_ref":  [
                    "r261"
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Per share increase in conversion price of convertible preferred stock.  Excludes change due to standard antidilution provision.",
                            "label":  "Preferred Stock Convertible Conversion Price Increase",
                            "terseLabel":  "Conversion price"
                            }
                        }
                    },
                "localname":  "PreferredStockConvertibleConversionPriceIncrease",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureRedeemablePreferredStockAndStockholdersEquityAdditionalInformationDetail"
                    ],
                "xbrltype":  "perShareItemType"
                },
            "us-gaap_PreferredStockMember":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation.  Preferred shares typically represent an ownership interest in the company.",
                            "label":  "Preferred Stock [Member]",
                            "terseLabel":  "Convertible Preferred Stock"
                            }
                        }
                    },
                "localname":  "PreferredStockMember",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_StatementConsolidatedStatementsOfRedeemablePreferredStockAndStockholdersEquityUnaudited"
                    ],
                "xbrltype":  "domainItemType"
                },
            "us-gaap_PreferredStockNoParValue":  {
                "auth_ref":  [
                    "r21"
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Face amount per share of no-par value preferred stock nonredeemable or redeemable solely at the option of the issuer.",
                            "label":  "Preferred Stock No Par Value",
                            "terseLabel":  "Preferred stock par value"
                            }
                        }
                    },
                "localname":  "PreferredStockNoParValue",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureRedeemablePreferredStockAndStockholdersEquityAdditionalInformationDetail"
                    ],
                "xbrltype":  "perShareItemType"
                },
            "us-gaap_PreferredStockParOrStatedValuePerShare":  {
                "auth_ref":  [
                    "r21"
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
                            "label":  "Preferred Stock Par Or Stated Value Per Share",
                            "terseLabel":  "Series F Preferred stock, par value",
                            "verboseLabel":  "Preferred stock par value"
                            }
                        }
                    },
                "localname":  "PreferredStockParOrStatedValuePerShare",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetail",
                    "http://www.biolase.com/20210331/taxonomy/role/Role_StatementConsolidatedBalanceSheetsUnauditedParenthetical"
                    ],
                "xbrltype":  "perShareItemType"
                },
            "us-gaap_PreferredStockSharesAuthorized":  {
                "auth_ref":  [
                    "r21"
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
                            "label":  "Preferred Stock Shares Authorized",
                            "terseLabel":  "Series F Preferred stock, shares authorized"
                            }
                        }
                    },
                "localname":  "PreferredStockSharesAuthorized",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_StatementConsolidatedBalanceSheetsUnauditedParenthetical"
                    ],
                "xbrltype":  "sharesItemType"
                },
            "us-gaap_PreferredStockSharesIssued":  {
                "auth_ref":  [
                    "r21"
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury).  May be all or portion of the number of preferred shares authorized.  Excludes preferred shares that are classified as debt.",
                            "label":  "Preferred Stock Shares Issued",
                            "terseLabel":  "Series F Preferred stock, shares issued",
                            "totalLabel":  "Preferred Stock, Shares Issued, Total",
                            "verboseLabel":  "Preferred stock, shares issued"
                            }
                        }
                    },
                "localname":  "PreferredStockSharesIssued",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetail",
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureDescriptionOfBusinessAndBasisOfPresentationAdditionalInformationDetail",
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureRedeemablePreferredStockAndStockholdersEquityAdditionalInformationDetail",
                    "http://www.biolase.com/20210331/taxonomy/role/Role_StatementConsolidatedBalanceSheetsUnauditedParenthetical"
                    ],
                "xbrltype":  "sharesItemType"
                },
            "us-gaap_PreferredStockSharesOutstanding":  {
                "auth_ref":  [
                    "r21"
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders.  Does not include preferred shares that have been repurchased.",
                            "label":  "Preferred Stock Shares Outstanding",
                            "periodEndLabel":  "Preferred Stock, Shares Outstanding, Ending Balance",
                            "periodStartLabel":  "Preferred Stock, Shares Outstanding, Beginning Balance",
                            "terseLabel":  "Series F Preferred stock, shares outstanding"
                            }
                        }
                    },
                "localname":  "PreferredStockSharesOutstanding",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_StatementConsolidatedBalanceSheetsUnauditedParenthetical"
                    ],
                "xbrltype":  "sharesItemType"
                },
            "us-gaap_PreferredStockValue":  {
                "auth_ref":  [
                    "r21"
                    ],
                "calculation":  {
                    "http://www.biolase.com/20210331/taxonomy/role/Role_StatementConsolidatedBalanceSheetsUnaudited":  {
                        "order":  0.0,
                        "parentTag":  "us-gaap_StockholdersEquity",
                        "weight":  1.0
                        }
                    },
                "crdr":  "credit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer).  This item includes treasury stock repurchased by the entity.  Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
                            "label":  "Preferred Stock Value",
                            "periodEndLabel":  "Preferred Stock, Value, Issued, Ending Balance",
                            "periodStartLabel":  "Preferred Stock, Value, Issued, Beginning Balance",
                            "terseLabel":  "Series F Preferred stock, par value $0.001 per share; 18 shares authorized, 0 and 1 shares issued and outstanding as of March 31, 2021 and December 31, 2020, respectively",
                            "totalLabel":  "Preferred Stock, Value, Issued, Total"
                            }
                        }
                    },
                "localname":  "PreferredStockValue",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_StatementConsolidatedBalanceSheetsUnaudited"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "us-gaap_PrepaidExpenseAndOtherAssetsCurrent":  {
                "auth_ref":  [
                    "r5",
                    "r36",
                    "r37"
                    ],
                "calculation":  {
                    "http://www.biolase.com/20210331/taxonomy/role/Role_StatementConsolidatedBalanceSheetsUnaudited":  {
                        "order":  4.0,
                        "parentTag":  "us-gaap_AssetsCurrent",
                        "weight":  1.0
                        }
                    },
                "crdr":  "debit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
                            "label":  "Prepaid Expense And Other Assets Current",
                            "terseLabel":  "Prepaid expenses and other current assets"
                            }
                        }
                    },
                "localname":  "PrepaidExpenseAndOtherAssetsCurrent",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_StatementConsolidatedBalanceSheetsUnaudited"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "us-gaap_PrivatePlacementMember":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts.",
                            "label":  "Private Placement [Member]",
                            "terseLabel":  "Private Placement"
                            }
                        }
                    },
                "localname":  "PrivatePlacementMember",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureRedeemablePreferredStockAndStockholdersEquityAdditionalInformationDetail"
                    ],
                "xbrltype":  "domainItemType"
                },
            "us-gaap_ProceedsFromInterestReceived":  {
                "auth_ref":  [
                    "r94"
                    ],
                "crdr":  "debit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Interest received on loans and other debt instruments during the current period.",
                            "label":  "Proceeds from Interest Received",
                            "terseLabel":  "Cash received for interest"
                            }
                        }
                    },
                "localname":  "ProceedsFromInterestReceived",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlowsUnaudited"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "us-gaap_ProceedsFromIssuanceInitialPublicOffering":  {
                "auth_ref":  [
                    "r89"
                    ],
                "crdr":  "debit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "The cash inflow associated with the amount received from entity's first offering of stock to the public.",
                            "label":  "Proceeds From Issuance Initial Public Offering",
                            "terseLabel":  "Proceeds from offering"
                            }
                        }
                    },
                "localname":  "ProceedsFromIssuanceInitialPublicOffering",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetail",
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureRedeemablePreferredStockAndStockholdersEquityAdditionalInformationDetail"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "us-gaap_ProceedsFromIssuanceOfCommonStock":  {
                "auth_ref":  [
                    "r89"
                    ],
                "calculation":  {
                    "http://www.biolase.com/20210331/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlowsUnaudited":  {
                        "order":  0.0,
                        "parentTag":  "us-gaap_NetCashProvidedByUsedInFinancingActivities",
                        "weight":  1.0
                        }
                    },
                "crdr":  "debit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "The cash inflow from the additional capital contribution to the entity.",
                            "label":  "Proceeds From Issuance Of Common Stock",
                            "terseLabel":  "Proceeds from the issuance of common stock, net of offering costs"
                            }
                        }
                    },
                "localname":  "ProceedsFromIssuanceOfCommonStock",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureDescriptionOfBusinessAndBasisOfPresentationAdditionalInformationDetail",
                    "http://www.biolase.com/20210331/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlowsUnaudited"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "us-gaap_ProceedsFromIssuanceOfWarrants":  {
                "auth_ref":  [
                    "r89"
                    ],
                "crdr":  "debit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).",
                            "label":  "Proceeds From Issuance Of Warrants",
                            "terseLabel":  "Proceeds from issuance of warrants",
                            "verboseLabel":  "Warrants issued in connection with debt instruments"
                            }
                        }
                    },
                "localname":  "ProceedsFromIssuanceOfWarrants",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureRedeemablePreferredStockAndStockholdersEquityAdditionalInformationDetail"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "us-gaap_ProceedsFromIssuanceOrSaleOfEquity":  {
                "auth_ref":  [
                    "r89"
                    ],
                "crdr":  "debit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.",
                            "label":  "Proceeds From Issuance Or Sale Of Equity",
                            "terseLabel":  "Proceeds from issuance of equity securities",
                            "totalLabel":  "Proceeds from Issuance or Sale of Equity, Total",
                            "verboseLabel":  "Proceeds from offering, net of underwriting discounts and commissions"
                            }
                        }
                    },
                "localname":  "ProceedsFromIssuanceOrSaleOfEquity",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetail",
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureDescriptionOfBusinessAndBasisOfPresentationAdditionalInformationDetail",
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureRedeemablePreferredStockAndStockholdersEquityAdditionalInformationDetail"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "us-gaap_ProceedsFromLinesOfCredit":  {
                "auth_ref":  [
                    "r90",
                    "r117"
                    ],
                "crdr":  "debit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Amount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.",
                            "label":  "Proceeds From Lines Of Credit",
                            "terseLabel":  "Borrowings on credit facility",
                            "totalLabel":  "Proceeds from Lines of Credit, Total",
                            "verboseLabel":  "Borrowings under lines of credit"
                            }
                        }
                    },
                "localname":  "ProceedsFromLinesOfCredit",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetail"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "us-gaap_ProceedsFromOtherEquity":  {
                "auth_ref":  [
                    "r89"
                    ],
                "crdr":  "debit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Amount of cash inflow from the issuance of equity classified as other.",
                            "label":  "Proceeds From Other Equity",
                            "terseLabel":  "Equity raise of gross proceeds"
                            }
                        }
                    },
                "localname":  "ProceedsFromOtherEquity",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureDescriptionOfBusinessAndBasisOfPresentationAdditionalInformationDetail",
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureRedeemablePreferredStockAndStockholdersEquityAdditionalInformationDetail"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "us-gaap_ProceedsFromStockOptionsExercised":  {
                "auth_ref":  [
                    "r89",
                    "r328"
                    ],
                "crdr":  "debit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Amount of cash inflow from exercise of option under share-based payment arrangement.",
                            "label":  "Proceeds From Stock Options Exercised",
                            "verboseLabel":  "Proceeds from stock options exercised"
                            }
                        }
                    },
                "localname":  "ProceedsFromStockOptionsExercised",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureCashProceedsAlongWithFairValueDisclosuresRelatedToGrantsExercisesAndVestedOptionsDetail"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "us-gaap_ProceedsFromWarrantExercises":  {
                "auth_ref":  [
                    "r89"
                    ],
                "calculation":  {
                    "http://www.biolase.com/20210331/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlowsUnaudited":  {
                        "order":  2.0,
                        "parentTag":  "us-gaap_NetCashProvidedByUsedInFinancingActivities",
                        "weight":  1.0
                        }
                    },
                "crdr":  "debit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "The cash inflow associated with the amount received from holders exercising their stock warrants.",
                            "label":  "Proceeds From Warrant Exercises",
                            "terseLabel":  "Proceeds from the exercise of common stock warrants",
                            "verboseLabel":  "Gross proceeds from warrant exercises"
                            }
                        }
                    },
                "localname":  "ProceedsFromWarrantExercises",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureDescriptionOfBusinessAndBasisOfPresentationAdditionalInformationDetail",
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureRedeemablePreferredStockAndStockholdersEquityAdditionalInformationDetail",
                    "http://www.biolase.com/20210331/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlowsUnaudited"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "us-gaap_ProductConcentrationRiskMember":  {
                "auth_ref":  [
                    "r161"
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Reflects the percentage that revenues during the period from a specified product are to a specified benchmark, such as total net revenues, segment revenues or product line revenues.  May also reflect the percentage contribution the product made to operating results.  Risk is materially adverse effects of a loss of sales of a significant product or line of products, which could occur upon loss of rights to sell, distribute or license others; loss of patent or copyright protection; or technological obsolescence.",
                            "label":  "Product Concentration Risk [Member]",
                            "terseLabel":  "Product Concentration Risk"
                            }
                        }
                    },
                "localname":  "ProductConcentrationRiskMember",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureConcentrationsAdditionalInformationDetail",
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureConcentrationsSummaryOfNetRevenueFromVariousProductsDetail"
                    ],
                "xbrltype":  "domainItemType"
                },
            "us-gaap_ProductWarrantyAccrual":  {
                "auth_ref":  [
                    "r249",
                    "r250",
                    "r442"
                    ],
                "crdr":  "credit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Carrying value as of the balance sheet date of obligations incurred through that date and payable for estimated claims under standard and extended warranty protection rights granted to customers.",
                            "label":  "Product Warranty Accrual",
                            "periodEndLabel":  "Balance, end of period",
                            "periodStartLabel":  "Balance, beginning of period",
                            "totalLabel":  "Standard and Extended Product Warranty Accrual, Total"
                            }
                        }
                    },
                "localname":  "ProductWarrantyAccrual",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureChangesInInitialProductWarrantyAccrualAndExpensesUnderInitialAndExtendedWarrantiesDetail"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "us-gaap_ProductWarrantyAccrualClassifiedCurrent":  {
                "auth_ref":  [
                    "r47",
                    "r243",
                    "r246"
                    ],
                "calculation":  {
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureComponentsOfAccruedLiabilitiesDetail":  {
                        "order":  1.0,
                        "parentTag":  "us-gaap_AccruedLiabilitiesCurrent",
                        "weight":  1.0
                        }
                    },
                "crdr":  "credit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Carrying value as of the balance sheet date of obligations incurred through that date and payable for estimated claims under standard and extended warranty protection rights granted to customers.  For classified balance sheets, represents the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
                            "label":  "Product Warranty Accrual Classified Current",
                            "terseLabel":  "Current portion of warranty accrual",
                            "verboseLabel":  "Warranty accrual, current portion"
                            }
                        }
                    },
                "localname":  "ProductWarrantyAccrualClassifiedCurrent",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureChangesInInitialProductWarrantyAccrualAndExpensesUnderInitialAndExtendedWarrantiesDetail",
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureComponentsOfAccruedLiabilitiesDetail"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "us-gaap_ProductWarrantyAccrualNoncurrent":  {
                "auth_ref":  [
                    "r55",
                    "r233",
                    "r235"
                    ],
                "calculation":  {
                    "http://www.biolase.com/20210331/taxonomy/role/Role_StatementConsolidatedBalanceSheetsUnaudited":  {
                        "order":  2.0,
                        "parentTag":  "us-gaap_Liabilities",
                        "weight":  1.0
                        }
                    },
                "crdr":  "credit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Carrying value as of the balance sheet date of obligations incurred through that date and due after one year (or beyond the operating cycle if longer) for estimated claims under standard and extended warranty protection rights granted to customers.",
                            "label":  "Product Warranty Accrual Noncurrent",
                            "terseLabel":  "Less: long-term portion of warranty accrual",
                            "verboseLabel":  "Warranty accrual"
                            }
                        }
                    },
                "localname":  "ProductWarrantyAccrualNoncurrent",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureChangesInInitialProductWarrantyAccrualAndExpensesUnderInitialAndExtendedWarrantiesDetail",
                    "http://www.biolase.com/20210331/taxonomy/role/Role_StatementConsolidatedBalanceSheetsUnaudited"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "us-gaap_ProductWarrantyAccrualPayments":  {
                "auth_ref":  [
                    "r247"
                    ],
                "crdr":  "debit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Amount of decrease in the standard and extended product warranty accrual from payments made in cash or in kind to satisfy claims under the terms of the standard and extended product warranty.",
                            "label":  "Product Warranty Accrual Payments",
                            "negatedLabel":  "Warranty expenditures",
                            "totalLabel":  "Standard and Extended Product Warranty Accrual, Decrease for Payments, Total"
                            }
                        }
                    },
                "localname":  "ProductWarrantyAccrualPayments",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureChangesInInitialProductWarrantyAccrualAndExpensesUnderInitialAndExtendedWarrantiesDetail"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "us-gaap_ProductWarrantyAccrualPreexistingIncreaseDecrease":  {
                "auth_ref":  [
                    "r248"
                    ],
                "crdr":  "credit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Amount of increase (decrease) in the standard and extended product warranty accrual from changes in estimates attributable to preexisting product warranties.",
                            "label":  "Product Warranty Accrual Preexisting Increase Decrease",
                            "terseLabel":  "Provision for estimated warranty cost",
                            "totalLabel":  "Standard and Extended Product Warranty Accrual, Increase (Decrease) for Preexisting Warranties, Total"
                            }
                        }
                    },
                "localname":  "ProductWarrantyAccrualPreexistingIncreaseDecrease",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureChangesInInitialProductWarrantyAccrualAndExpensesUnderInitialAndExtendedWarrantiesDetail"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "us-gaap_ProfitLoss":  {
                "auth_ref":  [
                    "r0",
                    "r69",
                    "r71",
                    "r96",
                    "r114",
                    "r124",
                    "r134",
                    "r135",
                    "r177",
                    "r181",
                    "r185",
                    "r188",
                    "r191",
                    "r205",
                    "r366",
                    "r370",
                    "r371",
                    "r375",
                    "r376",
                    "r387",
                    "r448"
                    ],
                "calculation":  {
                    "http://www.biolase.com/20210331/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlowsUnaudited":  {
                        "order":  0.0,
                        "parentTag":  "us-gaap_NetCashProvidedByUsedInOperatingActivities",
                        "weight":  1.0
                        }
                    },
                "crdr":  "credit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
                            "label":  "Profit Loss",
                            "terseLabel":  "Net loss",
                            "totalLabel":  "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Total"
                            }
                        }
                    },
                "localname":  "ProfitLoss",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlowsUnaudited"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "us-gaap_PropertyPlantAndEquipmentAbstract":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "label":  "Property Plant And Equipment [Abstract]"
                            }
                        }
                    },
                "localname":  "PropertyPlantAndEquipmentAbstract",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "xbrltype":  "stringItemType"
                },
            "us-gaap_PropertyPlantAndEquipmentByTypeAxis":  {
                "auth_ref":  [
                    "r40",
                    "r227"
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
                            "label":  "Property Plant And Equipment By Type [Axis]",
                            "terseLabel":  "Long-Lived Tangible Asset"
                            }
                        }
                    },
                "localname":  "PropertyPlantAndEquipmentByTypeAxis",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureSummaryOfPropertyPlantAndEquipmentDetail"
                    ],
                "xbrltype":  "stringItemType"
                },
            "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock":  {
                "auth_ref":  [
                    "r229",
                    "r488",
                    "r489",
                    "r490"
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale.  Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
                            "label":  "Property Plant And Equipment Disclosure [Text Block]",
                            "terseLabel":  "Property, Plant, and Equipment"
                            }
                        }
                    },
                "localname":  "PropertyPlantAndEquipmentDisclosureTextBlock",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosurePropertyPlantAndEquipment"
                    ],
                "xbrltype":  "textBlockItemType"
                },
            "us-gaap_PropertyPlantAndEquipmentLineItems":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Line items represent financial concepts included in a table.  These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
                            "label":  "Property Plant And Equipment [Line Items]",
                            "terseLabel":  "Property Plant And Equipment [Line Items]"
                            }
                        }
                    },
                "localname":  "PropertyPlantAndEquipmentLineItems",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureSummaryOfPropertyPlantAndEquipmentDetail"
                    ],
                "xbrltype":  "stringItemType"
                },
            "us-gaap_PropertyPlantAndEquipmentNet":  {
                "auth_ref":  [
                    "r14",
                    "r15",
                    "r227",
                    "r461"
                    ],
                "calculation":  {
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureSummaryOfPropertyPlantAndEquipmentDetail":  {
                        "order":  null,
                        "parentTag":  null,
                        "root":  true,
                        "weight":  null
                        },
                    "http://www.biolase.com/20210331/taxonomy/role/Role_StatementConsolidatedBalanceSheetsUnaudited":  {
                        "order":  1.0,
                        "parentTag":  "us-gaap_Assets",
                        "weight":  1.0
                        }
                    },
                "crdr":  "debit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale.  Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
                            "label":  "Property Plant And Equipment Net",
                            "periodEndLabel":  "Property, Plant and Equipment, Net, Ending Balance",
                            "periodStartLabel":  "Property, Plant and Equipment, Net, Beginning Balance",
                            "terseLabel":  "Property, plant, and equipment, net",
                            "totalLabel":  "Property, plant, and equipment, net"
                            }
                        }
                    },
                "localname":  "PropertyPlantAndEquipmentNet",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureSummaryOfPropertyPlantAndEquipmentByGeographicLocationDetail",
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureSummaryOfPropertyPlantAndEquipmentDetail",
                    "http://www.biolase.com/20210331/taxonomy/role/Role_StatementConsolidatedBalanceSheetsUnaudited"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "us-gaap_PropertyPlantAndEquipmentTextBlock":  {
                "auth_ref":  [
                    "r14",
                    "r227"
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale.  Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
                            "label":  "Property Plant And Equipment [Text Block]",
                            "terseLabel":  "Summary of Property, Plant, and Equipment"
                            }
                        }
                    },
                "localname":  "PropertyPlantAndEquipmentTextBlock",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosurePropertyPlantAndEquipmentTables"
                    ],
                "xbrltype":  "textBlockItemType"
                },
            "us-gaap_PropertyPlantAndEquipmentTypeDomain":  {
                "auth_ref":  [
                    "r14",
                    "r225"
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.  Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
                            "label":  "Property Plant And Equipment Type [Domain]",
                            "terseLabel":  "Long-Lived Tangible Asset"
                            }
                        }
                    },
                "localname":  "PropertyPlantAndEquipmentTypeDomain",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureSummaryOfPropertyPlantAndEquipmentDetail"
                    ],
                "xbrltype":  "domainItemType"
                },
            "us-gaap_ProvisionForDoubtfulAccounts":  {
                "auth_ref":  [
                    "r80",
                    "r213"
                    ],
                "calculation":  {
                    "http://www.biolase.com/20210331/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlowsUnaudited":  {
                        "order":  2.0,
                        "parentTag":  "us-gaap_NetCashProvidedByUsedInOperatingActivities",
                        "weight":  1.0
                        }
                    },
                "crdr":  "debit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Amount of expense (reversal of expense) for expected credit loss on accounts receivable.",
                            "label":  "Provision For Doubtful Accounts",
                            "terseLabel":  "Provision for bad debts"
                            }
                        }
                    },
                "localname":  "ProvisionForDoubtfulAccounts",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlowsUnaudited"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "us-gaap_RepaymentsOfLinesOfCredit":  {
                "auth_ref":  [
                    "r91",
                    "r117"
                    ],
                "crdr":  "credit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Amount of cash outflow for payment of an obligation from a lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.",
                            "label":  "Repayments Of Lines Of Credit",
                            "terseLabel":  "Repayments of lines of credit"
                            }
                        }
                    },
                "localname":  "RepaymentsOfLinesOfCredit",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetail"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "us-gaap_ResearchAndDevelopmentExpense":  {
                "auth_ref":  [
                    "r341",
                    "r500"
                    ],
                "calculation":  {
                    "http://www.biolase.com/20210331/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited":  {
                        "order":  2.0,
                        "parentTag":  "us-gaap_OperatingExpenses",
                        "weight":  1.0
                        }
                    },
                "crdr":  "debit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
                            "label":  "Research And Development Expense",
                            "terseLabel":  "Engineering and development",
                            "totalLabel":  "Research and Development Expense, Total"
                            }
                        }
                    },
                "localname":  "ResearchAndDevelopmentExpense",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue":  {
                "auth_ref":  [
                    "r2",
                    "r13",
                    "r104",
                    "r109"
                    ],
                "calculation":  {
                    "http://www.biolase.com/20210331/taxonomy/role/Role_StatementConsolidatedBalanceSheetsUnaudited":  {
                        "order":  1.0,
                        "parentTag":  "us-gaap_AssetsCurrent",
                        "weight":  1.0
                        }
                    },
                "crdr":  "debit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as current.  Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.  Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
                            "label":  "Restricted Cash And Cash Equivalents At Carrying Value",
                            "terseLabel":  "Restricted cash",
                            "totalLabel":  "Restricted Cash and Cash Equivalents, Current, Total"
                            }
                        }
                    },
                "localname":  "RestrictedCashAndCashEquivalentsAtCarryingValue",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_StatementConsolidatedBalanceSheetsUnaudited"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "us-gaap_RestrictedStockUnitsRSUMember":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
                            "label":  "Restricted Stock Units R S U [Member]",
                            "terseLabel":  "Restricted Stock Units (RSUs)"
                            }
                        }
                    },
                "localname":  "RestrictedStockUnitsRSUMember",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureRedeemablePreferredStockAndStockholdersEquityAdditionalInformationDetail",
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureSummaryOfUnvestedRestrictedStockUnitsDetail"
                    ],
                "xbrltype":  "domainItemType"
                },
            "us-gaap_RetainedEarningsAccumulatedDeficit":  {
                "auth_ref":  [
                    "r25",
                    "r266",
                    "r336",
                    "r459",
                    "r480",
                    "r485"
                    ],
                "calculation":  {
                    "http://www.biolase.com/20210331/taxonomy/role/Role_StatementConsolidatedBalanceSheetsUnaudited":  {
                        "order":  4.0,
                        "parentTag":  "us-gaap_StockholdersEquity",
                        "weight":  1.0
                        }
                    },
                "crdr":  "credit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
                            "label":  "Retained Earnings Accumulated Deficit",
                            "periodEndLabel":  "Retained Earnings (Accumulated Deficit), Ending Balance",
                            "periodStartLabel":  "Retained Earnings (Accumulated Deficit), Beginning Balance",
                            "terseLabel":  "Accumulated deficit",
                            "totalLabel":  "Retained Earnings (Accumulated Deficit), Total"
                            }
                        }
                    },
                "localname":  "RetainedEarningsAccumulatedDeficit",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_StatementConsolidatedBalanceSheetsUnaudited"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "us-gaap_RetainedEarningsMember":  {
                "auth_ref":  [
                    "r121",
                    "r122",
                    "r123",
                    "r125",
                    "r133",
                    "r135",
                    "r209",
                    "r333",
                    "r334",
                    "r335",
                    "r353",
                    "r354",
                    "r476",
                    "r478"
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
                            "label":  "Retained Earnings [Member]",
                            "terseLabel":  "Accumulated Deficit"
                            }
                        }
                    },
                "localname":  "RetainedEarningsMember",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_StatementConsolidatedStatementsOfRedeemablePreferredStockAndStockholdersEquityUnaudited"
                    ],
                "xbrltype":  "domainItemType"
                },
            "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax":  {
                "auth_ref":  [
                    "r173",
                    "r174",
                    "r180",
                    "r186",
                    "r187",
                    "r193",
                    "r194",
                    "r199",
                    "r278",
                    "r279",
                    "r432"
                    ],
                "calculation":  {
                    "http://www.biolase.com/20210331/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited":  {
                        "order":  0.0,
                        "parentTag":  "us-gaap_GrossProfit",
                        "weight":  1.0
                        }
                    },
                "crdr":  "credit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer.  Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
                            "label":  "Revenue From Contract With Customer Excluding Assessed Tax",
                            "terseLabel":  "Net revenue",
                            "totalLabel":  "Revenue from Contract with Customer, Excluding Assessed Tax, Total",
                            "verboseLabel":  "Total revenue"
                            }
                        }
                    },
                "localname":  "RevenueFromContractWithCustomerExcludingAssessedTax",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureConcentrationsSummaryOfNetRevenueFromVariousProductsDetail",
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureSummaryOfDisaggregationOfRevenuesRelatedToGeographicAreasDetail",
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureSummaryOfNetRevenueByGeographicLocationDetail",
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureSummaryOfRevenuesDisaggregatedByTimingOfGoodsAndServicesTransferredDetail",
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureSummaryOfSalesByEndMarketDetail",
                    "http://www.biolase.com/20210331/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "us-gaap_RevenueFromContractWithCustomerTextBlock":  {
                "auth_ref":  [
                    "r270",
                    "r271",
                    "r272",
                    "r273",
                    "r274",
                    "r275",
                    "r276",
                    "r277",
                    "r281",
                    "r289"
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset.  Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer.  Excludes insurance and lease contracts.",
                            "label":  "Revenue From Contract With Customer [Text Block]",
                            "terseLabel":  "Revenue Recognition"
                            }
                        }
                    },
                "localname":  "RevenueFromContractWithCustomerTextBlock",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureRevenueRecognition"
                    ],
                "xbrltype":  "textBlockItemType"
                },
            "us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock":  {
                "auth_ref":  [
                    "r196"
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Tabular disclosure of revenue from external customers by geographic areas attributed to the entity's country of domicile and to foreign countries from which the entity derives revenue.",
                            "label":  "Revenue From External Customers By Geographic Areas Table [Text Block]",
                            "terseLabel":  "Summary of Net Revenue by Geographic Location"
                            }
                        }
                    },
                "localname":  "RevenueFromExternalCustomersByGeographicAreasTableTextBlock",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureSegmentInformationTables"
                    ],
                "xbrltype":  "textBlockItemType"
                },
            "us-gaap_RevenueRecognitionAbstract":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "label":  "Revenue Recognition [Abstract]"
                            }
                        }
                    },
                "localname":  "RevenueRecognitionAbstract",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "xbrltype":  "stringItemType"
                },
            "us-gaap_RevenueRecognitionPolicyTextBlock":  {
                "auth_ref":  [
                    "r111",
                    "r112"
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Disclosure of accounting policy for revenue.  Includes revenue from contract with customer and from other sources.",
                            "label":  "Revenue Recognition Policy [Text Block]",
                            "terseLabel":  "Revenue Recognition"
                            }
                        }
                    },
                "localname":  "RevenueRecognitionPolicyTextBlock",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
                    ],
                "xbrltype":  "textBlockItemType"
                },
            "us-gaap_Revenues":  {
                "auth_ref":  [
                    "r74",
                    "r114",
                    "r173",
                    "r174",
                    "r180",
                    "r186",
                    "r187",
                    "r193",
                    "r194",
                    "r199",
                    "r205",
                    "r387",
                    "r448"
                    ],
                "crdr":  "credit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process.  Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).",
                            "label":  "Revenues",
                            "totalLabel":  "Revenues, Total",
                            "verboseLabel":  "Revenue target"
                            }
                        }
                    },
                "localname":  "Revenues",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetail"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "us-gaap_RevolvingCreditFacilityMember":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount.",
                            "label":  "Revolving Credit Facility [Member]",
                            "terseLabel":  "Revolving Credit Facility"
                            }
                        }
                    },
                "localname":  "RevolvingCreditFacilityMember",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetail"
                    ],
                "xbrltype":  "domainItemType"
                },
            "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability":  {
                "auth_ref":  [
                    "r417",
                    "r420"
                    ],
                "crdr":  "debit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
                            "label":  "Right Of Use Asset Obtained In Exchange For Operating Lease Liability",
                            "terseLabel":  "Right-of-use assets obtained in exchange for new operating lease obligations"
                            }
                        }
                    },
                "localname":  "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureLeasesInformationRelatedToRightOfUseAssetsAndLiabilitiesDetail"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "us-gaap_RightsMember":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "A security giving shareholders entitlement to acquire new shares issued by the entity at an established price in proportion to the number of shares already owned.  Generally, rights expire within in a short time after issuance.",
                            "label":  "Rights [Member]",
                            "terseLabel":  "Rights Offering"
                            }
                        }
                    },
                "localname":  "RightsMember",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureRedeemablePreferredStockAndStockholdersEquityAdditionalInformationDetail"
                    ],
                "xbrltype":  "domainItemType"
                },
            "us-gaap_RisksAndUncertaintiesAbstract":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "label":  "Risks And Uncertainties [Abstract]"
                            }
                        }
                    },
                "localname":  "RisksAndUncertaintiesAbstract",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "xbrltype":  "stringItemType"
                },
            "us-gaap_SaleOfStockNameOfTransactionDomain":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
                            "label":  "Sale Of Stock Name Of Transaction [Domain]",
                            "terseLabel":  "Sale of Stock"
                            }
                        }
                    },
                "localname":  "SaleOfStockNameOfTransactionDomain",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureRedeemablePreferredStockAndStockholdersEquityAdditionalInformationDetail"
                    ],
                "xbrltype":  "domainItemType"
                },
            "us-gaap_SalesChannelDirectlyToConsumerMember":  {
                "auth_ref":  [
                    "r288"
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Contract with customer in which good or service is transferred directly to consumer.",
                            "label":  "Sales Channel Directly To Consumer [Member]",
                            "terseLabel":  "End-customer"
                            }
                        }
                    },
                "localname":  "SalesChannelDirectlyToConsumerMember",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureSummaryOfSalesByEndMarketDetail"
                    ],
                "xbrltype":  "domainItemType"
                },
            "us-gaap_SalesChannelThroughIntermediaryMember":  {
                "auth_ref":  [
                    "r288"
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Contract with customer in which good or service is transferred through intermediary.",
                            "label":  "Sales Channel Through Intermediary [Member]",
                            "terseLabel":  "Distributors"
                            }
                        }
                    },
                "localname":  "SalesChannelThroughIntermediaryMember",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureSummaryOfSalesByEndMarketDetail"
                    ],
                "xbrltype":  "domainItemType"
                },
            "us-gaap_SalesRevenueNetMember":  {
                "auth_ref":  [
                    "r163",
                    "r199"
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation.",
                            "label":  "Sales Revenue Net [Member]",
                            "terseLabel":  "Sales Revenue, Net"
                            }
                        }
                    },
                "localname":  "SalesRevenueNetMember",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureConcentrationsAdditionalInformationDetail",
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureConcentrationsSummaryOfNetRevenueFromVariousProductsDetail",
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureSegmentInformationAdditionalInformationDetail"
                    ],
                "xbrltype":  "domainItemType"
                },
            "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Tabular disclosure of the components of accrued liabilities.",
                            "label":  "Schedule Of Accrued Liabilities Table [Text Block]",
                            "terseLabel":  "Components of Accrued Liabilities"
                            }
                        }
                    },
                "localname":  "ScheduleOfAccruedLiabilitiesTableTextBlock",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureAccruedLiabilitiesTables"
                    ],
                "xbrltype":  "textBlockItemType"
                },
            "us-gaap_ScheduleOfDebtInstrumentsTextBlock":  {
                "auth_ref":  [
                    "r54",
                    "r116",
                    "r261",
                    "r263",
                    "r264",
                    "r265",
                    "r400",
                    "r401",
                    "r403",
                    "r452"
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation.  These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.",
                            "label":  "Schedule Of Debt Instruments [Text Block]",
                            "terseLabel":  "Summary of Principal Outstanding and Unamortized Discount"
                            }
                        }
                    },
                "localname":  "ScheduleOfDebtInstrumentsTextBlock",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureDebtTables"
                    ],
                "xbrltype":  "textBlockItemType"
                },
            "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock":  {
                "auth_ref":  [
                    "r295",
                    "r324",
                    "r338"
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position.  Includes, but is not limited to, corresponding line item in financial statement.",
                            "label":  "Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Text Block]",
                            "terseLabel":  "Summary of Income Statement Classification of Compensation Expense"
                            }
                        }
                    },
                "localname":  "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureRedeemablePreferredStockAndStockholdersEquityTables"
                    ],
                "xbrltype":  "textBlockItemType"
                },
            "us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock":  {
                "auth_ref":  [
                    "r406"
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Tabular disclosure of future minimum payments required in the aggregate and for each of the five succeeding fiscal years for operating leases having initial or remaining noncancelable lease terms in excess of one year and the total minimum rentals to be received in the future under noncancelable subleases as of the balance sheet date.",
                            "label":  "Schedule Of Future Minimum Rental Payments For Operating Leases Table [Text Block]",
                            "terseLabel":  "Future minimum rental commitments under lease agreements with non-cancelable Operating Leases"
                            }
                        }
                    },
                "localname":  "ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureLeasesTables"
                    ],
                "xbrltype":  "textBlockItemType"
                },
            "us-gaap_ScheduleOfInventoryCurrentTableTextBlock":  {
                "auth_ref":  [
                    "r11",
                    "r33",
                    "r34",
                    "r35"
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
                            "label":  "Schedule Of Inventory Current Table [Text Block]",
                            "terseLabel":  "Components of Inventory"
                            }
                        }
                    },
                "localname":  "ScheduleOfInventoryCurrentTableTextBlock",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureInventoryTables"
                    ],
                "xbrltype":  "textBlockItemType"
                },
            "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock":  {
                "auth_ref":  [
                    "r252"
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Tabular disclosure of maturity and sinking fund requirement for long-term debt.",
                            "label":  "Schedule Of Maturities Of Long Term Debt Table [Text Block]",
                            "terseLabel":  "Summary of Future Minimum Principal and Interest Payments"
                            }
                        }
                    },
                "localname":  "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureDebtTables"
                    ],
                "xbrltype":  "textBlockItemType"
                },
            "us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock":  {
                "auth_ref":  [
                    "r308"
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Tabular disclosure of the changes in outstanding nonvested restricted stock units.",
                            "label":  "Schedule Of Nonvested Restricted Stock Units Activity Table [Text Block]",
                            "terseLabel":  "Summary of Unvested Restricted Stock Units"
                            }
                        }
                    },
                "localname":  "ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureRedeemablePreferredStockAndStockholdersEquityTables"
                    ],
                "xbrltype":  "textBlockItemType"
                },
            "us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock":  {
                "auth_ref":  [
                    "r308"
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Tabular disclosure of the changes in outstanding nonvested shares.",
                            "label":  "Schedule Of Nonvested Share Activity Table [Text Block]",
                            "terseLabel":  "Summary of Unvested Stock Option Activity"
                            }
                        }
                    },
                "localname":  "ScheduleOfNonvestedShareActivityTableTextBlock",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureRedeemablePreferredStockAndStockholdersEquityTables"
                    ],
                "xbrltype":  "textBlockItemType"
                },
            "us-gaap_ScheduleOfProductWarrantyLiabilityTableTextBlock":  {
                "auth_ref":  [
                    "r251"
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Tabular disclosure of the changes in the guarantor's aggregate product warranty liability, including the beginning balance of the aggregate product warranty liability, the aggregate reductions in that liability for payments made (in cash or in kind) under the warranty, the aggregate changes in the liability for accruals related to product warranties issued during the reporting period, the aggregate changes in the liability for accruals related to preexisting warranties (including adjustments related to changes in estimates), and the ending balance of the aggregate product warranty liability.",
                            "label":  "Schedule Of Product Warranty Liability Table [Text Block]",
                            "terseLabel":  "Changes in Initial Product Warranty Accrual and Expenses Under Initial and Extended Warranties"
                            }
                        }
                    },
                "localname":  "ScheduleOfProductWarrantyLiabilityTableTextBlock",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureAccruedLiabilitiesTables"
                    ],
                "xbrltype":  "textBlockItemType"
                },
            "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable":  {
                "auth_ref":  [
                    "r40",
                    "r227"
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale.  Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
                            "label":  "Schedule Of Property Plant And Equipment [Table]",
                            "terseLabel":  "Schedule Of Property Plant And Equipment [Table]"
                            }
                        }
                    },
                "localname":  "ScheduleOfPropertyPlantAndEquipmentTable",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureSummaryOfPropertyPlantAndEquipmentDetail"
                    ],
                "xbrltype":  "stringItemType"
                },
            "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable":  {
                "auth_ref":  [
                    "r177",
                    "r178",
                    "r184",
                    "r220"
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "A table disclosing the profit or loss and total assets for each reportable segment of the entity.  An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.",
                            "label":  "Schedule Of Segment Reporting Information By Segment [Table]",
                            "terseLabel":  "Schedule Of Segment Reporting Information By Segment [Table]"
                            }
                        }
                    },
                "localname":  "ScheduleOfSegmentReportingInformationBySegmentTable",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureSegmentInformationAdditionalInformationDetail",
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureSummaryOfNetRevenueByGeographicLocationDetail",
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureSummaryOfPropertyPlantAndEquipmentByGeographicLocationDetail"
                    ],
                "xbrltype":  "stringItemType"
                },
            "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable":  {
                "auth_ref":  [
                    "r296",
                    "r327"
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Disclosure of information about share-based payment arrangement.",
                            "label":  "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]",
                            "terseLabel":  "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]"
                            }
                        }
                    },
                "localname":  "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureClassificationOfCompensationExpenseAssociatedWithShareBasedPaymentsDetail",
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureSummaryOfUnvestedRestrictedStockUnitsDetail",
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureSummaryOfUnvestedStockOptionActivityDetail"
                    ],
                "xbrltype":  "stringItemType"
                },
            "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock":  {
                "auth_ref":  [
                    "r300",
                    "r313",
                    "r316"
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Tabular disclosure for stock option plans.  Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
                            "label":  "Schedule Of Share Based Compensation Stock Options Activity Table [Text Block]",
                            "terseLabel":  "Summary of Option Activity"
                            }
                        }
                    },
                "localname":  "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureRedeemablePreferredStockAndStockholdersEquityTables"
                    ],
                "xbrltype":  "textBlockItemType"
                },
            "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock":  {
                "auth_ref":  [
                    "r318"
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
                            "label":  "Schedule Of Share Based Payment Award Stock Options Valuation Assumptions Table [Text Block]",
                            "terseLabel":  "Assumptions on Estimation of Stock Option Fair Values"
                            }
                        }
                    },
                "localname":  "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureRedeemablePreferredStockAndStockholdersEquityTables"
                    ],
                "xbrltype":  "textBlockItemType"
                },
            "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock":  {
                "auth_ref":  [
                    "r267",
                    "r294"
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Tabular disclosure of warrants or rights issued.  Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame.  Warrants are often included in a new debt issue to entice investors by a higher return potential.  The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company.  Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months.  Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.",
                            "label":  "Schedule Of Stockholders Equity Note Warrants Or Rights [Text Block]",
                            "terseLabel":  "Summary of Warrant Activity"
                            }
                        }
                    },
                "localname":  "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureRedeemablePreferredStockAndStockholdersEquityTables"
                    ],
                "xbrltype":  "textBlockItemType"
                },
            "us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock":  {
                "auth_ref":  [
                    "r159",
                    "r163",
                    "r164",
                    "r165",
                    "r384",
                    "r386"
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.",
                            "label":  "Schedules Of Concentration Of Risk By Risk Factor [Text Block]",
                            "terseLabel":  "Summary of Net Revenue from Various Products"
                            }
                        }
                    },
                "localname":  "SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureConcentrationsTables"
                    ],
                "xbrltype":  "textBlockItemType"
                },
            "us-gaap_SegmentReportingAbstract":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "label":  "Segment Reporting [Abstract]"
                            }
                        }
                    },
                "localname":  "SegmentReportingAbstract",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "xbrltype":  "stringItemType"
                },
            "us-gaap_SegmentReportingDisclosureTextBlock":  {
                "auth_ref":  [
                    "r170",
                    "r171",
                    "r172",
                    "r177",
                    "r179",
                    "r185",
                    "r189",
                    "r190",
                    "r191",
                    "r192",
                    "r193",
                    "r198",
                    "r199",
                    "r200"
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "The entire disclosure for reporting segments including data and tables.  Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.",
                            "label":  "Segment Reporting Disclosure [Text Block]",
                            "terseLabel":  "Segment Information"
                            }
                        }
                    },
                "localname":  "SegmentReportingDisclosureTextBlock",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureSegmentInformation"
                    ],
                "xbrltype":  "textBlockItemType"
                },
            "us-gaap_SegmentReportingInformationLineItems":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Line items represent financial concepts included in a table.  These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
                            "label":  "Segment Reporting Information [Line Items]",
                            "terseLabel":  "Segment Reporting Information [Line Items]"
                            }
                        }
                    },
                "localname":  "SegmentReportingInformationLineItems",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureSegmentInformationAdditionalInformationDetail",
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureSummaryOfNetRevenueByGeographicLocationDetail",
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureSummaryOfPropertyPlantAndEquipmentByGeographicLocationDetail"
                    ],
                "xbrltype":  "stringItemType"
                },
            "us-gaap_SellingAndMarketingExpense":  {
                "auth_ref":  [
                    ],
                "calculation":  {
                    "http://www.biolase.com/20210331/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited":  {
                        "order":  0.0,
                        "parentTag":  "us-gaap_OperatingExpenses",
                        "weight":  1.0
                        }
                    },
                "crdr":  "debit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "The aggregate total amount of expenses directly related to the marketing or selling of products or services.",
                            "label":  "Selling And Marketing Expense",
                            "terseLabel":  "Sales and marketing",
                            "totalLabel":  "Selling and Marketing Expense, Total"
                            }
                        }
                    },
                "localname":  "SellingAndMarketingExpense",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "us-gaap_SellingAndMarketingExpenseMember":  {
                "auth_ref":  [
                    "r79"
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Primary financial statement caption encompassing selling and marketing expense.",
                            "label":  "Selling And Marketing Expense [Member]",
                            "terseLabel":  "Sales and Marketing"
                            }
                        }
                    },
                "localname":  "SellingAndMarketingExpenseMember",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureClassificationOfCompensationExpenseAssociatedWithShareBasedPaymentsDetail"
                    ],
                "xbrltype":  "domainItemType"
                },
            "us-gaap_SeriesEPreferredStockMember":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Outstanding nonredeemable series E preferred stock or outstanding series E preferred stock.  Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer.  Classified within temporary equity if redemption is outside the control of the issuer.",
                            "label":  "Series E Preferred Stock [Member]",
                            "terseLabel":  "Series E Convertible Preferred Stock",
                            "verboseLabel":  "Series E Convertible Preferred Stock"
                            }
                        }
                    },
                "localname":  "SeriesEPreferredStockMember",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureRedeemablePreferredStockAndStockholdersEquityAdditionalInformationDetail",
                    "http://www.biolase.com/20210331/taxonomy/role/Role_StatementConsolidatedStatementsOfRedeemablePreferredStockAndStockholdersEquityUnaudited"
                    ],
                "xbrltype":  "domainItemType"
                },
            "us-gaap_SeriesFPreferredStockMember":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Outstanding nonredeemable series F preferred stock or outstanding series F preferred stock.  Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer.  Classified within temporary equity if redemption is outside the control of the issuer.",
                            "label":  "Series F Preferred Stock [Member]",
                            "terseLabel":  "Series F Convertible Preferred Stock",
                            "verboseLabel":  "Series F Convertible Preferred Stock"
                            }
                        }
                    },
                "localname":  "SeriesFPreferredStockMember",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetail",
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureRedeemablePreferredStockAndStockholdersEquityAdditionalInformationDetail",
                    "http://www.biolase.com/20210331/taxonomy/role/Role_StatementConsolidatedStatementsOfRedeemablePreferredStockAndShareholdersEquityParenthetical",
                    "http://www.biolase.com/20210331/taxonomy/role/Role_StatementConsolidatedStatementsOfRedeemablePreferredStockAndStockholdersEquityUnaudited"
                    ],
                "xbrltype":  "domainItemType"
                },
            "us-gaap_ServiceMember":  {
                "auth_ref":  [
                    "r282"
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Assistance, including, but not limited to, technology, license and maintenance, license and service, maintenance, oil and gas, and financial service.",
                            "label":  "Service [Member]",
                            "terseLabel":  "Services"
                            }
                        }
                    },
                "localname":  "ServiceMember",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureConcentrationsSummaryOfNetRevenueFromVariousProductsDetail"
                    ],
                "xbrltype":  "domainItemType"
                },
            "us-gaap_SettledLitigationMember":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Agreement reached between parties in a litigation that occurs without judicial intervention, supervision or approval.",
                            "label":  "Settled Litigation [Member]",
                            "terseLabel":  "CAO Settlement Agreement"
                            }
                        }
                    },
                "localname":  "SettledLitigationMember",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
                    ],
                "xbrltype":  "domainItemType"
                },
            "us-gaap_ShareBasedCompensation":  {
                "auth_ref":  [
                    "r101"
                    ],
                "calculation":  {
                    "http://www.biolase.com/20210331/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlowsUnaudited":  {
                        "order":  8.0,
                        "parentTag":  "us-gaap_NetCashProvidedByUsedInOperatingActivities",
                        "weight":  1.0
                        }
                    },
                "crdr":  "debit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Amount of noncash expense for share-based payment arrangement.",
                            "label":  "Share Based Compensation",
                            "terseLabel":  "Stock-based compensation",
                            "totalLabel":  "Share-based Payment Arrangement, Noncash Expense, Total"
                            }
                        }
                    },
                "localname":  "ShareBasedCompensation",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlowsUnaudited"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod":  {
                "auth_ref":  [
                    "r306"
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.",
                            "label":  "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period",
                            "negatedLabel":  "Forfeited or cancelled",
                            "negatedTerseLabel":  "Forfeited, cancelled, or expired"
                            }
                        }
                    },
                "localname":  "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureSummaryOfUnvestedRestrictedStockUnitsDetail",
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureSummaryOfWarrantActivityDetail"
                    ],
                "xbrltype":  "sharesItemType"
                },
            "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue":  {
                "auth_ref":  [
                    "r312"
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.",
                            "label":  "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value",
                            "terseLabel":  "Forfeited or cancelled"
                            }
                        }
                    },
                "localname":  "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureSummaryOfUnvestedRestrictedStockUnitsDetail"
                    ],
                "xbrltype":  "perShareItemType"
                },
            "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod":  {
                "auth_ref":  [
                    "r310"
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
                            "label":  "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period",
                            "terseLabel":  "Granted",
                            "verboseLabel":  "Granted or Issued"
                            }
                        }
                    },
                "localname":  "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureSummaryOfUnvestedRestrictedStockUnitsDetail",
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureSummaryOfWarrantActivityDetail"
                    ],
                "xbrltype":  "sharesItemType"
                },
            "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue":  {
                "auth_ref":  [
                    "r310"
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
                            "label":  "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value",
                            "terseLabel":  "Granted",
                            "verboseLabel":  "Granted or Issued"
                            }
                        }
                    },
                "localname":  "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureSummaryOfUnvestedRestrictedStockUnitsDetail",
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureSummaryOfWarrantActivityDetail"
                    ],
                "xbrltype":  "perShareItemType"
                },
            "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber":  {
                "auth_ref":  [
                    "r309"
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
                            "label":  "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number",
                            "periodEndLabel":  "Ending Balance",
                            "periodStartLabel":  "Beginning Balance"
                            }
                        }
                    },
                "localname":  "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureSummaryOfUnvestedRestrictedStockUnitsDetail",
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureSummaryOfWarrantActivityDetail"
                    ],
                "xbrltype":  "sharesItemType"
                },
            "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue":  {
                "auth_ref":  [
                    "r309"
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement.  Excludes share and unit options.",
                            "label":  "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value",
                            "periodEndLabel":  "Unvested RSUs at March 31, 2021",
                            "periodStartLabel":  "Unvested RSUs at December 31, 2020"
                            }
                        }
                    },
                "localname":  "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureSummaryOfUnvestedRestrictedStockUnitsDetail"
                    ],
                "xbrltype":  "perShareItemType"
                },
            "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod":  {
                "auth_ref":  [
                    "r311"
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
                            "label":  "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period",
                            "negatedLabel":  "Vested"
                            }
                        }
                    },
                "localname":  "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureSummaryOfUnvestedRestrictedStockUnitsDetail"
                    ],
                "xbrltype":  "sharesItemType"
                },
            "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue":  {
                "auth_ref":  [
                    "r311"
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.",
                            "label":  "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value",
                            "terseLabel":  "Vested",
                            "verboseLabel":  "Exercised"
                            }
                        }
                    },
                "localname":  "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureSummaryOfUnvestedRestrictedStockUnitsDetail",
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureSummaryOfWarrantActivityDetail"
                    ],
                "xbrltype":  "perShareItemType"
                },
            "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "label":  "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions And Methodology [Abstract]"
                            }
                        }
                    },
                "localname":  "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "xbrltype":  "stringItemType"
                },
            "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate":  {
                "auth_ref":  [
                    "r321"
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
                            "label":  "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate",
                            "terseLabel":  "Dividend yield"
                            }
                        }
                    },
                "localname":  "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureRedeemablePreferredStockAndStockholdersEquityAdditionalInformationDetail"
                    ],
                "xbrltype":  "percentItemType"
                },
            "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate":  {
                "auth_ref":  [
                    "r320"
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "The estimated measure of the percentage by which a share price is expected to fluctuate during a period.  Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean.  The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period.  That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
                            "label":  "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate",
                            "terseLabel":  "Volatility"
                            }
                        }
                    },
                "localname":  "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureAssumptionsUsedInEstimatingFairValueOfStockOptionsGrantedDetail",
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureRedeemablePreferredStockAndStockholdersEquityAdditionalInformationDetail"
                    ],
                "xbrltype":  "percentItemType"
                },
            "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate":  {
                "auth_ref":  [
                    "r322"
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
                            "label":  "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate",
                            "terseLabel":  "Risk-free interest rate"
                            }
                        }
                    },
                "localname":  "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureAssumptionsUsedInEstimatingFairValueOfStockOptionsGrantedDetail",
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureRedeemablePreferredStockAndStockholdersEquityAdditionalInformationDetail"
                    ],
                "xbrltype":  "percentItemType"
                },
            "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Line items represent financial concepts included in a table.  These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
                            "label":  "Share Based Compensation Arrangement By Share Based Payment Award [Line Items]",
                            "terseLabel":  "Share Based Compensation Arrangement By Share Based Payment Award [Line Items]"
                            }
                        }
                    },
                "localname":  "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureClassificationOfCompensationExpenseAssociatedWithShareBasedPaymentsDetail",
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureSummaryOfUnvestedRestrictedStockUnitsDetail",
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureSummaryOfUnvestedStockOptionActivityDetail"
                    ],
                "xbrltype":  "stringItemType"
                },
            "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised":  {
                "auth_ref":  [
                    "r305"
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Number of non-option equity instruments exercised by participants.",
                            "label":  "Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised",
                            "negatedLabel":  "Exercised"
                            }
                        }
                    },
                "localname":  "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureSummaryOfWarrantActivityDetail"
                    ],
                "xbrltype":  "sharesItemType"
                },
            "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted":  {
                "auth_ref":  [
                    "r304"
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Net number of non-option equity instruments granted to participants.",
                            "label":  "Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted"
                            }
                        }
                    },
                "localname":  "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureRedeemablePreferredStockAndStockholdersEquityAdditionalInformationDetail"
                    ],
                "xbrltype":  "sharesItemType"
                },
            "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized":  {
                "auth_ref":  [
                    "r297"
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Number of shares authorized for issuance under share-based payment arrangement.",
                            "label":  "Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized",
                            "terseLabel":  "Common stock authorized for issuance"
                            }
                        }
                    },
                "localname":  "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureRedeemablePreferredStockAndStockholdersEquityAdditionalInformationDetail"
                    ],
                "xbrltype":  "sharesItemType"
                },
            "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant":  {
                "auth_ref":  [
                    "r327"
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
                            "label":  "Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant",
                            "terseLabel":  "Options available for future grants"
                            }
                        }
                    },
                "localname":  "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureRedeemablePreferredStockAndStockholdersEquityAdditionalInformationDetail"
                    ],
                "xbrltype":  "sharesItemType"
                },
            "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber":  {
                "auth_ref":  [
                    "r303"
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
                            "label":  "Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number",
                            "terseLabel":  "Options exercisable at September 30, 2020",
                            "verboseLabel":  "Options exercisable at March 31, 2021"
                            }
                        }
                    },
                "localname":  "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureSummaryOfOptionActivityDetail"
                    ],
                "xbrltype":  "sharesItemType"
                },
            "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice":  {
                "auth_ref":  [
                    "r303"
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
                            "label":  "Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price",
                            "terseLabel":  "Options exercisable at September 30, 2020",
                            "verboseLabel":  "Options exercisable at March 31, 2021"
                            }
                        }
                    },
                "localname":  "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureSummaryOfOptionActivityDetail"
                    ],
                "xbrltype":  "perShareItemType"
                },
            "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue":  {
                "auth_ref":  [
                    "r315"
                    ],
                "crdr":  "debit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.",
                            "label":  "Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value",
                            "terseLabel":  "Intrinsic value of stock options exercised"
                            }
                        }
                    },
                "localname":  "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureCashProceedsAlongWithFairValueDisclosuresRelatedToGrantsExercisesAndVestedOptionsDetail"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod":  {
                "auth_ref":  [
                    "r307"
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.",
                            "label":  "Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period",
                            "negatedLabel":  "Forfeited, cancelled, or expired",
                            "totalLabel":  "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Total"
                            }
                        }
                    },
                "localname":  "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureSummaryOfOptionActivityDetail"
                    ],
                "xbrltype":  "sharesItemType"
                },
            "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice":  {
                "auth_ref":  [
                    "r307"
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Weighted average price of options that were either forfeited or expired.",
                            "label":  "Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price",
                            "terseLabel":  "Forfeited, cancelled, or expired"
                            }
                        }
                    },
                "localname":  "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureSummaryOfOptionActivityDetail"
                    ],
                "xbrltype":  "perShareItemType"
                },
            "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Gross number of share options (or share units) granted during the period.",
                            "label":  "Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross",
                            "terseLabel":  "Granted"
                            }
                        }
                    },
                "localname":  "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureSummaryOfUnvestedStockOptionActivityDetail"
                    ],
                "xbrltype":  "sharesItemType"
                },
            "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue":  {
                "auth_ref":  [
                    "r314"
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
                            "label":  "Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value",
                            "terseLabel":  "Weighted-average fair value of options granted during period",
                            "verboseLabel":  "Granted"
                            }
                        }
                    },
                "localname":  "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureCashProceedsAlongWithFairValueDisclosuresRelatedToGrantsExercisesAndVestedOptionsDetail",
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureSummaryOfUnvestedStockOptionActivityDetail"
                    ],
                "xbrltype":  "perShareItemType"
                },
            "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue":  {
                "auth_ref":  [
                    "r327"
                    ],
                "crdr":  "debit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
                            "label":  "Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value",
                            "terseLabel":  "Options outstanding"
                            }
                        }
                    },
                "localname":  "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureSummaryOfOptionActivityDetail"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber":  {
                "auth_ref":  [
                    "r302",
                    "r327"
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Number of options outstanding, including both vested and non-vested options.",
                            "label":  "Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number",
                            "periodEndLabel":  "Ending Balance",
                            "periodStartLabel":  "Beginning Balance"
                            }
                        }
                    },
                "localname":  "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureSummaryOfOptionActivityDetail"
                    ],
                "xbrltype":  "sharesItemType"
                },
            "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice":  {
                "auth_ref":  [
                    "r301"
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
                            "label":  "Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price",
                            "periodEndLabel":  "Ending Balance",
                            "periodStartLabel":  "Beginning Balance"
                            }
                        }
                    },
                "localname":  "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureSummaryOfOptionActivityDetail"
                    ],
                "xbrltype":  "perShareItemType"
                },
            "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain":  {
                "auth_ref":  [
                    "r294",
                    "r298"
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Award under share-based payment arrangement.",
                            "label":  "Share Based Compensation Arrangements By Share Based Payment Award Award Type And Plan Name [Domain]",
                            "terseLabel":  "Award Type"
                            }
                        }
                    },
                "localname":  "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureRedeemablePreferredStockAndStockholdersEquityAdditionalInformationDetail",
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureSummaryOfUnvestedRestrictedStockUnitsDetail",
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureSummaryOfUnvestedStockOptionActivityDetail"
                    ],
                "xbrltype":  "domainItemType"
                },
            "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
                            "label":  "Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price",
                            "terseLabel":  "Exercised"
                            }
                        }
                    },
                "localname":  "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureSummaryOfOptionActivityDetail"
                    ],
                "xbrltype":  "perShareItemType"
                },
            "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1":  {
                "auth_ref":  [
                    "r319",
                    "r337"
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
                            "label":  "Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1",
                            "terseLabel":  "Expected term (years)"
                            }
                        }
                    },
                "localname":  "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureAssumptionsUsedInEstimatingFairValueOfStockOptionsGrantedDetail",
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureRedeemablePreferredStockAndStockholdersEquityAdditionalInformationDetail"
                    ],
                "xbrltype":  "durationItemType"
                },
            "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1":  {
                "auth_ref":  [
                    "r327"
                    ],
                "crdr":  "debit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
                            "label":  "Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1",
                            "terseLabel":  "Options exercisable"
                            }
                        }
                    },
                "localname":  "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureSummaryOfOptionActivityDetail"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1":  {
                "auth_ref":  [
                    "r327"
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
                            "label":  "Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1",
                            "terseLabel":  "Options exercisable"
                            }
                        }
                    },
                "localname":  "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureSummaryOfOptionActivityDetail"
                    ],
                "xbrltype":  "durationItemType"
                },
            "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Number of non-vested options outstanding.",
                            "label":  "Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares",
                            "periodEndLabel":  "Ending Balance",
                            "periodStartLabel":  "Beginning Balance"
                            }
                        }
                    },
                "localname":  "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureSummaryOfUnvestedStockOptionActivityDetail"
                    ],
                "xbrltype":  "sharesItemType"
                },
            "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Number of non-vested options forfeited.",
                            "label":  "Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Number Of Shares",
                            "negatedLabel":  "Forfeited or cancelled"
                            }
                        }
                    },
                "localname":  "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureSummaryOfUnvestedStockOptionActivityDetail"
                    ],
                "xbrltype":  "sharesItemType"
                },
            "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Weighted average grant-date fair value of non-vested options forfeited.",
                            "label":  "Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Weighted Average Grant Date Fair Value",
                            "terseLabel":  "Forfeited or cancelled"
                            }
                        }
                    },
                "localname":  "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureSummaryOfUnvestedStockOptionActivityDetail"
                    ],
                "xbrltype":  "perShareItemType"
                },
            "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Weighted average grant-date fair value of non-vested options outstanding.",
                            "label":  "Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value",
                            "periodEndLabel":  "Ending Balance",
                            "periodStartLabel":  "Beginning Balance"
                            }
                        }
                    },
                "localname":  "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureSummaryOfUnvestedStockOptionActivityDetail"
                    ],
                "xbrltype":  "perShareItemType"
                },
            "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2":  {
                "auth_ref":  [
                    "r317"
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
                            "label":  "Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2",
                            "terseLabel":  "Options outstanding"
                            }
                        }
                    },
                "localname":  "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureSummaryOfOptionActivityDetail"
                    ],
                "xbrltype":  "durationItemType"
                },
            "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1":  {
                "auth_ref":  [
                    "r299"
                    ],
                "crdr":  "credit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Fair value of options vested.  Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.",
                            "label":  "Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1",
                            "terseLabel":  "Total fair value of shares vested during the period"
                            }
                        }
                    },
                "localname":  "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureCashProceedsAlongWithFairValueDisclosuresRelatedToGrantsExercisesAndVestedOptionsDetail"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Number of options vested.",
                            "label":  "Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares",
                            "negatedLabel":  "Vested"
                            }
                        }
                    },
                "localname":  "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureSummaryOfUnvestedStockOptionActivityDetail"
                    ],
                "xbrltype":  "sharesItemType"
                },
            "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Weighted average grant-date fair value of options vested.",
                            "label":  "Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value",
                            "terseLabel":  "Vested"
                            }
                        }
                    },
                "localname":  "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureSummaryOfUnvestedStockOptionActivityDetail"
                    ],
                "xbrltype":  "perShareItemType"
                },
            "us-gaap_SharesIssuedPricePerShare":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Per share or per unit amount of equity securities issued.",
                            "label":  "Shares Issued, Price Per Share",
                            "terseLabel":  "Shares issued price per share"
                            }
                        }
                    },
                "localname":  "SharesIssuedPricePerShare",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureRedeemablePreferredStockAndStockholdersEquityAdditionalInformationDetail"
                    ],
                "xbrltype":  "perShareItemType"
                },
            "us-gaap_SignificantAccountingPoliciesTextBlock":  {
                "auth_ref":  [
                    "r120"
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "The entire disclosure for all significant accounting policies of the reporting entity.",
                            "label":  "Significant Accounting Policies [Text Block]",
                            "terseLabel":  "Summary of Significant Accounting Policies"
                            }
                        }
                    },
                "localname":  "SignificantAccountingPoliciesTextBlock",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies"
                    ],
                "xbrltype":  "textBlockItemType"
                },
            "us-gaap_StatementClassOfStockAxis":  {
                "auth_ref":  [
                    "r20",
                    "r21",
                    "r22",
                    "r113",
                    "r114",
                    "r139",
                    "r140",
                    "r141",
                    "r144",
                    "r146",
                    "r151",
                    "r152",
                    "r153",
                    "r205",
                    "r260",
                    "r387"
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Information by the different classes of stock of the entity.",
                            "label":  "Statement Class Of Stock [Axis]",
                            "terseLabel":  "Class of Stock"
                            }
                        }
                    },
                "localname":  "StatementClassOfStockAxis",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetail",
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureDescriptionOfBusinessAndBasisOfPresentationAdditionalInformationDetail",
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureRedeemablePreferredStockAndStockholdersEquityAdditionalInformationDetail",
                    "http://www.biolase.com/20210331/taxonomy/role/Role_StatementConsolidatedStatementsOfRedeemablePreferredStockAndShareholdersEquityParenthetical",
                    "http://www.biolase.com/20210331/taxonomy/role/Role_StatementConsolidatedStatementsOfRedeemablePreferredStockAndStockholdersEquityUnaudited"
                    ],
                "xbrltype":  "stringItemType"
                },
            "us-gaap_StatementEquityComponentsAxis":  {
                "auth_ref":  [
                    "r58",
                    "r121",
                    "r122",
                    "r123",
                    "r125",
                    "r133",
                    "r135",
                    "r150",
                    "r209",
                    "r260",
                    "r266",
                    "r333",
                    "r334",
                    "r335",
                    "r353",
                    "r354",
                    "r393",
                    "r394",
                    "r395",
                    "r396",
                    "r397",
                    "r398",
                    "r476",
                    "r477",
                    "r478"
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Information by component of equity.",
                            "label":  "Statement Equity Components [Axis]",
                            "terseLabel":  "Equity Components"
                            }
                        }
                    },
                "localname":  "StatementEquityComponentsAxis",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetail",
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureRedeemablePreferredStockAndStockholdersEquityAdditionalInformationDetail",
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureSummaryOfWarrantActivityDetail",
                    "http://www.biolase.com/20210331/taxonomy/role/Role_StatementConsolidatedStatementsOfRedeemablePreferredStockAndStockholdersEquityUnaudited"
                    ],
                "xbrltype":  "stringItemType"
                },
            "us-gaap_StatementLineItems":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Line items represent financial concepts included in a table.  These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
                            "label":  "Statement [Line Items]",
                            "terseLabel":  "Statement [Line Items]"
                            }
                        }
                    },
                "localname":  "StatementLineItems",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_StatementConsolidatedStatementsOfRedeemablePreferredStockAndShareholdersEquityParenthetical",
                    "http://www.biolase.com/20210331/taxonomy/role/Role_StatementConsolidatedStatementsOfRedeemablePreferredStockAndStockholdersEquityUnaudited"
                    ],
                "xbrltype":  "stringItemType"
                },
            "us-gaap_StatementOfCashFlowsAbstract":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "label":  "Statement Of Cash Flows [Abstract]"
                            }
                        }
                    },
                "localname":  "StatementOfCashFlowsAbstract",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "xbrltype":  "stringItemType"
                },
            "us-gaap_StatementOfFinancialPositionAbstract":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "label":  "Statement Of Financial Position [Abstract]"
                            }
                        }
                    },
                "localname":  "StatementOfFinancialPositionAbstract",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "xbrltype":  "stringItemType"
                },
            "us-gaap_StatementOfStockholdersEquityAbstract":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "label":  "Statement Of Stockholders Equity [Abstract]"
                            }
                        }
                    },
                "localname":  "StatementOfStockholdersEquityAbstract",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "xbrltype":  "stringItemType"
                },
            "us-gaap_StatementTable":  {
                "auth_ref":  [
                    "r121",
                    "r122",
                    "r123",
                    "r150",
                    "r432"
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
                            "label":  "Statement [Table]",
                            "terseLabel":  "Statement [Table]"
                            }
                        }
                    },
                "localname":  "StatementTable",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_StatementConsolidatedStatementsOfRedeemablePreferredStockAndShareholdersEquityParenthetical",
                    "http://www.biolase.com/20210331/taxonomy/role/Role_StatementConsolidatedStatementsOfRedeemablePreferredStockAndStockholdersEquityUnaudited"
                    ],
                "xbrltype":  "stringItemType"
                },
            "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities":  {
                "auth_ref":  [
                    "r57",
                    "r260",
                    "r261",
                    "r266"
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Number of shares issued during the period as a result of the conversion of convertible securities.",
                            "label":  "Stock Issued During Period Shares Conversion Of Convertible Securities",
                            "terseLabel":  "Conversion of convertible preferred stock, shares"
                            }
                        }
                    },
                "localname":  "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_StatementConsolidatedStatementsOfRedeemablePreferredStockAndStockholdersEquityUnaudited"
                    ],
                "xbrltype":  "sharesItemType"
                },
            "us-gaap_StockIssuedDuringPeriodSharesNewIssues":  {
                "auth_ref":  [
                    "r21",
                    "r22",
                    "r260",
                    "r266"
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Number of new stock issued during the period.",
                            "label":  "Stock Issued During Period Shares New Issues",
                            "terseLabel":  "Sale of common stock, shares"
                            }
                        }
                    },
                "localname":  "StockIssuedDuringPeriodSharesNewIssues",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureRedeemablePreferredStockAndStockholdersEquityAdditionalInformationDetail",
                    "http://www.biolase.com/20210331/taxonomy/role/Role_StatementConsolidatedStatementsOfRedeemablePreferredStockAndStockholdersEquityUnaudited"
                    ],
                "xbrltype":  "sharesItemType"
                },
            "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross":  {
                "auth_ref":  [
                    "r260",
                    "r266"
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.",
                            "label":  "Stock Issued During Period Shares Restricted Stock Award Gross",
                            "terseLabel":  "Issuance of stock from RSUs, net, shares"
                            }
                        }
                    },
                "localname":  "StockIssuedDuringPeriodSharesRestrictedStockAwardGross",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_StatementConsolidatedStatementsOfRedeemablePreferredStockAndStockholdersEquityUnaudited"
                    ],
                "xbrltype":  "sharesItemType"
                },
            "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised":  {
                "auth_ref":  [
                    "r21",
                    "r22",
                    "r260",
                    "r266",
                    "r305"
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Number of share options (or share units) exercised during the current period.",
                            "label":  "Stock Issued During Period Shares Stock Options Exercised",
                            "negatedLabel":  "Exercised",
                            "terseLabel":  "Exercise of stock options, net, shares"
                            }
                        }
                    },
                "localname":  "StockIssuedDuringPeriodSharesStockOptionsExercised",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureSummaryOfOptionActivityDetail"
                    ],
                "xbrltype":  "sharesItemType"
                },
            "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities":  {
                "auth_ref":  [
                    "r58",
                    "r260",
                    "r266"
                    ],
                "crdr":  "credit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "The gross value of stock issued during the period upon the conversion of convertible securities.",
                            "label":  "Stock Issued During Period Value Conversion Of Convertible Securities",
                            "terseLabel":  "Conversion of convertible preferred stock"
                            }
                        }
                    },
                "localname":  "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_StatementConsolidatedStatementsOfRedeemablePreferredStockAndStockholdersEquityUnaudited"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "us-gaap_StockIssuedDuringPeriodValueNewIssues":  {
                "auth_ref":  [
                    "r21",
                    "r22",
                    "r260",
                    "r266"
                    ],
                "crdr":  "credit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Equity impact of the value of new stock issued during the period.  Includes shares issued in an initial public offering or a secondary public offering.",
                            "label":  "Stock Issued During Period Value New Issues",
                            "terseLabel":  "Sale of common stock"
                            }
                        }
                    },
                "localname":  "StockIssuedDuringPeriodValueNewIssues",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_StatementConsolidatedStatementsOfRedeemablePreferredStockAndStockholdersEquityUnaudited"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross":  {
                "auth_ref":  [
                    "r21",
                    "r22",
                    "r260",
                    "r266"
                    ],
                "crdr":  "credit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Aggregate value of stock related to Restricted Stock Awards issued during the period.",
                            "label":  "Stock Issued During Period Value Restricted Stock Award Gross",
                            "terseLabel":  "Issuance of stock from RSUs, net"
                            }
                        }
                    },
                "localname":  "StockIssuedDuringPeriodValueRestrictedStockAwardGross",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_StatementConsolidatedStatementsOfRedeemablePreferredStockAndStockholdersEquityUnaudited"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "us-gaap_StockholdersEquity":  {
                "auth_ref":  [
                    "r22",
                    "r27",
                    "r28",
                    "r114",
                    "r204",
                    "r205",
                    "r387"
                    ],
                "calculation":  {
                    "http://www.biolase.com/20210331/taxonomy/role/Role_StatementConsolidatedBalanceSheetsUnaudited":  {
                        "order":  2.0,
                        "parentTag":  "us-gaap_LiabilitiesAndStockholdersEquity",
                        "weight":  1.0
                        }
                    },
                "crdr":  "credit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent.  The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest).  This excludes temporary equity and is sometimes called permanent equity.",
                            "label":  "Stockholders Equity",
                            "periodEndLabel":  "Ending balance",
                            "periodStartLabel":  "Beginning balance",
                            "totalLabel":  "Total stockholders' equity"
                            }
                        }
                    },
                "localname":  "StockholdersEquity",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_StatementConsolidatedBalanceSheetsUnaudited",
                    "http://www.biolase.com/20210331/taxonomy/role/Role_StatementConsolidatedStatementsOfRedeemablePreferredStockAndStockholdersEquityUnaudited"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "us-gaap_StockholdersEquityAbstract":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "label":  "Stockholders Equity [Abstract]",
                            "terseLabel":  "Stockholders' equity:"
                            }
                        }
                    },
                "localname":  "StockholdersEquityAbstract",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_StatementConsolidatedBalanceSheetsUnaudited"
                    ],
                "xbrltype":  "stringItemType"
                },
            "us-gaap_SubordinatedLongTermDebt":  {
                "auth_ref":  [
                    "r54"
                    ],
                "crdr":  "credit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Carrying value as of the balance sheet date of collateralized/uncollateralized debt obligation (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.  Subordinated debt places a lender in a lien position behind the primary lender of the company.",
                            "label":  "Subordinated Long Term Debt",
                            "terseLabel":  "Subordinated debt issued"
                            }
                        }
                    },
                "localname":  "SubordinatedLongTermDebt",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetail"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "us-gaap_SubsequentEventLineItems":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Detail information of subsequent event by type.  User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.",
                            "label":  "Subsequent Event [Line Items]"
                            }
                        }
                    },
                "localname":  "SubsequentEventLineItems",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail"
                    ],
                "xbrltype":  "stringItemType"
                },
            "us-gaap_SubsequentEventMember":  {
                "auth_ref":  [
                    "r399",
                    "r423"
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
                            "label":  "Subsequent Event [Member]",
                            "terseLabel":  "Subsequent Event"
                            }
                        }
                    },
                "localname":  "SubsequentEventMember",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail",
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureDescriptionOfBusinessAndBasisOfPresentationAdditionalInformationDetail"
                    ],
                "xbrltype":  "domainItemType"
                },
            "us-gaap_SubsequentEventTable":  {
                "auth_ref":  [
                    "r399",
                    "r423"
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.",
                            "label":  "Subsequent Event [Table]"
                            }
                        }
                    },
                "localname":  "SubsequentEventTable",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail"
                    ],
                "xbrltype":  "stringItemType"
                },
            "us-gaap_SubsequentEventTypeAxis":  {
                "auth_ref":  [
                    "r399",
                    "r423"
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
                            "label":  "Subsequent Event Type [Axis]"
                            }
                        }
                    },
                "localname":  "SubsequentEventTypeAxis",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail",
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureDescriptionOfBusinessAndBasisOfPresentationAdditionalInformationDetail"
                    ],
                "xbrltype":  "stringItemType"
                },
            "us-gaap_SubsequentEventTypeDomain":  {
                "auth_ref":  [
                    "r399",
                    "r423"
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
                            "label":  "Subsequent Event Type [Domain]"
                            }
                        }
                    },
                "localname":  "SubsequentEventTypeDomain",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail",
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureDescriptionOfBusinessAndBasisOfPresentationAdditionalInformationDetail"
                    ],
                "xbrltype":  "domainItemType"
                },
            "us-gaap_SubsequentEventsAbstract":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "label":  "Subsequent Events [Abstract]"
                            }
                        }
                    },
                "localname":  "SubsequentEventsAbstract",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "xbrltype":  "stringItemType"
                },
            "us-gaap_SubsequentEventsTextBlock":  {
                "auth_ref":  [
                    "r422",
                    "r424"
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.  Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
                            "label":  "Subsequent Events [Text Block]",
                            "terseLabel":  "Subsequent Events"
                            }
                        }
                    },
                "localname":  "SubsequentEventsTextBlock",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/DisclosureSubsequentEvents"
                    ],
                "xbrltype":  "textBlockItemType"
                },
            "us-gaap_SubsidiarySaleOfStockAxis":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Information by type of sale of the entity's stock.",
                            "label":  "Subsidiary Sale Of Stock [Axis]",
                            "terseLabel":  "Sale of Stock"
                            }
                        }
                    },
                "localname":  "SubsidiarySaleOfStockAxis",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureRedeemablePreferredStockAndStockholdersEquityAdditionalInformationDetail"
                    ],
                "xbrltype":  "stringItemType"
                },
            "us-gaap_SupplementalCashFlowInformationAbstract":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "label":  "Supplemental Cash Flow Information [Abstract]",
                            "terseLabel":  "Supplemental cash flow disclosure:"
                            }
                        }
                    },
                "localname":  "SupplementalCashFlowInformationAbstract",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlowsUnaudited"
                    ],
                "xbrltype":  "stringItemType"
                },
            "us-gaap_TaxesPayableCurrent":  {
                "auth_ref":  [
                    "r45"
                    ],
                "calculation":  {
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureComponentsOfAccruedLiabilitiesDetail":  {
                        "order":  2.0,
                        "parentTag":  "us-gaap_AccruedLiabilitiesCurrent",
                        "weight":  1.0
                        }
                    },
                "crdr":  "credit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes.  Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
                            "label":  "Taxes Payable Current",
                            "terseLabel":  "Taxes",
                            "totalLabel":  "Taxes Payable, Current, Total"
                            }
                        }
                    },
                "localname":  "TaxesPayableCurrent",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureComponentsOfAccruedLiabilitiesDetail"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "us-gaap_TemporaryEquityAbstract":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "label":  "Temporary Equity [Abstract]",
                            "terseLabel":  "Redeemable preferred stock:"
                            }
                        }
                    },
                "localname":  "TemporaryEquityAbstract",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_StatementConsolidatedBalanceSheetsUnaudited"
                    ],
                "xbrltype":  "stringItemType"
                },
            "us-gaap_TemporaryEquityCarryingAmountAttributableToParent":  {
                "auth_ref":  [
                    ],
                "calculation":  {
                    "http://www.biolase.com/20210331/taxonomy/role/Role_StatementConsolidatedBalanceSheetsUnaudited":  {
                        "order":  0.0,
                        "parentTag":  "us-gaap_LiabilitiesAndStockholdersEquity",
                        "weight":  1.0
                        }
                    },
                "crdr":  "credit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity.  Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable.  Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer.  Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.",
                            "label":  "Temporary Equity Carrying Amount Attributable To Parent",
                            "periodEndLabel":  "Ending Balance",
                            "periodStartLabel":  "Beginning balance",
                            "terseLabel":  "Series E Preferred stock, par value $0.001 per share; 1,000 shares authorized, 0 shares issued and outstanding as of March 31, 2021 and December 31, 2020"
                            }
                        }
                    },
                "localname":  "TemporaryEquityCarryingAmountAttributableToParent",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_StatementConsolidatedBalanceSheetsUnaudited",
                    "http://www.biolase.com/20210331/taxonomy/role/Role_StatementConsolidatedStatementsOfRedeemablePreferredStockAndStockholdersEquityUnaudited"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "us-gaap_TemporaryEquityDividendsAdjustment":  {
                "auth_ref":  [
                    ],
                "crdr":  "debit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Accretion of temporary equity during the period due to cash, stock, and in-kind dividends.  This item is an adjustment to net income necessary to derive net income apportioned to common stockholders and is to be distinguished from Temporary Equity, Accretion of Dividends (Temporary Equity, Accretion of Dividends).",
                            "label":  "Temporary Equity Dividends Adjustment",
                            "negatedLabel":  "Deemed dividend on convertible preferred stock",
                            "terseLabel":  "Deemed dividend on convertible preferred stock"
                            }
                        }
                    },
                "localname":  "TemporaryEquityDividendsAdjustment",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureRedeemablePreferredStockAndStockholdersEquityAdditionalInformationDetail"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "us-gaap_TemporaryEquityParOrStatedValuePerShare":  {
                "auth_ref":  [
                    "r12",
                    "r259"
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Per share amount of par value or stated value of stock classified as temporary equity.  Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable.",
                            "label":  "Temporary Equity Par Or Stated Value Per Share",
                            "terseLabel":  "Temporary equity, per share",
                            "verboseLabel":  "Preferred stock, par value"
                            }
                        }
                    },
                "localname":  "TemporaryEquityParOrStatedValuePerShare",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureRedeemablePreferredStockAndStockholdersEquityAdditionalInformationDetail",
                    "http://www.biolase.com/20210331/taxonomy/role/Role_StatementConsolidatedBalanceSheetsUnauditedParenthetical"
                    ],
                "xbrltype":  "perShareItemType"
                },
            "us-gaap_TemporaryEquitySharesAuthorized":  {
                "auth_ref":  [
                    "r19"
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "The maximum number of securities classified as temporary equity that are permitted to be issued by an entity's charter and bylaws.  Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable.  Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer.  If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity.  If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases.  Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.",
                            "label":  "Temporary Equity Shares Authorized",
                            "terseLabel":  "Temporary equity preferred stock, shares authorized",
                            "verboseLabel":  "Series E Preferred stock, shares authorized"
                            }
                        }
                    },
                "localname":  "TemporaryEquitySharesAuthorized",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureRedeemablePreferredStockAndStockholdersEquityAdditionalInformationDetail",
                    "http://www.biolase.com/20210331/taxonomy/role/Role_StatementConsolidatedBalanceSheetsUnauditedParenthetical"
                    ],
                "xbrltype":  "sharesItemType"
                },
            "us-gaap_TemporaryEquitySharesIssued":  {
                "auth_ref":  [
                    "r19"
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders.  Securities issued include securities outstanding and securities held in treasury.  Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable.  Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer.  If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity.  If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases.  Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.",
                            "label":  "Temporary Equity Shares Issued",
                            "terseLabel":  "Convertible preferred stock, shares issued",
                            "verboseLabel":  "Series E Preferred stock, shares issued"
                            }
                        }
                    },
                "localname":  "TemporaryEquitySharesIssued",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureRedeemablePreferredStockAndStockholdersEquityAdditionalInformationDetail",
                    "http://www.biolase.com/20210331/taxonomy/role/Role_StatementConsolidatedBalanceSheetsUnauditedParenthetical"
                    ],
                "xbrltype":  "sharesItemType"
                },
            "us-gaap_TemporaryEquitySharesOutstanding":  {
                "auth_ref":  [
                    "r19"
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders.  Securities outstanding equals securities issued minus securities held in treasury.  Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable.  Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer.  If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity.  If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases.  Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.",
                            "label":  "Temporary Equity Shares Outstanding",
                            "periodEndLabel":  "Ending balance, shares",
                            "periodStartLabel":  "Beginning balance, shares",
                            "terseLabel":  "Convertible preferred stock, shares outstanding",
                            "verboseLabel":  "Series E Preferred stock, shares outstanding"
                            }
                        }
                    },
                "localname":  "TemporaryEquitySharesOutstanding",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureRedeemablePreferredStockAndStockholdersEquityAdditionalInformationDetail",
                    "http://www.biolase.com/20210331/taxonomy/role/Role_StatementConsolidatedBalanceSheetsUnauditedParenthetical",
                    "http://www.biolase.com/20210331/taxonomy/role/Role_StatementConsolidatedStatementsOfRedeemablePreferredStockAndStockholdersEquityUnaudited"
                    ],
                "xbrltype":  "sharesItemType"
                },
            "us-gaap_TimingOfTransferOfGoodOrServiceAxis":  {
                "auth_ref":  [
                    "r279",
                    "r287"
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Information by timing of transfer of good or service to customer.",
                            "label":  "Timing Of Transfer Of Good Or Service [Axis]",
                            "terseLabel":  "Timing of Transfer of Good or Service"
                            }
                        }
                    },
                "localname":  "TimingOfTransferOfGoodOrServiceAxis",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureSummaryOfRevenuesDisaggregatedByTimingOfGoodsAndServicesTransferredDetail"
                    ],
                "xbrltype":  "stringItemType"
                },
            "us-gaap_TimingOfTransferOfGoodOrServiceDomain":  {
                "auth_ref":  [
                    "r279",
                    "r287"
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Timing of transfer of good or service to customer.  Includes, but is not limited to, at point in time or over time.",
                            "label":  "Timing Of Transfer Of Good Or Service [Domain]",
                            "terseLabel":  "Timing of Transfer of Good or Service"
                            }
                        }
                    },
                "localname":  "TimingOfTransferOfGoodOrServiceDomain",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureSummaryOfRevenuesDisaggregatedByTimingOfGoodsAndServicesTransferredDetail"
                    ],
                "xbrltype":  "domainItemType"
                },
            "us-gaap_TransferredAtPointInTimeMember":  {
                "auth_ref":  [
                    "r287"
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Contract with customer in which good or service is transferred at point in time.",
                            "label":  "Transferred At Point In Time [Member]",
                            "terseLabel":  "Revenue Recognized at a Point in Time"
                            }
                        }
                    },
                "localname":  "TransferredAtPointInTimeMember",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureSummaryOfRevenuesDisaggregatedByTimingOfGoodsAndServicesTransferredDetail"
                    ],
                "xbrltype":  "domainItemType"
                },
            "us-gaap_TransferredOverTimeMember":  {
                "auth_ref":  [
                    "r287"
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Contract with customer in which good or service is transferred over time.",
                            "label":  "Transferred Over Time [Member]",
                            "terseLabel":  "Revenue Recognized Over Time"
                            }
                        }
                    },
                "localname":  "TransferredOverTimeMember",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureSummaryOfRevenuesDisaggregatedByTimingOfGoodsAndServicesTransferredDetail"
                    ],
                "xbrltype":  "domainItemType"
                },
            "us-gaap_TypeOfAdoptionMember":  {
                "auth_ref":  [
                    "r124",
                    "r125",
                    "r126",
                    "r127",
                    "r206",
                    "r207",
                    "r208",
                    "r209",
                    "r210",
                    "r211",
                    "r329",
                    "r330",
                    "r331",
                    "r332",
                    "r333",
                    "r334",
                    "r335",
                    "r336",
                    "r351",
                    "r352",
                    "r353",
                    "r354",
                    "r433",
                    "r434",
                    "r435",
                    "r474",
                    "r475",
                    "r476",
                    "r477",
                    "r478",
                    "r479",
                    "r480",
                    "r481",
                    "r482",
                    "r483",
                    "r484",
                    "r485"
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Amendment to accounting standards.",
                            "label":  "Type Of Adoption [Member]",
                            "terseLabel":  "Accounting Standards Update"
                            }
                        }
                    },
                "localname":  "TypeOfAdoptionMember",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail"
                    ],
                "xbrltype":  "domainItemType"
                },
            "us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease":  {
                "auth_ref":  [
                    "r345"
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Amount of increase (decrease) in unrecognized tax benefits attributable to uncertain tax positions taken in tax returns.",
                            "label":  "Unrecognized Tax Benefits Period Increase Decrease",
                            "terseLabel":  "Liability for unrecognized tax benefit, including related estimates of penalties and interest",
                            "totalLabel":  "Unrecognized Tax Benefits, Period Increase (Decrease), Total"
                            }
                        }
                    },
                "localname":  "UnrecognizedTaxBenefitsPeriodIncreaseDecrease",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "us-gaap_UnusualRiskOrUncertaintyByNatureAxis":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Information by nature of risk and uncertainty, for example, but not limited to, threat of expropriation of its assets by a foreign government, rapid technological obsolescence in the industry, risk of natural disaster from earthquake or weather events, and availability of or continuation of a labor force at a reasonable cost.",
                            "label":  "Unusual Risk Or Uncertainty By Nature [Axis]",
                            "terseLabel":  "Unusual Risk or Uncertainty, Nature"
                            }
                        }
                    },
                "localname":  "UnusualRiskOrUncertaintyByNatureAxis",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail"
                    ],
                "xbrltype":  "stringItemType"
                },
            "us-gaap_UnusualRiskOrUncertaintyNatureDomain":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Describes the nature of the unusual risk or uncertainty, such as the threat of expropriation of its assets by a foreign government, rapid technological obsolescence in the industry, risk of natural disaster from earthquake or weather events, and availability of or continuation of a labor force at a reasonable cost.",
                            "label":  "Unusual Risk Or Uncertainty Nature [Domain]",
                            "terseLabel":  "Unusual Risk or Uncertainty, Nature"
                            }
                        }
                    },
                "localname":  "UnusualRiskOrUncertaintyNatureDomain",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail"
                    ],
                "xbrltype":  "domainItemType"
                },
            "us-gaap_UseOfEstimates":  {
                "auth_ref":  [
                    "r154",
                    "r155",
                    "r157",
                    "r158",
                    "r166",
                    "r167",
                    "r168"
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
                            "label":  "Use Of Estimates",
                            "terseLabel":  "Use of Estimates"
                            }
                        }
                    },
                "localname":  "UseOfEstimates",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
                    ],
                "xbrltype":  "textBlockItemType"
                },
            "us-gaap_VariableRateAxis":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Information by type of variable rate.",
                            "label":  "Variable Rate [Axis]",
                            "terseLabel":  "Variable Rate"
                            }
                        }
                    },
                "localname":  "VariableRateAxis",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetail"
                    ],
                "xbrltype":  "stringItemType"
                },
            "us-gaap_VariableRateDomain":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index.",
                            "label":  "Variable Rate [Domain]",
                            "terseLabel":  "Variable Rate"
                            }
                        }
                    },
                "localname":  "VariableRateDomain",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetail"
                    ],
                "xbrltype":  "domainItemType"
                },
            "us-gaap_WarrantMember":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.",
                            "label":  "Warrant [Member]",
                            "terseLabel":  "Warrants",
                            "verboseLabel":  "Warrants"
                            }
                        }
                    },
                "localname":  "WarrantMember",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_DisclosureSummaryOfWarrantActivityDetail"
                    ],
                "xbrltype":  "domainItemType"
                },
            "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding":  {
                "auth_ref":  [
                    "r138",
                    "r146"
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
                            "label":  "Weighted Average Number Of Diluted Shares Outstanding",
                            "terseLabel":  "Diluted",
                            "totalLabel":  "Weighted Average Number of Shares Outstanding, Diluted, Total"
                            }
                        }
                    },
                "localname":  "WeightedAverageNumberOfDilutedSharesOutstanding",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited"
                    ],
                "xbrltype":  "sharesItemType"
                },
            "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "label":  "Weighted Average Number Of Shares Outstanding [Abstract]",
                            "terseLabel":  "Shares used in the calculation of net loss per share:"
                            }
                        }
                    },
                "localname":  "WeightedAverageNumberOfSharesOutstandingAbstract",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited"
                    ],
                "xbrltype":  "stringItemType"
                },
            "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic":  {
                "auth_ref":  [
                    "r136",
                    "r146"
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
                            "label":  "Weighted Average Number Of Shares Outstanding Basic",
                            "terseLabel":  "Basic",
                            "totalLabel":  "Weighted Average Number of Shares Outstanding, Basic, Total"
                            }
                        }
                    },
                "localname":  "WeightedAverageNumberOfSharesOutstandingBasic",
                "nsuri":  "http://fasb.org/us-gaap/2020-01-31",
                "presentation":  [
                    "http://www.biolase.com/20210331/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited"
                    ],
                "xbrltype":  "sharesItemType"
                }
            },
        "unitCount":  7
        }
    },
"std_ref":  {
    "r0":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "7",
        "Publisher":  "FASB",
        "Section":  "50",
        "SubTopic":  "20",
        "Topic":  "205",
        "URI":  "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
        },
    "r1":  {
        "Name":  "Accounting Standards Codification",
        "Publisher":  "FASB",
        "Topic":  "205",
        "URI":  "http://asc.fasb.org/topic&trid=2122149"
        },
    "r10":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "9",
        "Publisher":  "FASB",
        "Section":  "45",
        "SubTopic":  "10",
        "Topic":  "210",
        "URI":  "http://asc.fasb.org/extlink&oid=121566466&loc=d3e7018-107765"
        },
    "r100":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "25",
        "Publisher":  "FASB",
        "Section":  "45",
        "SubTopic":  "10",
        "Topic":  "230",
        "URI":  "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585"
        },
    "r101":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "28",
        "Publisher":  "FASB",
        "Section":  "45",
        "SubTopic":  "10",
        "Subparagraph":  "(a)",
        "Topic":  "230",
        "URI":  "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
        },
    "r102":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "28",
        "Publisher":  "FASB",
        "Section":  "45",
        "SubTopic":  "10",
        "Subparagraph":  "(b)",
        "Topic":  "230",
        "URI":  "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
        },
    "r103":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "28",
        "Publisher":  "FASB",
        "Section":  "45",
        "SubTopic":  "10",
        "Topic":  "230",
        "URI":  "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
        },
    "r104":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "4",
        "Publisher":  "FASB",
        "Section":  "45",
        "SubTopic":  "10",
        "Topic":  "230",
        "URI":  "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3044-108585"
        },
    "r105":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "2",
        "Publisher":  "FASB",
        "Section":  "50",
        "SubTopic":  "10",
        "Topic":  "230",
        "URI":  "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4297-108586"
        },
    "r106":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "3",
        "Publisher":  "FASB",
        "Section":  "50",
        "SubTopic":  "10",
        "Topic":  "230",
        "URI":  "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4304-108586"
        },
    "r107":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "4",
        "Publisher":  "FASB",
        "Section":  "50",
        "SubTopic":  "10",
        "Topic":  "230",
        "URI":  "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4313-108586"
        },
    "r108":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "5",
        "Publisher":  "FASB",
        "Section":  "50",
        "SubTopic":  "10",
        "Topic":  "230",
        "URI":  "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4332-108586"
        },
    "r109":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "8",
        "Publisher":  "FASB",
        "Section":  "50",
        "SubTopic":  "10",
        "Topic":  "230",
        "URI":  "http://asc.fasb.org/extlink&oid=121583591&loc=SL98516268-108586"
        },
    "r11":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "1",
        "Publisher":  "FASB",
        "Section":  "50",
        "SubTopic":  "10",
        "Topic":  "210",
        "URI":  "http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766"
        },
    "r110":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "3",
        "Publisher":  "FASB",
        "Section":  "50",
        "SubTopic":  "10",
        "Topic":  "235",
        "URI":  "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790"
        },
    "r111":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "4",
        "Publisher":  "FASB",
        "Section":  "50",
        "SubTopic":  "10",
        "Subparagraph":  "(e)",
        "Topic":  "235",
        "URI":  "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18823-107790"
        },
    "r112":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "4",
        "Publisher":  "FASB",
        "Section":  "50",
        "SubTopic":  "10",
        "Subparagraph":  "(f)",
        "Topic":  "235",
        "URI":  "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18823-107790"
        },
    "r113":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "1",
        "Publisher":  "FASB",
        "Section":  "S99",
        "SubTopic":  "10",
        "Subparagraph":  "(SX 210.4-08(d))",
        "Topic":  "235",
        "URI":  "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
        },
    "r114":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "1",
        "Publisher":  "FASB",
        "Section":  "S99",
        "SubTopic":  "10",
        "Subparagraph":  "(SX 210.4-08(g)(1)(ii))",
        "Topic":  "235",
        "URI":  "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
        },
    "r115":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "1",
        "Publisher":  "FASB",
        "Section":  "S99",
        "SubTopic":  "10",
        "Subparagraph":  "(SX 210.4-08(h))",
        "Topic":  "235",
        "URI":  "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
        },
    "r116":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "1",
        "Publisher":  "FASB",
        "Section":  "S99",
        "SubTopic":  "10",
        "Subparagraph":  "(SX 210.4-08.(e),(f))",
        "Topic":  "235",
        "URI":  "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
        },
    "r117":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "1",
        "Publisher":  "FASB",
        "Section":  "S99",
        "SubTopic":  "10",
        "Subparagraph":  "(SX 210.4-08.(f))",
        "Topic":  "235",
        "URI":  "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
        },
    "r118":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "3",
        "Publisher":  "FASB",
        "Section":  "S99",
        "SubTopic":  "10",
        "Subparagraph":  "(SX 210.12-04.(a))",
        "Topic":  "235",
        "URI":  "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690"
        },
    "r119":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "4",
        "Publisher":  "FASB",
        "Section":  "S99",
        "SubTopic":  "10",
        "Subparagraph":  "(SX 210.12-09)",
        "Topic":  "235",
        "URI":  "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690"
        },
    "r12":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "1",
        "Publisher":  "FASB",
        "Section":  "S99",
        "SubTopic":  "10",
        "Subparagraph":  "(27)",
        "Topic":  "210",
        "URI":  "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
        },
    "r120":  {
        "Name":  "Accounting Standards Codification",
        "Publisher":  "FASB",
        "Topic":  "235",
        "URI":  "http://asc.fasb.org/topic&trid=2122369"
        },
    "r121":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "23",
        "Publisher":  "FASB",
        "Section":  "45",
        "SubTopic":  "10",
        "Subparagraph":  "(b)",
        "Topic":  "250",
        "URI":  "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21914-107793"
        },
    "r122":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "24",
        "Publisher":  "FASB",
        "Section":  "45",
        "SubTopic":  "10",
        "Topic":  "250",
        "URI":  "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21930-107793"
        },
    "r123":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "5",
        "Publisher":  "FASB",
        "Section":  "45",
        "SubTopic":  "10",
        "Subparagraph":  "(b)",
        "Topic":  "250",
        "URI":  "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21711-107793"
        },
    "r124":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "1",
        "Publisher":  "FASB",
        "Section":  "50",
        "SubTopic":  "10",
        "Subparagraph":  "(b)(2)",
        "Topic":  "250",
        "URI":  "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
        },
    "r125":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "1",
        "Publisher":  "FASB",
        "Section":  "50",
        "SubTopic":  "10",
        "Subparagraph":  "(b)(3)",
        "Topic":  "250",
        "URI":  "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
        },
    "r126":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "1",
        "Publisher":  "FASB",
        "Section":  "50",
        "SubTopic":  "10",
        "Subparagraph":  "(b)(4)",
        "Topic":  "250",
        "URI":  "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
        },
    "r127":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "1",
        "Publisher":  "FASB",
        "Section":  "50",
        "SubTopic":  "10",
        "Subparagraph":  "(c)(2)",
        "Topic":  "250",
        "URI":  "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
        },
    "r128":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "11",
        "Publisher":  "FASB",
        "Section":  "50",
        "SubTopic":  "10",
        "Subparagraph":  "(a)",
        "Topic":  "250",
        "URI":  "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
        },
    "r129":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "11",
        "Publisher":  "FASB",
        "Section":  "50",
        "SubTopic":  "10",
        "Subparagraph":  "(b)",
        "Topic":  "250",
        "URI":  "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
        },
    "r13":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "1",
        "Publisher":  "FASB",
        "Section":  "S99",
        "SubTopic":  "10",
        "Subparagraph":  "(SX 210.5-02(1))",
        "Topic":  "210",
        "URI":  "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
        },
    "r130":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "3",
        "Publisher":  "FASB",
        "Section":  "50",
        "SubTopic":  "10",
        "Topic":  "250",
        "URI":  "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794"
        },
    "r131":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "4",
        "Publisher":  "FASB",
        "Section":  "50",
        "SubTopic":  "10",
        "Topic":  "250",
        "URI":  "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794"
        },
    "r132":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "7",
        "Publisher":  "FASB",
        "Section":  "50",
        "SubTopic":  "10",
        "Subparagraph":  "(a)",
        "Topic":  "250",
        "URI":  "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794"
        },
    "r133":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "7",
        "Publisher":  "FASB",
        "Section":  "50",
        "SubTopic":  "10",
        "Subparagraph":  "(b)",
        "Topic":  "250",
        "URI":  "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794"
        },
    "r134":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "8",
        "Publisher":  "FASB",
        "Section":  "50",
        "SubTopic":  "10",
        "Topic":  "250",
        "URI":  "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794"
        },
    "r135":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "9",
        "Publisher":  "FASB",
        "Section":  "50",
        "SubTopic":  "10",
        "Topic":  "250",
        "URI":  "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794"
        },
    "r136":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "10",
        "Publisher":  "FASB",
        "Section":  "45",
        "SubTopic":  "10",
        "Topic":  "260",
        "URI":  "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1448-109256"
        },
    "r137":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "11",
        "Publisher":  "FASB",
        "Section":  "45",
        "SubTopic":  "10",
        "Topic":  "260",
        "URI":  "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1377-109256"
        },
    "r138":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "16",
        "Publisher":  "FASB",
        "Section":  "45",
        "SubTopic":  "10",
        "Topic":  "260",
        "URI":  "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1505-109256"
        },
    "r139":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "2",
        "Publisher":  "FASB",
        "Section":  "45",
        "SubTopic":  "10",
        "Topic":  "260",
        "URI":  "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1252-109256"
        },
    "r14":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "1",
        "Publisher":  "FASB",
        "Section":  "S99",
        "SubTopic":  "10",
        "Subparagraph":  "(SX 210.5-02(13))",
        "Topic":  "210",
        "URI":  "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
        },
    "r140":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "3",
        "Publisher":  "FASB",
        "Section":  "45",
        "SubTopic":  "10",
        "Topic":  "260",
        "URI":  "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1278-109256"
        },
    "r141":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "55",
        "Publisher":  "FASB",
        "Section":  "45",
        "SubTopic":  "10",
        "Subparagraph":  "(b)",
        "Topic":  "260",
        "URI":  "http://asc.fasb.org/extlink&oid=121326447&loc=d3e2626-109256"
        },
    "r142":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "60B",
        "Publisher":  "FASB",
        "Section":  "45",
        "SubTopic":  "10",
        "Subparagraph":  "(a)",
        "Topic":  "260",
        "URI":  "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256"
        },
    "r143":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "60B",
        "Publisher":  "FASB",
        "Section":  "45",
        "SubTopic":  "10",
        "Subparagraph":  "(c)",
        "Topic":  "260",
        "URI":  "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256"
        },
    "r144":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "60B",
        "Publisher":  "FASB",
        "Section":  "45",
        "SubTopic":  "10",
        "Subparagraph":  "(d)",
        "Topic":  "260",
        "URI":  "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256"
        },
    "r145":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "7",
        "Publisher":  "FASB",
        "Section":  "45",
        "SubTopic":  "10",
        "Topic":  "260",
        "URI":  "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1337-109256"
        },
    "r146":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "1",
        "Publisher":  "FASB",
        "Section":  "50",
        "SubTopic":  "10",
        "Subparagraph":  "(a)",
        "Topic":  "260",
        "URI":  "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
        },
    "r147":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "1",
        "Publisher":  "FASB",
        "Section":  "50",
        "SubTopic":  "10",
        "Subparagraph":  "(c)",
        "Topic":  "260",
        "URI":  "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
        },
    "r148":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "15",
        "Publisher":  "FASB",
        "Section":  "55",
        "SubTopic":  "10",
        "Topic":  "260",
        "URI":  "http://asc.fasb.org/extlink&oid=120380238&loc=d3e3842-109258"
        },
    "r149":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "52",
        "Publisher":  "FASB",
        "Section":  "55",
        "SubTopic":  "10",
        "Topic":  "260",
        "URI":  "http://asc.fasb.org/extlink&oid=120380238&loc=d3e4984-109258"
        },
    "r15":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "1",
        "Publisher":  "FASB",
        "Section":  "S99",
        "SubTopic":  "10",
        "Subparagraph":  "(SX 210.5-02(14))",
        "Topic":  "210",
        "URI":  "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
        },
    "r150":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "1",
        "Publisher":  "FASB",
        "Section":  "45",
        "SubTopic":  "10",
        "Topic":  "272",
        "URI":  "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70191-108054"
        },
    "r151":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "3",
        "Publisher":  "FASB",
        "Section":  "45",
        "SubTopic":  "10",
        "Topic":  "272",
        "URI":  "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70229-108054"
        },
    "r152":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "1",
        "Publisher":  "FASB",
        "Section":  "50",
        "SubTopic":  "10",
        "Topic":  "272",
        "URI":  "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055"
        },
    "r153":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "3",
        "Publisher":  "FASB",
        "Section":  "50",
        "SubTopic":  "10",
        "Subparagraph":  "(b)",
        "Topic":  "272",
        "URI":  "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055"
        },
    "r154":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "1",
        "Publisher":  "FASB",
        "Section":  "50",
        "SubTopic":  "10",
        "Subparagraph":  "(b)",
        "Topic":  "275",
        "URI":  "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
        },
    "r155":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "1",
        "Publisher":  "FASB",
        "Section":  "50",
        "SubTopic":  "10",
        "Subparagraph":  "(c)",
        "Topic":  "275",
        "URI":  "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
        },
    "r156":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "1",
        "Publisher":  "FASB",
        "Section":  "50",
        "SubTopic":  "10",
        "Subparagraph":  "(d)",
        "Topic":  "275",
        "URI":  "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
        },
    "r157":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "11",
        "Publisher":  "FASB",
        "Section":  "50",
        "SubTopic":  "10",
        "Topic":  "275",
        "URI":  "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
        },
    "r158":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "12",
        "Publisher":  "FASB",
        "Section":  "50",
        "SubTopic":  "10",
        "Topic":  "275",
        "URI":  "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
        },
    "r159":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "16",
        "Publisher":  "FASB",
        "Section":  "50",
        "SubTopic":  "10",
        "Topic":  "275",
        "URI":  "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6327-108592"
        },
    "r16":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "1",
        "Publisher":  "FASB",
        "Section":  "S99",
        "SubTopic":  "10",
        "Subparagraph":  "(SX 210.5-02(19))",
        "Topic":  "210",
        "URI":  "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
        },
    "r160":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "18",
        "Publisher":  "FASB",
        "Section":  "50",
        "SubTopic":  "10",
        "Subparagraph":  "(a)",
        "Topic":  "275",
        "URI":  "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
        },
    "r161":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "18",
        "Publisher":  "FASB",
        "Section":  "50",
        "SubTopic":  "10",
        "Subparagraph":  "(b)",
        "Topic":  "275",
        "URI":  "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
        },
    "r162":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "18",
        "Publisher":  "FASB",
        "Section":  "50",
        "SubTopic":  "10",
        "Subparagraph":  "(d)",
        "Topic":  "275",
        "URI":  "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
        },
    "r163":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "18",
        "Publisher":  "FASB",
        "Section":  "50",
        "SubTopic":  "10",
        "Topic":  "275",
        "URI":  "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
        },
    "r164":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "20",
        "Publisher":  "FASB",
        "Section":  "50",
        "SubTopic":  "10",
        "Topic":  "275",
        "URI":  "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592"
        },
    "r165":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "21",
        "Publisher":  "FASB",
        "Section":  "50",
        "SubTopic":  "10",
        "Topic":  "275",
        "URI":  "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6442-108592"
        },
    "r166":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "4",
        "Publisher":  "FASB",
        "Section":  "50",
        "SubTopic":  "10",
        "Topic":  "275",
        "URI":  "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
        },
    "r167":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "8",
        "Publisher":  "FASB",
        "Section":  "50",
        "SubTopic":  "10",
        "Topic":  "275",
        "URI":  "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
        },
    "r168":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "9",
        "Publisher":  "FASB",
        "Section":  "50",
        "SubTopic":  "10",
        "Topic":  "275",
        "URI":  "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
        },
    "r169":  {
        "Name":  "Accounting Standards Codification",
        "Publisher":  "FASB",
        "Topic":  "275",
        "URI":  "http://asc.fasb.org/topic&trid=2134479"
        },
    "r17":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "1",
        "Publisher":  "FASB",
        "Section":  "S99",
        "SubTopic":  "10",
        "Subparagraph":  "(SX 210.5-02(20))",
        "Topic":  "210",
        "URI":  "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
        },
    "r170":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "15",
        "Publisher":  "FASB",
        "Section":  "50",
        "SubTopic":  "10",
        "Topic":  "280",
        "URI":  "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8657-108599"
        },
    "r171":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "21",
        "Publisher":  "FASB",
        "Section":  "50",
        "SubTopic":  "10",
        "Subparagraph":  "(a)",
        "Topic":  "280",
        "URI":  "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8721-108599"
        },
    "r172":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "21",
        "Publisher":  "FASB",
        "Section":  "50",
        "SubTopic":  "10",
        "Subparagraph":  "(b)",
        "Topic":  "280",
        "URI":  "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8721-108599"
        },
    "r173":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "22",
        "Publisher":  "FASB",
        "Section":  "50",
        "SubTopic":  "10",
        "Subparagraph":  "(a)",
        "Topic":  "280",
        "URI":  "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
        },
    "r174":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "22",
        "Publisher":  "FASB",
        "Section":  "50",
        "SubTopic":  "10",
        "Subparagraph":  "(b)",
        "Topic":  "280",
        "URI":  "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
        },
    "r175":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "22",
        "Publisher":  "FASB",
        "Section":  "50",
        "SubTopic":  "10",
        "Subparagraph":  "(e)",
        "Topic":  "280",
        "URI":  "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
        },
    "r176":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "22",
        "Publisher":  "FASB",
        "Section":  "50",
        "SubTopic":  "10",
        "Subparagraph":  "(h)",
        "Topic":  "280",
        "URI":  "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
        },
    "r177":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "22",
        "Publisher":  "FASB",
        "Section":  "50",
        "SubTopic":  "10",
        "Topic":  "280",
        "URI":  "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
        },
    "r178":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "25",
        "Publisher":  "FASB",
        "Section":  "50",
        "SubTopic":  "10",
        "Topic":  "280",
        "URI":  "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8813-108599"
        },
    "r179":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "26",
        "Publisher":  "FASB",
        "Section":  "50",
        "SubTopic":  "10",
        "Topic":  "280",
        "URI":  "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8844-108599"
        },
    "r18":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "1",
        "Publisher":  "FASB",
        "Section":  "S99",
        "SubTopic":  "10",
        "Subparagraph":  "(SX 210.5-02(22))",
        "Topic":  "210",
        "URI":  "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
        },
    "r180":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "30",
        "Publisher":  "FASB",
        "Section":  "50",
        "SubTopic":  "10",
        "Subparagraph":  "(a)",
        "Topic":  "280",
        "URI":  "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
        },
    "r181":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "30",
        "Publisher":  "FASB",
        "Section":  "50",
        "SubTopic":  "10",
        "Subparagraph":  "(b)",
        "Topic":  "280",
        "URI":  "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
        },
    "r182":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "30",
        "Publisher":  "FASB",
        "Section":  "50",
        "SubTopic":  "10",
        "Subparagraph":  "(c)",
        "Topic":  "280",
        "URI":  "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
        },
    "r183":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "30",
        "Publisher":  "FASB",
        "Section":  "50",
        "SubTopic":  "10",
        "Subparagraph":  "(d)",
        "Topic":  "280",
        "URI":  "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
        },
    "r184":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "30",
        "Publisher":  "FASB",
        "Section":  "50",
        "SubTopic":  "10",
        "Topic":  "280",
        "URI":  "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
        },
    "r185":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "31",
        "Publisher":  "FASB",
        "Section":  "50",
        "SubTopic":  "10",
        "Topic":  "280",
        "URI":  "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599"
        },
    "r186":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "32",
        "Publisher":  "FASB",
        "Section":  "50",
        "SubTopic":  "10",
        "Subparagraph":  "(a)",
        "Topic":  "280",
        "URI":  "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
        },
    "r187":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "32",
        "Publisher":  "FASB",
        "Section":  "50",
        "SubTopic":  "10",
        "Subparagraph":  "(b)",
        "Topic":  "280",
        "URI":  "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
        },
    "r188":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "32",
        "Publisher":  "FASB",
        "Section":  "50",
        "SubTopic":  "10",
        "Subparagraph":  "(c)",
        "Topic":  "280",
        "URI":  "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
        },
    "r189":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "32",
        "Publisher":  "FASB",
        "Section":  "50",
        "SubTopic":  "10",
        "Subparagraph":  "(d)",
        "Topic":  "280",
        "URI":  "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
        },
    "r19":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "1",
        "Publisher":  "FASB",
        "Section":  "S99",
        "SubTopic":  "10",
        "Subparagraph":  "(SX 210.5-02(27)(b))",
        "Topic":  "210",
        "URI":  "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
        },
    "r190":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "32",
        "Publisher":  "FASB",
        "Section":  "50",
        "SubTopic":  "10",
        "Subparagraph":  "(e)",
        "Topic":  "280",
        "URI":  "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
        },
    "r191":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "32",
        "Publisher":  "FASB",
        "Section":  "50",
        "SubTopic":  "10",
        "Subparagraph":  "(f)",
        "Topic":  "280",
        "URI":  "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
        },
    "r192":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "34",
        "Publisher":  "FASB",
        "Section":  "50",
        "SubTopic":  "10",
        "Topic":  "280",
        "URI":  "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8981-108599"
        },
    "r193":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "40",
        "Publisher":  "FASB",
        "Section":  "50",
        "SubTopic":  "10",
        "Topic":  "280",
        "URI":  "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599"
        },
    "r194":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "41",
        "Publisher":  "FASB",
        "Section":  "50",
        "SubTopic":  "10",
        "Subparagraph":  "(a)",
        "Topic":  "280",
        "URI":  "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599"
        },
    "r195":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "41",
        "Publisher":  "FASB",
        "Section":  "50",
        "SubTopic":  "10",
        "Subparagraph":  "(b)",
        "Topic":  "280",
        "URI":  "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599"
        },
    "r196":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "41",
        "Publisher":  "FASB",
        "Section":  "50",
        "SubTopic":  "10",
        "Subparagraph":  "a",
        "Topic":  "280",
        "URI":  "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599"
        },
    "r197":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "41",
        "Publisher":  "FASB",
        "Section":  "50",
        "SubTopic":  "10",
        "Subparagraph":  "b",
        "Topic":  "280",
        "URI":  "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599"
        },
    "r198":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "41",
        "Publisher":  "FASB",
        "Section":  "50",
        "SubTopic":  "10",
        "Topic":  "280",
        "URI":  "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599"
        },
    "r199":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "42",
        "Publisher":  "FASB",
        "Section":  "50",
        "SubTopic":  "10",
        "Topic":  "280",
        "URI":  "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599"
        },
    "r2":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "1",
        "Publisher":  "FASB",
        "Section":  "45",
        "SubTopic":  "10",
        "Subparagraph":  "(a)",
        "Topic":  "210",
        "URI":  "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
        },
    "r20":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "1",
        "Publisher":  "FASB",
        "Section":  "S99",
        "SubTopic":  "10",
        "Subparagraph":  "(SX 210.5-02(27))",
        "Topic":  "210",
        "URI":  "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
        },
    "r200":  {
        "Name":  "Accounting Standards Codification",
        "Publisher":  "FASB",
        "Topic":  "280",
        "URI":  "http://asc.fasb.org/topic&trid=2134510"
        },
    "r201":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "2",
        "Publisher":  "FASB",
        "Section":  "45",
        "SubTopic":  "10",
        "Topic":  "310",
        "URI":  "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4428-111522"
        },
    "r202":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "9",
        "Publisher":  "FASB",
        "Section":  "45",
        "SubTopic":  "10",
        "Topic":  "310",
        "URI":  "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4531-111522"
        },
    "r203":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "4",
        "Publisher":  "FASB",
        "Section":  "50",
        "SubTopic":  "10",
        "Topic":  "310",
        "URI":  "http://asc.fasb.org/extlink&oid=121611835&loc=d3e5074-111524"
        },
    "r204":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "2",
        "Publisher":  "FASB",
        "Section":  "S99",
        "SubTopic":  "10",
        "Subparagraph":  "(SAB Topic 4.E)",
        "Topic":  "310",
        "URI":  "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707"
        },
    "r205":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "3",
        "Publisher":  "FASB",
        "Section":  "50",
        "SubTopic":  "10",
        "Subparagraph":  "(c)",
        "Topic":  "323",
        "URI":  "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
        },
    "r206":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "4",
        "Publisher":  "FASB",
        "Section":  "65",
        "SubTopic":  "10",
        "Subparagraph":  "(a)",
        "Topic":  "326",
        "URI":  "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
        },
    "r207":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "4",
        "Publisher":  "FASB",
        "Section":  "65",
        "SubTopic":  "10",
        "Subparagraph":  "(b)",
        "Topic":  "326",
        "URI":  "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
        },
    "r208":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "4",
        "Publisher":  "FASB",
        "Section":  "65",
        "SubTopic":  "10",
        "Subparagraph":  "(c)",
        "Topic":  "326",
        "URI":  "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
        },
    "r209":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "4",
        "Publisher":  "FASB",
        "Section":  "65",
        "SubTopic":  "10",
        "Subparagraph":  "(d)",
        "Topic":  "326",
        "URI":  "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
        },
    "r21":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "1",
        "Publisher":  "FASB",
        "Section":  "S99",
        "SubTopic":  "10",
        "Subparagraph":  "(SX 210.5-02(28))",
        "Topic":  "210",
        "URI":  "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
        },
    "r210":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "4",
        "Publisher":  "FASB",
        "Section":  "65",
        "SubTopic":  "10",
        "Subparagraph":  "(e)(3)",
        "Topic":  "326",
        "URI":  "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
        },
    "r211":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "4",
        "Publisher":  "FASB",
        "Section":  "65",
        "SubTopic":  "10",
        "Subparagraph":  "(e)(4)",
        "Topic":  "326",
        "URI":  "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
        },
    "r212":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "1",
        "Publisher":  "FASB",
        "Section":  "45",
        "SubTopic":  "20",
        "Topic":  "326",
        "URI":  "http://asc.fasb.org/extlink&oid=121599878&loc=SL82895884-210446"
        },
    "r213":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "13",
        "Publisher":  "FASB",
        "Section":  "50",
        "SubTopic":  "20",
        "Subparagraph":  "(b)",
        "Topic":  "326",
        "URI":  "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919249-210447"
        },
    "r214":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "2",
        "Publisher":  "FASB",
        "Section":  "50",
        "SubTopic":  "10",
        "Topic":  "330",
        "URI":  "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4542-108314"
        },
    "r215":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "2",
        "Publisher":  "FASB",
        "Section":  "S99",
        "SubTopic":  "10",
        "Subparagraph":  "(SAB TOPIC 5.BB)",
        "Topic":  "330",
        "URI":  "http://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729"
        },
    "r216":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "2",
        "Publisher":  "FASB",
        "Section":  "S99",
        "SubTopic":  "10",
        "Subparagraph":  "(SAB Topic 5.BB)",
        "Topic":  "330",
        "URI":  "http://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729"
        },
    "r217":  {
        "Name":  "Accounting Standards Codification",
        "Publisher":  "FASB",
        "Topic":  "330",
        "URI":  "http://asc.fasb.org/topic&trid=2126998"
        },
    "r218":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "1",
        "Publisher":  "FASB",
        "Section":  "45",
        "SubTopic":  "20",
        "Topic":  "350",
        "URI":  "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266"
        },
    "r219":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "5",
        "Publisher":  "FASB",
        "Section":  "45",
        "SubTopic":  "20",
        "Topic":  "350",
        "URI":  "http://asc.fasb.org/extlink&oid=120320667&loc=SL49117168-202975"
        },
    "r22":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "1",
        "Publisher":  "FASB",
        "Section":  "S99",
        "SubTopic":  "10",
        "Subparagraph":  "(SX 210.5-02(29))",
        "Topic":  "210",
        "URI":  "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
        },
    "r220":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "1",
        "Publisher":  "FASB",
        "Section":  "50",
        "SubTopic":  "20",
        "Topic":  "350",
        "URI":  "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
        },
    "r221":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "2",
        "Publisher":  "FASB",
        "Section":  "45",
        "SubTopic":  "30",
        "Topic":  "350",
        "URI":  "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274"
        },
    "r222":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "2",
        "Publisher":  "FASB",
        "Section":  "50",
        "SubTopic":  "30",
        "Subparagraph":  "(a)(2)",
        "Topic":  "350",
        "URI":  "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
        },
    "r223":  {
        "Name":  "Accounting Standards Codification",
        "Publisher":  "FASB",
        "Topic":  "350",
        "URI":  "http://asc.fasb.org/topic&trid=2144416"
        },
    "r224":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "1",
        "Publisher":  "FASB",
        "Section":  "50",
        "SubTopic":  "10",
        "Subparagraph":  "(a)",
        "Topic":  "360",
        "URI":  "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
        },
    "r225":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "1",
        "Publisher":  "FASB",
        "Section":  "50",
        "SubTopic":  "10",
        "Subparagraph":  "(b)",
        "Topic":  "360",
        "URI":  "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
        },
    "r226":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "1",
        "Publisher":  "FASB",
        "Section":  "50",
        "SubTopic":  "10",
        "Subparagraph":  "(c)",
        "Topic":  "360",
        "URI":  "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
        },
    "r227":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "1",
        "Publisher":  "FASB",
        "Section":  "50",
        "SubTopic":  "10",
        "Topic":  "360",
        "URI":  "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
        },
    "r228":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "3",
        "Publisher":  "FASB",
        "Section":  "50",
        "SubTopic":  "10",
        "Subparagraph":  "(d)",
        "Topic":  "360",
        "URI":  "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
        },
    "r229":  {
        "Name":  "Accounting Standards Codification",
        "Publisher":  "FASB",
        "Topic":  "360",
        "URI":  "http://asc.fasb.org/topic&trid=2155823"
        },
    "r23":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "1",
        "Publisher":  "FASB",
        "Section":  "S99",
        "SubTopic":  "10",
        "Subparagraph":  "(SX 210.5-02(3))",
        "Topic":  "210",
        "URI":  "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
        },
    "r230":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "4",
        "Publisher":  "FASB",
        "Section":  "50",
        "SubTopic":  "10",
        "Subparagraph":  "(a)",
        "Topic":  "440",
        "URI":  "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308"
        },
    "r231":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "4",
        "Publisher":  "FASB",
        "Section":  "50",
        "SubTopic":  "10",
        "Subparagraph":  "(c)",
        "Topic":  "440",
        "URI":  "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308"
        },
    "r232":  {
        "Name":  "Accounting Standards Codification",
        "Publisher":  "FASB",
        "Topic":  "440",
        "URI":  "http://asc.fasb.org/topic&trid=2144648"
        },
    "r233":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "1",
        "Publisher":  "FASB",
        "Section":  "50",
        "SubTopic":  "20",
        "Topic":  "450",
        "URI":  "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
        },
    "r234":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "10",
        "Publisher":  "FASB",
        "Section":  "50",
        "SubTopic":  "20",
        "Topic":  "450",
        "URI":  "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349"
        },
    "r235":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "3",
        "Publisher":  "FASB",
        "Section":  "50",
        "SubTopic":  "20",
        "Topic":  "450",
        "URI":  "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14394-108349"
        },
    "r236":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "4",
        "Publisher":  "FASB",
        "Section":  "50",
        "SubTopic":  "20",
        "Subparagraph":  "(a)",
        "Topic":  "450",
        "URI":  "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349"
        },
    "r237":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "4",
        "Publisher":  "FASB",
        "Section":  "50",
        "SubTopic":  "20",
        "Topic":  "450",
        "URI":  "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349"
        },
    "r238":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "5",
        "Publisher":  "FASB",
        "Section":  "50",
        "SubTopic":  "20",
        "Topic":  "450",
        "URI":  "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14453-108349"
        },
    "r239":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "6",
        "Publisher":  "FASB",
        "Section":  "50",
        "SubTopic":  "20",
        "Topic":  "450",
        "URI":  "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14472-108349"
        },
    "r24":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "1",
        "Publisher":  "FASB",
        "Section":  "S99",
        "SubTopic":  "10",
        "Subparagraph":  "(SX 210.5-02(30)(a)(1))",
        "Topic":  "210",
        "URI":  "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
        },
    "r240":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "9",
        "Publisher":  "FASB",
        "Section":  "50",
        "SubTopic":  "20",
        "Subparagraph":  "(a)",
        "Topic":  "450",
        "URI":  "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349"
        },
    "r241":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "9",
        "Publisher":  "FASB",
        "Section":  "50",
        "SubTopic":  "20",
        "Topic":  "450",
        "URI":  "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349"
        },
    "r242":  {
        "Name":  "Accounting Standards Codification",
        "Publisher":  "FASB",
        "Topic":  "450",
        "URI":  "http://asc.fasb.org/topic&trid=2127136"
        },
    "r243":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "5",
        "Publisher":  "FASB",
        "Section":  "25",
        "SubTopic":  "10",
        "Topic":  "460",
        "URI":  "http://asc.fasb.org/extlink&oid=68070138&loc=d3e11281-110244"
        },
    "r244":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "2",
        "Publisher":  "FASB",
        "Section":  "50",
        "SubTopic":  "10",
        "Topic":  "460",
        "URI":  "http://asc.fasb.org/extlink&oid=121555522&loc=d3e12021-110248"
        },
    "r245":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "3",
        "Publisher":  "FASB",
        "Section":  "50",
        "SubTopic":  "10",
        "Topic":  "460",
        "URI":  "http://asc.fasb.org/extlink&oid=121555522&loc=d3e12053-110248"
        },
    "r246":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "7",
        "Publisher":  "FASB",
        "Section":  "50",
        "SubTopic":  "10",
        "Topic":  "460",
        "URI":  "http://asc.fasb.org/extlink&oid=68068213&loc=d3e12524-110249"
        },
    "r247":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "8",
        "Publisher":  "FASB",
        "Section":  "50",
        "SubTopic":  "10",
        "Subparagraph":  "((c)(2))",
        "Topic":  "460",
        "URI":  "http://asc.fasb.org/extlink&oid=68068213&loc=d3e12565-110249"
        },
    "r248":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "8",
        "Publisher":  "FASB",
        "Section":  "50",
        "SubTopic":  "10",
        "Subparagraph":  "((c)(4))",
        "Topic":  "460",
        "URI":  "http://asc.fasb.org/extlink&oid=68068213&loc=d3e12565-110249"
        },
    "r249":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "8",
        "Publisher":  "FASB",
        "Section":  "50",
        "SubTopic":  "10",
        "Subparagraph":  "(c)(1)",
        "Topic":  "460",
        "URI":  "http://asc.fasb.org/extlink&oid=68068213&loc=d3e12565-110249"
        },
    "r25":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "1",
        "Publisher":  "FASB",
        "Section":  "S99",
        "SubTopic":  "10",
        "Subparagraph":  "(SX 210.5-02(30)(a)(3))",
        "Topic":  "210",
        "URI":  "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
        },
    "r250":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "8",
        "Publisher":  "FASB",
        "Section":  "50",
        "SubTopic":  "10",
        "Subparagraph":  "(c)(5)",
        "Topic":  "460",
        "URI":  "http://asc.fasb.org/extlink&oid=68068213&loc=d3e12565-110249"
        },
    "r251":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "8",
        "Publisher":  "FASB",
        "Section":  "50",
        "SubTopic":  "10",
        "Topic":  "460",
        "URI":  "http://asc.fasb.org/extlink&oid=68068213&loc=d3e12565-110249"
        },
    "r252":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "1",
        "Publisher":  "FASB",
        "Section":  "50",
        "SubTopic":  "10",
        "Topic":  "470",
        "URI":  "http://asc.fasb.org/extlink&oid=6802200&loc=d3e1835-112601"
        },
    "r253":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "4",
        "Publisher":  "FASB",
        "Section":  "50",
        "SubTopic":  "20",
        "Subparagraph":  "(b)(1)",
        "Topic":  "470",
        "URI":  "http://asc.fasb.org/extlink&oid=120520924&loc=SL6031897-161870"
        },
    "r254":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "4",
        "Publisher":  "FASB",
        "Section":  "50",
        "SubTopic":  "20",
        "Subparagraph":  "(b)(2)",
        "Topic":  "470",
        "URI":  "http://asc.fasb.org/extlink&oid=120520924&loc=SL6031897-161870"
        },
    "r255":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "4",
        "Publisher":  "FASB",
        "Section":  "50",
        "SubTopic":  "20",
        "Subparagraph":  "(b)(3)",
        "Topic":  "470",
        "URI":  "http://asc.fasb.org/extlink&oid=120520924&loc=SL6031897-161870"
        },
    "r256":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "6",
        "Publisher":  "FASB",
        "Section":  "50",
        "SubTopic":  "20",
        "Subparagraph":  "(b)",
        "Topic":  "470",
        "URI":  "http://asc.fasb.org/extlink&oid=120520924&loc=SL6036836-161870"
        },
    "r257":  {
        "Name":  "Accounting Standards Codification",
        "Publisher":  "FASB",
        "Topic":  "470",
        "URI":  "http://asc.fasb.org/topic&trid=2208564"
        },
    "r258":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "13",
        "Publisher":  "FASB",
        "Section":  "25",
        "SubTopic":  "10",
        "Topic":  "480",
        "URI":  "http://asc.fasb.org/extlink&oid=109262497&loc=d3e20148-110875"
        },
    "r259":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "1",
        "Publisher":  "FASB",
        "Section":  "S99",
        "SubTopic":  "10",
        "Topic":  "480",
        "URI":  "http://asc.fasb.org/extlink&oid=65877616&loc=d3e177068-122764"
        },
    "r26":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "1",
        "Publisher":  "FASB",
        "Section":  "S99",
        "SubTopic":  "10",
        "Subparagraph":  "(SX 210.5-02(30)(a)(4))",
        "Topic":  "210",
        "URI":  "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
        },
    "r260":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "2",
        "Publisher":  "FASB",
        "Section":  "50",
        "SubTopic":  "10",
        "Topic":  "505",
        "URI":  "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644"
        },
    "r261":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "3",
        "Publisher":  "FASB",
        "Section":  "50",
        "SubTopic":  "10",
        "Topic":  "505",
        "URI":  "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644"
        },
    "r262":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "6",
        "Publisher":  "FASB",
        "Section":  "50",
        "SubTopic":  "10",
        "Subparagraph":  "(b)",
        "Topic":  "505",
        "URI":  "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644"
        },
    "r263":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "6",
        "Publisher":  "FASB",
        "Section":  "50",
        "SubTopic":  "10",
        "Topic":  "505",
        "URI":  "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644"
        },
    "r264":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "7",
        "Publisher":  "FASB",
        "Section":  "50",
        "SubTopic":  "10",
        "Topic":  "505",
        "URI":  "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21521-112644"
        },
    "r265":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "8",
        "Publisher":  "FASB",
        "Section":  "50",
        "SubTopic":  "10",
        "Topic":  "505",
        "URI":  "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21538-112644"
        },
    "r266":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "1",
        "Publisher":  "FASB",
        "Section":  "S99",
        "SubTopic":  "10",
        "Subparagraph":  "(SX 210.3-04)",
        "Topic":  "505",
        "URI":  "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
        },
    "r267":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "1",
        "Publisher":  "FASB",
        "Section":  "S99",
        "SubTopic":  "50",
        "Topic":  "505",
        "URI":  "http://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775"
        },
    "r268":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "1",
        "Publisher":  "FASB",
        "Section":  "45",
        "SubTopic":  "10",
        "Topic":  "606",
        "URI":  "http://asc.fasb.org/extlink&oid=121556615&loc=SL49130531-203044"
        },
    "r269":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "2",
        "Publisher":  "FASB",
        "Section":  "45",
        "SubTopic":  "10",
        "Topic":  "606",
        "URI":  "http://asc.fasb.org/extlink&oid=121556615&loc=SL49130532-203044"
        },
    "r27":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "1",
        "Publisher":  "FASB",
        "Section":  "S99",
        "SubTopic":  "10",
        "Subparagraph":  "(SX 210.5-02(30))",
        "Topic":  "210",
        "URI":  "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
        },
    "r270":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "10",
        "Publisher":  "FASB",
        "Section":  "50",
        "SubTopic":  "10",
        "Topic":  "606",
        "URI":  "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130551-203045"
        },
    "r271":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "12",
        "Publisher":  "FASB",
        "Section":  "50",
        "SubTopic":  "10",
        "Subparagraph":  "(a)",
        "Topic":  "606",
        "URI":  "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045"
        },
    "r272":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "12",
        "Publisher":  "FASB",
        "Section":  "50",
        "SubTopic":  "10",
        "Subparagraph":  "(b)",
        "Topic":  "606",
        "URI":  "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045"
        },
    "r273":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "12",
        "Publisher":  "FASB",
        "Section":  "50",
        "SubTopic":  "10",
        "Subparagraph":  "(c)",
        "Topic":  "606",
        "URI":  "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045"
        },
    "r274":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "12",
        "Publisher":  "FASB",
        "Section":  "50",
        "SubTopic":  "10",
        "Subparagraph":  "(d)",
        "Topic":  "606",
        "URI":  "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045"
        },
    "r275":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "12",
        "Publisher":  "FASB",
        "Section":  "50",
        "SubTopic":  "10",
        "Subparagraph":  "(e)",
        "Topic":  "606",
        "URI":  "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045"
        },
    "r276":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "13",
        "Publisher":  "FASB",
        "Section":  "50",
        "SubTopic":  "10",
        "Subparagraph":  "(b)(2)",
        "Topic":  "606",
        "URI":  "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130556-203045"
        },
    "r277":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "15",
        "Publisher":  "FASB",
        "Section":  "50",
        "SubTopic":  "10",
        "Topic":  "606",
        "URI":  "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130558-203045"
        },
    "r278":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "4",
        "Publisher":  "FASB",
        "Section":  "50",
        "SubTopic":  "10",
        "Subparagraph":  "(a)",
        "Topic":  "606",
        "URI":  "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130543-203045"
        },
    "r279":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "5",
        "Publisher":  "FASB",
        "Section":  "50",
        "SubTopic":  "10",
        "Topic":  "606",
        "URI":  "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130545-203045"
        },
    "r28":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "1",
        "Publisher":  "FASB",
        "Section":  "S99",
        "SubTopic":  "10",
        "Subparagraph":  "(SX 210.5-02(31))",
        "Topic":  "210",
        "URI":  "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
        },
    "r280":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "8",
        "Publisher":  "FASB",
        "Section":  "50",
        "SubTopic":  "10",
        "Subparagraph":  "(a)",
        "Topic":  "606",
        "URI":  "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130549-203045"
        },
    "r281":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "9",
        "Publisher":  "FASB",
        "Section":  "50",
        "SubTopic":  "10",
        "Topic":  "606",
        "URI":  "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130550-203045"
        },
    "r282":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "91",
        "Publisher":  "FASB",
        "Section":  "55",
        "SubTopic":  "10",
        "Subparagraph":  "(a)",
        "Topic":  "606",
        "URI":  "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
        },
    "r283":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "91",
        "Publisher":  "FASB",
        "Section":  "55",
        "SubTopic":  "10",
        "Subparagraph":  "(b)",
        "Topic":  "606",
        "URI":  "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
        },
    "r284":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "91",
        "Publisher":  "FASB",
        "Section":  "55",
        "SubTopic":  "10",
        "Subparagraph":  "(c)",
        "Topic":  "606",
        "URI":  "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
        },
    "r285":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "91",
        "Publisher":  "FASB",
        "Section":  "55",
        "SubTopic":  "10",
        "Subparagraph":  "(d)",
        "Topic":  "606",
        "URI":  "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
        },
    "r286":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "91",
        "Publisher":  "FASB",
        "Section":  "55",
        "SubTopic":  "10",
        "Subparagraph":  "(e)",
        "Topic":  "606",
        "URI":  "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
        },
    "r287":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "91",
        "Publisher":  "FASB",
        "Section":  "55",
        "SubTopic":  "10",
        "Subparagraph":  "(f)",
        "Topic":  "606",
        "URI":  "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
        },
    "r288":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "91",
        "Publisher":  "FASB",
        "Section":  "55",
        "SubTopic":  "10",
        "Subparagraph":  "(g)",
        "Topic":  "606",
        "URI":  "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
        },
    "r289":  {
        "Name":  "Accounting Standards Codification",
        "Publisher":  "FASB",
        "Topic":  "606",
        "URI":  "http://asc.fasb.org/topic&trid=49130388"
        },
    "r29":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "1",
        "Publisher":  "FASB",
        "Section":  "S99",
        "SubTopic":  "10",
        "Subparagraph":  "(SX 210.5-02(32))",
        "Topic":  "210",
        "URI":  "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
        },
    "r290":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "1",
        "Publisher":  "FASB",
        "Section":  "50",
        "SubTopic":  "20",
        "Subparagraph":  "(d)(i)",
        "Topic":  "715",
        "URI":  "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
        },
    "r291":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "5",
        "Publisher":  "FASB",
        "Section":  "50",
        "SubTopic":  "80",
        "Subparagraph":  "(d)",
        "Topic":  "715",
        "URI":  "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
        },
    "r292":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "8",
        "Publisher":  "FASB",
        "Section":  "55",
        "SubTopic":  "80",
        "Topic":  "715",
        "URI":  "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
        },
    "r293":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "2",
        "Publisher":  "FASB",
        "Section":  "35",
        "SubTopic":  "10",
        "Topic":  "718",
        "URI":  "http://asc.fasb.org/extlink&oid=121326096&loc=d3e4534-113899"
        },
    "r294":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "1",
        "Publisher":  "FASB",
        "Section":  "50",
        "SubTopic":  "10",
        "Subparagraph":  "(a)",
        "Topic":  "718",
        "URI":  "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
        },
    "r295":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "1",
        "Publisher":  "FASB",
        "Section":  "50",
        "SubTopic":  "10",
        "Subparagraph":  "(b)",
        "Topic":  "718",
        "URI":  "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
        },
    "r296":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "1",
        "Publisher":  "FASB",
        "Section":  "50",
        "SubTopic":  "10",
        "Topic":  "718",
        "URI":  "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
        },
    "r297":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "2",
        "Publisher":  "FASB",
        "Section":  "50",
        "SubTopic":  "10",
        "Subparagraph":  "(a)(3)",
        "Topic":  "718",
        "URI":  "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
        },
    "r298":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "2",
        "Publisher":  "FASB",
        "Section":  "50",
        "SubTopic":  "10",
        "Subparagraph":  "(a),(g)",
        "Topic":  "718",
        "URI":  "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
        },
    "r299":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "2",
        "Publisher":  "FASB",
        "Section":  "50",
        "SubTopic":  "10",
        "Subparagraph":  "(c)",
        "Topic":  "718",
        "URI":  "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
        },
    "r3":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "1",
        "Publisher":  "FASB",
        "Section":  "45",
        "SubTopic":  "10",
        "Subparagraph":  "(b)",
        "Topic":  "210",
        "URI":  "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
        },
    "r30":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "1",
        "Publisher":  "FASB",
        "Section":  "S99",
        "SubTopic":  "10",
        "Subparagraph":  "(SX 210.5-02(4)",
        "Topic":  "210",
        "URI":  "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
        },
    "r300":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "2",
        "Publisher":  "FASB",
        "Section":  "50",
        "SubTopic":  "10",
        "Subparagraph":  "(c)(1)",
        "Topic":  "718",
        "URI":  "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
        },
    "r301":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "2",
        "Publisher":  "FASB",
        "Section":  "50",
        "SubTopic":  "10",
        "Subparagraph":  "(c)(1)(i)",
        "Topic":  "718",
        "URI":  "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
        },
    "r302":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "2",
        "Publisher":  "FASB",
        "Section":  "50",
        "SubTopic":  "10",
        "Subparagraph":  "(c)(1)(i)-(ii)",
        "Topic":  "718",
        "URI":  "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
        },
    "r303":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "2",
        "Publisher":  "FASB",
        "Section":  "50",
        "SubTopic":  "10",
        "Subparagraph":  "(c)(1)(iii)",
        "Topic":  "718",
        "URI":  "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
        },
    "r304":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "2",
        "Publisher":  "FASB",
        "Section":  "50",
        "SubTopic":  "10",
        "Subparagraph":  "(c)(1)(iv)(1)",
        "Topic":  "718",
        "URI":  "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
        },
    "r305":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "2",
        "Publisher":  "FASB",
        "Section":  "50",
        "SubTopic":  "10",
        "Subparagraph":  "(c)(1)(iv)(2)",
        "Topic":  "718",
        "URI":  "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
        },
    "r306":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "2",
        "Publisher":  "FASB",
        "Section":  "50",
        "SubTopic":  "10",
        "Subparagraph":  "(c)(1)(iv)(3)",
        "Topic":  "718",
        "URI":  "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
        },
    "r307":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "2",
        "Publisher":  "FASB",
        "Section":  "50",
        "SubTopic":  "10",
        "Subparagraph":  "(c)(1)(iv)(3)-(4)",
        "Topic":  "718",
        "URI":  "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
        },
    "r308":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "2",
        "Publisher":  "FASB",
        "Section":  "50",
        "SubTopic":  "10",
        "Subparagraph":  "(c)(2)",
        "Topic":  "718",
        "URI":  "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
        },
    "r309":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "2",
        "Publisher":  "FASB",
        "Section":  "50",
        "SubTopic":  "10",
        "Subparagraph":  "(c)(2)(i)-(ii)",
        "Topic":  "718",
        "URI":  "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
        },
    "r31":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "1",
        "Publisher":  "FASB",
        "Section":  "S99",
        "SubTopic":  "10",
        "Subparagraph":  "(SX 210.5-02(5))",
        "Topic":  "210",
        "URI":  "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
        },
    "r310":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "2",
        "Publisher":  "FASB",
        "Section":  "50",
        "SubTopic":  "10",
        "Subparagraph":  "(c)(2)(iii)(1)",
        "Topic":  "718",
        "URI":  "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
        },
    "r311":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "2",
        "Publisher":  "FASB",
        "Section":  "50",
        "SubTopic":  "10",
        "Subparagraph":  "(c)(2)(iii)(2)",
        "Topic":  "718",
        "URI":  "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
        },
    "r312":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "2",
        "Publisher":  "FASB",
        "Section":  "50",
        "SubTopic":  "10",
        "Subparagraph":  "(c)(2)(iii)(3)",
        "Topic":  "718",
        "URI":  "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
        },
    "r313":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "2",
        "Publisher":  "FASB",
        "Section":  "50",
        "SubTopic":  "10",
        "Subparagraph":  "(d)",
        "Topic":  "718",
        "URI":  "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
        },
    "r314":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "2",
        "Publisher":  "FASB",
        "Section":  "50",
        "SubTopic":  "10",
        "Subparagraph":  "(d)(1)",
        "Topic":  "718",
        "URI":  "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
        },
    "r315":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "2",
        "Publisher":  "FASB",
        "Section":  "50",
        "SubTopic":  "10",
        "Subparagraph":  "(d)(2)",
        "Topic":  "718",
        "URI":  "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
        },
    "r316":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "2",
        "Publisher":  "FASB",
        "Section":  "50",
        "SubTopic":  "10",
        "Subparagraph":  "(e)",
        "Topic":  "718",
        "URI":  "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
        },
    "r317":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "2",
        "Publisher":  "FASB",
        "Section":  "50",
        "SubTopic":  "10",
        "Subparagraph":  "(e)(1)",
        "Topic":  "718",
        "URI":  "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
        },
    "r318":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "2",
        "Publisher":  "FASB",
        "Section":  "50",
        "SubTopic":  "10",
        "Subparagraph":  "(f)(2)",
        "Topic":  "718",
        "URI":  "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
        },
    "r319":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "2",
        "Publisher":  "FASB",
        "Section":  "50",
        "SubTopic":  "10",
        "Subparagraph":  "(f)(2)(i)",
        "Topic":  "718",
        "URI":  "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
        },
    "r32":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "1",
        "Publisher":  "FASB",
        "Section":  "S99",
        "SubTopic":  "10",
        "Subparagraph":  "(SX 210.5-02(6)(a)(1))",
        "Topic":  "210",
        "URI":  "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
        },
    "r320":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "2",
        "Publisher":  "FASB",
        "Section":  "50",
        "SubTopic":  "10",
        "Subparagraph":  "(f)(2)(ii)",
        "Topic":  "718",
        "URI":  "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
        },
    "r321":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "2",
        "Publisher":  "FASB",
        "Section":  "50",
        "SubTopic":  "10",
        "Subparagraph":  "(f)(2)(iii)",
        "Topic":  "718",
        "URI":  "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
        },
    "r322":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "2",
        "Publisher":  "FASB",
        "Section":  "50",
        "SubTopic":  "10",
        "Subparagraph":  "(f)(2)(iv)",
        "Topic":  "718",
        "URI":  "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
        },
    "r323":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "2",
        "Publisher":  "FASB",
        "Section":  "50",
        "SubTopic":  "10",
        "Subparagraph":  "(g)",
        "Topic":  "718",
        "URI":  "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
        },
    "r324":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "2",
        "Publisher":  "FASB",
        "Section":  "50",
        "SubTopic":  "10",
        "Subparagraph":  "(h)(1)",
        "Topic":  "718",
        "URI":  "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
        },
    "r325":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "2",
        "Publisher":  "FASB",
        "Section":  "50",
        "SubTopic":  "10",
        "Subparagraph":  "(h)(1)(i)",
        "Topic":  "718",
        "URI":  "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
        },
    "r326":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "2",
        "Publisher":  "FASB",
        "Section":  "50",
        "SubTopic":  "10",
        "Subparagraph":  "(i)",
        "Topic":  "718",
        "URI":  "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
        },
    "r327":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "2",
        "Publisher":  "FASB",
        "Section":  "50",
        "SubTopic":  "10",
        "Topic":  "718",
        "URI":  "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
        },
    "r328":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "2A",
        "Publisher":  "FASB",
        "Section":  "50",
        "SubTopic":  "10",
        "Subparagraph":  "(a)",
        "Topic":  "718",
        "URI":  "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901"
        },
    "r329":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "15",
        "Publisher":  "FASB",
        "Section":  "65",
        "SubTopic":  "10",
        "Subparagraph":  "(a)",
        "Topic":  "718",
        "URI":  "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
        },
    "r33":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "1",
        "Publisher":  "FASB",
        "Section":  "S99",
        "SubTopic":  "10",
        "Subparagraph":  "(SX 210.5-02(6)(a))",
        "Topic":  "210",
        "URI":  "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
        },
    "r330":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "15",
        "Publisher":  "FASB",
        "Section":  "65",
        "SubTopic":  "10",
        "Subparagraph":  "(b)",
        "Topic":  "718",
        "URI":  "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
        },
    "r331":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "15",
        "Publisher":  "FASB",
        "Section":  "65",
        "SubTopic":  "10",
        "Subparagraph":  "(c)",
        "Topic":  "718",
        "URI":  "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
        },
    "r332":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "15",
        "Publisher":  "FASB",
        "Section":  "65",
        "SubTopic":  "10",
        "Subparagraph":  "(d)",
        "Topic":  "718",
        "URI":  "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
        },
    "r333":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "15",
        "Publisher":  "FASB",
        "Section":  "65",
        "SubTopic":  "10",
        "Subparagraph":  "(e)",
        "Topic":  "718",
        "URI":  "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
        },
    "r334":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "15",
        "Publisher":  "FASB",
        "Section":  "65",
        "SubTopic":  "10",
        "Subparagraph":  "(f)(1)",
        "Topic":  "718",
        "URI":  "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
        },
    "r335":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "15",
        "Publisher":  "FASB",
        "Section":  "65",
        "SubTopic":  "10",
        "Subparagraph":  "(f)(2)",
        "Topic":  "718",
        "URI":  "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
        },
    "r336":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "15",
        "Publisher":  "FASB",
        "Section":  "65",
        "SubTopic":  "10",
        "Subparagraph":  "(g)(2)",
        "Topic":  "718",
        "URI":  "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
        },
    "r337":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "1",
        "Publisher":  "FASB",
        "Section":  "S99",
        "SubTopic":  "10",
        "Subparagraph":  "(SAB Topic 14.D.2)",
        "Topic":  "718",
        "URI":  "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809"
        },
    "r338":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "1",
        "Publisher":  "FASB",
        "Section":  "S99",
        "SubTopic":  "10",
        "Subparagraph":  "(SAB Topic 14.F)",
        "Topic":  "718",
        "URI":  "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809"
        },
    "r339":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "12",
        "Publisher":  "FASB",
        "Section":  "55",
        "SubTopic":  "20",
        "Topic":  "718",
        "URI":  "http://asc.fasb.org/extlink&oid=120383193&loc=d3e11149-113907"
        },
    "r34":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "1",
        "Publisher":  "FASB",
        "Section":  "S99",
        "SubTopic":  "10",
        "Subparagraph":  "(SX 210.5-02(6)(b))",
        "Topic":  "210",
        "URI":  "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
        },
    "r340":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "13",
        "Publisher":  "FASB",
        "Section":  "55",
        "SubTopic":  "20",
        "Topic":  "718",
        "URI":  "http://asc.fasb.org/extlink&oid=120383193&loc=d3e11178-113907"
        },
    "r341":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "1",
        "Publisher":  "FASB",
        "Section":  "50",
        "SubTopic":  "10",
        "Topic":  "730",
        "URI":  "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
        },
    "r342":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "10",
        "Publisher":  "FASB",
        "Section":  "50",
        "SubTopic":  "10",
        "Topic":  "740",
        "URI":  "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32672-109319"
        },
    "r343":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "12",
        "Publisher":  "FASB",
        "Section":  "50",
        "SubTopic":  "10",
        "Topic":  "740",
        "URI":  "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32687-109319"
        },
    "r344":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "14",
        "Publisher":  "FASB",
        "Section":  "50",
        "SubTopic":  "10",
        "Topic":  "740",
        "URI":  "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32705-109319"
        },
    "r345":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "15A",
        "Publisher":  "FASB",
        "Section":  "50",
        "SubTopic":  "10",
        "Subparagraph":  "(a)",
        "Topic":  "740",
        "URI":  "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319"
        },
    "r346":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "17",
        "Publisher":  "FASB",
        "Section":  "50",
        "SubTopic":  "10",
        "Subparagraph":  "(b)",
        "Topic":  "740",
        "URI":  "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32809-109319"
        },
    "r347":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "21",
        "Publisher":  "FASB",
        "Section":  "50",
        "SubTopic":  "10",
        "Topic":  "740",
        "URI":  "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32857-109319"
        },
    "r348":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "6",
        "Publisher":  "FASB",
        "Section":  "50",
        "SubTopic":  "10",
        "Topic":  "740",
        "URI":  "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32621-109319"
        },
    "r349":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "8",
        "Publisher":  "FASB",
        "Section":  "50",
        "SubTopic":  "10",
        "Topic":  "740",
        "URI":  "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32632-109319"
        },
    "r35":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "1",
        "Publisher":  "FASB",
        "Section":  "S99",
        "SubTopic":  "10",
        "Subparagraph":  "(SX 210.5-02(6)(c))",
        "Topic":  "210",
        "URI":  "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
        },
    "r350":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "9",
        "Publisher":  "FASB",
        "Section":  "50",
        "SubTopic":  "10",
        "Subparagraph":  "(b)",
        "Topic":  "740",
        "URI":  "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319"
        },
    "r351":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "8",
        "Publisher":  "FASB",
        "Section":  "65",
        "SubTopic":  "10",
        "Subparagraph":  "(a)",
        "Topic":  "740"
        },
    "r352":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "8",
        "Publisher":  "FASB",
        "Section":  "65",
        "SubTopic":  "10",
        "Subparagraph":  "(b)",
        "Topic":  "740"
        },
    "r353":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "8",
        "Publisher":  "FASB",
        "Section":  "65",
        "SubTopic":  "10",
        "Subparagraph":  "(d)(2)",
        "Topic":  "740"
        },
    "r354":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "8",
        "Publisher":  "FASB",
        "Section":  "65",
        "SubTopic":  "10",
        "Subparagraph":  "(d)(3)",
        "Topic":  "740"
        },
    "r355":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "1",
        "Publisher":  "FASB",
        "Section":  "S99",
        "SubTopic":  "10",
        "Subparagraph":  "(SAB TOPIC 6.I.5.Q1)",
        "Topic":  "740",
        "URI":  "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
        },
    "r356":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "1",
        "Publisher":  "FASB",
        "Section":  "S99",
        "SubTopic":  "10",
        "Subparagraph":  "(SAB TOPIC 6.I.7)",
        "Topic":  "740",
        "URI":  "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
        },
    "r357":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "1",
        "Publisher":  "FASB",
        "Section":  "S99",
        "SubTopic":  "10",
        "Subparagraph":  "(SAB Topic 6.I.7)",
        "Topic":  "740",
        "URI":  "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
        },
    "r358":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "1",
        "Publisher":  "FASB",
        "Section":  "S99",
        "SubTopic":  "10",
        "Subparagraph":  "(SAB Topic 6.I.Fact.1)",
        "Topic":  "740",
        "URI":  "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
        },
    "r359":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "1",
        "Publisher":  "FASB",
        "Section":  "S99",
        "SubTopic":  "10",
        "Subparagraph":  "(SAB Topic 6.I.Fact.2)",
        "Topic":  "740",
        "URI":  "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
        },
    "r36":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "1",
        "Publisher":  "FASB",
        "Section":  "S99",
        "SubTopic":  "10",
        "Subparagraph":  "(SX 210.5-02(7))",
        "Topic":  "210",
        "URI":  "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
        },
    "r360":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "1",
        "Publisher":  "FASB",
        "Section":  "S99",
        "SubTopic":  "10",
        "Subparagraph":  "(SAB Topic 6.I.Fact.4)",
        "Topic":  "740",
        "URI":  "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
        },
    "r361":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "2",
        "Publisher":  "FASB",
        "Section":  "S99",
        "SubTopic":  "10",
        "Subparagraph":  "(SAB Topic 11.C)",
        "Topic":  "740",
        "URI":  "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330215-122817"
        },
    "r362":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "2",
        "Publisher":  "FASB",
        "Section":  "45",
        "SubTopic":  "20",
        "Subparagraph":  "(a)",
        "Topic":  "740",
        "URI":  "http://asc.fasb.org/extlink&oid=120385591&loc=d3e38679-109324"
        },
    "r363":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "1",
        "Publisher":  "FASB",
        "Section":  "50",
        "SubTopic":  "270",
        "Topic":  "740",
        "URI":  "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338"
        },
    "r364":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "2",
        "Publisher":  "FASB",
        "Section":  "50",
        "SubTopic":  "30",
        "Subparagraph":  "(a)",
        "Topic":  "740",
        "URI":  "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331"
        },
    "r365":  {
        "Name":  "Accounting Standards Codification",
        "Publisher":  "FASB",
        "Topic":  "740",
        "URI":  "http://asc.fasb.org/topic&trid=2144680"
        },
    "r366":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "19",
        "Publisher":  "FASB",
        "Section":  "45",
        "SubTopic":  "10",
        "Topic":  "810",
        "URI":  "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683"
        },
    "r367":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "25",
        "Publisher":  "FASB",
        "Section":  "45",
        "SubTopic":  "10",
        "Subparagraph":  "(a)",
        "Topic":  "810",
        "URI":  "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
        },
    "r368":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "25",
        "Publisher":  "FASB",
        "Section":  "45",
        "SubTopic":  "10",
        "Subparagraph":  "(b)",
        "Topic":  "810",
        "URI":  "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
        },
    "r369":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "1",
        "Publisher":  "FASB",
        "Section":  "50",
        "SubTopic":  "10",
        "Topic":  "810",
        "URI":  "http://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684"
        },
    "r37":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "1",
        "Publisher":  "FASB",
        "Section":  "S99",
        "SubTopic":  "10",
        "Subparagraph":  "(SX 210.5-02(8))",
        "Topic":  "210",
        "URI":  "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
        },
    "r370":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "1A",
        "Publisher":  "FASB",
        "Section":  "50",
        "SubTopic":  "10",
        "Subparagraph":  "(a)(1)",
        "Topic":  "810",
        "URI":  "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
        },
    "r371":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "1A",
        "Publisher":  "FASB",
        "Section":  "50",
        "SubTopic":  "10",
        "Subparagraph":  "(c)(1)",
        "Topic":  "810",
        "URI":  "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
        },
    "r372":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "1A",
        "Publisher":  "FASB",
        "Section":  "50",
        "SubTopic":  "10",
        "Subparagraph":  "(c),(3)",
        "Topic":  "810",
        "URI":  "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
        },
    "r373":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "3",
        "Publisher":  "FASB",
        "Section":  "50",
        "SubTopic":  "10",
        "Subparagraph":  "(bb)",
        "Topic":  "810",
        "URI":  "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685"
        },
    "r374":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "3",
        "Publisher":  "FASB",
        "Section":  "50",
        "SubTopic":  "10",
        "Subparagraph":  "(c)",
        "Topic":  "810",
        "URI":  "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685"
        },
    "r375":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "4J",
        "Publisher":  "FASB",
        "Section":  "55",
        "SubTopic":  "10",
        "Topic":  "810",
        "URI":  "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686"
        },
    "r376":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "4K",
        "Publisher":  "FASB",
        "Section":  "55",
        "SubTopic":  "10",
        "Topic":  "810",
        "URI":  "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686"
        },
    "r377":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "2",
        "Publisher":  "FASB",
        "Section":  "50",
        "SubTopic":  "10",
        "Subparagraph":  "(a)",
        "Topic":  "820",
        "URI":  "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
        },
    "r378":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "2",
        "Publisher":  "FASB",
        "Section":  "50",
        "SubTopic":  "10",
        "Subparagraph":  "(bbb)(2)",
        "Topic":  "820",
        "URI":  "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
        },
    "r379":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "2",
        "Publisher":  "FASB",
        "Section":  "50",
        "SubTopic":  "10",
        "Subparagraph":  "(c)",
        "Topic":  "820",
        "URI":  "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
        },
    "r38":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "1",
        "Publisher":  "FASB",
        "Section":  "S99",
        "SubTopic":  "10",
        "Subparagraph":  "(SX 210.5-02.1)",
        "Topic":  "210",
        "URI":  "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
        },
    "r380":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "3",
        "Publisher":  "FASB",
        "Section":  "50",
        "SubTopic":  "10",
        "Topic":  "820",
        "URI":  "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19279-110258"
        },
    "r381":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "1",
        "Publisher":  "FASB",
        "Section":  "60",
        "SubTopic":  "10",
        "Topic":  "820",
        "URI":  "http://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260"
        },
    "r382":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "1",
        "Publisher":  "FASB",
        "Section":  "50",
        "SubTopic":  "10",
        "Topic":  "825",
        "URI":  "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13279-108611"
        },
    "r383":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "10",
        "Publisher":  "FASB",
        "Section":  "50",
        "SubTopic":  "10",
        "Topic":  "825",
        "URI":  "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13433-108611"
        },
    "r384":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "20",
        "Publisher":  "FASB",
        "Section":  "50",
        "SubTopic":  "10",
        "Topic":  "825",
        "URI":  "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13531-108611"
        },
    "r385":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "21",
        "Publisher":  "FASB",
        "Section":  "50",
        "SubTopic":  "10",
        "Subparagraph":  "(a)",
        "Topic":  "825",
        "URI":  "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13537-108611"
        },
    "r386":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "21",
        "Publisher":  "FASB",
        "Section":  "50",
        "SubTopic":  "10",
        "Topic":  "825",
        "URI":  "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13537-108611"
        },
    "r387":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "28",
        "Publisher":  "FASB",
        "Section":  "50",
        "SubTopic":  "10",
        "Subparagraph":  "(f)",
        "Topic":  "825",
        "URI":  "http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612"
        },
    "r388":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "17",
        "Publisher":  "FASB",
        "Section":  "45",
        "SubTopic":  "10",
        "Topic":  "830",
        "URI":  "http://asc.fasb.org/extlink&oid=120253306&loc=d3e28228-110885"
        },
    "r389":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "1",
        "Publisher":  "FASB",
        "Section":  "35",
        "SubTopic":  "20",
        "Topic":  "830",
        "URI":  "http://asc.fasb.org/extlink&oid=121605123&loc=d3e30226-110892"
        },
    "r39":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "1",
        "Publisher":  "FASB",
        "Section":  "S99",
        "SubTopic":  "10",
        "Subparagraph":  "(SX 210.5-02.13)",
        "Topic":  "210",
        "URI":  "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
        },
    "r390":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "1",
        "Publisher":  "FASB",
        "Section":  "45",
        "SubTopic":  "20",
        "Topic":  "830",
        "URI":  "http://asc.fasb.org/extlink&oid=109240200&loc=d3e30690-110894"
        },
    "r391":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "1",
        "Publisher":  "FASB",
        "Section":  "50",
        "SubTopic":  "20",
        "Topic":  "830",
        "URI":  "http://asc.fasb.org/extlink&oid=6450222&loc=d3e30840-110895"
        },
    "r392":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "1",
        "Publisher":  "FASB",
        "Section":  "45",
        "SubTopic":  "230",
        "Topic":  "830",
        "URI":  "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906"
        },
    "r393":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "17",
        "Publisher":  "FASB",
        "Section":  "45",
        "SubTopic":  "30",
        "Topic":  "830",
        "URI":  "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
        },
    "r394":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "20",
        "Publisher":  "FASB",
        "Section":  "45",
        "SubTopic":  "30",
        "Subparagraph":  "(a)",
        "Topic":  "830",
        "URI":  "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
        },
    "r395":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "20",
        "Publisher":  "FASB",
        "Section":  "45",
        "SubTopic":  "30",
        "Subparagraph":  "(b)",
        "Topic":  "830",
        "URI":  "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
        },
    "r396":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "20",
        "Publisher":  "FASB",
        "Section":  "45",
        "SubTopic":  "30",
        "Subparagraph":  "(c)",
        "Topic":  "830",
        "URI":  "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
        },
    "r397":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "20",
        "Publisher":  "FASB",
        "Section":  "45",
        "SubTopic":  "30",
        "Subparagraph":  "(d)",
        "Topic":  "830",
        "URI":  "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
        },
    "r398":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "1",
        "Publisher":  "FASB",
        "Section":  "50",
        "SubTopic":  "30",
        "Topic":  "830",
        "URI":  "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
        },
    "r399":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "2",
        "Publisher":  "FASB",
        "Section":  "50",
        "SubTopic":  "30",
        "Topic":  "830",
        "URI":  "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901"
        },
    "r4":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "1",
        "Publisher":  "FASB",
        "Section":  "45",
        "SubTopic":  "10",
        "Subparagraph":  "(c)",
        "Topic":  "210",
        "URI":  "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
        },
    "r40":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "1",
        "Publisher":  "FASB",
        "Section":  "S99",
        "SubTopic":  "10",
        "Subparagraph":  "(SX 210.5-02.14)",
        "Topic":  "210",
        "URI":  "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
        },
    "r400":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "1A",
        "Publisher":  "FASB",
        "Section":  "45",
        "SubTopic":  "30",
        "Topic":  "835",
        "URI":  "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28541-108399"
        },
    "r401":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "2",
        "Publisher":  "FASB",
        "Section":  "45",
        "SubTopic":  "30",
        "Topic":  "835",
        "URI":  "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28551-108399"
        },
    "r402":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "3",
        "Publisher":  "FASB",
        "Section":  "45",
        "SubTopic":  "30",
        "Topic":  "835",
        "URI":  "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28555-108399"
        },
    "r403":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "8",
        "Publisher":  "FASB",
        "Section":  "55",
        "SubTopic":  "30",
        "Topic":  "835",
        "URI":  "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400"
        },
    "r404":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "40",
        "Publisher":  "FASB",
        "Section":  "55",
        "SubTopic":  "10",
        "Subparagraph":  "(Note 3)",
        "Topic":  "840",
        "URI":  "http://asc.fasb.org/extlink&oid=121580752&loc=d3e38371-112697"
        },
    "r405":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "2",
        "Publisher":  "FASB",
        "Section":  "50",
        "SubTopic":  "20",
        "Subparagraph":  "(a)",
        "Topic":  "840",
        "URI":  "http://asc.fasb.org/extlink&oid=121573735&loc=d3e41502-112717"
        },
    "r406":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "2",
        "Publisher":  "FASB",
        "Section":  "50",
        "SubTopic":  "20",
        "Topic":  "840",
        "URI":  "http://asc.fasb.org/extlink&oid=121573735&loc=d3e41502-112717"
        },
    "r407":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "1",
        "Publisher":  "FASB",
        "Section":  "65",
        "SubTopic":  "10",
        "Topic":  "842",
        "URI":  "http://asc.fasb.org/extlink&oid=121329987&loc=SL77916155-209984"
        },
    "r408":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "1",
        "Publisher":  "FASB",
        "Section":  "45",
        "SubTopic":  "20",
        "Subparagraph":  "(a)",
        "Topic":  "842",
        "URI":  "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977"
        },
    "r409":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "1",
        "Publisher":  "FASB",
        "Section":  "45",
        "SubTopic":  "20",
        "Subparagraph":  "(b)",
        "Topic":  "842",
        "URI":  "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977"
        },
    "r41":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "1",
        "Publisher":  "FASB",
        "Section":  "S99",
        "SubTopic":  "10",
        "Subparagraph":  "(SX 210.5-02.17)",
        "Topic":  "210",
        "URI":  "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
        },
    "r410":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "2",
        "Publisher":  "FASB",
        "Section":  "45",
        "SubTopic":  "20",
        "Topic":  "842",
        "URI":  "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918631-209977"
        },
    "r411":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "5",
        "Publisher":  "FASB",
        "Section":  "45",
        "SubTopic":  "20",
        "Subparagraph":  "(c)",
        "Topic":  "842",
        "URI":  "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918643-209977"
        },
    "r412":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "3",
        "Publisher":  "FASB",
        "Section":  "50",
        "SubTopic":  "20",
        "Subparagraph":  "(a)(3)",
        "Topic":  "842",
        "URI":  "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918673-209980"
        },
    "r413":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "3",
        "Publisher":  "FASB",
        "Section":  "50",
        "SubTopic":  "20",
        "Subparagraph":  "(b)",
        "Topic":  "842",
        "URI":  "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918673-209980"
        },
    "r414":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "3",
        "Publisher":  "FASB",
        "Section":  "50",
        "SubTopic":  "20",
        "Subparagraph":  "(c)(3)",
        "Topic":  "842",
        "URI":  "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918673-209980"
        },
    "r415":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "3",
        "Publisher":  "FASB",
        "Section":  "50",
        "SubTopic":  "20",
        "Topic":  "842",
        "URI":  "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918673-209980"
        },
    "r416":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "4",
        "Publisher":  "FASB",
        "Section":  "50",
        "SubTopic":  "20",
        "Subparagraph":  "(g)(1)",
        "Topic":  "842",
        "URI":  "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
        },
    "r417":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "4",
        "Publisher":  "FASB",
        "Section":  "50",
        "SubTopic":  "20",
        "Subparagraph":  "(g)(2)",
        "Topic":  "842",
        "URI":  "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
        },
    "r418":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "4",
        "Publisher":  "FASB",
        "Section":  "50",
        "SubTopic":  "20",
        "Subparagraph":  "(g)(4)",
        "Topic":  "842",
        "URI":  "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
        },
    "r419":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "6",
        "Publisher":  "FASB",
        "Section":  "50",
        "SubTopic":  "20",
        "Topic":  "842",
        "URI":  "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918701-209980"
        },
    "r42":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "1",
        "Publisher":  "FASB",
        "Section":  "S99",
        "SubTopic":  "10",
        "Subparagraph":  "(SX 210.5-02.19(a))",
        "Topic":  "210",
        "URI":  "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
        },
    "r420":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "53",
        "Publisher":  "FASB",
        "Section":  "55",
        "SubTopic":  "20",
        "Topic":  "842",
        "URI":  "http://asc.fasb.org/extlink&oid=121568110&loc=SL77918982-209971"
        },
    "r421":  {
        "Name":  "Accounting Standards Codification",
        "Publisher":  "FASB",
        "SubTopic":  "20",
        "Topic":  "842",
        "URI":  "http://asc.fasb.org/subtopic&trid=77888251"
        },
    "r422":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "2",
        "Publisher":  "FASB",
        "Section":  "50",
        "SubTopic":  "10",
        "Subparagraph":  "(a)",
        "Topic":  "855",
        "URI":  "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
        },
    "r423":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "2",
        "Publisher":  "FASB",
        "Section":  "50",
        "SubTopic":  "10",
        "Topic":  "855",
        "URI":  "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
        },
    "r424":  {
        "Name":  "Accounting Standards Codification",
        "Publisher":  "FASB",
        "Topic":  "855",
        "URI":  "http://asc.fasb.org/topic&trid=2122774"
        },
    "r425":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "3",
        "Publisher":  "FASB",
        "Section":  "50",
        "SubTopic":  "20",
        "Subparagraph":  "(c)(1)",
        "Topic":  "860",
        "URI":  "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
        },
    "r426":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "3",
        "Publisher":  "FASB",
        "Section":  "50",
        "SubTopic":  "20",
        "Subparagraph":  "(c)(2)",
        "Topic":  "860",
        "URI":  "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
        },
    "r427":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "3",
        "Publisher":  "FASB",
        "Section":  "50",
        "SubTopic":  "20",
        "Subparagraph":  "(c)(3)",
        "Topic":  "860",
        "URI":  "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
        },
    "r428":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "4",
        "Publisher":  "FASB",
        "Section":  "50",
        "SubTopic":  "20",
        "Subparagraph":  "(b)(1)",
        "Topic":  "860",
        "URI":  "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
        },
    "r429":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "4",
        "Publisher":  "FASB",
        "Section":  "50",
        "SubTopic":  "20",
        "Subparagraph":  "(b)(2)",
        "Topic":  "860",
        "URI":  "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
        },
    "r43":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "1",
        "Publisher":  "FASB",
        "Section":  "S99",
        "SubTopic":  "10",
        "Subparagraph":  "(SX 210.5-02.19(a),20,24)",
        "Topic":  "210",
        "URI":  "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
        },
    "r430":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "4",
        "Publisher":  "FASB",
        "Section":  "50",
        "SubTopic":  "20",
        "Subparagraph":  "(b)(3)",
        "Topic":  "860",
        "URI":  "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
        },
    "r431":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "6",
        "Publisher":  "FASB",
        "Section":  "50",
        "SubTopic":  "10",
        "Subparagraph":  "(b)",
        "Topic":  "910",
        "URI":  "http://asc.fasb.org/extlink&oid=119991564&loc=SL119991595-234733"
        },
    "r432":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "1",
        "Publisher":  "FASB",
        "Section":  "S99",
        "SubTopic":  "10",
        "Subparagraph":  "(SAB Topic 11.L)",
        "Topic":  "924",
        "URI":  "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
        },
    "r433":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "2",
        "Publisher":  "FASB",
        "Section":  "65",
        "SubTopic":  "20",
        "Subparagraph":  "(a)",
        "Topic":  "926",
        "URI":  "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
        },
    "r434":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "2",
        "Publisher":  "FASB",
        "Section":  "65",
        "SubTopic":  "20",
        "Subparagraph":  "(b)",
        "Topic":  "926",
        "URI":  "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
        },
    "r435":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "2",
        "Publisher":  "FASB",
        "Section":  "65",
        "SubTopic":  "20",
        "Subparagraph":  "(c)",
        "Topic":  "926",
        "URI":  "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
        },
    "r436":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "1",
        "Publisher":  "FASB",
        "Section":  "25",
        "SubTopic":  "20",
        "Topic":  "940",
        "URI":  "http://asc.fasb.org/extlink&oid=68072869&loc=d3e41242-110953"
        },
    "r437":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "1",
        "Publisher":  "FASB",
        "Section":  "S99",
        "SubTopic":  "210",
        "Subparagraph":  "(SX 210.9-03(10)(1))",
        "Topic":  "942",
        "URI":  "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
        },
    "r438":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "1",
        "Publisher":  "FASB",
        "Section":  "S99",
        "SubTopic":  "210",
        "Subparagraph":  "(SX 210.9-03(11))",
        "Topic":  "942",
        "URI":  "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
        },
    "r439":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "1",
        "Publisher":  "FASB",
        "Section":  "S99",
        "SubTopic":  "210",
        "Subparagraph":  "(SX 210.9-03(13))",
        "Topic":  "942",
        "URI":  "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
        },
    "r44":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "1",
        "Publisher":  "FASB",
        "Section":  "S99",
        "SubTopic":  "10",
        "Subparagraph":  "(SX 210.5-02.19(b),22(b))",
        "Topic":  "210",
        "URI":  "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
        },
    "r440":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "1",
        "Publisher":  "FASB",
        "Section":  "S99",
        "SubTopic":  "210",
        "Subparagraph":  "(SX 210.9-03(16))",
        "Topic":  "942",
        "URI":  "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
        },
    "r441":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "1",
        "Publisher":  "FASB",
        "Section":  "S99",
        "SubTopic":  "210",
        "Subparagraph":  "(SX 210.9-03(23))",
        "Topic":  "942",
        "URI":  "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
        },
    "r442":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "1",
        "Publisher":  "FASB",
        "Section":  "S99",
        "SubTopic":  "210",
        "Subparagraph":  "(SX 210.9-03.15(5))",
        "Topic":  "942",
        "URI":  "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
        },
    "r443":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "1",
        "Publisher":  "FASB",
        "Section":  "S99",
        "SubTopic":  "210",
        "Subparagraph":  "(SX 210.9-03.17)",
        "Topic":  "942",
        "URI":  "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
        },
    "r444":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "1",
        "Publisher":  "FASB",
        "Section":  "S99",
        "SubTopic":  "220",
        "Subparagraph":  "(SX 210.9-04(15))",
        "Topic":  "942",
        "URI":  "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
        },
    "r445":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "1",
        "Publisher":  "FASB",
        "Section":  "S99",
        "SubTopic":  "220",
        "Subparagraph":  "(SX 210.9-04(22))",
        "Topic":  "942",
        "URI":  "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
        },
    "r446":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "1",
        "Publisher":  "FASB",
        "Section":  "S99",
        "SubTopic":  "220",
        "Subparagraph":  "(SX 210.9-04(26))",
        "Topic":  "942",
        "URI":  "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
        },
    "r447":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "1",
        "Publisher":  "FASB",
        "Section":  "S99",
        "SubTopic":  "220",
        "Subparagraph":  "(SX 210.9-04(27))",
        "Topic":  "942",
        "URI":  "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
        },
    "r448":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "1",
        "Publisher":  "FASB",
        "Section":  "S99",
        "SubTopic":  "235",
        "Subparagraph":  "(SX 210.9-05(b)(2))",
        "Topic":  "942",
        "URI":  "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
        },
    "r449":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "3",
        "Publisher":  "FASB",
        "Section":  "50",
        "SubTopic":  "470",
        "Subparagraph":  "(c)",
        "Topic":  "942",
        "URI":  "http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823"
        },
    "r45":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "1",
        "Publisher":  "FASB",
        "Section":  "S99",
        "SubTopic":  "10",
        "Subparagraph":  "(SX 210.5-02.19,20)",
        "Topic":  "210",
        "URI":  "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
        },
    "r450":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "3",
        "Publisher":  "FASB",
        "Section":  "50",
        "SubTopic":  "470",
        "Subparagraph":  "(g)",
        "Topic":  "942",
        "URI":  "http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823"
        },
    "r451":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "3",
        "Publisher":  "FASB",
        "Section":  "50",
        "SubTopic":  "470",
        "Subparagraph":  "e",
        "Topic":  "942",
        "URI":  "http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823"
        },
    "r452":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "3",
        "Publisher":  "FASB",
        "Section":  "50",
        "SubTopic":  "470",
        "Topic":  "942",
        "URI":  "http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823"
        },
    "r453":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "1",
        "Publisher":  "FASB",
        "Section":  "50",
        "SubTopic":  "825",
        "Topic":  "942",
        "URI":  "http://asc.fasb.org/extlink&oid=108315417&loc=d3e61044-112788"
        },
    "r454":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "1",
        "Publisher":  "FASB",
        "Section":  "S99",
        "SubTopic":  "210",
        "Subparagraph":  "(SX 210.7-03(16))",
        "Topic":  "944",
        "URI":  "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
        },
    "r455":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "1",
        "Publisher":  "FASB",
        "Section":  "S99",
        "SubTopic":  "210",
        "Subparagraph":  "(SX 210.7-03(a)(12))",
        "Topic":  "944",
        "URI":  "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
        },
    "r456":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "1",
        "Publisher":  "FASB",
        "Section":  "S99",
        "SubTopic":  "210",
        "Subparagraph":  "(SX 210.7-03(a)(16)(a)(2))",
        "Topic":  "944",
        "URI":  "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
        },
    "r457":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "1",
        "Publisher":  "FASB",
        "Section":  "S99",
        "SubTopic":  "210",
        "Subparagraph":  "(SX 210.7-03(a)(16))",
        "Topic":  "944",
        "URI":  "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
        },
    "r458":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "1",
        "Publisher":  "FASB",
        "Section":  "S99",
        "SubTopic":  "210",
        "Subparagraph":  "(SX 210.7-03(a)(23)(a)(3))",
        "Topic":  "944",
        "URI":  "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
        },
    "r459":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "1",
        "Publisher":  "FASB",
        "Section":  "S99",
        "SubTopic":  "210",
        "Subparagraph":  "(SX 210.7-03(a)(23)(a)(4))",
        "Topic":  "944",
        "URI":  "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
        },
    "r46":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "1",
        "Publisher":  "FASB",
        "Section":  "S99",
        "SubTopic":  "10",
        "Subparagraph":  "(SX 210.5-02.19-26)",
        "Topic":  "210",
        "URI":  "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
        },
    "r460":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "1",
        "Publisher":  "FASB",
        "Section":  "S99",
        "SubTopic":  "210",
        "Subparagraph":  "(SX 210.7-03(a)(25))",
        "Topic":  "944",
        "URI":  "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
        },
    "r461":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "1",
        "Publisher":  "FASB",
        "Section":  "S99",
        "SubTopic":  "210",
        "Subparagraph":  "(SX 210.7-03(a)(8))",
        "Topic":  "944",
        "URI":  "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
        },
    "r462":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "1",
        "Publisher":  "FASB",
        "Section":  "S99",
        "SubTopic":  "210",
        "Subparagraph":  "(SX 210.7-03.(a),19)",
        "Topic":  "944",
        "URI":  "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
        },
    "r463":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "1",
        "Publisher":  "FASB",
        "Section":  "S99",
        "SubTopic":  "220",
        "Subparagraph":  "(SX 210.7-04(18))",
        "Topic":  "944",
        "URI":  "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
        },
    "r464":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "1",
        "Publisher":  "FASB",
        "Section":  "S99",
        "SubTopic":  "220",
        "Subparagraph":  "(SX 210.7-04(22))",
        "Topic":  "944",
        "URI":  "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
        },
    "r465":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "1",
        "Publisher":  "FASB",
        "Section":  "S99",
        "SubTopic":  "220",
        "Subparagraph":  "(SX 210.7-04(23))",
        "Topic":  "944",
        "URI":  "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
        },
    "r466":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "1",
        "Publisher":  "FASB",
        "Section":  "S99",
        "SubTopic":  "220",
        "Subparagraph":  "(SX 210.7-04(8))",
        "Topic":  "944",
        "URI":  "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
        },
    "r467":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "1",
        "Publisher":  "FASB",
        "Section":  "S99",
        "SubTopic":  "220",
        "Subparagraph":  "(SX 210.7-04(9))",
        "Topic":  "944",
        "URI":  "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
        },
    "r468":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "1",
        "Publisher":  "FASB",
        "Section":  "S99",
        "SubTopic":  "220",
        "Subparagraph":  "(SX 210.7-04.7)",
        "Topic":  "944",
        "URI":  "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
        },
    "r469":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "4H",
        "Publisher":  "FASB",
        "Section":  "50",
        "SubTopic":  "40",
        "Topic":  "944",
        "URI":  "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
        },
    "r47":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "1",
        "Publisher":  "FASB",
        "Section":  "S99",
        "SubTopic":  "10",
        "Subparagraph":  "(SX 210.5-02.20)",
        "Topic":  "210",
        "URI":  "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
        },
    "r470":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "7A",
        "Publisher":  "FASB",
        "Section":  "50",
        "SubTopic":  "40",
        "Subparagraph":  "(d)",
        "Topic":  "944",
        "URI":  "http://asc.fasb.org/extlink&oid=121643868&loc=SL117782755-158439"
        },
    "r471":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "13H",
        "Publisher":  "FASB",
        "Section":  "55",
        "SubTopic":  "40",
        "Subparagraph":  "(a)",
        "Topic":  "944",
        "URI":  "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441"
        },
    "r472":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "13H",
        "Publisher":  "FASB",
        "Section":  "55",
        "SubTopic":  "40",
        "Subparagraph":  "(b)",
        "Topic":  "944",
        "URI":  "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441"
        },
    "r473":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "29F",
        "Publisher":  "FASB",
        "Section":  "55",
        "SubTopic":  "40",
        "Topic":  "944",
        "URI":  "http://asc.fasb.org/extlink&oid=121639165&loc=SL117819544-158441"
        },
    "r474":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "2",
        "Publisher":  "FASB",
        "Section":  "65",
        "SubTopic":  "40",
        "Subparagraph":  "(a)",
        "Topic":  "944",
        "URI":  "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
        },
    "r475":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "2",
        "Publisher":  "FASB",
        "Section":  "65",
        "SubTopic":  "40",
        "Subparagraph":  "(b)",
        "Topic":  "944",
        "URI":  "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
        },
    "r476":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "2",
        "Publisher":  "FASB",
        "Section":  "65",
        "SubTopic":  "40",
        "Subparagraph":  "(e)",
        "Topic":  "944",
        "URI":  "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
        },
    "r477":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "2",
        "Publisher":  "FASB",
        "Section":  "65",
        "SubTopic":  "40",
        "Subparagraph":  "(f)(1)",
        "Topic":  "944",
        "URI":  "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
        },
    "r478":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "2",
        "Publisher":  "FASB",
        "Section":  "65",
        "SubTopic":  "40",
        "Subparagraph":  "(f)(2)",
        "Topic":  "944",
        "URI":  "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
        },
    "r479":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "2",
        "Publisher":  "FASB",
        "Section":  "65",
        "SubTopic":  "40",
        "Subparagraph":  "(g)(1)",
        "Topic":  "944",
        "URI":  "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
        },
    "r48":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "1",
        "Publisher":  "FASB",
        "Section":  "S99",
        "SubTopic":  "10",
        "Subparagraph":  "(SX 210.5-02.21)",
        "Topic":  "210",
        "URI":  "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
        },
    "r480":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "2",
        "Publisher":  "FASB",
        "Section":  "65",
        "SubTopic":  "40",
        "Subparagraph":  "(g)(2)(i)",
        "Topic":  "944",
        "URI":  "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
        },
    "r481":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "2",
        "Publisher":  "FASB",
        "Section":  "65",
        "SubTopic":  "40",
        "Subparagraph":  "(g)(2)(ii)",
        "Topic":  "944",
        "URI":  "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
        },
    "r482":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "2",
        "Publisher":  "FASB",
        "Section":  "65",
        "SubTopic":  "40",
        "Subparagraph":  "(g)(2)(iii)",
        "Topic":  "944",
        "URI":  "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
        },
    "r483":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "2",
        "Publisher":  "FASB",
        "Section":  "65",
        "SubTopic":  "40",
        "Subparagraph":  "(g)(2)(iv)",
        "Topic":  "944",
        "URI":  "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
        },
    "r484":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "2",
        "Publisher":  "FASB",
        "Section":  "65",
        "SubTopic":  "40",
        "Subparagraph":  "(h)(1)",
        "Topic":  "944",
        "URI":  "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
        },
    "r485":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "2",
        "Publisher":  "FASB",
        "Section":  "65",
        "SubTopic":  "40",
        "Subparagraph":  "(h)(2)",
        "Topic":  "944",
        "URI":  "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
        },
    "r486":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "1B",
        "Publisher":  "FASB",
        "Section":  "50",
        "SubTopic":  "825",
        "Topic":  "944",
        "URI":  "http://asc.fasb.org/extlink&oid=99380617&loc=SL75241803-196195"
        },
    "r487":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "1",
        "Publisher":  "FASB",
        "Section":  "S99",
        "SubTopic":  "310",
        "Subparagraph":  "(SX 210.12-29(Footnote 4))",
        "Topic":  "948",
        "URI":  "http://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014"
        },
    "r488":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "1",
        "Publisher":  "FASB",
        "Section":  "50",
        "SubTopic":  "360",
        "Subparagraph":  "(d)",
        "Topic":  "958",
        "URI":  "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916"
        },
    "r489":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "6",
        "Publisher":  "FASB",
        "Section":  "50",
        "SubTopic":  "360",
        "Topic":  "958",
        "URI":  "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916"
        },
    "r49":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "1",
        "Publisher":  "FASB",
        "Section":  "S99",
        "SubTopic":  "10",
        "Subparagraph":  "(SX 210.5-02.22(a)(1))",
        "Topic":  "210",
        "URI":  "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
        },
    "r490":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "7",
        "Publisher":  "FASB",
        "Section":  "50",
        "SubTopic":  "360",
        "Topic":  "958",
        "URI":  "http://asc.fasb.org/extlink&oid=120429125&loc=SL120174063-112916"
        },
    "r491":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "1",
        "Publisher":  "FASB",
        "Section":  "S99",
        "SubTopic":  "360",
        "Subparagraph":  "(SX 210.12-28(Column B))",
        "Topic":  "970",
        "URI":  "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
        },
    "r492":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "1",
        "Publisher":  "FASB",
        "Section":  "S99",
        "SubTopic":  "360",
        "Subparagraph":  "(SX 210.12-28(Column C))",
        "Topic":  "970",
        "URI":  "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
        },
    "r493":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "1",
        "Publisher":  "FASB",
        "Section":  "S99",
        "SubTopic":  "360",
        "Subparagraph":  "(SX 210.12-28(Column D))",
        "Topic":  "970",
        "URI":  "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
        },
    "r494":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "1",
        "Publisher":  "FASB",
        "Section":  "S99",
        "SubTopic":  "360",
        "Subparagraph":  "(SX 210.12-28(Column E))",
        "Topic":  "970",
        "URI":  "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
        },
    "r495":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "1",
        "Publisher":  "FASB",
        "Section":  "S99",
        "SubTopic":  "360",
        "Subparagraph":  "(SX 210.12-28(Column F))",
        "Topic":  "970",
        "URI":  "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
        },
    "r496":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "1",
        "Publisher":  "FASB",
        "Section":  "S99",
        "SubTopic":  "360",
        "Subparagraph":  "(SX 210.12-28(Column G))",
        "Topic":  "970",
        "URI":  "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
        },
    "r497":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "1",
        "Publisher":  "FASB",
        "Section":  "S99",
        "SubTopic":  "360",
        "Subparagraph":  "(SX 210.12-28(Column H))",
        "Topic":  "970",
        "URI":  "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
        },
    "r498":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "1",
        "Publisher":  "FASB",
        "Section":  "S99",
        "SubTopic":  "360",
        "Subparagraph":  "(SX 210.12-28(Column I))",
        "Topic":  "970",
        "URI":  "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
        },
    "r499":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "1",
        "Publisher":  "FASB",
        "Section":  "S99",
        "SubTopic":  "360",
        "Subparagraph":  "(SX 210.12-28(Footnote 2))",
        "Topic":  "970",
        "URI":  "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
        },
    "r5":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "1",
        "Publisher":  "FASB",
        "Section":  "45",
        "SubTopic":  "10",
        "Topic":  "210",
        "URI":  "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
        },
    "r50":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "1",
        "Publisher":  "FASB",
        "Section":  "S99",
        "SubTopic":  "10",
        "Subparagraph":  "(SX 210.5-02.22(a)(2))",
        "Topic":  "210",
        "URI":  "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
        },
    "r500":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "1",
        "Publisher":  "FASB",
        "Section":  "50",
        "SubTopic":  "20",
        "Topic":  "985",
        "URI":  "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
        },
    "r501":  {
        "Name":  "Exchange Act",
        "Number":  "240",
        "Publisher":  "SEC",
        "Section":  "12",
        "Subsection":  "b"
        },
    "r502":  {
        "Name":  "Exchange Act",
        "Number":  "240",
        "Publisher":  "SEC",
        "Section":  "12",
        "Subsection":  "d1-1"
        },
    "r503":  {
        "Name":  "Form 10-Q",
        "Number":  "240",
        "Publisher":  "SEC",
        "Section":  "308",
        "Subsection":  "a"
        },
    "r504":  {
        "Name":  "Forms 10-K, 10-Q, 20-F",
        "Number":  "240",
        "Publisher":  "SEC",
        "Section":  "13",
        "Subsection":  "a-1"
        },
    "r505":  {
        "Name":  "Regulation 12B",
        "Number":  "240",
        "Publisher":  "SEC",
        "Section":  "12",
        "Subsection":  "b-2"
        },
    "r506":  {
        "Name":  "Regulation S-T",
        "Number":  "232",
        "Publisher":  "SEC",
        "Section":  "405"
        },
    "r51":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "1",
        "Publisher":  "FASB",
        "Section":  "S99",
        "SubTopic":  "10",
        "Subparagraph":  "(SX 210.5-02.22(a)(3))",
        "Topic":  "210",
        "URI":  "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
        },
    "r52":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "1",
        "Publisher":  "FASB",
        "Section":  "S99",
        "SubTopic":  "10",
        "Subparagraph":  "(SX 210.5-02.22(a))",
        "Topic":  "210",
        "URI":  "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
        },
    "r53":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "1",
        "Publisher":  "FASB",
        "Section":  "S99",
        "SubTopic":  "10",
        "Subparagraph":  "(SX 210.5-02.22(b))",
        "Topic":  "210",
        "URI":  "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
        },
    "r54":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "1",
        "Publisher":  "FASB",
        "Section":  "S99",
        "SubTopic":  "10",
        "Subparagraph":  "(SX 210.5-02.22)",
        "Topic":  "210",
        "URI":  "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
        },
    "r55":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "1",
        "Publisher":  "FASB",
        "Section":  "S99",
        "SubTopic":  "10",
        "Subparagraph":  "(SX 210.5-02.24)",
        "Topic":  "210",
        "URI":  "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
        },
    "r56":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "1",
        "Publisher":  "FASB",
        "Section":  "S99",
        "SubTopic":  "10",
        "Subparagraph":  "(SX 210.5-02.25)",
        "Topic":  "210",
        "URI":  "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
        },
    "r57":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "1",
        "Publisher":  "FASB",
        "Section":  "S99",
        "SubTopic":  "10",
        "Subparagraph":  "(SX 210.5-02.29-30)",
        "Topic":  "210",
        "URI":  "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
        },
    "r58":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "1",
        "Publisher":  "FASB",
        "Section":  "S99",
        "SubTopic":  "10",
        "Subparagraph":  "(SX 210.5-02.29-31)",
        "Topic":  "210",
        "URI":  "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
        },
    "r59":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "1",
        "Publisher":  "FASB",
        "Section":  "S99",
        "SubTopic":  "10",
        "Subparagraph":  "(SX 210.5-02.6(a)(3))",
        "Topic":  "210",
        "URI":  "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
        },
    "r6":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "3",
        "Publisher":  "FASB",
        "Section":  "45",
        "SubTopic":  "10",
        "Topic":  "210",
        "URI":  "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6801-107765"
        },
    "r60":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "1",
        "Publisher":  "FASB",
        "Section":  "S99",
        "SubTopic":  "10",
        "Subparagraph":  "(SX 210.5-02.6(a)(4))",
        "Topic":  "210",
        "URI":  "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
        },
    "r61":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "1",
        "Publisher":  "FASB",
        "Section":  "S99",
        "SubTopic":  "10",
        "Subparagraph":  "(SX 210.5-02.6(a))",
        "Topic":  "210",
        "URI":  "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
        },
    "r62":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "1",
        "Publisher":  "FASB",
        "Section":  "S99",
        "SubTopic":  "10",
        "Subparagraph":  "(SX 210.5-02.9)",
        "Topic":  "210",
        "URI":  "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
        },
    "r63":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "10A",
        "Publisher":  "FASB",
        "Section":  "45",
        "SubTopic":  "10",
        "Subparagraph":  "(a)",
        "Topic":  "220",
        "URI":  "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
        },
    "r64":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "10A",
        "Publisher":  "FASB",
        "Section":  "45",
        "SubTopic":  "10",
        "Topic":  "220",
        "URI":  "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
        },
    "r65":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "11",
        "Publisher":  "FASB",
        "Section":  "45",
        "SubTopic":  "10",
        "Topic":  "220",
        "URI":  "http://asc.fasb.org/extlink&oid=121641772&loc=d3e637-108580"
        },
    "r66":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "14",
        "Publisher":  "FASB",
        "Section":  "45",
        "SubTopic":  "10",
        "Topic":  "220",
        "URI":  "http://asc.fasb.org/extlink&oid=121641772&loc=d3e681-108580"
        },
    "r67":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "14A",
        "Publisher":  "FASB",
        "Section":  "45",
        "SubTopic":  "10",
        "Topic":  "220",
        "URI":  "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669686-108580"
        },
    "r68":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "17B",
        "Publisher":  "FASB",
        "Section":  "45",
        "SubTopic":  "10",
        "Topic":  "220",
        "URI":  "http://asc.fasb.org/extlink&oid=121641772&loc=SL34724394-108580"
        },
    "r69":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "1A",
        "Publisher":  "FASB",
        "Section":  "45",
        "SubTopic":  "10",
        "Subparagraph":  "(a)",
        "Topic":  "220",
        "URI":  "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580"
        },
    "r7":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "4",
        "Publisher":  "FASB",
        "Section":  "45",
        "SubTopic":  "10",
        "Subparagraph":  "(e)",
        "Topic":  "210",
        "URI":  "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6812-107765"
        },
    "r70":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "1A",
        "Publisher":  "FASB",
        "Section":  "45",
        "SubTopic":  "10",
        "Subparagraph":  "(c)",
        "Topic":  "220",
        "URI":  "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580"
        },
    "r71":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "1B",
        "Publisher":  "FASB",
        "Section":  "45",
        "SubTopic":  "10",
        "Subparagraph":  "(a)",
        "Topic":  "220",
        "URI":  "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580"
        },
    "r72":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "1B",
        "Publisher":  "FASB",
        "Section":  "45",
        "SubTopic":  "10",
        "Subparagraph":  "(b)",
        "Topic":  "220",
        "URI":  "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580"
        },
    "r73":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "5",
        "Publisher":  "FASB",
        "Section":  "45",
        "SubTopic":  "10",
        "Topic":  "220",
        "URI":  "http://asc.fasb.org/extlink&oid=121641772&loc=d3e557-108580"
        },
    "r74":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "2",
        "Publisher":  "FASB",
        "Section":  "S99",
        "SubTopic":  "10",
        "Subparagraph":  "(SX 210.5-03(1))",
        "Topic":  "220",
        "URI":  "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
        },
    "r75":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "2",
        "Publisher":  "FASB",
        "Section":  "S99",
        "SubTopic":  "10",
        "Subparagraph":  "(SX 210.5-03(10))",
        "Topic":  "220",
        "URI":  "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
        },
    "r76":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "2",
        "Publisher":  "FASB",
        "Section":  "S99",
        "SubTopic":  "10",
        "Subparagraph":  "(SX 210.5-03(20))",
        "Topic":  "220",
        "URI":  "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
        },
    "r77":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "2",
        "Publisher":  "FASB",
        "Section":  "S99",
        "SubTopic":  "10",
        "Subparagraph":  "(SX 210.5-03(24))",
        "Topic":  "220",
        "URI":  "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
        },
    "r78":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "2",
        "Publisher":  "FASB",
        "Section":  "S99",
        "SubTopic":  "10",
        "Subparagraph":  "(SX 210.5-03(25))",
        "Topic":  "220",
        "URI":  "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
        },
    "r79":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "2",
        "Publisher":  "FASB",
        "Section":  "S99",
        "SubTopic":  "10",
        "Subparagraph":  "(SX 210.5-03(4))",
        "Topic":  "220",
        "URI":  "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
        },
    "r8":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "6",
        "Publisher":  "FASB",
        "Section":  "45",
        "SubTopic":  "10",
        "Topic":  "210",
        "URI":  "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6911-107765"
        },
    "r80":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "2",
        "Publisher":  "FASB",
        "Section":  "S99",
        "SubTopic":  "10",
        "Subparagraph":  "(SX 210.5-03(5))",
        "Topic":  "220",
        "URI":  "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
        },
    "r81":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "2",
        "Publisher":  "FASB",
        "Section":  "S99",
        "SubTopic":  "10",
        "Subparagraph":  "(SX 210.5-03(8))",
        "Topic":  "220",
        "URI":  "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
        },
    "r82":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "2",
        "Publisher":  "FASB",
        "Section":  "S99",
        "SubTopic":  "10",
        "Subparagraph":  "(SX 210.5-03.1,2)",
        "Topic":  "220",
        "URI":  "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
        },
    "r83":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "2",
        "Publisher":  "FASB",
        "Section":  "S99",
        "SubTopic":  "10",
        "Subparagraph":  "(SX 210.5-03.2)",
        "Topic":  "220",
        "URI":  "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
        },
    "r84":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "2",
        "Publisher":  "FASB",
        "Section":  "S99",
        "SubTopic":  "10",
        "Subparagraph":  "(SX 210.5-03.4)",
        "Topic":  "220",
        "URI":  "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
        },
    "r85":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "2",
        "Publisher":  "FASB",
        "Section":  "S99",
        "SubTopic":  "10",
        "Subparagraph":  "(SX 210.5-03.4,6)",
        "Topic":  "220",
        "URI":  "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
        },
    "r86":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "2",
        "Publisher":  "FASB",
        "Section":  "S99",
        "SubTopic":  "10",
        "Subparagraph":  "(SX 210.5-03.7)",
        "Topic":  "220",
        "URI":  "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
        },
    "r87":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "2",
        "Publisher":  "FASB",
        "Section":  "S99",
        "SubTopic":  "10",
        "Subparagraph":  "(SX 210.5-03.8)",
        "Topic":  "220",
        "URI":  "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
        },
    "r88":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "13",
        "Publisher":  "FASB",
        "Section":  "45",
        "SubTopic":  "10",
        "Subparagraph":  "(c)",
        "Topic":  "230",
        "URI":  "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585"
        },
    "r89":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "14",
        "Publisher":  "FASB",
        "Section":  "45",
        "SubTopic":  "10",
        "Subparagraph":  "(a)",
        "Topic":  "230",
        "URI":  "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585"
        },
    "r9":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "8",
        "Publisher":  "FASB",
        "Section":  "45",
        "SubTopic":  "10",
        "Topic":  "210",
        "URI":  "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6935-107765"
        },
    "r90":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "14",
        "Publisher":  "FASB",
        "Section":  "45",
        "SubTopic":  "10",
        "Subparagraph":  "(b)",
        "Topic":  "230",
        "URI":  "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585"
        },
    "r91":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "15",
        "Publisher":  "FASB",
        "Section":  "45",
        "SubTopic":  "10",
        "Subparagraph":  "(b)",
        "Topic":  "230",
        "URI":  "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585"
        },
    "r92":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "15",
        "Publisher":  "FASB",
        "Section":  "45",
        "SubTopic":  "10",
        "Subparagraph":  "(e)",
        "Topic":  "230",
        "URI":  "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585"
        },
    "r93":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "15",
        "Publisher":  "FASB",
        "Section":  "45",
        "SubTopic":  "10",
        "Topic":  "230",
        "URI":  "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585"
        },
    "r94":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "16",
        "Publisher":  "FASB",
        "Section":  "45",
        "SubTopic":  "10",
        "Subparagraph":  "(b)",
        "Topic":  "230",
        "URI":  "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3337-108585"
        },
    "r95":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "17",
        "Publisher":  "FASB",
        "Section":  "45",
        "SubTopic":  "10",
        "Subparagraph":  "(d)",
        "Topic":  "230",
        "URI":  "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3367-108585"
        },
    "r96":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "2",
        "Publisher":  "FASB",
        "Section":  "45",
        "SubTopic":  "10",
        "Topic":  "230",
        "URI":  "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3000-108585"
        },
    "r97":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "24",
        "Publisher":  "FASB",
        "Section":  "45",
        "SubTopic":  "10",
        "Topic":  "230",
        "URI":  "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3521-108585"
        },
    "r98":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "25",
        "Publisher":  "FASB",
        "Section":  "45",
        "SubTopic":  "10",
        "Subparagraph":  "(e)",
        "Topic":  "230",
        "URI":  "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585"
        },
    "r99":  {
        "Name":  "Accounting Standards Codification",
        "Paragraph":  "25",
        "Publisher":  "FASB",
        "Section":  "45",
        "SubTopic":  "10",
        "Subparagraph":  "(g)",
        "Topic":  "230",
        "URI":  "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585"
        }
    },
"version":  "2.1"
}

23 Previous Filings that this Filing References

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 3/31/21  Biolase, Inc.                     10-K       12/31/20   88:15M                                    ActiveDisclosure/FA
 2/10/21  Biolase, Inc.                     8-K:1,8,9   2/05/21    4:227K                                   Donnelley … Solutions/FA
11/13/20  Biolase, Inc.                     10-Q        9/30/20   81:11M                                    ActiveDisclosure/FA
 7/22/20  Biolase, Inc.                     8-K:1,3,5,8 7/15/20    6:7.8M                                   Donnelley … Solutions/FA
 6/19/20  Biolase, Inc.                     S-1/A                  3:736K                                   Donnelley … Solutions/FA
 6/09/20  Biolase, Inc.                     8-K:1,3,8,9 6/08/20    6:378K                                   Donnelley … Solutions/FA
 6/01/20  Biolase, Inc.                     8-K:5,9     5/28/20    2:26K                                    Donnelley … Solutions/FA
11/12/19  Biolase, Inc.                     10-Q        9/30/19   86:10M                                    ActiveDisclosure/FA
10/30/19  Biolase, Inc.                     8-K:1,3,9  10/24/19    4:406K                                   Donnelley … Solutions/FA
 5/10/19  Biolase, Inc.                     10-Q        3/31/19   86:8M                                     ActiveDisclosure/FA
11/14/18  Biolase, Inc.                     10-Q        9/30/18   81:11M                                    ActiveDisclosure/FA
10/09/18  Biolase, Inc.                     8-K:5,7,9  10/08/18    3:157K                                   Donnelley … Solutions/FA
 5/11/18  Biolase, Inc.                     8-K:5,9     5/10/18    2:26K                                    Donnelley … Solutions/FA
 3/14/18  Biolase, Inc.                     10-K       12/31/17   82:13M                                    ActiveDisclosure/FA
 7/21/17  Biolase, Inc.                     S-3                    4:281K                                   ActiveDisclosure/FA
 5/19/17  Biolase, Inc.                     DEF 14A     6/30/17    1:763K                                   Donnelley … Solutions/FA
 4/20/17  Biolase, Inc.                     8-K:3,5,9   4/18/17    3:67K                                    Donnelley Fi… Express/FA
 8/02/16  Biolase, Inc.                     8-K:1,7,9   8/01/16    5:359K                                   Donnelley … Solutions/FA
11/12/15  Biolase, Inc.                     8-K:1,3,5,911/10/15    5:62K                                    Donnelley … Solutions/FA
11/07/14  Biolase, Inc.                     8-K:1,3,9  11/03/14    3:247K                                   Donnelley … Solutions/FA
11/04/14  Biolase, Inc.                     8-A12B/A               3:38K                                    Donnelley … Solutions/FA
 5/16/12  Biolase, Inc.                     8-K:5,7,9   5/10/12    3:44K                                    Donnelley Fi… Express/FA
12/23/05  Biolase, Inc.                     S-1/A                  6:2.3M                                   Donnelley … Solutions/FA
↑Top
Filing Submission 0000950170-21-000226   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)
Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
About — Privacy — Redactions — Help — Fri., May 10, 8:37:58.8am ET